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1 Introduction 
1.1 The concept of Epigenetics 
The human genome project resulted in enormous amounts of genomic raw data. It is now 
known, that there are two meters of tightly compacted DNA, containing roughly 30,000 
genes, coiled into the nucleus of each cell. However, identity and developmental potential 
of individual cells within organisms is not only defined by its genetic component. It is 
important to understand changes that occur in the function of genes without a change in 
the genome sequence. This branch of research is known as “epigenetics”, and concerns 
itself with chemical interactions that modify either DNA itself or its packaging proteins, the 
histones. The term "epi" means "on top of", and the epigenetic code compromises a 
second layer of information on top of the genetic code. Figure 1.1 illustrates basic 
epigenetic modifications, observed on the level of DNA and histones. Epigenetics, in a 
broad sense, is a connection between genotype and phenotype that alters the final 
outcome of genomes without changing the underlying DNA sequences. For example, 
even though the great majority of cells in a multicellular organism share an identical 
genotype, organisms contain a variety of cell types with diverse, yet stable, profiles of 
gene expression and distinct cellular functions. More specifically, epigenetics can be 
defined as the study of any stable heritable change in gene expression or cellular 
phenotype that occurs without changes in the sequence of DNA. Epigenetic research 
nowadays includes the study of covalent and non-covalent modifications of DNA and 
histone proteins and the mechanisms by which such modifications influence overall 
chromatin structure. The following chapters particularly focus on DNA methylation, which 
provides a stable, heritable and critical component of epigenetic regulation. 
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Figure 1.1 Epigenetic regulatory mechanisms: DNA methylation and chromatin structure. 
Methylation of CpGs occurring in the regulatory region of genes causes gene silencing. Methylation 
of DNA and chromatin structure is coordinated through modification of histones, including by 
acetylation and methylation. In general, DNA methylation and chromatin condensation are 
associated with gene silencing. The epigenetic state consisting of DNA methylation and chromatin 
configuration results in changes in the differentiation of cells. Once established, the epigenetic 
state is maintained during the proliferation of cells (Figure taken from reference
1
). 
 
1.2 DNA methylation 
The longest known epigenetic modifications is the covalent addition of a methyl group to 
the 5' carbon atom of the base cytosine (C). In mammals, this modification is mainly 
assigned to cytosines followed by guanine (G), so called CpG dinucleotides (CpGs). DNA 
methylation is associated with gene silencing and was reported to be essential for 
embryonic development2, genomic imprinting3, X-inactivation in mammals4 and silencing 
of potential harmful DNA elements like transposons or endogenous retroviruses5. In 
addition, aberrant DNA methylation has been linked to abnormal developmental 
processes and cancer formation6. Interestingly, CpG dinucleotides are distributed 
unequally over the genome: Most CpGs in mammals are methylated, distributed randomly 
and appear rarer than statistically expected7. One possible explanation for this distribution 
is the observation that 5mC hydrolytically deaminates to thymine (T). Thymine - a 
naturally occurring genomic base - is not recognized as misplaced, resulting in a C to T 
Introduction 
 
3 
transition and a decrease of CpGs over time in evolution. However, there are regions with 
higher CpG density, so called CpG islands (CGIs). They were initially defined as regions 
with a GC content of 50 % or higher and a ratio of observed versus expected CpG 
frequency of 0.6 in a region of 200 base pairs minimum8. CGIs are often associated with 
promoter regions. More than half of the genes in the human genome are associated with 
one or more CGIs which are preferentially unmethylated, raising the question how the 
maintenance of hypomethylation in development and differentiation is achieved7.  
Two classes of proteins are involved in creating and recognizing methylated CpG‟s (DNA 
methyltransferases and Methyl-CpG-binding proteins) and are introduced in the next two 
sections.  
1.2.1 DNA methyltransferases 
DNA methyltransferase activity was first detected in crude cellular extracts and 
subsequently purified as a 200 kDa protein named DNA methyltransferase 1 (Dnmt1)9. In 
eukaryotes, three different families of DNA methyltransferases (Dnmts) have been 
identified (Dnmt1, Dnmt2 and Dnmt3)10,11. So far four different proteins belong to these 
families (1, 2, 3a and 3b). The different family members have similar molecular structures 
with most of them containing ten specific sequence motifs within the C-terminal catalytic 
domain, six of which are highly conserved12,13. However, the regulatory domains located 
at the N-terminal part of the proteins show little sequence homologies14 and are 
completely absent in Dnmt2. It was proposed, that DNA methyltransferases could act the 
same way than other enzymes catalyzing electrophilic substitutions at carbon-5 of 
pyrimidins15. The contact between DNA and enzyme is established by extreme distortion 
of the DNA helix. The reaction is started when cytosine is flipped out of the DNA and 
inserted into the binding pocket of a methyltransferase enzyme. In the active site, the 
catalytic cysteine thiolate forms a transition state intermediate with the carbon-6 of the 
cysteine‟s ring. This creates a reactive, negative charged 4-5 enamine, which attacks the 
methyl group provided by the AdoMet cofactor (S-adenosyl methionine, SAM) acting as 
methyl donor16. After transfer of the methyl group to the C-5 position within the cytosine 
ring the proton is removed from this position leading to reconstitution of the 5,6 double 
bond and the release of the enzyme by ß-elimination17. Although the mechanism of 
transfer is similar between the different family members, the biological roles are different. 
Dnmt1 enzyme exhibits a 5-10 fold preference for hemi-methylated DNA18, which 
suggests that this enzyme is responsible for the maintenance of DNA methylation patterns 
after daughter strand formation during the S-phase of cell cycle. Functional experiments in 
mammalian cells additionally proposed a role in the X-chromosome inactivation, allelic 
silencing of imprinted genes and silencing of incorporated transposons19. Silencing of 
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human Dnmt1 is lethal for normal cells20. The catalytic significance of Dnmt2 has not been 
identified. It was shown, that Dnmt2 is not essential for global de novo or maintenance 
methylation in embryonic stem cells21. It may be involved in maintenance of centromeric 
structure10. Dnmt3a and Dnmt3b are generally considered to be de novo DNA 
methyltransferases. During early development, when most of the de novo methylation 
occurs, both enzymes are highly expressed and essential for the establishment of new 
methylation patterns and following correct development2. Another nuclear protein not 
mentioned yet, DNA methyltransferase-like protein 3L (Dnmt3L), shows similarity to DNA 
methyltransferases. This protein is not thought to function as a DNA methyltransferase as 
it does not contain the amino acid residues necessary for methyltransferase activity. 
However, this protein does stimulate de novo methylation by Dnmt3a22 and it is thought to 
be required for the establishment of maternal genomic imprints23. This protein also plays 
an important role differentiation of spermatocytes24.  
1.2.2 Methyl-CpG-binding proteins 
Another class of proteins binds to methylated CpG‟s and comprises the so called methyl-
CpG-binding proteins (MBD). In 1993, Bird and colleagues defined the MBD domain by 
molecular analysis of the prototype MBD protein, MeCP225. This domain was both, 
necessary and sufficient, to bind mCpG DNA and was found in all MBD family members. 
The family contains 4 other proteins, named MBD1-4 (see Figure 1.2). MBD2 is the DNA- 
binding component of MeCP1 complex, which was observed to be specific for methylated 
DNA in a variety of mammalian cell types26. Three of these proteins (MBD1, MBD2 and 
MeCP2) are involved in methylation-dependent repression of transcription27. An unrelated 
protein named KAISO, which lacks the MBD domain, has also been shown to bind 
methylated DNA (via zinc fingers) leading to repression in model systems28,29. Each of the 
four methyl-CpG-binding proteins has been shown to associate with a different repressor 
complex30-32. A prerequisite for understanding the biological roles of the different MBD 
proteins is the knowledge of their target sites. One might expect that the various proteins 
compete with one another for access to methylated sites, due to their overlapping DNA 
sequence specificity. However, Klose et al. studied MBD binding sites within a primary 
human cell lines and demonstrated, that they were largely nonoverlapping33, suggesting 
that each protein is targeted independently. In this study MeCP2 strongly prefers mCpG 
sites flanked by a run of AT-rich DNA. MBD1 binds to mCpG via its MBD domain, but a 
major splice form is additionally able to bind unmethylated CpG via a CxxC domain. A pair 
of adjacent mCpG motifs is recognized by Kaiso28. Only MBD2 so far appears to have an 
exclusive affinity for methylated CpG dinucleotides.  
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Figure 1.2 Characteristic domains of the MBD protein family. Five members of the MBD 
protein family are shown. MBD domains are marked in red. Other domains are labelled as well and 
include transcriptional repression domains (TRD, colored in blue) CxxC domains (colored in green) 
GR repeats of unknown function (GR, labelled purple) and an E-repeat (E, labelled in rose). A DNA 
N-glycosylase domains in, which is involved in the T:G mismatch repair after 5‟-methylcytosine 
deamination (shown in light green) (Figure adopted from reference
34
).  
 
1.3 Functions and molecular consequences 
of DNA methylation in healthy cells 
Since every cell of a multicellular organism contains essentially the same genome, it is 
crucial to understand why genetically homogenous cells are different from each other and 
how this is controlled. As mentioned above, DNA methylation does not alter the base 
composition itself. Nevertheless, a fifth base is introduced to the genomic code, leading to 
an altered surficial area, which may trigger various reactions. Several observations 
indicate that DNA methylation has an essential regulatory function in mammalian 
development, which is to establish the correct pattern of gene expression, and that distinct 
DNA methylation patterns are tightly correlated to specific chromatin structures. Various 
physiological processes are controlled by specific DNA methylation patterns including 
genomic imprinting3, inactivation of one X chromosome in females4, regulation of tissue-
specific gene expression35,36 and silencing of transposons5. Moreover, aberrant 
methylation can confer a selective advantage, leading to cancerous growth37. The 
following part focuses on the epigenetic molecular mechanisms during normal 
development. 
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1.3.1 Global methylation landscapes 
In mammals DNA methylation is found throughout the genome in mammalian studies. 
Interestingly short regions - so called CpG islands (CGIs) - remained unmethylated38,39 
and are believed to be protected from methylation through cis-acting elements40. CpG 
islands typically occur at or near the transcription start site of genes, particularly 
housekeeping genes, in vertebrates41,42. CGIs are usually defined as regions with at least 
200 bp and with a GC percentage that is greater than 50% and with an 
observed/expected CpG ratio that is greater than 60%8. Based on an extensive search on 
the complete sequences of human chromosomes 21 and 22, DNA regions greater than 
500 bp with a GC content of more than 55% and observed/expected CpG ratio of 65% 
were more likely to be the true CpG islands associated with the 5' regions of genes43. 
However, the global DNA methylation pattern seen in vertebrates is not ubiquitous among 
eukaryotes. Several well-studied model systems have no recognizable Dnmt-like genes 
and are devoid of DNA methylation (for example, the yeast Saccharomyces cerevisiae 
and the nematode worm Caenorhabditis elegans). In fungi that have genomic 5-
methylcytosine (5mC), only repetitive DNA sequences are methylated44. Invertebrates 
mostly exhibit a „mosaic methylation‟, comprising domains of heavily methylated DNA 
interspersed with domains free of methylation45. In plants up to 50% of cytosine‟s have 
been reported to be methylated in some species, which represents the highest level of 
DNA methylation among eukaryotes46. Large numbers of methylated transposons, seem 
to be responsible for this high levels in maize47,48.  
An accumulation of 5-methylcytosines is also found in tandem and interspersed repeats, 
constituting a second group of CpG-rich regions beside CpG islands.  Among these 
repeats, Alu repeats with more than one million copies per haploid genome are 
considered to be the most dominant family49. They belong to the 'short interspersed 
nucleotide elements' (SINEs) and alone constitute for more than 10% of the human 
genome49. They are not randomly distributed within the human genome, but tend to 
accumulate in gene-rich regions50. Most Alu repeats have been reported to be highly 
methylated in somatic tissues51,52. DNA methylation in general represents the major 
mechanism to repress transposable elements, as detailed below. 
1.3.2 Genomic immunity: De novo methylation of 
integrated foreign DNA 
DNA methylation is an ancient process found in all domains of life. In eukaryotes, which 
include diverse organisms such as plants as well as humans, DNA methylation is found 
exclusively at cytosine residues. The observation, that mice lacking Dnmts die very early 
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during embryogenesis, suggests that this modification has important roles and is essential 
for mammalian embryonic development2,53. Dnmt-null mice show reduced DNA 
methylation levels but the specific reasons for death during development remain unclear. 
Defects in repression of the inactivated X chromosome in female cells and in the 
establishment and maintenance of allele-specific expression of imprinted genes have 
been observed54-56. Thus, lethality might result from aberrant gene dosage. In addition, 
increased expression of transposon RNA was reported in these embryos57.  
In Dnmt-knockout mice, global demethylation as a consequence of Dnmt1 absence likely 
triggers mutations through the activation of cryptic transposons, which might contribute to 
early lethality. Normally these transposons are methylated and thereby repressed. 
Consequently, DNA methylation masks the effects of transposon insertion by mechanisms 
that do not directly depend on regulation of transcription or transposition. Instead of that, 
methylated transposons are hidden from the genome mediated amongst others by DNA 
methylation5. This property may have allowed transposons to accumulate to high copy 
numbers without major scrambling effects on the host genome. Amongst others, these 
observations resulted in the conclusion that cytosine DNA methylation functions to 
maintain the repressed chromatin state leading to silencing of (alternative) promoter, 
pseudo gene or transposon activity27. It is therefore conceivable that intragenic 
methylation helps to weaken transcriptional noise58.  
However, DNA methylation has been adapted for a variety of uses throughout evolution, 
beside defense against transposable elements, including control of gene expression, 
discussed in the next paragraph. 
1.3.3 Development: Tissue specific DNA methylation 
As mentioned before, every cell of a multicellular organism contains essentially the same 
genome. However, entire organisms incorporate a huge variety of differentiated and 
specialized cells, all of them using only a small proportion of available genes.  
These patterns of differential gene activity are clonally inherited through cell division.  
Because specific methyl-CpG dinucleotides are maintained through DNA replication, DNA 
methylation states provide an attractive mechanism (epigenetic mark) to maintain a 
particular state of gene activity through cell division and, thus, to contribute to the 
maintenance of the differentiated state. However, the precise extent of tissue-specific 
hyper- or hypomethylation throughout the genome is largely unknown and has been 
controversially discussed35,36. 
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1.3.4 Imprinting 
Imprinting describes the rare but remarkable situation when alleles of the same gene are 
expressed unequal in a parent-of-origin dependent manner. This means that some genes 
within the diploid genome are only expressed from alleles inherited from the father, 
whereas some other are only expressed from alleles derived from the mother.  This 
phenomenon was first reported in 1984, when it was discovered, that parthogenic 
(maternal only) and androgenic (paternal only) embryos fail to develop after murine 
nuclear transfer experiments59,60. Shortly after, the responsible chromosomes carrying the 
imprinted loci where discovered via studies of UPD (uniparental contribution of one 
chromosome pair) in mice61. UPD for some chromosomes was lethal or with severe 
developmental defects contrary to other chromosomes, where according phenotypes were 
unaltered. Imprinted genes must carry some distinguishing mark on one parental allele in 
order to assure sex-specific gene expression. Igf2 and H19, nearby on murine 
chromosome 7, were the first mammalian imprinted genes to be identified62-64. In addition, 
a role for DNA methylation in imprinting was first demonstrated by defective imprinting 
observed in Dnmt-/- mice, where imprinting of the H19, Igf2 and Igf2r genes was 
disturbed3. This study revealed that maintenance of DNA methylation was essential for 
imprinted expression. This region is under the control of a differentially methylated region 
(DMR) which can bind an enhancer blocking protein (CTCF) in a methylation sensitive 
way6. The unmethylated DMR on the maternal allele binds the CCCTC-binding-factor 
CTCF and blocks a downstream enhancer of the Igf2 gene. In contrast H19, which is 
located upstream of the “blockade”, is expressed. The paternal allele is methylated at the 
DMR preventing the binding of CTCF, what enables the enhancer to stimulate 
transcription of Igf265.  
Differentially methylated regions are typically found within the vicinity of imprinted genes. 
Some of which are called imprinting control regions (ICR) and by definition are already 
established in germ cells and are resistant to early embryonic epigenetic reprogramming 
(see Figure 1.3). It is noteworthy that all ICRs/DMRs would not formally be defined as 
CGIs and differences in GC and CpG content between maternal and paternal have been 
reported66. 
1.3.5 Resetting of imprints 
During development two major waves of genome-wide demethylation take place affecting 
a substantial part of the genome. The first wave is in the germ cell stage and the second 
later after fertilization. Both are important for the inheritance of imprinting, though in a 
different mode. The first genome-wide demethylation is thought to erase methylation in 
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order for the new parent-of-origin methylation to be set. During the second wave after 
fertilization the methylation pattern of imprinted loci is believed to be protected, which is 
necessary for the proper dissemination of imprinting to somatic cells67. Interestingly, the 
mechanism of epigenetic reprogramming seems to differ between male and female germ 
cells, at least regarding establishment dynamics68. Snrpn (small nuclear riboprotein N) 
and Mest (mesoderm specific transcript homolog) are two examples of maternally 
expressed genes that were unmethylated in sperm but fully methylated in mature 
oocytes69. The latter two examples represent genes of particular interest, because of their 
important biological functions and characteristic phenotypes associated with the absence 
of their gene products. Snrpn is reported to be involved in the development of Angelmann 
or Prader-Willi syndromes70, whereas paternal transmission of Mest gene results in 
growth-retarded embryos and increased postnatal death. In addition abnormal adult 
maternal behavior has been noted for Mest-deficient females71,72. Reprogramming during 
development is summarized in Figure 1.3. 
 
 
Figure 1.3 Imprinting during developmental reprogramming. During germ cell formation DNA 
methylation is erased and re-established in a gender-dependent manner. After fertilization, the 
paternal genome (♂) is demethylated by an active mechanism whereas the maternal genome (♀) 
is demethylated by a passive mechanism that depends on DNA replication. After fertilization, 
imprints are resistant to global waves of de- and remethylation. (Adopted from reference
67
). 
1.3.6 X-chromosome inactivation 
Besides imprinting, another system of monoallelic gene exclusion in mammals is known. 
In mammals, sex is determined by differential inheritance of a pair of dimorphic 
chromosomes: the gene-rich X chromosome and the gene-poor Y chromosome. To 
balance the unequal X-chromosome dosage between the XX female and XY male, 
mammals have adopted a unique form of dosage compensation in which one of the two X 
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chromosomes is inactivated in the female. This mechanism involves a complex, highly 
coordinated sequence of events.  
X-chromosome inactivation in eutherian mammals was first discovered in 1961 by Mary 
Lyon in studies of coat-colour genes in mice73 and is a random process, commonly 
divided into the steps of counting, choice, initiation, establishment and maintenance (see 
Table 1.1). These steps are genetically separable and appear to be controlled by the X 
inactivation center (Xic) except for maintenance73-75. Xic contains Xist, a noncoding RNA 
gene first described 199176,77. During the counting step, the number of X-chromosomes is 
measured, in relation to haploid autosome sets. A region at the 3' end of the Xist gene is 
thought to be responsible for this initial step78. During choice all but one X-chromosome is 
committed to inactivation and it has been shown that the genes Xist and Tsix participate in 
regulating this step79,80. Tsix is the second non-translated RNA, transcribed antisense to 
Xist, encoded by the Xic region81. Xist RNA accumulates along the X chromosome 
containing the active Xist gene and proceeds to inactivate almost all of the other hundreds 
of genes on that chromosome82.  
Tsix mRNA has been shown to be a negative regulator of Xist and prevents its abundant 
accumulation on the active X chromosome81. Hence, the inition of silencing relies on Xist 
expression. However, once silencing is established, maintenance of the inactive X is 
apparently independent of further Xic and Xist function83,84. Following this physical 
deactivation, large parts of the chromosome are silenced by DNA methylation. For 
random X-inactivation maintenance, DNA methylation is the key stabilizing factor, as 
deletion of maintenance DNA methyltransferase Dnmt1 results in reactivation of the 
silenced X in the embryo85. In addition, DNA methylation is also required to stably repress 
the Xist gene on the active X chromosome82,86,87.  
It is worth mentioning, that X-inactivation exists in an imprinted form as well, which is 
believed to be the ancestral mechanism. Marsupial mammals undergo nonrandom X-
chromosome inactivation and preferentially shut off the paternally derived X-
chromosome88. 
 
Table 1.1 Steps and active components of mammalian X-inactivation 
Step Component  
Counting Xist 3‟ region 
Choice Xist and Tsix 
Initiation of silencing Xist 
Establishment Xist? 
Maintenance i.a. DNA methylation 
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1.3.7 Interindividual phenotypical differences and 
inheritance of DNA methylation 
In the past it has been considered that epigenetic differences participate in characteristic 
individual phenotypes too. Although phenotypic variation between individuals is mainly 
driven by genetic traits, there is also evidence that epigenetic mechanisms may contribute 
to phenotypic differences in mammals89. Examples for epigenetic differences between 
individuals are rare and mostly, but not exclusively, confined to the level of DNA 
methylation. It has been demonstrated that supposedly genetically identical, monozygotic 
twins can show differences at the level of DNA methylation90,91. These differences, 
however, are likely not inherited but acquired during the lifetime of each individual90. In 
addition, there are several reports demonstrating that DNA sequence variants associate 
with specific epigenetic states92-94. A recent study in humans identified several cases of 
allele-specific DNA-methylation at non-imprinted gene loci95, where the methylation status 
of each allele was likely controlled in cis by the local DNA sequence. This raises the 
question how epigenetic states can be inherited to the next generation. The underlying 
DNA sequence itself seems to play an important factor (regulated in cis), as highlighted 
before. In contrary, in mice there is well-documented evidence that epigenetic states can 
be inherited across generations, e.g. at the Agouti viable yellow (Avy) allele96,97, and that 
allelic variation at certain epigenetic modifier genes in mice, like DNA methyl-transferases 
or chromatin remodelling factors may influence the inheritance of CpG methylation 
patterns in trans98,99. 
Taken together, this suggests that three types of inheritance may exist in vivo: methylation 
patterns at non-imprinted loci may be inherited based on genetic mechanisms (in cis and 
in trans) or based on epigenetic mechanisms. The extent of contribution of each type of 
mechanism in shaping individual epigenetic or phenotypic differences is currently 
unknown. 
1.4 Mapping DNA methylation 
As detailed above, DNA methylation has various regulatory roles and functions in both 
healthy and malignant cells. On the basis of these discoveries, the investigation of DNA 
methylation has drawn much attention and was subjected to continuous further 
developments. However, the direct examination of DNA methylation has been hindered by 
the fact, that DNA methylation cannot be analyzed by standard DNA sequencing methods, 
since they are unable to distinguish 5-methylcytosine from unmodified cytosine. Thus, 
alternative techniques must be used to access normal or aberrant methylation. A number 
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of methodologies used for detection of DNA methylation have so far been developed, 
each with its own advantages and inherent disadvantages, but no single technique can 
provide a complete assessment, in terms of resolution (ideally single-base) and feasibility 
of high throughput and global covering.  
Early studies relied on methylation-sensitive restriction enzymes such as NotI, HpaII, or 
SmaI in conjunction with Southern hybridization100. While this provides information on the 
specific restriction enzyme site, southern hybridization is time-consuming and requires 
large quantities of DNA and it is not useful for determining global methylation patterns. A 
popular isoschizomer pair for methylation analysis is HpaII/MspI. Both enzymes cleave 
CCGG sites, but HpaII is unable to cleave if the internal cytosine is methylated. However, 
methods based on methylation specific restriction enzymes suffer from the limitation that 
they provide information only about CpGs within the cleavage site.  
Treatment of genomic DNA with sodium bisulfite (NaHSO3) overcomes this limitation and 
allows the analysis of virtually any CpG position within the genome. As stated previously, 
standard sequencing methods cannot distinguish 5-methylcytosine from unmodified 
cytosine, thus hindering the analysis of CpG site methylation. In 1992, Frommer and 
colleagues101 described genomic sequencing of bisulfite-treated DNA as a way to 
distinguish methylated from unmethylated cytosines at single base resolution level. When 
single stranded DNA is treated with sodium bisulfite, unmethylated cytosines are 
converted to uracil, whereas 5-methycytosines are unreactive102 (see Figure 1.4). 
 
 
 
Figure 1.4 Chemical reaction during bisulfite treatment. Cytosine-derivates undergo reversible 
reactions with bisulphite yielding a 5,6-Dihydro-6-sulfonate, which deaminates spontaneously. After 
that the sulphate is eliminated under alkaline conditions, leaving Uracil. Methylated cytosine is not 
affected by this reaction, due to sterical hindrance by the methyl-group in 5‟-position.  
 
Using primers that surround a CpG-containing area of interest, but do not contain CpGs 
themselves, the modified DNA strands are then amplified by PCR. The PCR-product can 
then be sequenced, directly or after subcloning of the amplified fragment. Direct 
sequencing gives information about the average methylation of a CpG site in a sample, 
while sequencing of cloned DNA allows the analysis of individual CpG sites on 
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independent half strand DNA molecules. However, sequencing of bisulfite-treated DNA is 
very laborious and time consuming and therefore not practicable on a global scale. This 
approach has become very important in the investigation of methylation of cancer-related 
genes and has been used in the analysis of novel methylation targets identified by 
restriction landmark genomic scanning (RLGS)103,104. 
Specific adapted PCR techniques have been developed in several laboratories to map 
DNA methylation without the need of sequencing. These methods rely on single 
nucleotide polymorphisms (SNPs) introduced by the bisulfite-treatment at the CpG site. 
Specific PCR primers for the methylated and unmethylated states (i.e. MSP)105 or 
methylation specific probes are used for real time PCR (i.e. MethyLight)106.  
Other methods to map DNA methylation utilize specific proteins or antibodies, which are 
able to bind methylated DNA. Methylated DNA can be immunoprecipitated using an 
antibody directed against 5-methyl Cytidine (5-meC). Immunoprecipitation of methylated 
DNA (Methyl DNA IP, also called MeDIP) was first described in 2004107,108. In brief, 
genomic DNA is sheared, either using restriction enzymes or via sonication, and 
denatured. Then, immunoselection and immunoprecipitation can take place using the 
antibody directed against 5-methyl Cytidine and antibody binding beads. Another strategy 
for in vitro methylation detection uses column- or bead-immobilized recombinant 
methylated-CpG binding domain (MBD) proteins, particularly MeCP2 and MBD2, to enrich 
for methylated DNA fragments for subsequent detection by PCR or microarray 
hybridization109,110. In 2006 a robust technique, called methyl-CpG-immunoprecipitation 
(MCIp) was established in our laboratory. The approach is based on a recombinant, 
antibody-like protein that efficiently binds native CpG-methylated DNA. In combination 
with CpG island microarrays, the technique was used to identify genes with aberrantly 
methylated CpG islands in three myeloid leukemia cell lines110. A great advantage of this 
method is that DNA is not only enriched for highly methylated DNA (whereas 
unmethylated DNA is lost, as in MeDIP), but also recovers mainly unmethylated DNA, 
since the DNA is fractionated depending on the methylation density and each individual 
fraction is kept. This methodology is intensively used in the present thesis and explained 
in more detail in subsequent sections. 
Most techniques used to map DNA methylation described in the literature depend more or 
less on the principles explained above, but may contain certain modifications or specific 
adjustments. Besides different pretreatment techniques much effort was done in 
establishing new downstream high-throughput readout principles. Thus, microarrays, 
mass spectrometry and next generation sequencing were intensively used to globally 
mine DNA methylation in various approaches. 
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Hence, new readout approaches arose, by combination of bisulfite treatment of DNA and 
next-generation sequencing (NGS)111,112. NGS platforms share a common technological 
feature: massively parallel sequencing of clonally amplified or single DNA molecules that 
are spatially separated in a flow cell. As a massively parallel process, NGS generates 
hundreds of mega bases to giga bases of nucleotide-sequence output in a single 
instrument run, depending on the platform. Ehrich and colleagues recently advanced the 
treatment of genomic DNA with sodium bisulfite in an alternative direction by combination 
with mass spectrometry (MS)113. This method employs a PCR step after bisulfite treatment 
during which a T7 promoter primer is incorporated into the PCR product. In vitro 
transcription and subsequent T-specific cleavage follows the PCR. The method then 
utilizes matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF MS)114 in order to detect the G to A sequence difference in the generated 
RNA fragments. This permits high-throughput identification of methylation sites and their 
semi quantitative measurement at single or multiple CpG positions. 
 
Table 1.2 (page 15) summarizes several methodologies used to explore DNA 
methylation, ether globally or gene specifically, and points out underlying sample 
pretreatment techniques. Current high throughput readout methods together with key 
references are summarized in Table 1.3 (page 16). 
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Table 1.2 Current methods for DNA methylation analysis: sample pretreatment 
Method (+reference) General basis 
Bisulphite conversion101 Sodium bisulphite converts unmethylated 
cytosine to uracil, whereas methylated 
cytosines are protected from conversion 
Resolution: high, single base 
RLGS; HELP assay115,116 DNA is differentially fragmented with a 
methylation-sensitive restriction enzyme. 
Following size fractionation, this method 
enriches methylated DNA 
Resolution: moderate 
McrBC digestion117-119 DNA digestion with a methylation-specific 
restriction enzyme, McrBC. Following size 
fractionation, this method enriches 
unmethylated DNA 
Resolution: moderate 
Methylated DNA immunoprecipitation 
(MeDIP)107,120-123 
Immunoprecipitates DNA containing 
methylated cytosines using a monoclonal 
antibody; requires single strand DNA 
Resolution: moderate 
MBD affinity purification 
(e.g. MAP; MCIp; MB-PCR)109,110,120,124-126 
Immunoprecipitates DNA containing 
methylated CpG using an MBD column 
Resolution: moderate 
CXXC affinity purification 
(CAP)126 
Immunoprecipitates DNA containing 
unmethylated CpG using a CXXC-domain 
column 
Resolution: moderate 
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Table 1.3 Current methods for DNA methylation analysis: high-throughput readout 
Readout method (+reference) General basis Uses 
Oligonucleotide 
arrays110,120,121,127-130 
Short (25-mer) or long (60-
mer) oligonucleotide array 
Tiling genomic arrays, promoter 
arrays, CpG-island arrays and 
custom arrays 
Resolution: moderate 
SNP arrays131 SNP selective probe array Detection of allele-specific DNA 
methylation 
Resolution: moderate 
BeadArray132 Ratio of the methylated and 
unmethylated PCR products is 
determined at single CpG sites 
Detection of methylation 
polymorphisms. However, a large 
set of primers needs to be 
designed 
Resolution: high, quantitative 
Standard sequencing Sanger sequencing Expensive and labor intensive for 
genome-wide analysis 
Resolution: high, quantitative 
Direct large-scale sequencing 
(NGS)111,112 
Short-read sequencing (Solexa 
sequencing: 40 millon reads of 
25-30 bases; 454 sequencing: 
400,000 reads of >100 bases) 
Fast and relatively inexpensive. 
Genotype information can be 
obtained simultaneously. 
However, high-quality reference 
sequence is required 
Resolution: high, quantitative 
EpiTyper (MALDI-TOF)113 detection of polymorphisms via 
mass spectrometry  
Fast and relatively inexpensive. 
Resolution: high, quantitative 
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2 Aims 
A global picture of epigenetic variation between cell lineages or individuals will be key to a 
better understanding of DNA methylation and its contribution to phenotypes. The main 
goals of this thesis were to develop methods to address epigenetic variation, in particular 
on the level of DNA methylation, and to apply them to study tissue- and mouse strain- 
specific DNA methylation. Based on the previously developed methyl-CpG 
immunoprecipitation (MCIp) approach, this method should be modified and adapted to 
enable the comparative analysis of differential DNA methylation in regions with low or 
intermediate CpG content, which is difficult to study with existing technologies. One pilot 
study should compare the methylation profiles of three human tissues and correlate 
methylation differences with transcriptional activities of the corresponding genes. The 
second, major study should compare the methylation profiles of a defined cell type (bone 
marrow-derived macrophages) from two different inbred mouse strains. This study should 
aim at identifying interindividual differences in DNA methylation and provide details on 
how these differences are established in individuals. 
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3 Material 
3.1 Equipment  
8-Channel Pipettor MATRIX Impact2 Equalizer 384  Thermo Fisher Scientific, Hudson, USA 
Autoclave  Technomara, Fernwald, Germany 
Biofuge fresco Heraeus, Osterode, Germany 
BioPhotometer  Eppendorf, Hamburg, Germany 
Camera Polaroid, Cambridge, USA 
Densitometer  Molecular Dynamics, Krefeld, Germany 
Electrophoresis equipment  Biometra, Göttingen, Germany 
Heat sealer Fermant 400  Josten & Kettenbaum, Bensberg, Germany 
Heatblock  Stuart Scientific, Staffordshire, UK 
Incubators  Heraeus, Hanau, Germany 
Laminar air flow cabinet Lamin Air HA 2472 Heraeus, Osterode, Germany 
Luminometer Sirius  Berthold Detec. Systems, Pforzheim, 
Germany 
MassARRAY Compact System Sequenom, Hamburg, Germany 
MassARRAY MATRIX Liquid Handler  Sequenom, Hamburg, Germany 
MassARRAY Phusio chip module Sequenom, Hamburg, Germany 
Megafuge 3,0 R Heraeus, Osterode, Germany 
Microarray hybridisation chambers SureHyb Agilent Technologies, Böblingen, Germany 
Microarray scanner; 5 micron resolution Agilent Technologies, Böblingen, Germany 
Microarray slide holder Agilent Technologies, Böblingen, Germany 
Microscopes Zeiss, Jena, Germany 
Multifuge 3S-R Heraeus, Osterode, Germany 
Multipipettor Multipette plus Eppendorf, Hamburg, Germany 
NanoDrop  PeqLab, Erlangen, Germany 
PCR-Thermocycler PTC-200 MJ-Research/Biometra, Oldendorf, Germany 
PCR-Thermocycler Veriti 384 well Applied Biosystems, Foster City, USA 
pH-Meter  Knick, Berlin, Germany 
Picofuge Heraeus, Osterode, Germany 
Power supplies  Biometra, Göttingen, Germany 
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Realplex Mastercycler epGradient S  Eppendorf, Hamburg, Germany 
Sigma 2 - Sartorius Sartorius, Göttingen, Germany 
Sonifier 250  Branson, Danbury, USA 
Sorvall RC 6 plus Thermo Fisher Scientific, Hudson, USA 
Spectra Fluor Plus Tecan, Salzburg, Austria 
Spectrophotometer  Perkin Elmer, Überlingen, Germany 
Speed Vac Christ, Osterode, Germany 
Thermomixer  Eppendorf, Hamburg, Germany 
Typhoon 9200 Molecular Dynamics, Krefeld, Germany 
Water purification system  Millipore, Eschborn, Germany 
Waterbath Julabo, Seelstadt, Germany 
 
3.2 Consumables 
384-well PCR plates  Thermo Fisher Scientific, Hudson, USA 
8-channel pipettor tips Impact 384 Thermo Fisher Scientific, Hudson, USA 
adhesive PCR sealing film Thermo Fisher Scientific, Hudson, USA 
Cell culture flasks and pipettes  Costar, Cambridge, USA 
CLEAN resin Sequenom, Hamburg, Germany 
Cryo tubes  Nunc, Wiesbaden, Germany 
Eppendorf reaction tubes Eppendorf, Hamburg, Germany 
filter tubes: Millipore Ultrafree-MC Millipore, Eschborn, Germany 
Heat sealing film  Eppendorf, Hamburg, Germany 
Luminometer vials Falcon, Heidelberg, Germany 
MATRIX Liquid Handler D.A.R.Ts tips Thermo Fisher Scientific, Hudson, USA 
Micro test tubes (0.5, 1.5, 2 ml)  Eppendorf, Hamburg, Germany 
Microarray gasket slides Agilent Technologies, Santa Clara, USA 
Multiwell cell culture plates and tubes  Falcon, Heidelberg, Germany 
nProteinA Sepharose 4 FastFlow GE Healthcare, Munic, Germany 
PCR plate Twin.tec 96 well Eppendorf, Hamburg, Germany 
rProteinA Sepharose 4 FastFlow GE Healthcare, Munic, Germany 
Sepharose Cl-4 beads Sigma-Aldrich, Munic, Germany 
SpectroCHIP bead array Sequenom, Hamburg, Germany 
Sterile combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Sterile micropore filters  Millipore, Eschborn, Germany 
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Sterile plastic pipettes Costar, Cambridge, USA 
Syringes and needles Becton Dickinson, Heidelberg, Germany 
 
3.3 Chemicals 
Unless noted otherwise, chemicals used in this thesis were purchased either from Sigma 
Chemicals (Deisenhofen, Germany) or from Merck (Darmstadt, Germany). Readymade 
buffers and cell culture media were obtained from Biochrom (Berlin, Germany) or from 
Invitrogen (Karlsruhe, Germany). Water was generally of Millipore-purified/distilled quality. 
If denoted, ultra-pure, DEPC-treated H2OUSB purchased from USB Corporation through 
Amersham (Braunschweig, Germany) was used. 
3.4 DNA oligonucleotides  
Utilized DNA oligonucleotide primers are listed according to species and application. All 
standard primers were purchased from Metabion (Martinsried, Germany) or Operon 
(Cologne, Germany) at a synthesis scale of usually 0.02 µmol and HPLC purified. Primers 
for the MassARRAY application were ordered from Sigma (Deisenhofen, Germany) in 96-
deep well plates. 
3.4.1 Human 
3.4.1.1 Real-time primer for MCIp 
Gene Primer sequence (sense & antisense) 
AKAP3 5`-AAATGAATGGTCAACAGGACAAAGAGG-3` 
 5`-CCCAGTCCTTCTAAACTAAACATCAGCC-3` 
APBA2 5`-ATTTACGCGTTGCTGAATCTCCTG-3` 
 5`-CGGGTTCTACTCACTCAGAATCTCCA-3` 
AURKC 5`-AATATTTGGCGAGTGGGAGGAGAG-3` 
 5`-GCTTCAAGGTCACGTCCGATTCAG-3` 
BACH 5`-GGCTCAGCTTCATTACCCTCC-3` 
 5`-AAAGCCCGGAGCTAACGAC-3` 
CORT 5`-GGCACAATTTCACATTCAAGCTCCT-3` 
 5`-AGTTCTGCTTCCTCGTAATTATGCC-3` 
DAZ 5`-CAGAGGCAGTGTTTCACCCACC-3` 
 5`-TCCTTTGACCACTCGAAGCCC-3` 
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Gene Primer sequence (sense & antisense) 
DAZL 5`-CAGGAAAGCCGAGGATGACTTCAC-3` 
 5`-ATCATGGTGAGTTGAGGGAGAGG-3` 
DCX 5`-TCTGAGCTCCAAGCAAGAAATTCCTG-3` 
 5`-GATTCACTAAGCCTGAGTTACATGGGAG-3` 
DDX3Y 5`-AATCTGGACTAGAGGGAGGACTGAG-3` 
 5`-CTGAAGGAACCACTACACCAAAGTTGTC-3` 
DMRT1 5`-CCCAGGCCGCTCTGTATCTC-3` 
 5`-GACTCCAGCCACCGCTCTC-3` 
EIF1AY 5`-AGCTGGGAATGCCCTATTTGGTC-3` 
 5`-GTTAAGGTCCCTCAACCGTCCC-3` 
FGF6 5`-AAAGCCTCCATCGGGCACTC-3` 
 5`-ATCATCAACTAGGGACGGAGCA-3` 
H1FNT 5`-ACTAAAGAAAGCGGTGGAGATCGAG-3` 
 5`-TCCTTCTAGGTCTAAACCAATCCAAGTC-3` 
LMO2 5`-AGACGCAATGCAGTTCCATGG-3` 
 5`-ATCTCCCTACACCGTGAACCC-3` 
MAGEB10 5`-ATGTCTACATTTCGCCAGTGAAGAG-3` 
 5`-TTCCAGGCTTGATGGGAGAAGAG-3` 
MGP 5`-TTTCCCAAACAGTCATTCCTTCCAG-3` 
 5`-GTAACACAGTCAGGTCCAGCAG-3` 
MIRN127 5`-TTTGTGAACCACTCGGCTCC-3` 
 5`-TGACCAACAGACAGGACTACATACAG-3` 
MIRN142 5`-GCCAGACTTGCCTCCTCTACCT-3` 
 5`-GAGGCCCTAGTCTCTACCTGAGTG-3` 
MIRN338 5`-GATATTGTTGGAGAGGACAGCCGT-3` 
 5`-CTGGAAGAAGTGGCGAAGGAC-3` 
MIRN363 5`-AAATTGCATCGTGATCCACCCGAC-3` 
 5`-CCGGCCTGTGGAAGAAAGGA-3` 
MORC1 5`-AAGCTCCCACTGCGTCGTC-3` 
 5`-AGATACGTCATTCTCAAATTGTGGCTC-3` 
NLGN4Y 5`-CAGATGACGAGTGGGTTGGG-3` 
 5`-GAGACCGCCTGAAGGATGAGAG-3` 
PRAME 5`-GAAGTACTCCGCCTCCACAAACTC-3` 
 5`-TGTTGCTCTTAGCCACCATGCC-3` 
PRM1 5`-GTGAGCAGGTGGAACTCTGTGG-3` 
 5`-GGTTTGTGAGGTCCCAGCCC-3` 
PRY 5`-ACACCTGCATGTCTTGGCCC-3` 
 5`-CTGTTGCTTTGTTTGTGCTGTGG-3` 
RBMX 5`-GCAACGAGGGCGAACAAAGG-3` 
 5`-GCGTTTCAAATTCTAAGCTCCGTTTCC-3` 
RBMY1A1 5`-CGCGTGTGCCTTAATCCACC-3` 
 5`-AGTTACTGCAAAGGCTGTGGG-3` 
SKD3 5`-TCCACAGCCCTAAGCCTTTCC-3` 
Material 
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Gene Primer sequence (sense & antisense) 
 5`-CCCGAACTCTATTTCCCAATATGCC-3` 
SNRPN 5`-TACATCAGGGTGATTGCAGTTCC-3` 
 5`-TACCGATCACTTCACGTACCTTCG-3` 
SPTBN2 5`-GACAGCAGTGTGCAGCCC-3` 
 5`-TGCCACTTTCTAGTCATTATTGCCTG-3` 
SYBL1 5`-GCTCTTCATTTATGCCGCCTACTC-3` 
 5`-ACAGCTCTTGTGGTAAACAGCGTC-3` 
TAF7L 5`-ATCACCCTAGTGGCTCTTCTGC-3` 
 5`-CTTTTATGGGAACTGAGCTATGTGTC-3` 
TEKT3 5`-CCGCCTTTCCTATCTGTGACGA-3` 
 5`-GCTCCCGCCTCTCCTATAACTG-3` 
TGIF2L 5`-CAGCGTGGAGAAGAAAGGATGTG-3` 
 5`-CTCACCTGTTGTTTCCGAGAAAGAC-3` 
TLR4 5`-CGCTATCACCGTCTGACCGAG-3` 
 5`-CTTTCACTTCCTCTCACCCTTTAGCC-3` 
TMSB4Y 5`-TGCTCTCAAAGGTATTGTGCGTTGTC-3` 
 5`-TCGGGAGATGAGTGAGCCTCAG-3` 
TSPY 5`-CGGAGCCTCTATTTGCCTCGAC-3` 
 5`-CGGTGCTGAGGTGGAATTGATCTG-3` 
TSPYL5 5`-AACGCTAAGAGCCATCACCACC-3` 
 5`-CTTTCTTCATGACAGATGCCACAAGAG-3` 
TTTY14 5`-CTGAGCAAGTTATGCGGTCGG-3` 
 5`-AATGCGACGTCCTCCTACTCC-3` 
TYROBP 5`-GGGTGGTGGCAGAAGGGA-3` 
 5`-CCTTCACGTCTAGTTGCTGGG-3` 
UTY 5`-CCGTGAGGTCTCAGTAAGAGTAGG-3` 
 5`-TACTGCATCTTGAAAGTGTGATGAAGG-3` 
VCX 5`-TGTAGCCCTCCATCCATCCC-3` 
 5`-CCACACCTGCCATCATTACCC-3` 
VCY 5`-GTCTTCGTACAGCCCTCCATCC-3` 
 5`-GTTCCTCCACAACTACCATCATTACCC-3` 
 
 
3.4.1.2 Nested amplification of bisulfite-treated primer 
Gene   Primer sequence (sense & antisense) 
ZSCAN5 
(down) 
outer 5`-ATTTTTATTGGTTTAGTAGGTTGATG-3` 
5`-CTTTACACCCCATAATTAACTCT-3` 
 inner 5`-TTAAAAAGGGTGTGTGGTAGGT-3` 
5`-AAAAATAATACTAACTTTCTCATCAAACT-3` 
ZSCAN5 
(up) 
outer 5`-TTAGGAATTTTAGGTTAGTTTGGA-3` 
5`-CAAATCTATATTTTCTAAAACCACC-3` 
Material 
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Gene   Primer sequence (sense & antisense) 
 inner 5`-AATTTAAGTTTGATGAGAAAGTTAGT-3` 
5`-CAAATACTTCAACAATATAACAACTC-3` 
MAGEB10 outer 5`-TTAGTGAAGAGATTTTATAGTTATAATGT-3` 
5`-TCTCTAATAACTTAATACCAACACCT-3` 
 inner 5`-TTTGTTTTGGGTATTTTATTTTTGTG-3` 
5`-TACTATCACTTCCCTAACTCTCCA-3` 
TGIF2LY outer 5`-ATAGAGAAGAAAAATTTAAGTAGTAAGG-3` 
5`-TTACTATATTAAAAATCACAAACAACT-3` 
 inner 5`-TTTGAATATGGAAGAATGGAAGAGG-3` 
5`-AACAAATCTATAAAAAAAATTCTCACCT-3` 
BACH outer 5`-TTTTAGTAATGTAGGTTTTATAGGGTGG-3` 
5`-CTATAAACCAAAACCTCTCTACCCA-3` 
 inner 5`-TAGGGTGGGAGATTAGTTTTGGG-3` 
5`-AACTCATTCTTCTACTTACCTAAAAACCA-3` 
TLR4 outer 5`-TAGGTAGAGGTTAGATGATTAATTGGG-3` 
5`-ACAAAAATAAACAAACCAAAACACAC-3` 
 inner 5`-TATTAGAGAAATAAAAGTTTAGAATGTTAAGG-3` 
5`-AAAAAAACTAACTCCAACCACATACCT-3` 
 
3.4.2 Murine 
3.4.2.1 MassARRAY Primer 
Gene Symbol Primer Ids Primer Sequences 
1600021P15Rik Epi01 10F 5'-aggaagagagGGATTTATAATAGGTTATGGAATGATGAAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAATTTCCCCAAATATAAAAAACTC-3' 
 
Epi02 10F 5'-aggaagagagTTTGTTAATGGGAATAAAGTTGGTTTG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAACCCAAACACACAACTCTCC-3' 
Asb4 Epi03 10F 5'-aggaagagagGATATGAAAGGTAGATGGTTTGGGTATTAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTTTTCTCCTTCCACCAATTAAAAAC-3' 
 
Epi04 10F 5'-aggaagagagAGGAAAGTTTGTTTTGGTATTATGGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTCTCTACTAAAATTTTACCATAAATTTACC-3' 
 
Epi05 10F 5'-aggaagagagGGAGGTGGGTTTTGTATTTTTTTAAAAAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctATCCCAAAATACCCTTTAACCCTCA-3' 
 
Epi06 10F 5'-aggaagagagAGTGGGGGTATTAGTTGTGTGTAGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTCCCACATAAAAAACAATTTTCTTCC-3' 
 
Epi07 10F 5'-aggaagagagGTTTTTATAAATGATTGAAATGGTTGTTTG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCATTATACCAAAAACCAAAAACCTCC-3' 
 
Epi08 10F 5'-aggaagagagGAGGATGAATTTTTTTGTTGAAATTTTATT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCAAACTTATCTTACTTTCCCACAACCC-3' 
Coro2a Epi09 10F 5'-aggaagagagTTGGTTTTGGTGGATGAATTTTTTATT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCATCTCATCCCAAACCCTTATTCTAAA-3' 
 
Epi10 10F 5'-aggaagagagTTTAGAATAAGGGTTTGGGATGAGATG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCCTATAACCCCAACCTAAAACTTC-3' 
Material 
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Gene Symbol Primer Ids Primer Sequences 
Coro2a Epi11 10F 5'-aggaagagagTTAGGTTGGGGTTATAGGGTAAGGTTTT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCCCACTAAAAAACAAACTCAACAC-3' 
 
Epi12 10F 5'-aggaagagagTAGAGGGTTGGGTGGGTATTATAGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTTCAAATCAAAAAATCCACAACTCC-3' 
Eps8l1 Epi13 10F 5'-aggaagagagTTTGTTGTTTTTTTAGGATTGTGGAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctACCTCCAACTCTAATACTTTTTCTCTATCC-3' 
 
Epi14 10F 5'-aggaagagagTTTTGTGTTAATGAGGAGTTGTAGT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAACCCTTAATCTACAACCAAACAC-3' 
 
Epi15 10F 5'-aggaagagagTTTGTGGTTTTTAATTAGAGTTTGTTTTTG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTCCCTAACCCCAACACCTAAAATAC-3' 
Frap1 Epi16 10F 5'-aggaagagagAGGTTTTGGTTTATTTGGGTTGAGAT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAAATCAAACCCACTCACTACTACCC-3' 
 
Epi17 10F 5'-aggaagagagAGAATTTGATAGAAGTGTGGATGATTAATT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCAAACAAAATAAAAAACTTTCCCAACTC-3' 
 
Epi18 10F 5'-aggaagagagTTGAGGGATTAGGGTAGGTAAAGTTGTAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctACCCAAAACTCAAACTCAAAAAAAA-3' 
Isoc2b Epi19 10F 5'-aggaagagagGGGGATATAGATGGGAGAGGATTTA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAACTATTTACAAACCCACCATCCC-3' 
 
Epi20 10F 5'-aggaagagagGTTTAATTTTGGTTAGTGTAGGGTTTATGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCACCCAAAAAAACAAATCCTAAATTC-3' 
Isoc2b Epi21 10F 5'-aggaagagagGGTGGGTTTGTAAATAGTTAGTAAGTAA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAACTCTCAACCAAAACCCTCCCT-3' 
 
Epi22 10F 5'-aggaagagagTTGGTAAGTAGTGGGGGAAAATGTTT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAATTCATAACACCATCCACTCCATC-3' 
 
Epi23 10F 5'-aggaagagagTTATAAAGGGTAAAAAGGAGGTTTAGTA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTTTTTCTCCAAAATTAACTCACTAAC-3' 
 
Epi24 10F 5'-aggaagagagGTGGATGGTGTTATGAATTTTATATTAGTT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctACCTCCTTTTTACCCTTTATAAACAC-3' 
Pdgfrb Epi25 10F 5'-aggaagagagTTGTTGGAGATATTGGGAGATGTAGAA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCCCCACTAAAAAAAACAAAACAAC-3' 
 
Epi26 10F 5'-aggaagagagGGTGATTGAAGGTTTTAGGTTGTTTG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTCCAAAAACCCTCCACTAAAAATAAAC-3' 
Pik2b Epi27 10F 5'-aggaagagagTTTAGATGATTTGGAATTTTTGGAATTATA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTTCCTTCCCAATAAAAAAATTAACAC-3' 
 
Epi28 10F 5'-aggaagagagGGTTGTTGGGATTTGAATTTAGGATT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAACACCTCCTATAAAACCTTTTCCC-3' 
Pop4 Epi29 10F 5'-aggaagagagGGTGAGGTAGAGAGATTTTGAGTTTTTAGA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCTATAACCATAACCCATACTCCCAAC-3' 
Ppp1r14d Epi30 10F 5'-aggaagagagTTTTGAGAAGAGGAAGAAGGAGTTTTT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCACCCAAACACAAAACAAAAATAACC-3' 
 
Epi31 10F 5'-aggaagagagTTTTATTTATTGGTTGAGATTGTTTT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAATATAAAACTCCCACCTATCTTCC-3' 
Rab6b Epi32 10F 5'-aggaagagagTTAGTAAGTGGTTGGAGAGGAAGAGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAACAACTCCACTAACCCAAAAACAATAC-3' 
 
Epi33 10F 5'-aggaagagagGGTATATGGTTTGTGGATAGTGGGT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCCTCACAAAAAACTCCATAAAAACA-3' 
Material 
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Sfi1 Epi34 10F 5'-aggaagagagTTAGGGGGAGAAGGATGTATAGATTTTG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCTAAAAAATCACCTCCCTCAAATAC-3' 
 
Epi35 10F 5'-aggaagagagTTGAGGGAGGTGATTTTTTAGTAGA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctATCATATCTCCTACCCCTTAATTTTC-3' 
 
Epi36 10F 5'-aggaagagagGAGAAGTTTTTGTTTTTTGGAAGATAGAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctATAACAAAAAACCCCAACCCAAAAT-3' 
 
Epi37 10F 5'-aggaagagagATTTTGGGTTGGGGTTTTTTGTTAT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCTCAACTCCTTACTTAATCACTTAAACTCA-3' 
Slc13a3 Epi38 10F 5'-aggaagagagTAGAGTTTAAATTTTAGAAGAGTGGGAGGA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAAACCCCTTCCCTACTCCTTATCC-3' 
 
Epi39 10F 5'-aggaagagagTTTAAATTTTAGAAGAGTGGGAGGAT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctATCCCACCTAAACTTTACCCCATTT-3' 
 
Epi40 10F 5'-aggaagagagTTTTAAGTTTGGAAGAGGTTGTAATTA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctACACCAACAACAACACCAAAAAAC-3' 
Slc27a6 Epi41 10F 5'-aggaagagagGGAAAGTTTTTATTATTTATGAGGGGGA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCAATTTAACCAAACCAAACCACA-3' 
 
Epi42 10F 5'-aggaagagagAAGGTTGGAGTTGAGGAAGGTTATTA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCTAAACCACACCAAAAAACAACCAC-3' 
 
Epi43 10F 5'-aggaagagagATGTTGTGGGTTTATTAGGTGTTTA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTTACAAAATTACAACAAATCAATTATTAAC-3' 
 
Epi44 10F 5'-aggaagagagTTAAGTGTTGTTATATTTAAAGTAGGGGAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAAAATCTCAAACAAAACAAATAAC-3' 
Spint1 Epi45 10F 5'-aggaagagagTGTGGAGTGTAGGGAGTAGGATATATAGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctATTCCAAAAAAATCCCCATTCTAAC-3' 
 
Epi46 10F 5'-aggaagagagGGGGGATGTTGTGAAGTAGGTATTTTAT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACCCAAACCACCCATTCTAA-3' 
 
Epi47 10F 5'-aggaagagagGGGTAGGGTTTAGGTGTTGTGTGTATT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCAAACCACCCATTCTAAAAAAAATT-3' 
 
Epi48 10F 5'-aggaagagagTATTGGGTTGGAGTTTTTTTGTTTG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctATCCTAAAACCAACCTTCCTCTTTC-3' 
Zfp568 Epi49 10F 5'-aggaagagagTTTTGGGAAATGTAGTTTATAAAGGGATAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAACACAAATACTCCCAAAAAAACCC-3' 
 
Epi50 10F 5'-aggaagagagATGTTTTAGAGTATAGGTGTTTTTAGAAGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctATCCACAAAAAAACAACCACCTAAC-3' 
3110007F17Rik Epi51 10F 5'-aggaagagagGGTTTAGTTTTTTGGTGAATGTTTTGT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTACTCTCCCCATATCCTACCTACAC-3' 
 
Epi52 10F 5'-aggaagagagGTGTAGGTAGGATATGGGGAGAGTA-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCCCACCATAACAATACACCAAAAC-3' 
 
Epi53 10F 5'-aggaagagagAATTTTAGGGTTTAGAAAGTTAGATGTTTG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctACCCACTAATCTAACTCCTTAATAAATACC-3' 
Pop4 Epi54 10F 5'-aggaagagagGTTTTTTAAGTGTTGGGATTAAAGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCAAAAATTCAAAAAAACAAAAATTAC-3' 
Zfp568 Epi55 10F 5'-aggaagagagGAGAATGGAGATTAGGAGAGAATTGGTATT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctTCCCAAAAAAACTAATAACCTATCCAAC-3' 
3110007F17Rik Epi56 10F 5'-aggaagagagTTTTAGGGTTTAGAAAGTTAGATGTTTGT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctACCCACTAATCTAACTCCTTAATAAATACC-3' 
Material 
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3110007F17Rik Epi57 10F 5'-aggaagagagGTTGGGGATTGTTTTTTTTGGTTAG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAAACATCTAACTTTCTAAACCCTAAAATTT-3' 
Zfp568 Epi58 10F 5'-aggaagagagTTTTGGAATTTATTTTGTAGATTAGGTTGG-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctCATTTCCCAAAAAAACTAATAACCTATCC-3' 
 
Epi59 10F 5'-aggaagagagGAAAGGTTAGTGGTTTGTTTAGTTTTT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctACCCTAACTATCCTAAAACTCACTCTATAA-3' 
Sfi1 Epi60 10F 5'-aggaagagagATTTTGGGTTGGGGTTTTTTGTTAT-3' 
  
T7R 5'-cagtaatacgactcactatagggagaaggctAACRCAACRTAAACTCAATATACCAAC-3' 
 
3.4.2.2 Real-time PCR primer for MCIp 
Gene Primer sequence (sense & antisense) 
“empty” 5‟-GGTGAGTTGTATGACCTTGTTCAATTCC-3‟ 
 5‟-AGTGCAGTGAGTCAGACATAACCC-3‟ 
Mest 5‟-CAGACGCCACCTCCGATCC-3‟ 
 5‟- GGCCGCATTATCCCATGCC-3‟ 
Snrpn 5‟- ACATTCCGGTCAGAGGGACGAAG-3‟ 
 5‟- CCGCAATGGCTCAGGTTTGTC-3‟ 
 
3.4.2.3 Real-time PCR primer for validation of CNV 
Gene Primer sequence (sense & antisense) 
Camk2b 5'-CTTCACTTTCTCTTTCTGTCTTTGCCTC-3' 
 5'-TAAATAATCCATCTCGCCATAGTGCCAG-3' 
Chst10 5'-CAGTTGAACCAGGTTTGTGAGGGAG-3' 
 5'-ATGAGGTGGGAAGCTAAATGGTATGTG-3' 
Marco 5'-GAATGCAAACCAGGATGCCCAC-3' 
 5'-GGGTAGGTGAGTAGTGGATGGAG-3' 
Chia 5'-TTTACTGCCACTGCTTCATCAAGCC-3' 
 5'-CACTTCCTGGAGGAGTAGTCACTG-3' 
Chi3l3 5'-TCAGTTTATGTCCAAAGTGCACATACC-3' 
 5'-GAACACAGCACACTGTCCTTTCAC-3' 
Chi3l4 5'-TTTCAGTAAGGAGGCACAGGAAGAG-3' 
 5'-CCACAGGCTTAGCACTGATACC-3' 
Glp1r 5'-GCTCTCGGAAGGACACTCATCTC-3' 
 5'-CCTATGACATCACCAGAGAACAACAC-3' 
Dnahc8 (1) 5'-CTTCATCCTCCCTTCATCGCTTCAC-3' 
 5'-AGACAATCGCCTGCCCATCC-3' 
Dnahc8 (2) 5'-AATTCAGTTGGCAGCAGGGAG-3' 
 5'-ATTGTAGCTCTGTCAATCAACCTGTC-3' 
Glo1 5'-CATGAAATATTAGGACAGTGGGCAAAGG-3' 
 5'-GGTCATTGCTACTGTTCTCATCCC-3' 
Btbd9 5'-CTCTCCTTTCACAACCTGAGCC-3' 
Material 
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Gene Primer sequence (sense & antisense) 
 5'-TCTCCTTTCCCTCGTTACCTAGTTACC-3' 
Gpb1 5'-TTTCCAGTATTCTACCTACCACACCAG-3' 
 5'-GAGGCACAATGACAGTCCCTAGAG-3' 
 
3.4.2.4 Real-time PCR primer for RT-PCR 
Gene Primer sequence (sense & antisense) 
Abcb10 5'-TGCCTATGGAGCTGACAACCT-3' 
 
5'-TGCAATCCTCTGCTTCTGCC-3' 
Adamts1 5'-GCTGTGATCGCATCATAGACTCCA-3' 
 
5'-GCTGCCATTGTTTCTGGACCC-3' 
Asb4 5'-GCACAGCCTGAGATCTGCTACC-3' 
 
5'-AATGGCTTTCGGGCAAGAGTG-3' 
Ccl24 5'-CTTGCTGCACGTCCTTTATTTCCA-3' 
 
5'-GGTCAGTACAGATCTTATGGCCCT-3' 
Ctse 5'-CACCCAGTATTCCATCCATCGCA-3' 
 
5'-CCATCCACAGTCAACCCTTCC-3' 
Gbp1 5'-AGCAGGAACGGAAAGAGTTAATGG-3' 
 
5'-TGGTGCATGATCGAGGTGGAG-3' 
Ifi202b 5'-AAAGAAAGGCTGGTTGATGGAGAG-3' 
 
5'-ATACCACCACTTTCATTGCTCCTG-3' 
Isoc2b 5'-TGGCGTCTTTCTGTCCACGAG-3' 
 
5'-TTGCCTTGGAAGAAGCCTAACAG-3' 
Itga9 5'-GCATGACAACACTCTCACACTGAC-3' 
 
5'-CGTCCACAGACTCGCCATACAC-3' 
Ltb 5'-AGCTACTTCCCTGGTGACCCTG-3' 
 
5'-ACGACGGTTTGCTGTCATCCA-3' 
Marco 5'-GGGCAGCACAGAAGACAGAG-3' 
 
5'-CGTGAGCAGGATCAGGTGGA-3' 
Msh5 5'-AGTTGTCCCACACCAAGGTCAG-3' 
 
5'-GCAAGACTTTCCTCAAAGTCCACC-3' 
Pdgfrb 5'-CCAACAAGCATTGTCCGCCC-3' 
 
5'-TCCATGTAGCCACCGTCACTC-3' 
Phemx 5'-AGGCAGATACTCCCTGACACCA-3' 
 
5'-GCACTTCAGCAGGGCATTGAG-3' 
Plau 5'-TTCTCATGAACAGTGTATGCAGCCC-3' 
 
5'-GCCTTCGATGTTACAGATAAGCGG-3' 
Sfi1 5'-TGGCACAGAGACTCAGTCGG-3' 
 
5'-CTTTGCTTGTAGTGAGAAGGCCC-3' 
SpiC 5'-ACCAATCCGTACAGAACATAGCTG-3' 
 
5'-AAGGTATTCAAACAGCCGAAGC-3' 
Trim12 5'-CTCTCATTGAAGAGGTGGCCCAG-3' 
 
5'-AAACTCTGACCGAACATTCTGCAC-3' 
Vill 5'-CCGACTGTTCGAGTGCTCCA-3' 
 
5'-ATTGCAGATCCCGGTCCCAG-3' 
Material 
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3.4.2.5 Primer for amplification of genomic DNA for sequencing 
Gene Primer sequence (sense & antisense) 
md_1 5'-GCTGAGCTGGCTAGGTAGG-3' 
 
5'-ACGATCCTTTGTCATTAACGG-3' 
md_3 5'-CCTCATGTTTCCACACATTGAC-3' 
 
5'-GTGCTCTGTCAATTTTGCTCAG-3' 
md_4 5'-TGCCTCCCAGTAAGTTCTATCC-3' 
 
5'-ATTCAGTTACCTGATCATCATGG-3' 
md_5 5'-ACAGCGTAACTATGTTCCATGTC-3' 
 
5'-ACACATACCCCATACATATAAAACAAC-3' 
Tbc1d2 5'-ATTTGGGGTTGCTACAACTG-3' 
 
5'-CATGTTTTATGTAGCTGAGTGGC-3' 
Cd48 5'-AGGGCCATGTGAACGG-3' 
 
5'-CAGCCCAGGAGCATGC-3' 
Tmtc2 5'-AGTACATTTACTGACACAACGTTCAAG-3' 
 
5'-CTGGACAGAAGAGATGCTATTTGC-3' 
Pgbd5 5'-GCTGAGAACCTTGTAGAAAACG-3' 
 
5'-GGCTGGTATGGATCCTGG-3' 
Tmtc2 5'-GATGGTGTTGAAAATTAATAAGGATG-3' 
 
5'-GTGTGGGCAGCTATGTGAG-3' 
1600021P15Rik 5'-GCAGGAGGAGTTTCTATCCTGTGTAGTC-3' 
 
5'-CACAGGTCCTAGCTAGCCTGGT-3' 
2310009E04Rik (fggy) (1) 5'-TGAGCTAGCACTGGCAATGAG-3' 
 
5'-CACAAGCAGCAAACACCAGC-3' 
2310009E04Rik (fggy) (2) 5'-ATGCATAAGGACAGAACACAGG -3' 
 
5'-ACCATGATTTGCCATCTGTG-3' 
3110007F17Rik 5'-TGCACAGTGGCTGTTTACTCTC-3' 
 
5'-AAAGGCGCACGTCCAACTG-3' 
Arhgdib 5'-TGCTTCACCTCTGACTCTCACAC-3' 
 
5'-CACTCAAGAAGAACCCAGAACCCA-3' 
Asb4 5'-ACCTGAAGGAACTGAGATCTGG -3' 
 
5'-ACTAACAAGTTGATCCTGATGCC-3' 
Cd48 5'-CATCCATCAACTTTGTGCTTTGTCC-3' 
 
5'-GTGTGCCAATACCTGAAACCTGAG-3' 
Coro2a 5'-CTGGCTTTGGTGGATGAATTCCC-3' 
 
5'-CTTTAAAGACCTCTGGTGTAGGGCTG-3' 
Eps8l1 5'-TAGAGGCTCCCGAATCCCTG-3' 
 
5'-CTTCTCCATCACGGCCTCCA-3' 
Frap1 5'-GGGCAGTGTTTGTTTCCTCGT-3' 
 
5'-AGTGCCATCACCCAGTCAGATACTC-3' 
Isoc2b 5'-CATGACAGCCAGGCTCAG -3' 
 
5'-AGACCAACTTTGAACCTCTGC-3' 
Pdgfrb 5'-CCCAATGAAGTATAGCAGTCCCAC-3' 
 
5'-GGCCAGGGTGTATACCCATCTC-3' 
Pi4k2b 5'-AGGTAGGTGGACTCAGAGATAACAAAGG-3' 
 
5'-ACTTGCATTTATGTCACATGCTCCTC-3' 
Pop4 5'-TTCCCACTTTCCTGTTCTCTAAGACCA-3' 
 
5'-GGAAATCAGGCAAGAGTAGAGGGA-3' 
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Gene Primer sequence (sense & antisense) 
Ppp1r14d 5'-CCTGGGCAACTTAGAAATGTCC-3' 
 
5'-GGGTTACATCTGGAGAAGGGAG-3' 
Rab6b 5'-GGCTCTGCTAAGGTACCGTG -3' 
 
5'-CCCTTCTTCCGTCTCAGACCCA-3' 
Sfi1 5'-GATACACCTTCAGGAACTAAACCAGA-3' 
 
5'-CGCGACTTGGGAGTCACGG-3' 
Sfi1 (ps) 5'-TCATGGCACCATCATAATTAAGGC -3' 
 
5'-CCACAAATGACTGTTACCAATAATTGC-3' 
Slc13a3 5'-AAAGCAGTTAGCACCCATTTAAGACAC-3' 
 
5'-CGTCCATAATGCCAACCCTCAG-3' 
Slc27a6 (1) 5'-CTCAGCTCCAAAGTAGATCCC -3' 
 
5'-TATTGCATACGCATATCTTACATTCC-3' 
Slc27a6 (2) 5'-GGCACACGTGATGATGTTAGC -3' 
 
5'-ACAAATTAGCATCCTTTCTACAAGCC-3' 
Spint1 5'-ACATAGGACCACCTCCTTAGTAGAACAG-3' 
 
5'-CTAAGTGAAAGTGGCAGGCAGG-3' 
Tiam2 5'-GAGGTCATGAAGCATCTCAAGTG -3' 
 
5'-TGGAACGCTATGAGGCAGAC-3' 
Zfp568 5'-GGTGTGGCAGGTAGGAGG -3' 
 
5'-CTCTCCGCAAAGCTGTGAC-3' 
 
3.4.2.6 Additional internal sequencing primer 
Gene Primer sequence 
Asb4 5'-CTGGAGCTATCAAAGGCCAC-3' 
 
5'-TCTGCGTTTGATTTCATCTAGACC-3' 
 
5'-AAGGACTGAAATTTGACTCTCC-3' 
 
5'-GGGTCAGTGTTCTGATTGAG-3' 
 
5'-TCCAAATAGAGGACCTTGAGTC-3' 
 
5'-GCATCGAGACCAGAATCATCC-3' 
 
5'-GTCCCACTCTTAAACTTTACTGC-3' 
 
5'-GTTGTTGCAGAGGTCCACAC-3' 
 
5'-CATGCAAATGAAGCTGCAGGAC-3' 
 
5'-ATGTGGGAAAGAAATATGGCAGGC-3' 
Isoc2b 5'-CTCAGTTCGCCAGATTTGATCG-3' 
 
5'-TTCGCCTCACTCTGTTCTACTC-3' 
 
5'-AAAGAACAAGCCTCGTAAGAC-3' 
 
5'-CCTGGCATGAATAAAGCCT-3' 
Ppp1r14d 5'-CCACCTGTCTTCCGGGATAGCT-3' 
 
5'-TTCTCCCTTCTCCAGATGTAACCC-3' 
Rab6b 5'-GGCTCTGCTAAGGTACCG-3' 
 
5'-TATCTATCACATGGGAAATGCC-3' 
 
5'-GCATATGGCCTGTGGACAG-3' 
Sfi1 (ps) 5'-CATGGAATTGGTGATATGAGCT-3' 
 
5'-GTGGCTCACAATCACCTG-3' 
 
5'-ATTAAGACAGCATTTACAGCACGG-3' 
 
5'-CAGAAGAAAGCAGAAGCCC-3' 
 
5'-AAACTAGTGGGTGGGTGTC-3' 
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3.5 Enzymes, kits and reagents 
BioPrime Purification Module Invitrogen, Karlsruhe, Germany 
BioPrime Total Genomic Labelling System Invitrogen, Karlsruhe, Germany 
Blood & Cell Culture DNA Midi Kit  Qiagen, Hilden, Germany 
BSA Sigma, Deisenhofen, Germany 
DNA Ladder 1 kb plus Invitrogen, Karlsruhe, Germany 
DNA molecular weight standard Invitrogen, Karlsruhe, Germany 
dNTPs NEB, Frankfurt, Germany 
Dual-Luciferase Reporter Assay System Promega, Madison, USA 
EZ DNA methylation kit Zymo Research, Orange, USA 
Genomic DNA isolation kit Qiagen, Hilden, Germany 
Glycogen Ambion, Austin, USA 
Human Cot-1 DNA Invitrogen, Karlsruhe, Germany 
In-Fusion cloning kit Clonetech, Saint-Germain-en-Laye, France 
Klenow Enzyme  NEB, Frankfurt, Germany 
Klenow exo- (3‟-5‟ exo minus)  NEB, Frankfurt, Germany 
MinElute PCR Purification Kit Qiagen, Hilden, Germany 
NucleoSpin Plasmid Quick Pure  Macherey-Nagel, Düren, Germany 
Phusion DNA Polymerase  NEB, Frankfurt, Germany 
Phusion DNA Polymerase hot-start NEB, Frankfurt, Germany 
Plasmid Midi Kit  Qiagen, Hilden, Germany 
Proteinase K  Roche, Mannheim 
QIAEX II gel extraction kit  Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
QuantiTect SYBR green  Qiagen, Hilden, Germany 
Quick Ligation Kit NEB, Frankfurt, Germany 
Repli-G Midi Kit Qiagen, Hilden, Germany 
Restriction endonucleases NEB, Roche 
Reverse Transkriptase SuperSkript II  Promega, Madison, USA 
RNAse A Qiagen, Hilden, Germany 
S-Adenosyl-Methionin (SAM) NEB, Frankfurt, Germany 
Shrimp Alkaline Phosphatase (SAP) Sequenom, Hamburg, Germany 
SssI CpG methylase NEB, Frankfurt, Germany 
T-Cleavage MassCleave Reagent kit Sequenom, Hamburg, Germany 
T4 DNA Ligase  Promega, Madison, USA 
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T4 DNA Ligase buffer NEB, Frankfurt, Germany 
T4 DNA Polymerase  NEB, Frankfurt, Germany 
T4 Poly-Nucleotide-Kinase  NEB, Frankfurt, Germany 
 
3.6 Molecular weight standards 
DNA Ladder 1 kb Plus was purchased from Invitrogen (Karlsruhe, Germany). The 
Kaleidoscope pre-stained standard protein marker was purchased from BioRad 
Laboratories (Munich, Germany) 
3.7 Bacterial strains and plasmids 
The following bacterial strains were used: 
  
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) Ф80lacZΔM15 ΔlacΧ74 recA1 deoR 
araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
  
DH10ß F-mcrA Δ(mrr-hsdRMS-mcrBC) Ф80lacZΔM15 ΔlacΧ74 recA1 deoR 
araD139 Δ(ara-leu)7697 galU galK rpsL endA1 nupG 
  
  
Following plasmid was used: 
  
pCR®2.1-TOPO Invitrogen, Karlsruhe, Germany 
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3.8 Databases and software 
Adobe Illustrator CS4  
Agilent feature extraction version 9.5.1  
BioEdit version 7.0.9.0  
BioGPS (formerly SymATLAS) http://biogps.gnf.org/#goto=welcome 
Corel Draw10  
EpiTyper 1.0.5  
GeneRunner version 3.05 http://www.generunner.net/ 
GEO (Gene Expression Omnibus) http://www.ncbi.nlm.nih.gov/geo/ 
ImageQuant 5.0  
Microsoft Office 2003 and 2007  
Mouse Ancestry Mapper http://mouse.perlegen.com/mouse/index.html 
Mouse Haplotype Block Viewer http://mouse.perlegen.com/mouse/index.html 
PerlPrimer version 1.1.14 http://perlprimer.sourceforge.net 
PubMed www.ncbi.nlm.nih.gov/entrez 
Reference Manager 10  
RefExA http://157.82.78.238/refexa/main_search.jsp 
Spotfire decision site  
UCSC Genome Browser http://genome.ucsc.edu/ 
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4 Methods 
Unless otherwise mentioned, all methods were based on protocols described in „Current 
protocols of Molecular Biology“133 and in the “Molecular cloning laboratory manual”134. 
4.1 General molecular biology 
4.1.1 Bacterial culture 
4.1.1.1 Bacterial growth medium 
LB-medium for bacterial growth was prepared using the following protocol: 
 
o LB broth 10 g NaCL 
 10 g Bacto Tryptone (Difco) 
 5 g Yeast extract 
  Add H2O to 1 l 
  Adjust to pH 7.5 with NaOH, autoclave 
   
o LB-agar 
plates 
15 g Agar 
 10 g NaCL 
 10 g Bacto Tryptone (Difco) 
 5 g Yeast extract 
  Add H2O to 1 L, 
  Adjust pH to 7.5 with NaOH, autoclave 
  Cool to 50°C and add desired antibiotic 
  Pour into 10 cm petri dishes and store inverted at 4°C 
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E. coli strains (DH10ß, Top10 or Pir1) were streaked out on solid LB-agar plates with 
specific antibiotics and grown over night at 37°C. Then single colonies were picked and 
used to inoculate liquid LB broth, which were incubated with shaking at 200 rpm at 37°C 
over night. Different antibiotics were used for selective growth of E. coli strains based on 
the resistance provided on the plasmids used, namely: Ampicillin or Kanamycin at 
concentration of 50µg/ml.  
4.1.1.2 Preparation of chemically competent E. coli 
The desired bacterial strain was streaked out on solid LB agar without antibiotic, grown 
overnight and a single bacterial colony was picked into 5 ml Ψ Broth. Bacteria were grown 
at 37°C with shaking to an OD 550 of 0.3 and the 5 ml culture was used to inoculate 100 
ml Ψ Broth prewarmed to 37°C. After growing to an OD 550 of 0.48, cells were chilled on 
ice and pelleted at 1300 g and 4°C for 15 min. The pellet was loosened up by vortexing 
and resuspended in 30 ml ice-cold TFBI. After incubation on ice for 5 min, cells were 
collected via centrifugation (5 min, 4000 g, 4°C) and resuspended in 4 ml ice-cold TFBII. 
The suspension was dispensed into 50 µl aliquots and frozen at -80°C. Required broth 
and buffers: 
 
o Ψ Broth 2 % 20 g Bacto Tryptone (Difco) 
 0.5 % 5 g Bacto Yeast extract (Difco) 
 0.4 % 8.18 g MgSO4*7H2O 
 10 mM 0.745 g KCL 
  Adjust to pH 7.6 with KOH and add H2O to 1 l 
    
o TFBI 100 mM 6.045 g RbCL2 
 50 mM 4.5 g MnCl2 
 30 mM 1.472 g KOAc 
 10 mM 0.735 g CaCL2*2H2O 
 15 % 75 ml Glycerol 
  Adjust pH to 5.8 with 0.2 M HOAc 
 Add H2O to500 ml, filter sterile and store at 4°C  
    
o TFBII 10 mM 1.047 g MOPS/NaOH, pH 7.0 
 10 mM 0.605 g RbCL2 
 75 mM 5.513 g CaCL2 
 15 % 75 ml Glycerol 
  Add H2O to 500 ml, filter sterile and store at 4°C 
Methods 
 
35 
4.1.1.3 Transformation of chemically competent E. coli 
Chemically competent E. coli were thawed on ice, 2 µl of the certain ligation reaction (e.g. 
from TOPO cloning) was added to the bacterial suspension, was mixed gently and 
incubated on ice for 30 min. Cells were then heat-shocked in a water bath at 42°C for 30 s 
or 90 s, depending on the bacterial strain and immediately cooled on ice for 2 min. On ice 
250 µl SOC medium was added and the bacteria and subsequently incubated at 37°C for 
one hour with shaking in order to express the resistance. For blue/white screening of 
insert-containing clones after transformation (in case of TOP10 cells), 40 µl of X-gal was 
dispersed on a prewarmed LB-plate prior to use and incubated at 37°C for an additional 
30 min. Afterwards 50-150 µl of the transformation reaction were plated and incubated at 
37°C on LB-agar containing the antibiotic necessary for selection of transformed cells over 
night.  
 
o SOC medium 2% 20 g Bacto Trypton 
 0.5% 5 g Bacto YeastExtract 
 10 mM 0.6 g NaCl 
 3 mM 0.2 g KCl 
  Add H2O to 1 L, autoclave  
 Add to the to the cooled solution: 
 10 mM 10 ml MgCl2 1 M sterile filtered 
 10 mM 10 ml MgSO4 1 M sterile filtered 
 20 mM 10 ml Glucose 2 M, sterile filtered 
    
o X-gal  40 mg X-gal (5-bromo-4-chloro-3-indolyl-
ß-D-galactoside) 
   In 1 ml DMF, store at -20°C protected 
from light 
4.1.1.4 Glycerol stocks 
For long-term storage, bacteria were stored in autoclaved LB-Glycerol containing 40 % 
LB-medium and 60 % glycerol. 250 µl of bacterial suspension was added to 750 µl of LB-
glycerol, mixed and frozen at -20°C followed by storage at -80°C.  
4.1.1.5 Plasmid isolation from E. coli 
For plasmid isolation from single E. coli colonies, DNA mini-prep was carried out using 
NucleoSpin® Plasmid Quick Pure Kit from Macherey-Nagel following the supplied 
instructions. To isolate larger amounts of ultra pure Plasmid-DNA (ca. 100 µg) for 
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transfection experiments, plasmids were isolated using QIAGEN Plasmid Midi-Kit for 
endotoxin-free midipreps, according to the manufacturers‟ instructions.  
4.2 Molecular technologies 
4.2.1 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) allows in-vitro synthesis of large amounts of DNA 
by primed, sequence specific polymerization catalysed by DNA polymerase135,136. A 
thermo stable DNA polymerase synthesizes the sister strand of a heat denatured single 
stranded DNA-fragment when deoxynucleotide triphosphates are added under 
appropriate conditions. The polymerisation reaction is “primed” with small oligonucleotides 
that anneal to the template DNA strand through base pairing, giving the reaction its 
specificity by defining the borders of the segment to be amplified. Standard applications of 
PCR reactions are explained in the following and are used unless otherwise mentioned. 
More specialized applications are explained in more detail within the specific method.  
4.2.1.1 Primer design 
Unless otherwise mentioned sequences for generating primers were extracted using the 
UCSC Genome Browser. In general primers were designed using PerlPrimer Software 
and controlled using PCR and BLAT functions of the UCSC Genome Browser and 
GeneRunner Software. Following settings were used to design primers 
 
Primer Tm: 65-68°C 
Primer Length: 18-28 bp 
Amplicon size: 80-150 bp 
 
Primers for cloning were designed according to the utilized cloning technique. For in-
Fusion cloning, the PCR product was inserted into the target vector by recombination. 
Therefore the primers for amplification are tagged with sequences overlapping the target 
vector sequence at the desired recombination site, whereas recombination of linearised 
vector and PCR product is enhanced by the dry-down reaction from the In-Fusion cloning 
kit.  
For direct cloning into the vector by restriction digest and fragment combination through 
ligation, PCR products were PEG-precipitated (see section 4.2.7) and the precipitate as 
well as the cloning vector were digested with the adequate restriction endonucleases. 
Restriction sites were introduced by adding the appropriate recognition sites to the primer 
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sequences. To prevent re-assembly of the cut vector ends, the digested vector was CIAP 
treated (see section 4.2.5). The cut fragment and vector were gel-purified (see section 
4.2.8) and combined in a ligation reaction. 1- 5 μl of the reaction was used to transform 
chemically competent E. coli cells (see section 4.1.1.3). 
4.2.1.2 Standard PCR for cloning or sequencing of gDNA 
Standard PCRs were generally performed in PCR tubes in 20-100 µl reaction volume in a 
MJ Research PTC 200 thermocycler (BioZym). The “calculated temperature” feature was 
used to decrease temperature hold times and additionally the lid was heated to 105°C to 
prevent vaporisation. The nucleotide sequences of the utilized primers are given in section 
3.4. The primer annealing temperatures varied between 57 and 66°C. This method was 
used to generate PCR products for sequencing or cloning reactions. Slightly different 
protocols were used for the MassARRAY application and for real-time PCR. For a typical 
reaction the PhusionTM Hot Start High-Fidelity DNA Polymerase (Finnzymes; Espoo, 
Finnland) was used with the following basic reaction conditions: 
 
Component Volume Final concentration 
H2O Add 50 µl  
5 x Phusion HF buffer 10 µl 1 x 
10 mM dNTPs 1 µl 200 µM each 
Primer S 1 µl 0.2 µM 
Primer AS 1 µl 0.2 µM 
Template DNA X µl  
Phusion Polymerase (2 U/ml) 0.5 µl 0.02 U/µl 
 
Typical thermocycler programme: 
 
Cycle step Temp. Time Number of cycles 
Initial denaturation 98°C 30 s 1 
Denaturation 
Annealing 
Extension 
98°C 
60-66°C 
72°C 
10 s 
20 s 
30 s / 1 kb 
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Final extension 72°C 
4°C 
5 min 
hold 
1 
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PCR-reactions were either gel purified using agarose gel electrophoresis followed by 
purification with a PCR-Purification kit (Quiagen) or directly used for PEG precipitation.  
4.2.1.3 Reverse transcription (RT-PCR) 
RT-PCR was used to quantitatively measure the mRNA level of certain transcript within 
cells total RNA preparations. RNA was first transcribed into cDNA using 1 µg RNA and the 
M-MLV Reverse Transcriptase Kit (Promega) together with random decamers (Ambion) 
using following schema: 
 
RT-PCR reaction: 1 µg  Total RNA  
 1 µl  Random Decamers  
 1 µl dNTP‟s (10 µM each)  
   Ad H2O 15 µl  5 min 65°C 
   Cool on ice and spin down 
    
 4 µl M-MLV Buffer (5x)  2 min, 42°C 
 1 µl M-MLV reverse transcriptase  50 min, 42°C 
     15 min, 70°C 
 
4.2.1.4 Real-time quantitative PCR analysis 
Real-time polymerase chain reaction, also called quantitative real time polymerase chain 
reaction (Q-PCR/qPCR) is laboratory technique based on the polymerase chain reaction, 
which is used to amplify and simultaneously quantify a targeted DNA molecule. It enables 
both detection and quantification (as absolute number of copies or relative amount when 
normalized to DNA input or additional normalizing genes) of a specific sequence in a DNA 
sample. The procedure follows the general principle of polymerase chain reaction; its key 
feature is that the amplified DNA is quantified as it accumulates in the reaction in real time 
after each amplification cycle. On the one hand, this method was used to quantify cDNA 
after reverse transcription (see section 4.2.1.3).On the other hand to quantitatively 
analyse genomic DNA in order to detect copy number variations or after fragmentation by 
Methyl-CpG-immunoprecipitation (MCIp, see section 4.3).  
Real time-PCR‟s were performed in 96-well optical plates (Eppendorf), in a volume of 10 
µl per well, using the QuantiFast SYBR Green PCR Kit (Qiagen). cDNA was used 1:5 
diluted with H2O. Reaction conditions were as follows: 
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Component Volume 
SYBR Green Mix (2x) 5 µl 
Primer S (10 µM) 0.5 µl 
Primer AS (10 µM) 0.5 µl 
H2O 2 µl 
Template DNA 2 µl 
 
 
Typical Two step real-time programme: 
 
Cycle step Temp. Time Number of cycles 
Initial denaturation 95°C 5 min 1 
Denaturation 
Annealing/Extension 
95°C 
60 
8 s 
20 s 
50 
Melting curve 95°C 
65°C 
65-95°C 
15 sec 
15 sec 
10 min 
1 
 
For all primer pairs a standard curve was performed by diluting an appropriate sample 
(1:1000; 1:100; 1:50; 1:10, 1) to measure the efficiency of amplification. SYBR green is a 
fluorescent dye which is able to intercalate into double stranded DNA. After each cycle the 
fluorescence is measured in all wells. For each sample a “ct-value” is created which refers 
to the reflection point of the sigmoidal curve after plotting the fluorescence signal of the 
exponential PCR-amplification against its cycle number. The points of the standard curve 
were used to generate a linear fitting. The slope of this straight line and its intercept 
(calculated value for the undiluted standard) was used to calculate the particular DNA 
amounts of the certain samples relative to the undiluted sample using following formula: 
 
(10
−1
𝑠 )(𝑌−𝑐𝑡) 
 
S=slope; Y=intercept; ct=ct-value 
 
All measurements were performed in duplicates and repeated two to three times. The 
specificity of the PCR was controlled by melting curve analysis. Expression values were 
normalized against the expression of the housekeeper HPRT. PCR reactions were run 
and analyzed using the Mastercycler EP Realplex (Eppendorf). 
Nested PCR for quantitative methylation analysis 
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Methylation analysis of specific DNA fragments was performed using a nested PCR after 
bisulfite treatment of genomic DNA (see section 4.5.3). Nested PCR means that the PCR-
product of initial PCR reaction generated with an outer primer pair is used as a template 
for a second PCR using a different set of primers inside of the first PCR-product (inner or 
nested primer). A common reaction was prepared as follows: 
 
Components 1°PCR 2°PCR 
Bisulfite DNA 10 µl  
DNA from 1°PCR  0.5 µl 
10 x Taq-Buffer 5 µl 5 µl 
dNTPs (10 mM each) 1 µl 1 µl 
Out S (10 µM) 2 µl  
Out AS (10 µM) 2 µl  
In S (10 µM)  2 µl 
In AS (10 µM)  2 µl 
Taq 0.5 µl  
FastStart-Taq  0.5 µl 
H2O Ad 50 µl Ad 50 µl 
 
 
step 1°PCR  2°PCR 
 Temp Time cycle  Temp Time cycle 
Initial denaturation 93°C 5 sec 1  94°C 3 min 1 
Denaturation 
Annealing 
Extension 
93°C 
55°C 
72°C 
15 sec 
15 sec 
70 sec 
 
30 
 
 94°C 
55°C 
72°C 
15 sec 
15 sec 
80 sec 
 
30-35 
 
 
 
Final extension 72°C 5 min 1  72°C 5 min 1 
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4.2.2 Creation of 0% to 100% methylated DNA as a 
control 
In order to generate fully unmethylated genomic DNA in vitro as a control for methylation 
analysis (e.g. for section 4.5), genomic DNA was amplified using the REPLI-g Mini/Midi kit 
(Qiagen) according to the manufacturer‟s instructions. Purification of amplification 
products was performed using QIAamp DNA Micro Kit (Qiagen) as indicated in the 
manufacturer‟s manual. Secondary, to generate fully methylated DNA as a control for 
methylation analysis genomic DNA was methylated using SssI methyltransferase (New 
England Biolabs). S-Adenosylmethionin (SAM) was used as a methyl donor. In general 
following reaction conditions were used: 
 
DNA 20 µg 
NEB buffer 2 10 µl 
SAM 0.5 µl 
SssI 5 µl 
H2O Ad 100 µl 
 
After 2 hours incubation at 37°C the reaction was supplied with additional 0.75 µl SAM 
and 1 µl SssI followed by incubation of another hour. 
A desired percentage of methylation was generated by mixing an appropriate amount of 
unmethylated (0%) and fully methylated (100%) DNA.  
4.2.3 Molecular cloning 
Direct cloning of PCR-products was done using the TOPO-TA Cloning kit (Invitrogen) 
according to the manufacturers‟ instructions. Alternatively DNA fragments were PEG-
precipitated and the precipitates as well as the cloning vector were digested with the 
appropriate restriction endonucleases (New England Biolabs or Roche). For directional 
cloning, adapter sequences were added to the 5‟-end of the PCR-primers containing the 
appropriate recognition sequences. The cut fragments and the vector were gel-purified 
and combined in a 10 µl ligation reaction with a 3- to 5-fold molar excess of insert to 
vector, using 25-50 ng of vector. Ligation was carried out over night at 16°C with 1U T4 
DNA Ligase or alternatively 5 min using a rapid ligation system. Two µl of the reaction was 
then used to transform chemically competent E. coli.  
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4.2.4 Restriction digest 
To verify the presence and orientation of plasmid-inserts, and to clone PCR-products into 
plasmids, DNA was digested with the appropriate restriction enzymes. The digestion of 
plasmid DNA or PCR products was carried out at 37°C for 2 hours using 5 U enzyme for 
every µg DNA in a volume of 20 µl. 
4.2.5 CIAP treatment 
To prevent re-ligation of restriction digested vectors, vector-ends were treated with CIAP 
(calf intestine alkaline phosphatise, Roche) at 37°C for 30 min prior to gel purification and 
cloning.  
4.2.6 Ligation reaction 
Restriction enzyme treated vectors and PCR products were ligated in a 10 µl reaction at 
3- to 5-fold molar excess of insert to vector, using 25-50 ng of vector. Ligation was carried 
out over night at 16°C with 1 U T4 DNA ligase and 1 µl T4 DNA ligase buffer.  
4.2.7 PEG-precipitation 
To precipitate DNA from small volumes, e.g. PCR reactions or endonuclease digestion, 
one volume of PEG-mix was added to the DNA-containing solution. This mix was vortexed 
and incubated for 10 min at room temperature. After centrifugation (10 min, 13000 g, RT), 
the supernatant was discarded and the precipitated DNA was  washed by carefully adding 
200 µl 100 % EtOH to the tube wall without disturbing the pellet, followed by a 
centrifugation step (10 min, 13000 g, RT). After centrifugation the supernatant was 
carefully removed and the remaining pellet was air-dried for 5 to 10 min. The pellet was 
resuspended in 20 to 30 µl H2O. 
 
 
PEG-mix 26.2 % 26.2 g PEG 8000 
 0.67 M 20 ml NaOAc (3 M) pH 5.2 
 0.67 mM 660 µl MgCl2 (1 M) 
 Add H2O to 250 ml  
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4.2.8 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to determine the length of linearized DNA-
fragments and to separate them for further applications. It was also used to check the 
integrity of genomic DNA. The required amount of agarose was determined according to 
Table 4.1: 
 
Table 4.1 Agarose concentration for different separation ranges 
Agarose powder was added to TAE (1x) and the slurry was heatedin a microwave oven 
until the agarose was completely dissolved. Ethidium bromide was added after cooling the 
solution to 50-60°C. The gel was cast after hardening and mounted in the electrophoresis 
tank and covered with TAE (1x). DNA-containing samples were diluted 4:1 with DNA 
loading Dye (5x), mixed and loaded into the slots of the submerged gel. One slot was 
used for a 1kb size standard (invitrogen). Depending on the size and the desired 
resolution, gels were run at 40-100 V for 30 min to 3 hours. Required buffers: 
 
o TAE (50x) 2 M 252.3 g Tris 
 250 mM 20.5 g NaOAc/HOAc pH 7.8 
 50 mM 18.5 g EDTA 
 Add H2O to 1 l 
    
o EDTA (0.5 M) 0.5 M 18.6 g EDTA/NaOH, pH 8.0 
 Add H2O to 100 ml 
    
o DNA loading dye (5x) 50 mM 500 µl Tris/HCl, pH 7.8 
 1 % 500 µl SDS (20 %) 
 50 mM 1 ml EDTA (0.5 M), pH 8.0 
 40 % 4 ml Glycerol 
 1 % 10 mg Bromophenol blue 
 Add H2O to 10 ml and store at 4°C 
Agarose concentration in gel in % Efficient range of separation in kb 
0.3 5-60 
0.6 1-20 
1.2 0.4-6 
1.5 0.2-3 
2.0 0.1-2 
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o 1.0 % Agarose (w/v) 1 % 1 g  Agarose (Biozym) 
 Add 1 x TAE to 100 ml and heat till agarose dissolves 
Cool to 50°C and add 1 µl EtBr per 10 ml gel  
(EtBr: 10 mg/ml; Sigma) 
 
 
4.2.9 Purification of DNA fragment by gel extraction 
PCR fragments were purified by running on an ethidium bromide containing agarose gel. 
Specific bands were excised under UV illumination and subsequent gel extracted using 
QIAEX II Gel Extraction Kit (Qiagen) or NucleoSpin® Extract II following the 
manufacterer‟s instructions. 
4.2.10 Sequencing of genomic DNA  
Primers for amplifying specific genomic region were designed and controlled as described 
above. PCR-reactions were carried out using Phusion Hot Start High Fidelity DNA 
Polymerase (Finnzymes, Espoo, Finland) according to the manufacturer‟s instructions and 
100 ng gDNA as a template. The cycling parameters were as follows: initial denaturation 
98°C for 30 s, amplification at 98°C for 10 s, 62°C for 20 s, 72°C for 30 s / 1 kb, for 35 
cycles. PCR-reactions were either gel purified using agarose gel electrophoresis followed 
by purification with a PCR-Purification kit (Qiagen) or directly used for PEG precipitation. 
Purified PCR-products were sequenced using the PCR primers and additional internal 
sequencing primers in corporation with GENART (Regensburg, Germany) and analysed 
using the UCSC Browser and GeneRunner and BioEdit Software, respectively.  
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4.3 Methyl-CpG-immunoprecipitation (MCIp) 
In general, the MCIp procedure allows rapid enrichment of CpG methylated DNA. DNA 
was bound to the MBD2-Fc fusion protein produced and purified in our lab110 (The entire 
procedure is also available from the lab‟s webpage: www.ag-rehli.de). The affinity to DNA 
is increased with the density of methylated CpGs and lowered with higher salt 
concentrations in the buffer, allowing enrichment of methylated DNA on a matrix-protein 
complex with increasing NaCl concentration in the wash buffer. Washing with buffers 
containing different NaCl concentrations and collection of according flow through‟s leads 
to the fragmentation of DNA depending on the methylation status of CpG dinucleotides.  
 
 
Required buffers: 
 
o TME (10x) 200 mM Tris-HCl (1 M) pH 8.0 
 20 mM MgCl2 (1 M) 
 5 mM EDTA (500 mM) 
   
o Buffer A 1x TME (10x) 
           (300 mM NaCl) 300 mM NaCL (5M) 
 0.1% NP-40 (10%) 
   
o Buffer X 1x TME (10x) 
            (300 mM NaCl) 300 mM NaCL (5M) 
 0.1% NP-40 (10%) 
   
o Buffer B-G 1x TME (10x) 
 0.1% NP-40 (10%) 
 350 (B), 400 (C), 450 (D), 500 (E), 600 (F), 1000 mM (G), 
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4.3.1 Preparation of MBD2-Fc Fusionprotein 
4.3.1.1 Protein production using MBD2-Fc expressing Drosophila S2 cells 
MBD2-Fc expressing Drosophila S2 cells were previously produced by our lab110. For 
large scale protein production the cells are in seeded in 2000 ml roller bottles (Corning, 
USA) and incubated at 21°C during permanent rolling. The protein production is separated 
in two phases: selection and production. For protein production the cells are spun down 
(without loosening the adherent cells) at 300xg for 8 minutes at 4°C. Subsequently the 
cells are transferred back to the same roller bottle at a density of 10-15 million cells/ml in 
400 ml Insect-Xpress medium (Lonza, Walkersville, MD USA) and supplemented with 0.5 
mM CuSO4. The MBD2-Fc containing culture medium is harvested after 4 days 
(production phase) via centrifugation at 300xg at 4°C for 8 minutes. After production 
phase the cells are re-cultured in 400 ml Insect-Xpress medium at a density of 3-4 million 
cells/ml supplemented with 400 µg/ml hygromycin B (Clontech Laboratories, USA) and 
incubated for 3 days in the same bottle (selection phase). A continuing protein production 
was maintained by alternating cycles of production and selection phases always using the 
same bottle. 
4.3.1.2 MBD2-Fc protein purification 
Cell culture supernatant of production phase were combined (from different bottles or 
production phases) and centrifuged at 2000xg for 20min at 4°C and subsequently at 
15000xg, 40 60 min, 4°C in order to remove remaining cells and debris. In the following 
supernatants are dialyzed against 1xTBS (pH 7.4) for 72h at 4°C (whereas TBS was 
replaced 3 times) using Dialysis Tubing VISKING (diameter 32mm; Serva, Heidelberg). 
The MBD-Fc protein was afterwards affinity-purified using rProtein A Sepharose Fast Flow 
(GE Healthcare, Uppsala, Sweden) together with a Pharmacia column (Pharmacia, ). 
Constant flow rate of dialysed cell culture supernatant was achieved using a peristaltic 
pump (Heidolph, Schwabach, Germany). Elution was performed in 1 ml fractions with 
elution buffer into 1.5 ml tubes each containing 50 µl neutralization buffer. The different 
fractions were measured at a Biophotometer (Eppendorf, Hamburg, Germany) and protein 
containing fractions were combined and dialyzed against 1xTBS using Slide-A-Lyzer 
Dialysis Cassettes (Pierce, Rockford, USA). Dialysis was carried out for 48h and TBs was 
replaced once. For long term storage gelatine and sodium azid was added to final 
concentrations of 0.2% and 0.05%, respectively. The preserved MBD2-Fc solution was 
stored at 4°C. After each protein preparation the rProtein A Sepharose containing column 
was washed with 3 M KCL and 1xTBS, in order to remove all remaining proteins and to 
recover its binding capacity.  
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Required buffers and solutions: 
 
o 10x TBS 500 mM 302.85 g Tris/HCl pH 7.4 
 1.5 M 438.3 g NaCl 
 10 mM 18.6 g EDTA 
 0.05 % 2.5 g NaN3 
 Adjust to pH 7.4 with HCl and add H2O to 5 L 
    
o Elution buffer 0.1 M 2.9 g Citric acid  
 Adjust pH to 3.0 and add H2O to 100 ml 
    
o Neutralisation buffer 1.5 M 18 g Tris/HCl pH 8.8 
 Adjust to pH 8.8 with HCl and add H2O to 100 ml 
    
o KCl 3M 223.65 g KCl 
 Add H2O to 1 L 
4.3.1.3 MBD2-Fc quality and quantity assessment 
Each MBD-Fc protein preparation was quality controlled and quantified using sodium 
dodecyl sulfate (SDS) polyacrylamide (AA) gel electrophoresis (SDS-PAGE). This 
technique separates proteins according to their electrophoretic mobility, which is, besides 
other characteristics, a function of the polypeptide chain length. A polyacrylamide gel is 
composed of stacking and separating gel layers that differ in acrylamide concentration. 
For a SDS-PAGE the protein preparation was diluted 1:5 with H2O in a volume of 10 µ 
and supplemented with 10 µl SDS-sample buffer. Accordingly, a bovine serum albumin 
(BSA) standard curve was prepared containing 4 different dilutions comprising 1, 0.5, 0.25 
and 0.125 mg/ml. All samples were incubated to 95°C for 5 minutes and subsequently 
loaded into a SDS-PAGE assembly together with a pre-stained protein size standard (Bio-
Rad Laboratories, Munich, Germany). 
 
SDS-PAGE stock solutions: 
Stock solution Separating gel stock (13.5%) Stacking gel stock (5%) 
Stacking buffer - 25 ml 
Separating buffer 25 ml - 
SDS (10%) 1 ml 1 ml 
Rotiphorese Gel (30%) 45 ml 16.65 ml 
H2O Add 100 ml Add 100 ml 
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SDS-PAGE gel mixture: 
Stock solution Separating gel  Stacking gel 
Stock solution 10 ml 5 ml 
TEMED 10 µl 5 µl 
APS (10%) 50 µl 40 µl 
 
Prior to loading, a 13.5 % polyacrylamide SDS gel was prepared as follows: The 
separating gel was cast and overlaid with water-saturated isobutanol until polymerized. 
Isobutanol was exchanged for separating gel buffer diluted 1:3 with water. The stacking 
gel was poured on top of the separating gel, and the comb inserted immediately. After 
polymerization, the stacking gel was mounted in the electrophoresis tank, which was filled 
with 1x Laemmli buffer. Meanwhile, the protein and BSA solutions (prepared as described 
above) were loaded in the wells. The gel was run with 25 mA/110 volts till the sample 
buffer bands reached the surface of the stacking gel, then the current was increased to 
200 volts and the gel was run for 2-3 h. Afterwards the bands were stained using 
Coomassie BLUE solution (Biorad) for one hour with gentle shaking. De-staining was 
carried out over night in desalted Millipore water. For documentation purposes the ready 
stained gel was scanned using a personal Densitometer SI (Molecular Dynamics). The gel 
image was loaded into the ImageQuant 5.0 software and protein bands were quantified 
using the BSA-standard curve as a reference. 
 
Required buffers and solutions: 
 
o Separating buffer 1.5 M 90.83 g Tris/HCl pH 8.8 
 Add H2O to 500 ml 
  
o Stacking buffer 0.5 M 30 g Tris/HCl pH 8.8 
 Add H2O to 500 ml 
    
o SDS (10%) 10% (w/v) 10 g SDS 
 Add H2O to 100 ml 
    
o AP (fresh prepared) 10% 100 mg Ammonium 
persulfate 
 Add H2O to 1 ml 
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o Laemmli (5x) 40 mM 15 g Tris 
 0.95 M 21 g Glycin 
 0.5 % 15 g SDS 
 Add H2O to 3 L 
 
4.3.2 Binding MBD2-Fc to beads 
For single-gene analysis, typically 18 μg purified MBD2–Fc protein per 40 μl nProtein A–
Sepharose 4 Fast Flow beads (Amersham Biosciences) were rotated in 2 ml TBS 
overnight at 4°C in order to bind the Fc-part of the protein to the beads. On the next day, 
the MBD2–Fc-bead complexes (40μl/assay) were transferred and dispersed equally into 
0.5-ml Ultrafree-MC centrifugal filter devices (Millipore) and spinwashed twice with buffer 
A. 
4.3.3 DNA fragmentation 
Genomic DNA was fragmented as follows: To reduce viscosity, gDNA was initially 
sheared using a 20 gauge needle attached to a 2 ml syringe (BD) before quantification 
using the NanoDrop ND 1000 spectrophotometer (Peqlab). Sonication to a mean 
fragment size of 400–500 bp was carried out with the Branson Sonifier 250 (Danbury) 
using settings shown below. After sonication the sample was immediately cooled on ice. 
Fragment range was controlled using agarose gel electrophoresis. 
 
For 5 µg DNA in 500 µl TE Duty cycle 30 % 
 output 3 
 Sonication time 60 sec 
   
For 2.5 µg DNA in 500 µl TE Duty cycle 80 % 
 output 0.5 
 Sonication time 2*30 sec 
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4.3.4 Enrichment of highly methylated DNA 
Sonicated DNA (300 ng) was added to the washed MBD2–Fc beads in 350 μl buffer X 
and rotated for 3 h at 4°C. Beads were centrifuged to recover unbound DNA fragments 
(300 mM fraction) and subsequently washed twice with 200 μl and 150 μl of buffers 
containing increasing NaCl concentrations (350-1000 mM, see buffers B-G). The flow-
through of each washing step was collected in separate tubes and desalted using a 
QIAquick PCR Purification Kit (Qiagen). In parallel, 300 ng sonicated input DNA was 
resuspended in 350 μl buffer X and desalted using a QIAquick PCR Purification Kit 
(Qiagen) as a control. This MCIp protocol was scaled up to generate DNA fragments for 
direct microarray hybridisation. Here, for each sample, 84 μg purified MBD2–Fc protein 
was added to 200 μl Protein A–Sepharose beads (Amersham Biosciences) in 15 ml TBS 
and rotated overnight at 4°C. For the precipitation, 2-ml Ultrafree-MC centrifugal filter 
devices (Millipore) were used and 2 or 4 μg of sonicated DNA was added to the washed 
MBD2–Fc bead complexes in 2000 μl buffer X. Unbound DNA fragments (300 mM 
fraction) were collected and desalted using a QIAquick PCR Purification Kit (Qiagen) 
Flow-throughs were analysed for successful enrichment of highly methylated DNA with 
the real-time PCR (see section 4.2.1.4). Based on the distribution of fragments analysed 
with RT-PCR primers, a conclusion could be made about the methylation level of the 
sample DNA in this region. For the “mirror image approach” a threshold was defined and 
flow-throughs were combined to a hypomethylated and a hypermethylated fraction for 
subsequent labeling and microarray analysis. 
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4.4 Microarray handling and analysis 
To generate fluorescently labelled DNA for microarray hybridization, the hypo- and 
hypermethylated pools of the MCIp immunoprecipitation of C57BL/6 were directly labelled 
with Alexa Fluor 5. The corresponding pools from BALB/c were labelled with Alexa Fluor 
3. In both cases labelling was performed with the BioPrime Total Genomic Labeling 
System (Invitrogen, Carlsbad, CA, USA). The labelling reaction was performed using the 
manufacturer‟s instructions. The differently labelled fractions of the two mice strains were 
combined to a final volume of 80 µl, supplemented with 50 µg mouse Cot-1 DNA 
(Invitrogen), 52 µl of Agilent blocking agent (10-fold) (Agilent Technologies, Böblingen, 
Germany), 78 µl Deionized formamide (Sigma) and 250 µl Agilent hybridization buffer (2-
fold) as supplied in the Agilent oligo aCGH Hybridization kit. The samples are heated to 
95° for 3 min, mixed and subsequently incubated at 37°C for 30 min and spun down 
afterwards for 1 min. Hybridization on a custom designed Mouse array (Agilent) was then 
carried out 65°C for 40 h using an SureHyb chamber and an Agilent hybridization oven. 
Slides were washed in Wash I (6xSSPE, 0.005% N-lauroylsarcosine) at room temperature 
for 5 min and in Wash II (0.06xSSPE) for an additional 5 min. Afterwards slides were dried 
and incubated using acetonitrile within an ozone free facility. Images were scanned 
immediately and analysed using a DNA Microarray scanner (Agilent) and processed using 
Feature Extraction Software 9.5.1 (Agilent). 
4.4.1 Gene Expression analysis 
Total RNA preparations from BMM cultures from two independent experiments were used 
to globally analyse gene expression patterns on Whole Mouse Genome Oligo Microarrays 
(Agilent).  
4.4.1.1 Labelling reaction 
Labelling was performed using the Agilent Gene Expression system according to the 
manufacturer‟s instructions. In brief, 200 ng to 1000 ng of high-quality RNA were amplified 
and Cyanine 3-CTP labelled with the One Color Low RNA Input Linear Amplification Kit 
(Agilent). Labelling efficiency was controlled using the NanoDrop ND-1000 
Spectrophotometer (PeqLab, Erlangen, Germany).  
4.4.1.2 Microarray hybridization 
Of each sample 1.65 µg labelled cRNA was fragmented and hybridized on the Whole 
Mouse Genome Expression Array (4x44K, Agilent). Fragmantation mix was prepared as 
follows: 
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Component Volume/Mass 
Labelled, linearly amplified cRNA 1.65 µg 
Agilent Blocking Agent (10x) 11 µl 
Nuclease free water Ad 52.8 µl 
Fragmentation Buffer (25x) 2.2 µl 
 
The sample was incubated at 60°C for exactly 30 minutes in order to fragment RNA. 
Afterwards the fragmentation was stopped by adding of 2x Hybridisation buffer. The final 
hybridization mixture for the 4x44k (4 array/slide; total volume 110 µl each) Whole Mouse 
Genome microarrays was prepared as follows: 
 
Component Volume 
cRNA from Fragmentation Mix 55 µl 
Agilent Hybridization Buffer (2x) 
(2xGE, HI-RPM) 
55 µl 
Agilent Blocking Agent (10x) 50 µl 
 
The sample was spun down afterward for 1 min and kept on ice until loading onto array, 
which was performed as soon as possible. Hybridization on microarrays slides (Agilent) 
was then carried out at 65°C for 17 h using an Agilent SureHyb chamber and an Agilent 
hybridization oven. Slides were washed in Gene Expression Wash Buffer I (Agilent) at 
room temperature for one minute and in Gene Expression Wash Buffer II (Agilent, 
prewarmed to 37°C) for an additional minute. Afterwards slides were dried and incubated 
using acetonitrile for 30 s. Images were scanned immediately using a DNA microarray 
scanner (Agilent), and processed with Feature Extraction Software 9.5.1 (Agilent) using 
default parameters (protocol GE1-v5_95_Feb 97) to obtain background subtracted and 
spatially detrended, processed signal intensities. Extracted data were further processed 
with GeneSpring GX 7.3.1 as follows: Data Values below 10.0 were set to 10.0. Each 
measurement was divided by the 50,0th percentile of all measurements in that sample. 
The percentile was calculated using only genes marked present. Each gene was divided 
by the median of its measurements in all samples. If the median of the raw values was 
below 0 then each measurement for that gene was divided by 0 if the numerator was 
above 0, otherwise the measurement was thrown out. Median polishing was done, where 
each chip was normalized to its median and each gene was normalized to its median. 
These normalizations were repeated until the medians converged.  
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4.4.2 CGH microarrays 
Samples for DNA methylation mapping were analysed using comparative genome 
hybridization microarrays (CGH) either using human proximal promoter microarrays or 
murine custom arrays, both purchased from Agilent.  
4.4.2.1 Labelling reaction 
Samples from MCIp (section 4.3) were labelled directly with Alexa Fluor® 3–aha–dCTP 
and Alexa Fluor® 5–aha–dCTP, respectively, using the BioPrime Plus Array CGH 
Genomic Labelling System (Invitrogen). The labelling reaction was carried out according 
to the manufacturer‟s Manual. Labelling efficiency was controlled using the NanoDrop ND-
1000 Spectrophotometer (PeqLab, Erlangen, Germany). 
4.4.2.2 Microarray hybridization 
The differently labelled DNA fragments or pools of two samples were combined and 
supplemented with human or mouse Cot-1 DNA, depending on the samples used, 
(Invitrogen), Agilent blocking agent (10-fold) (Agilent Technologies, Böblingen, Germany), 
Agilent hybridization buffer (2-fold) as supplied in the Agilent oligo aCGH Hybridization Kit. 
For more stringent hybridisation conditions deionised formamide was additionally added in 
order to prevent cross-hybridisation of GC-rich DNA sequences. The correct amount 
differed according to the arrays format used: 
 
44k (1 array/slide; total volume 500 µl) human proximal promoter microarrays 
Component 1x Mix Final concentration 
DNA samples combined in 150 µl TE 80 µl  
Cot-1 DNA (1.0 mg/ml) 50 µl 0.1 mg/ml 
Agilent Blocking Agent (10x) 50 µl 1x 
Agilent Hybridisation Buffer (2x) 250 µl 1x 
 
244k (1 array/slide; total volume 500 µl) custom arrays 
Component 1x Mix Final concentration 
DNA samples combined in 80 µl TE 80 µl  
Cot-1 DNA (1.0 mg/ml) 50 µl 0.1 mg/ml 
Agilent Blocking Agent (10x) 52 µl 1x 
Deionized formamide 78 µl 15 % 
Agilent Hybridisation Buffer (2x) 250 µl 1x 
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The sample was heated to 95°C for 3 min, mixed, and subsequently incubated at 37°C for 
30 min and spun down afterward for 1 min. Hybridization on microarrays slides (Agilent) 
was then carried out at 65°C (or 67°C for the stringent protocol) for 40 h using an Agilent 
SureHyb chamber and an Agilent hybridization oven. Slides were washed in Wash I (6× 
SSPE, 0.005% N-lauroylsarcosine) at room temperature for 5 min and in Wash II (0.06× 
SSPE; prewarmed to 37°C for stringent protocol) for additional 5 min. Afterwards slides 
were dried and incubated using acetonitrile for 30 s. Images were scanned immediately 
and analyzed using a DNA microarray scanner (Agilent). Microarray images were 
processed using Feature Extraction Software 9.5.1 (Agilent) using the standard CGH 
protocol for samples from MCIp. Processed data was imported into Microsoft Office Excel 
for further analysis. Graphical presentations of datasets were obtained using Spotfire 
Decision Site Software 7.0 (Spotfire). 
Calculation of CpG index 
At a mean fragment size of 400-500 bp, a single oligonucleotide probe should detect 
methylation events within a radius of at least 350 bp. During the MCIp procedure the 
fragments of the 350 mM fraction were allowed to be methylated at one or two CpG 
dinucleotides. A given DNA fragment should contain at least four or five CpG residues 
within the above radius, in order to allow the reproducible separation of unmethylated and 
methylated fragments. To calculate the CpG index for each individual microarray probe, 
the relative chromosomal location and in a next step the genomic DNA sequence 
surrounding each individual probe was extracted using the UCSC Genome Browser 
(http://genome.ucsc.edu/). The number of CpG residues in a region 250, 350 and 850 bp 
upstream and downstream of each probe (CpG index) was calculated using Microsoft 
Exel 2007. Following analyses was restricted to probes with a CpG index above 4. 
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4.5 Quantitative DNA methylation analysis 
with the MassARRAY Compact System 
4.5.1 General overview 
All reagents were purchased from Sequenom unless otherwise mentioned. All 
centrifugation steps were carried out at 3000rpm unless otherwise mentioned. 
Quantitative methylation analysis of the regions of interest was performed with the 
MassARRAY Compact System (Sequenom). This method is based on matrix assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
measurement of bisulphite converted DNA. Bisulphite treatment generates methylation 
dependent sequence variations: Cytosine (C) is deaminated to uracil (U) which generates 
Thymine (T) after PCR-amplification, whereas 5‟-methyl-Cytosine remains unchanged. 
This C/T variation appears as a G/A (guanine/adenine) variation after in vitro RNA 
transcription resulting in a mass difference of 16 kDa (the mass difference between G and 
A) in the fragments which can be quantified with the MassARRAY Compact System. In 
the mass spectrum, the relative amount of methylation can be calculated by comparing 
the signal intensity between the mass signals of methylated and non-methylated DNA-
template. Primers were designed using Methprimer software 
(www.urogene.org/methprimer/), which is available online. Genomic DNA (gDNA) was 
extracted from cell cultures of murine bone-marrow derived macrophages (BMM), spleen 
and testis with the DNeasy Blood and Tissue Kit (Qiagen). At the beginning, the genomic 
DNA was treated with sodium bisulphite (Zymo Research), where unmethylated cytosine 
is converted to uracil whereas 5‟-methyl-cytosine is not affected. The regions of interest 
were then amplified by PCR with the reverse primer harbouring a T7-Polymerase 
promoter for in vitro transcription. Unincorporated deoxynucleotide triphosphates were 
inactivated by dephosphorylation with shrimp alkaline phosphatase (SAP, Sequenom).  
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Figure 4.1 MassARRAY workflow overview: Genomic DNA is isolated and bisulphite treated to 
generate methylation specific mass differences. Regions of interest are amplified by PCR following 
in vitro transcription and base specific cleavage (in the figure U-specific, in the assay used for this 
work T-specific). Mass differences are then analysed with MALDI-TOF MS (Figure taken from 
www.sequenom.com).  
 
 
After SAP treatment the amplicons were transcribed in vitro into RNA using a T7-RNA 
Polymerase and simultaneously “T”-specific cleavage was achieved with RNaseA and 
modified cytosine triphosphate nucleotides to avoid “C” cleavage within the same reaction. 
Water was added and reactions were desalted with 6 mg of cation exchange resin 
(Sequenom). Finally reactions were spotted on a SpectroCHIP with the Phusio Chip 
Module and measured with the MassARRAY Compact System (all Sequenom) 
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4.5.2 Primer Design 
The primers were designed to amplify fragments with the limited size of 200 to 600 base 
pairs, because bisulphite conversion destabilises the integrity of gDNA and may lead to 
fragmentation of template DNA and therefore limits PCR-amplification. Unlike methylation-
specific primers these primers here bind to both methylated and unmethylated template 
because the software excludes regions with CpG dinucleotides for potential primer binding 
sites. The reverse primer is tagged with a T7-promoter sequence and a short eight base 
pair spacer sequence while the forward primer has a ten mere tag to balance primer 
lengths. The primers were designed using Methprimer software 
(www.urogene.org/methprimer/) and purchased from Sigma in a 96 deep well system.  
4.5.3 Bisulfite treatment of genomic DNA 
A common method for analyzing cytosine methylation is bisulphite conversion of DNA 
followed by sequencing. Cytosine-derivates undergo reversible reactions with bisulphite 
yielding a 5,6-Dihydro-6-sulfonate, which deaminates spontaneously. After that the 
sulphate is eliminated under alkaline conditions, leaving Uracil. 5‟-methyl Cytosine is not 
affected by this reaction and so unmethylated Cytosine appears as a Uracil in the 
sequencing reaction whereas 5‟-methyl Cytosine remains cytosine. As already mentioned, 
in the following procedure this methylation specific difference is not used for sequencing 
but for generating methylation depending mass differences to be analysed by mass 
spectrometry. All reagents in this section were obtained from the EZ DNA methylation kit 
(Zymo). 1 μg of gDNA was brought to a volume of 45 μl and was diluted with 5 μl M-
Dilution Buffer, mixed and incubated at 37°C for 15 minutes. After incubation 100 μl of CT 
Conversion Reagent was added, lightly vortexed and incubated in the dark with the 
following protocol: 
 
Step 1: 95°C 30 sec 
Step 2: 50°C 15 min 
Step 3: Repeat steps 1-2 for 20 cycles  
Step 4: 4°C hold 
 
Afterwards the samples were incubated on ice for 10 minutes, 400 μl of M-Binding Buffer 
was added and the sample was loaded on a Zymo-Spin I Column placed in a 2 ml 
collection tube. DNA was bound by centrifuging at full speed for 15-30 seconds, washed 
with 200 μl M-Wash Buffer, centrifuged again for 15-30 seconds and then treated with 200 
μl M-Desulphonation Buffer for 15 minutes at room temperature. After incubation the 
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column was centrifuged for 15-30 seconds, washed twice with 200 μl M-Wash Buffer 
centrifuging 30 seconds and 1 minute respectively at full speed to remove wash buffer 
residues. To elute the DNA 100 μl water was added directly to the centre of the column 
and centrifuged 30 seconds at 3000 rpm. The procedure yields 100 μl of bisulphite 
converted DNA with a concentration of 7-8 ng/μl. 
4.5.4 PCR-amplification 
Polymerase Chain Reaction (PCR) allows the specific amplification of DNA segments 
(see 4.2.1). The PCR-reactions were prepared in 384 well plates (ABgene) with the 
following reagents according to the manufacturer: 
 
Component Volume for single reaction Final concentration 
ddH2O 1.42 µl N/A 
10x HotStarBuffer 0.5 µl 1x 
dNTP mix 25 mM each 0.04 µl 200 µM 
5 U/µl Hot Star Taq 0.04 ml 0.2 U 
DNA Template 1 µl 5-10 ng 
 
To each reaction 2 μl primer mix was added, giving a final reaction volume of 5 µl, with the 
concentration of 500 pM of the forward and reverse primer. Then the plate was sealed 
with AB-0558 spun down, centrifuged and incubated in a Veriti 384 well thermal cycler 
(Applied Biosystems) with the following programme: 
 
Step Temperature Time Cycle 
Initial denaturation 94°C 4 min 1 
Denaturation 
Annealing 
Elongation 
94°C 
59°C 
72°C 
20 sec 
30 sec 
1 min 
 
45 
 
Final elongation 72°C 3 min 1 
Cooling 4°C hold 1 
 
4.5.5 Shrimp Alkaline Phosphatase (SAP) Treatment 
Unincorporated nucleotides can disturb downstream applications and are therefore 
enzymatically inactivated. Under alkaline conditions SAP removes phosphate groups from 
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several substrates including deoxynucleotide triphosphates, rendering it unavailable for 
further polymerase catalyzed reactions. The SAP solution was prepared as follows: 
 
Component Volume for single reaction 
RNAse free water 1,7 µl 
SAP 0.3 µl 
 
 
2 μl of the SAP solution was added to each PCR-reaction with the 96 channel pippeting 
robot MassARRAY Liquid Handler and FusioTM Chip Module (Matrix). The plate was 
sealed with AB-0558, centrifuged and incubated as follows on a Veriti 384 well thermal 
cycler (Applied Biosystems): 
 
Step 1: 37°C 20 min 
Step 2: 85°C 5 min 
Step 3: 4°C hold 
 
4.5.6 In vitro transcription and RNaseA treatment 
The PCR reaction is transcribed into RNA in vitro with the T7 RNA polymerase, which is 
guided to the amplified PCR-products by the introduced T7 promoter tag in the reverse 
primer. The transcribed RNA is in the same reaction enzymatically cleaved by RNaseA, 
cleaving specifically after cytosine and thymine. T-specific cleavage is achieved by using 
modified cytosine triphosphate nucleotides which protect from RNaseA digestion when 
incorporated in an RNA polymer. The RNase and T-cleavage mix was prepared according 
to the manufacturer‟s instruction: 
 
Component Volume for single reaction 
RNase free water 3.21 µl 
5x T7 Polymerase buffer 0.89 µl 
Cleavage Mix (T mix) 0.22 µl 
DTT (100 mM) 0.22 µl 
T7 R&DNA Polymerase (50 U/µl) 0.4 µl 
RNaseA 0.06 µl 
Total volmume 5 µl 
 
Methods 
 
60 
5 μl of the mix and 2μl of the SAP treated PCR reaction were transferred into a new 386-
well plate with the 96 channel pippeting robot MassARRAY Liquid Handler and FusioTM 
Chip Module (Matrix), sealed with AB-0558, centrifuged and incubated on a Veriti 384 well 
thermocycler C (Applied Biosystems) for three hours at 37°C. 
4.5.7 Desalting of Cleavage Reaction: resin treatment 
Because salt ions are co-vaporised when acquired during MALDI-TOF analysis they are 
therefore visible in the mass-spectra. This would irritate the analysis of the mass-spectra 
and therefore the reactions need to be desalted. For desalting of the 
transcription/cleavage mix 20 μl water was added to each reaction with the MassARRAY 
Liquid Handler (Matrix) followed by the addition of 6 mg CLEAN resin per reaction. This 
mix was rotated for slowly for 10 minutes and spun down to collect the resin at the bottom 
of the wells. 
4.5.8 Transfer on SpectroCHIP and acquisition 
The SpectroCHIP holds the matrix on which the sample probes are spotted and consists 
of a crystallized acidic compound. When the analyte is spotted on the matrix its solvent 
dissolves the matrix, and when the solvent evaporates the matrix recrystallizes with 
analyte-molecules spread enclosed in the crystals. The DNA samples are transferred on a 
SpectroCHIP with the Phusio Chip Module and analysed with the MassARRAY Compact 
System MALDI-TOF MS (all Sequenom). The co-crystallized analyte is acquired with a 
laser while the matrix is predominantly ionized, protecting the DNA from the disruptive 
laser beam. Eventually the charge is transferred to the sample and charged ions are 
created which are accelerated in a vacuum towards a detector that measures the 
particle‟s time of flight. 
4.5.9 Data processing 
Acquired data was processed with the EpiTyper Analyzer software (version 1.0.5, 
Sequenom). The MS is calibrated with a four point calibrant (Sequenom) containing 1479, 
3004, 5044.4 and 8486.6 kDa particles. Relative to this calibration the accelerated 
analytes generate signal intensity (y-axis) versus mass (kDa, x-axis) plots. With the 
sequence of every amplicon known, the software can virtually process the sequence and 
predict the fragments from the in vitro transcription/RNase digestion and relocate CpG 
units. If fragments contain a single CpG this is called a CpG-site. More CpG-sites within 
one fragment are summarized to a CpG-unit get a sum methylation value since the 
software averages the methylation of the individual CpG-sites. If expected and incoming 
information match, the signal intensities of the methylated and unmethylated DNA 
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templates are compared and quantified. A normal calibrated system is able to measure 
fragments between a range of 1500 and 7000 Dalton. Fragments outside of this range 
and fragments whose mass peaks are overlapping with multiple other fragments cannot 
be analysed.  
4.6 Laboratory animals 
Wild-type inbred mice were purchased from Charles River (Sulzfeld, Germany).  
4.6.1 Wild-type inbred mice 
Wild-type inbred C57BL/6JCrl and BALB/cAnNCrl mice were purchased from Charles 
River (Sulzfeld, Germany). Bone marrow derived macrophages (BMM) of different mice 
were produced as described in section 4.7.6. Total cellular RNA was isolated using the 
RNeasy Kit (Qiagen). Genomic DNA was prepared using the Qiagen Blood & Cell Culture 
DNA Kit. DNA and RNA concentrations were determined using the NanoDrop ND-1000 
Spectrophotometer (PeqLab, Erlangen, Germany) and quality was assessed by agarose 
gel electrophoresis. In addition, spleen and testis DNA were prepared using a TissueLyser 
(Qiagen) and the DNeasy Blood&Tissue kit (Qiagen). 
4.6.2 F1 Hybrids 
F1 hybrid offspring were produced by natural matings within our animal facility. Two 
female mice from one strain and one male mouse from the other strain were kept together 
to produce hybrid mice separately for both possible sires. Different gender of F1 hybrids 
were separated at time of fertility. Genomic DNA and RNA from bone marrow derived 
macrophages, spleen and testis (RNA and DNA), were produced as described for wild-
type mice.  
4.7 Cell culturing methods 
4.7.1 Cell culture 
RAW264.7 cells were grown in 90 % 1640 RPMI plus 10 % fetal calf serum (FCS) 
supplied with 1 mM sodium pyruvate (Gibco), 2 mM L-Glutamine (Biochrome), 2 ml MEM 
Non-essential amino acids (Gibco), MEM Vitamines (Gibco), 50U/ml 
Penicillin/Streptomycin (Gibco), 50 µM 2-Mercaptoethanol (Gibco) in an humified 
incubator at 37°C and 5 % CO2. Cells were passaged every two to three days using a Cell 
scraper (Sarstedt). 
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4.7.2 Analysing cell vitality 
The numbers of viable and dead cells were determined by trypan blue exclusion. 
Therefore the cell suspension was diluted with trypan blue solution and counted in a 
Neubauer haemocytometer. Dead cells appear blue since the blue stain is able to enter 
the cytoplasm. The concentration of viable cells was then calculated using following 
formula: 
 
Number of viable cells per ml = Z * D * 104 
 
Z=average of unstained cells per corner square (1 mm containing 16 sub-squares); 
D=dilution factor 
 
Required solution: 0.2 % (w/v)  trypan blue in 0.9 % NaCl solution 
 
4.7.3 Freezing and thawing cells 
Cells were harvested and about 6*106 cells per ml were suspended in 800 µl ice-cold 
medium, including 10 % FCS. After inverting the mix and transferring into cryo-
vials(Corning), 160 µl DMSO (Sigma) and 640 µ FCS were added and the tubes were 
rapidly inverted to mix the cells properly. In order to allow gradual freezing at a rate of 
~1°C/min, the cryo-vials were placed in isopropanol-filled cryo-containers (Nalgene) and 
frozen at -20°C. After 2 hours the vials were transferred to -80°C for 48 hours. Long-term 
storage was accomplished in liquid nitrogen (-196°C).  
4.7.4 Mycoplasma assay 
Cells were routinely checked for mycoplasma contamination by ELISA with a Mycoplasma 
Detection Kit (Roche, Germany) or by a biochemical test with a MycoAlert® Mycoplasma 
detection assay (Cambrex, Rocheland, USA) according to the manufacturer‟s intructions. 
4.7.5 Isolation of human monocytes 
Leukapheresis, which is a procedure to separate white blood cells from peripheral blood, 
was used to extract a leukocyte-enriched concentrate of blood from healthy volunteers 
(Graw et al, 1971). Mononuclear cells (MNC) were isolated by density-gradient 
centrifugation using the Ficoll-Paque technique (Pharmacia, Freiburg) and were washed 
three times with phosphate buffered saline (PBS) (Johnson et al, 1977). Subsequently 
monocytes were isolated from the MNC mixture by counterflow centrifugation (Elutriation) 
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(Sanderson et al, 1977). Elutriation was performed using a Beckman centrifuge (J6-MC) 
within a 50 ml chamber. Prior to use the assembly was sterilised by incubation with 6% 
H2O2-solution and washed twice for 20 minutes with PBS and HANKS (balanced salt 
solution), respectively. The peristaltic pump was calibrated with HANKS prior to use at a 
constant centrifugation force of 1500 rpm at 4°C. HANKS used in the following, was 
supplemented with autologous plasma, which was collected as a by-product during the 
leukaphoresis procedure, to a final concentration of 6%. Table 4.2 shows an exemplary 
flow rate pattern which varied marginally between individual preparations. 
 
Table 4.2 Elutriation steps, settings and expected cells 
In this example the MNC were loaded at a flow-rate of 52 ml/min. In the following the 
inflow of HANKS (including 6% plasma) was continued and the flow-rate was stepwise 
increased. Different fractions were collected as depicted in Table 4.2. The biggest cells 
within the MNC preparation, the monocytes, eluted in the last fraction (fraction 3) using 
the highest flow-rate. The monocytes were subsequently pelleted at 300 g at 4°C for 8 
minutes and resuspended in RPMI medium prior to counting. Normally the MNC 
preparation contained 10-30% monocytes. In addition, flow-cytometry was used to 
determine the proportion of CD14-positive cells (monocytes). Usually the preparation 
yielded 85-95% monocytes. Yield and purity varied slightly, depending on the donor. 
  
Fraction Flowrate (ml/min) Volume (ml) Cell in fraction 
1a 52 500 Thrombocytes 
1b 57 500 Lymphocytes (B-and T-cells) 
2a 64 500 Lymphocytes (B-and T-cells) 
2b 74 400 Lymphocytes (B-and T-cells) 
2c 92 400 Lymphocytes (B-and T-cells) 
3 111 4*200 Monocytes 
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4.7.6 Mouse bone marrow macrophage preparation 
Mouse bone marrow progenitor cells were extracted from the femurs and tibia of 8-12 
weeks old mice and differentiated in bone marrow derived macrophages (BMM) by adding 
rCSF to the culturing media. All Mice were ordered from Charles River (Sulzfeld) and F1 
hybrid offspring were generated by natural matings. Cells from several individual were 
ether pooled or treated separately depending on the experiment. Cells were flushed out of 
the bones with TBS using 27 gauge needle attached to a 5 ml syringe (BD) from both 
directions, centrifuged at 300 g, for 8 min at 4°C counted and seeded at a concentration of 
5*105 cells/ml culture medium in bacteriological square plates (Sterilin; Barloworld 
scientific, UK) After 5 days the medium was changed and cells were harvested on day 6 
and re-plated at a density of 10*106 cells/10 ml media in 10 cm tissue culture dish 
(Falcon). On day 7 the cells were harvested and DNA and RNA were prepared as 
described.  
 
Required cell culture medium: 
 
BMM growth medium 500 ml RPMI with supplements (see 4.7.1) 
 200 ng/ml rCSF (Cetus) 
 10 % 50 ml FCS (PAN Biotech) 
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5 Results 
Due to space limitations, this section only contains parts or summaries of the sequence, 
expression, MCIp-on-chip and MassARRAY data. Complete figures, tables, lists and 
UCSC tracks are or will be available online within the supplementary information of the 
corresponding publications.  
5.1 Global, comparative analysis of tissue 
specific promoter CpG methylation 
The data from this section has been published in the journal GenomicsA. Microarray data 
has been deposited with the GEO Data Library under Series Entry GSE5548.  
5.1.1 Adaptation of the MCIp-on-chip approach 
Methyl-CpG-immunoprecipitation (MCIp) is based on the recombinant antibody-like 
MBD2–Fc fusion protein that was originally designed by our lab to globally detect disease-
related hypermethylation in CpG islands110. In this work the existing MCIp procedure was 
modified and established for a novel application, the genome-wide detection of tissue-
specific methylation differences. In general, cell type-specific methylation differences are 
thought to mainly occur in CpG-depleted regulatory regions, whereas most CpG islands, 
in particular promoters, remain unmethylated in all tissues137. We therefore hypothesized, 
that those tissue-specific methylation differences may preferentially be detected in the 
nonbinding fraction of a MCIp experiment which contains mainly unmethylated CpG 
dinucleotides. The newly developed approach takes advantage of the fact that MCIp not 
only enriches hypermethylated DNA but separates DNA depending on its methylation 
grade and therefore also allows the collection of hypomethylated DNA. All fractions, 
hypomethylated as well as hypermethylated can be collected within one experiment. In 
this pilot study the original method was for the first time adapted to comparatively analyze 
the hypomethylated genomic DNA of different human tissues using microarray technology 
(MCIp-on-chip).  
  
                                               
A
 Schilling,E. & Rehli,M. Global, comparative analysis of tissue-specific promoter CpG methylation. 
Genomics. 90, 314-323 (2007). 
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5.1.1.1 Separation of differentially methylated DNA by MCIp 
The previously described procedure110 was adapted  to separate and isolate unmethylated 
DNA fragments as follows. In contrast to the original approach genomic DNA was 
fragmented to a mean length of 400-500 base pairs by ultrasonication rather than 
endonuclease digestion to avoid sequence bias and to generate fragments of a defined 
mean length. To allow the direct labeling of DNA fragments for subsequent microarray 
analysis without the need of prior amplification, which again can produce a bias, the whole 
procedure was scaled up (see methods section for details). All genomic DNA samples 
were derived from different human individuals. Genomic DNA from monocytes was 
obtained from male volunteers after their isolation from mononuclear cells via counter 
current centrifugation (Elutriation), whereas all other genomic DNA samples (brain, liver 
and two testis samples) were purchased from BioChain Institute (Hayward, CA, USA). 
Testis samples were chosen as a reference, because of their general low global 
methylation content. I used 4 µg of sonicated genomic DNA fragments together with large 
spin columns to get sufficient amounts of DNA fragments for the direct labeling of DNA for 
microarray hybridization experiments. The salt concentration of the binding buffer was 
adjusted to allow fragments methylated at only a few sites (one or two mCpG‟s) flow 
through into the 350 mM fraction. The affinity of the MBD2-Fc fusion protein to DNA is 
decreased with higher salt concentrations in the buffer, allowing separation of methylated 
DNA using increasing NaCl concentration in the wash buffer. Additional fractions were 
obtained at 400, 500, 570 and 1000 mM NaCl.  
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Figure 5.1 MCIp-on-Chip approach to detect promoter regions with tissue-specific 
demethylation. Genomic DNA of tissues or purified cell populations is fragmented to a mean size 
of 400-500 bp using ultrasonication (Step1). The material is bound to MBD-Fc sepharose beads at 
350 mM NaCl for 3 h (Step 2) and fractionated using wash/elution buffers containing increasing 
concentrations of NaCl (400-1000 mM, Step 3). For single gene analysis, the amount of a single 
gene fragment can be quantified by real-time PCR in each fraction (Step 4a). The data of an 
exemplary analysis of the SNRPN promoter is graphically shown as a bar chart and heat map. The 
percentage of amplified material in a given fraction is represented by a gray scale. Since the 
SNRPN promoter is subject to maternal imprinting, approximately half of the amplified material in 
somatic tissues is present in the 350 mM fraction (unmethylated) while the second half elutes 
mainly above 570 mM NaCl representing the methylated alleles. As expected, germ-line cells in 
testis lack the maternal imprint and approximately 75% of the SNRPN fragments are found in the 
unmethylated fraction. Alternative to single gene analysis, individual fractions (here the 
unmethylated 350 mM NaCl fraction) of two tissues may be used for dual color microarray analysis 
(Step 4b). 
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The strategy for purification and subsequent detection of the fractionated material is 
shown in Figure 5.1. Prior to labeling the separation of differentially methylated DNA 
during the MCIp procedure was controlled by qPCR using primers covering a maternally 
imprinted region of SNRPN, which gives rise to two elution peaks in somatic samples. In 
addition, the utilized MBD2-Fc lot was continuously tested for functionality prior to each 
experiment using a small scale MCIp followed by qPCR for SNRPN.  
The methylated and unmethylated alleles of SNRPN were separated in all three somatic 
tissues (brain, liver and monocytes) and were eluted in the low salt and high salt fractions, 
respectively. In germ-line cells (testis samples) both alleles were unmethylated and were 
collected mainly in the low salt fraction, as demonstrated by the heat map in Figure 5.1 
(Step 4a). Hence, it could be shown that the modified MCIp approach can be used to 
efficiently separate the methylated and the unmethylated alleles in somatic tissues, 
whereas the majority of this locus, as expected, appears unmethylated in germ line cells 
(testis).  
5.1.1.2 Detection of tissue specific hypomethylation by microarray readout 
To demonstrate the feasibility of this method to detect tissue-specific differences on a 
global scale, the microarray technology was chosen. I used the hypomethylated DNA from 
the MCIp separation (350 mM fractions) of the three different tissues (testis, brain and 
monocytes) as described above. Fractionated DNA fragments were directly labeled with 
different fluorescent dyes. All testis samples were labeled with Alexa-Fluor-555 (shown in 
green in Figure 5.1 Step 4b), whereas all brain and monocyte samples were labeled with 
Alexa-Fluor-567 (shown in red in Figure 5.1 Step 4b). Testis DNA fragments served as a 
reference and were co-hybridized with either monocyte or brain DNA fragments onto 
commercial available 44k human promoter arrays (Agilent). Each comparison uses a set 
of two microarray slides (Slide 1/2 and slide 2/2), each containing 44,000 oligonucleotide 
probes of 45 to 60 base pairs in length. In total these 88,000 probes per “array” 
corresponded to nonrepetitive sequences and represented approximately 17,000 
annotated genes and 20,000 promoters. Slide 1/2 contained probes for promoters on 
human chromosomes 1-10, whereas all other chromosomes including X- and Y-
chromosomes were represented on slide 2/2. In order to limit interindividual differences 
and to increase the significance of these analysis, two hybridizations per comparison were 
performed using two independent testis samples (biological replicates). Hence, every set 
included two hybridizations with independent testis samples for each comparison. 
Efficiency of labeling was controlled by UV-spectroscopy and samples were hybridized on 
microarrays as follows: 
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1) Monocyte  versus Testis I Slide 1/2; repl. 1 
2) Monocyte versus Testis I Slide 2/2; repl. 1 
3) Monocyte versus Testis II Slide 1/2; repl. 2 
4) Monocyte versus Testis II Slide 2/2; repl. 2 
5) Brain  versus Testis I Slide 1/2; repl. 1 
6) Brain versus Testis I Slide 2/2; repl. 1 
7) Brain versus Testis II Slide 1/2; repl. 2 
8) Brain versus Testis II Slide 2/2; repl. 2 
 
 
Representative scatter plots of MCIp microarray analyses are shown in Figure 5.2, where 
the Log2 signal ratios (testis/somatic tissue) were plotted against the Log2 processed 
signal of testis (reference). Each probe on the array is represented by a single dot. On a 
global scale, both testis MCIp preparations appeared to be less methylated than brain or 
monocytic DNA. In addition, brain was usually less different from testis than monocytes. 
Assuming that DNA methylation in proximal promoter regions would be most influential in 
terms of gene regulation the further analysis was restricted to oligonucleotide probes 
located at proximal promoter regions (-600 to +200 relative to the transcription start site). 
A probe was defined as differentially enriched when the fluorescent signal was 
significantly present (p<0.01 for processed signal) and more than 2.4-fold different 
between the samples (Figure 5.2; red spots). 
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Figure 5.2 Global profiling of tissue DNA methylation using human promoter microarrays. 
MvA plots (log2 signal ratio versus log2 processed signal testis) are shown for representative 
hybridization experiments of human testis versus monocytes (A) or brain (B). Black dots represent 
probes that were not significantly changed (p>0.01). Blue and red spots were significantly enriched 
(ratio < 2.4 fold and > 2.4 fold, respectively; p<0.01). 
 
5.1.2 Identification of differentially methylated promoters 
To identify differentially methylated promoters, the analysis was resticted to probes with a 
CpG index above 4. Assuming, that a single oligonucleotide probe should detect 
methylation events within a radius of at least 350 bp (see Figure 5.3A), a given DNA 
fragment should contain at least four or five CpG residues within this radius, in order to 
allow the reproducible separation of unmethylated and methylated fragment (see methods 
section 0). In total, less than 10% of all probes in proximal promoter regions and 4% of all 
proximal promoters were excluded. 
A proximal gene promoter was considered comparatively less methylated 
(hypomethylated) if at least one probe within this promoter was concordantly different in 
both hybridization experiments using the criteria explained above. A promoter was 
grouped as hypomethylated in testis if it was less methylated compared to both somatic 
tissues (brain and monocytes). Promoters were grouped as hypomethylated in brain if 
they appeared less methylated in the brain/testis comparisons but not significantly 
different in the monocytes/testis hybridizations. The latter was also used to identify 
promoters defined as hypomethylated in monocytes. In total, 283 gene promoters that 
were specifically hypomethylated in testis were identified. In addition, 123 gene promoters 
in brain as well as 190 gene promoters in monocytes were less methylated compared to 
testis (complete list is shown in Table 12.1 in the appendix section).  
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5.1.3 Correlation of promoters and nearby genetic 
elements (CGI and Alu repeats) 
As mentioned above, a single oligonucleotide probe should detect methylation events 
within a radius of at least 350 bp. Therefore it is possible that strongly methylated 
sequences (such as methylated CpG islands or Alu repeats) in the vicinity of a probe may 
affect its signal within a 250 to 350 bp distance. To address this question, the presence of 
classical CpG islands8 or Alu repeats138,139 near individual probes was determined at radii 
of 250, 350, and 850 bp around each probe. The relative locations of microarray probe, 
CpG islands, and Alu repeats were determined using the UCSC Genome Browser. As 
demonstrated in Figure 5.3B almost 50% of hypomethylated promoters were associated 
with nearby CpG islands in testis at all distances (p<0.0001; χ²-test). In contrast, less than 
5% of hypomethylated promoters found in the somatic tissues (brain and monocytes) 
showed the same association. When comparing the percentage of hypomethylated 
promoters that are associated with Alu repeats, a significantly higher incidence of Alu 
repeats (50%) was noticed in the vicinity of promoter sequences in testis (Figure 5.3C). 
Whereas in the brain sample only 30% of demethylated promoters were found close to 
Alu-repeats and even less in the monocytes sample (22%). The difference was obvious at 
all distances, but was most significant at 250 bp around individual hypomethylated probes 
(p<0.0001; χ²-test). Genes with tissue-specific demethylated promoters were generally 
distributed over all chromosomes (data not shown). In addition, the higher incidence of 
CpG islands or Alu-repeats in the vicinity of hypomethylated promoters in testis also 
resulted in the observation that these promoter generally showed higher median CpG 
indices (CpGindex=27) as corresponding promoters in brain (CpGindex=13) or monocytes 
(CpGindex=8).  
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Figure 5.3 Association of hypomethylated promoters with CpG islands and Alu repeats. (A) 
Graphical presentation of a probe (50 bp), detected fragments (mean of 450 bp) and distances 
used to determine overlaps with CpG islands and Alu repeats (shown in blue). The presence of 
CpG islands or Alu repeats in the vicinity of proximal promoter probes was calculated for all 
individual promoter regions with a CpG index above 4 (All, 19145 promoters in total) or within each 
hypomethylated group (testis, brain and monocytes with 283, 123, 190 promoters, respectively). 
The percentage of association of hypomethylated probes within a given radius (250 bp) with either 
CpG island (B) or Alu repeats (C) is shown relative to all promoters in a group.  
 
 
Interestingly, a previously unobserved accumulation of testis-specific hypomethylation 
was detected on the Y-chromosome. Several of the annotated Y-chromosomal genes 
appeared hypomethylated compared to both somatic tissues. These genes included VCY, 
DAZ, TSPY and RBMY, which reside in areas on the Y chromosome that are known as 
ampliconic areas140 (see Figure 5.4). These genes were chosen amongst others for the 
initial validation set. 
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Figure 5.4 Different areas on the human Y chromosome. The various areas on the human Y 
chromosome as defined by Skaletsky
140
 are shown color coded. The ampliconic areas include 
large regions (about 30% of the male-specific euchromatin on the Y-chromosome) where sequence 
pairs show greater than 99.9% identity, which is maintained by frequent gene conversion (non-
reciprocal transfer). The most prominent features here are eight massive palindromes, at least six 
of which contain testis genes. Arrows mark the position of 4 genes located within ampliconic areas, 
which are chosen among others for the initial single-gene MCIp validation set. Numbers in brackets 
indicate the number of amplicons detected by the corresponding primer pairs.  
 
5.1.4 Validation of MCIp microarray results by real-time 
PCR 
5.1.4.1 Y-chromosomal genes 
To validate the MCIp microarray data I initially focused on the Y chromosome and 
analyzed all CpG-rich promoters of testis-specific genes in ampliconic areas140 and also 
number of additionally randomly chosen genes of the Y chromosome. Some genes within 
this ampliconic area are present in multiple copies with highly similar promoter sequences 
for each gene cluster. Hence, primers for TSPY, VCY, PRY, RBMY1A1 and DAZ detect 
10, 2, 4, 6 and 4 copies, respectively. Furthermore, with the primer set for the TGIF2L 
gene, two copies were amplified, one of which is located on the Y chromosome and the 
other on the X chromosome. I designed primers for 12 different promoters within this 
region. In order to accomplish the validation I performed small scale MCIp‟s for single-
gene detection, which used 300 ng of DNA fragments per sample. In this experiment I 
also included genomic DNA derived from liver to increase the number of somatic tissues 
used. Each fraction of a MCIp was measured by subsequent real-time PCR independently 
for two times (technical replicates) and each MCIp was carried out twice (biological 
replicates).  
The MCIp data correlated well with the microarray data (see Figure 5.5). Most testis-
specific genes within the ampliconic regions of the Y-chromosome showed 
hypermethylation in somatic cells. In particular following genes, VCY, DAZ, TSPY, RBMY 
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and TGIF2LY, which are highly methylated according to the microarray analysis, showed 
strong hypermethylation in somatic tissues in comparison to the two testis samples. 
Furthermore, in randomly chosen control genes such as NLGN4Y and EIF1AY, 
methylation could be neither detected in the microarray experiment nor in the single-gene 
MCIp. 
 
 
 
 
Figure 5.5 Tissue-specific CpG methylation profiles of the human Y chromosome. (A) 
Schematic representation of microarray results from one of two hybridizations for the human Y 
chromosome. Log2 signal ratios for each probe are represented relative to their absolute 
chromosomal position (based on NCBI build 35 of the human genome sequence). Black spots 
represent probes that were not significantly changed (p>0.01), blue spots were significantly 
enriched but less than 2.4-fold different, and red spots were significantly enriched (p<0.01) and 
over 2.4-fold different. The positions of genes shown in (B) are indicated. (B) Graphical 
representation of single-gene MCIp real-time PCR data for several tested Y-chromosome genes. 
Gene symbols, copy numbers, and representative chromosomal localizations of the amplified 
product (based on NCBI build 35 of the human genome sequence) are given above the heat maps, 
which represent the percentages of amplified material in a given NaCl fraction by gray colouring for 
DNA samples of brain (B), liver (L), monocytes (M), testis sample 1 (T1), and testis sample 2 (T2) 
as described for Figure 5.1. 
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5.1.4.2 Autosomal Genes 
The validation of MCIp results was further extended to autosomes. In total, I designed 
real-time PCR primers for 25 coding and 4 non-coding gene promoters and performed 
single-gene MCIp‟s as described above. The real-time PCR results of these 25 coding 
genes are presented as heat maps in Figure 5.6A. A number of previous studies already 
noted the testis-specific hypomethylation of selected genes such as MAGE-A1140,141. Also 
in non-coding micro-RNAs a variation of tissue-specific promoter methylation could be 
detected. Therefore, 4 micro-RNA promoters (MIRN127, 142, 338 and 363) were included 
in the validation analysis. As illustrated in Figure 5.6B, tissue-specific hypomethylation as 
seen on the microarray was validated using single-gene MCIp analysis. The promoter 
region of MIRN142 was hypomethylated in monocytes, whereas promoters of MIRN338 
and 363 were hypomethylated in the brain sample compared to the other tissues. 
According to the literature, testis-specific hypomethylation was demonstrated for the 
MIRN127 promoter. A recent publication also described the testis-specific demethylation 
of MIRN127 and its activation in somatic tissues by chromatin-modifying drugs142, 
confirming the MCIp result. 
In total, 24 (out of 29) chosen gene promoters showed essentially the same tissue-specific 
methylation patterns as seen on the microarray (see Table 5.1 on page 80). Only DAZL, 
MGP and DCX gene promoters exhibited a different pattern. DAZL appears to be false 
negative on the microarray, whereas MGP and DCX seem to be false positive, because 
microarray data and validation results differed in these cases. Two examples (TYROBP 
and MIRN363), although correctly validated, were significantly different in only one of the 
two microarray hybridizations, but showed the same trend in each case.  
Besides the large number of testis-specific gene promoters that demonstrated 
hypermethylation in somatic tissues, a large group of testis-specific genes was also 
noticed, that did not exhibit a differential methylation status in any of the examined 
tissues. For instance AKAP3, DMRT1, TEKT3 and TTTY14 gene promoters were 
generally unmethylated in all tissues examined. Additionally it was observed, that copies 
of Y-linked genes on other chromosomes like DAZL (Chr. 3) or VCX (Chr. X), that share 
almost identical promoter regions with their homologue on chromosome Y, show somatic 
hypermethylation. Whereas homologous genes that are regulated by different promoter 
sequences like RBMX (Chr. X) or TSPYL5 (Chr. 8) show a different methylation profile as 
compared to their Y-chromosome homologues (data not shown). Only, the SYBL1 genes 
on both X and Y chromosomes appear to represent an exception in having almost 
identical promoters but being solely methylated on the Y chromosome143.  
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Figure 5.6 Heat maps of MCIp real-time PCR results. Graphical presentation of single gene 
MCIp real-time PCR data for several coding (A) and non-coding (B) genes listed in Table 5.1. 
Gene symbols, copy numbers and representative chromosomal localizations of the amplified 
product (based on the NCBI Build 35 of the human genome sequence) are given above the heat 
maps which are presented as described in Figure 5.1. 
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In total, 35 out of 40 (87.5%) validated gene promoters demonstrated the same 
methylation profile in global and single-gene analysis. Taken together, the MCIp 
microarray approach demonstrated a high reproducibility. For further confirmation I used 
another MCIp independent approach to validate the microarray results. 
5.1.4.3 Microarray-validation using bisulfite-treatment of genomic DNA 
As a second, MCIp-independent validation approach I directly analyzed cytosine 
methylation by bisulfite-treatment of genomic DNA followed by sequencing. Promoters of 
five genes were selected and primer pairs specific for bisulfite-treated DNA were 
designed. Three of them exhibited hypomethylation specifically in testis samples, whereas 
one was hypomethylated in the brain and one in the monocytes sample. For each 
promoter two pair of primers were used comprising of an „outer‟ pair and an „inner‟ pair. 
The „outer‟ primer pair was used in the initial amplification step (1st PCR), whose product 
was used as a template for the „inner‟ pair of primers during the 2nd PCR, in order to 
increase specificity of PCR amplification (nested PCR). Each PCR steps was monitored 
by agarose gel electrophoresis. The purified PCR products of the 2nd PCR were cloned 
into the pCR2.1-TOPO vector and transfected into chemically competent E. coli TOP10. 
Insert-containing plasmids were isolated from single colonies and sequenced. The results 
are shown in Figure 5.7. The hypomethylation patterns seen for BACH and TLR4 were 
clearly brain and monocyte-specific, respectively. BACH was hypomethylated to a 
stronger extend in the brain compared to the other tissues. TLR4 was completely 
unmethylated in monocytes only, whereas all other samples contained both fully and 
partially methylated sequences. The other two examples, MAGEB10 and TGIF2LY, 
exhibited almost complete methylation of all analyzed sequences only in somatic tissues 
(brain, monocytes and liver). In contrast, completely unmethylated fragments occurred 
only in both testis samples. Taken together these four gene promoters showed the same 
tissue-specific methylation pattern in the single-gene MCIp validation experiment (see 
Figure 5.5 and Figure 5.6), as well as in the microarray analysis.  
The fifth example gene shown in Figure 5.8 ZSCAN5 appeared to be strongly 
unmethylated in both testis samples. Interestingly, the promoter of this gene contained an 
Alu repeat, whose methylation status was also examined. Although it was not analysed by 
single gene-MCIp, the bisulfite sequencing result correlated well with the microarray 
result: ZSCAN5 exhibited hypomethylation only in the two testis samples. Interestingly the 
Alu repeat was mainly unmethylated as well.  
In total, all five bisulfite sequencing examples validated the microarray results, indicating 
that the initial global experiment correctly identified tissue-specific hypomethylation with a 
low false positive rate.  
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Figure 5.7 Bisulfite sequencing results of selected gene promoters. (A-D) Genomic DNA from 
the indicated tissues was analyzed for CpG methylation at BACH (A), TLR4 (B), MAGEB10 (C) and 
TGIF2LY (D) loci by bisulfite sequencing. Bisulfite-treated DNA was amplified in individual PCR 
reactions. PCR-products (representing the sense strand) were sub-cloned and several individual 
clones were sequenced. The analyzed fragment is schematically represented above each figure 
where a CpG dinucleotide is shown as a vertical line. The positions of exons are displayed as gray 
boxes and transcription start sites by arrows. For each tissue, the position of CpG dinucleotides is 
shown as a square (empty: unmethylated; filled: methylated).  
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Figure 5.8 Bisulfite sequencing of ZSCAN5. Additional example of bisulfite sequenced promoter 
region presented as described in Figure 5.7.  
 
5.1.4.4 Summary of validation 
In total, I validated 44 genes (summarized in Table 5.1) using single-gene MCIp and 
sequencing of bisulfite-treated genomic DNA as independent DNA methylation mapping 
techniques. Within Table 5.1 the MCIp-Array column indicates the tissues that were found 
to be less methylated (hypomethylated) compared to the two other tissues used in the 
microarray experiment. The promoters of TYROBP and MIRN363 were significantly 
different in only one of the two microarray hybridizations, but showed the same trend in 
each case. The data obtained from the liver DNA sample in single-gene MCIp were not 
included, since this sample was not analyzed by microarray. Single-gene MCIp validation 
data obtained from the brain, testis and monocyte samples is shown (MCIp-PCR), as well 
as data derived from sequencing of bisulfite-treated genomic DNA (Bisulfite). Primers for 
AURKC and DDX3Y were located more than 600 bp upstream (“up”) of the putative 
transcription start site in a region that was differentially methylated as indicated, whereas 
the proximal region was not different in both cases. In addition, Table 5.1 shows 
information obtained from public available databases. The presence or absence of a CpG 
island in the 5‟-proximal promoter region (CGI promoter) was determined using the UCSC 
Genome Browser (http://genome.ucsc.edu/). Expression data (mRNA expression) were 
downloaded from SymATLAS (http://symatlas.gnf.org/SymAtlas/) and RefEXA databases 
(http://www.lsbm.org/site_e/database/) and indicate the primary source of expression.  
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Table 5.1 Profiles of promoter hypomethylation and mRNA expression of selected genes 
Gene symbol CGI promoter Chr.  MCIp-Array MCIp-PCR Bisulfite mRNA Expression 
BACH (ACOT7) no 1 brain brain brain brain 
CORT no 1 brain brain - ubiq.* 
DAZL yes 3 not diff.* testis - testis 
MORC yes 3 testis testis - testis 
TSPYL5 yes 8 testis, brain testis, brain - testis, brain, blood 
DMRT1 yes 9 not diff. not diff. - testis 
TLR4 no 9 mono mono mono blood 
LMO2 no 11 mono mono - blood, endothelium 
SKD3 yes 11 testis, brain testis, brain - testis 
SPTBN2 no 11 brain brain - testis, brain, other 
AKAP3 no 12 not diff. not diff. - testis 
FGF6 yes 12 testis testis - testis, muscle 
H1T2 no 12 testis testis - testis 
MGP no 12 mono not diff. - ubiq. (not blood) 
MIRN127 yes 14 testis testis - testis 
APBA2 no 15 brain brain - brain, blood 
SNRPN yes 15 testis testis - ubiq. (impr.)* 
PRM1 no 16 not diff. not diff. - testis 
MIRN142 no 17 mono mono - n.a.* 
MIRN338 no 17 brain brain - n.a. 
TEKT3 yes 17 not diff. not diff. - testis 
AURKC (up)
6
 yes 19 testis testis - testis 
TYROBP no 19 not diff. (mono) mono - blood 
ZSCAN5 yes 19 testis - testis testis 
PRAME yes 22 testis testis - testis 
DCX no X mono not diff. - fetal brain 
MAGEB10 no X testis testis testis n.a. 
MIRN221 no X not diff. - not diff. n.a. 
MIRN363 no X not diff. (brain) brain - n.a. 
RBMX yes X not diff. not diff. - ubiq. 
TAF7L no X testis testis - testis 
VCX no X n.a. testis - testis 
DAZ yes Y n.a. testis - testis 
DDX3Y (up) no Y testis testis - testis, blood  
EIF1AY no Y not diff. not diff. - blood 
NLGN4Y yes Y not diff. not diff. - ubiq. 
PRY no Y not diff. not diff. - testis 
RBMY1A1 yes Y testis testis - testis 
SYBL1 yes Y n.a. testis - testis 
TGIF2LY no Y testis testis testis testis 
TMSB4Y yes Y not diff. not diff. - ubiq. 
TSPY yes Y testis testis - testis 
TTTY14 yes Y n.a. not diff. - testis 
UTY no Y testis, brain testis, brain - ubiq. 
VCY no Y testis testis - testis 
*ubig.: ubiquitous; not diff.: not different; impr.: imprinted; n.a.: not analyzed 
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The present microarray analysis confirmed the already published testis-specific 
methylation status of several genes, which were not independently validated by single-
gene MCIp. Those genes comprise DDX4144, ACTL7B145, as well as TAF7L and LUZP4146. 
MAGEA1 and TKTL1 that had been analyzed previously by bisulfite sequencing146,147 
were detected as hypomethylated in only one of the two testis samples tested. 
5.1.5 Relationship between DNA methylation and gene 
expression 
Next the relationship between CpG DNA methylation of gene promoters and the 
expression patterns of the corresponding genes was correlated. For this RNA expression 
data was extracted from publicly available reference databases for gene expression 
analysis for all corresponding differentially methylated fragments. In particular BioGPS 
(formerly SymATLAS) and RefExA databases were used. Genes with unknown 
transcription status were removed and the analysis was restricted to genes, for which 
expression data were available. Hence, in total 426 genes were analyzed composed of 
201 testis-, 88 brain- and 137 monocyte-specific hypomethylated genes. The distribution 
of expression patterns for tissue-specific hypomethylated fragments is summarized in 
Figure 5.9. The largest group of testis-hypomethylated genes (75; 37%) was specifically 
expressed exclusively in testis. Another 17% was expressed in testis but also in other 
tissues excluding (14; 7%) or including (19; 10%) monocytes or brain. Thus, 55% of 
hypomethylated genes were expressed in testis, even though not solely. Expression of 
genes that were hypomethylated in monocytes or brain was also often specific for the 
respective gene (19 or 21%, respectively). Similar to testis, 57% of hypomethylated genes 
were expressed in brain, but also in other tissues excluding or including testis or 
monocytes (18% each).  
Interestingly, most genes in the monocyte-hypomethylated group were transcribed 
specifically in the hematopoietic system (in total 104; 76%), rather than in the specialized 
cell type itself (monocyte). Only 4% of these genes were also expressed in brain or testis. 
The coexistence of DNA methylation and transcription in a certain tissue was also 
detected.  
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Figure 5.9 Comparison of methylation and expression profiles. Distribution of expression 
patterns for genes with hypomethylated promoters in (A) testis, (B) brain or (C) monocytes. The 
methylation data derived from microarray experiments while the expression data was obtained from 
publicly available reference databases for gene expression analysis (RefExa and BioGPS, formerly 
SymATLAS).  
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We also determined the number of genes showing a restricted expression pattern in 
testis, monocytes or brain within each group of hypomethylated genes. 95% of genes 
which were exclusively demethylated in testis were only expressed testis. Although 
slightly reduced, a similar degree of correlation appeared to be true for brain and 
monocytes, ranging from 90% to 79%, respectively. As a summary Figure 5.10 illustrates 
that the number of genes expressed in a certain tissue was significantly enriched 
(p<0.0001) in the hypomethylated group of the same tissue. This observation strongly 
suggests that tissue-specific hypomethylation significantly correlates with tissue-specific 
transcription.  
 
 
 
 
Figure 5.10 Correlation of tissue-specific expression and demethylation. Distribution of testis-, 
brain-, or monocytes-specific genes in each demethylated group.  
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5.2 Allele-specific DNA methylation in mouse 
strains is mainly determined by cis-
acting sequences 
The data obtained from this project has already been submittedB, but the review process 
was still in progress at time of writing this thesis. Microarray gene expression data was 
deposited with the NCBI GEO database and accession code GSE14644 and will be 
available upon publication. Results from locus-wide comparative hybridizations will be 
available under the accession code GSE14463. DNA sequencings were deposited with 
GenBank (Accession numbers: FJ751937-FJ752004). 
5.2.1 Inbred mice as model organisms & Preliminary 
work 
The true extent of epigenetic variation between individuals is still unknown. The 
development of assays to detect such variation will facilitate more systematic analyses 
and will contribute to a better understanding of the epigenetic influence on individual 
phenotypes. In addition, it is currently unknown as well, if such individual variations are 
inherited based on genetic mechanisms (in cis and in trans) or based on epigenetic 
mechanisms. To map interindividual DNA methylation differences we chose to analyze 
bone marrow-derived macrophages of two distinct inbred mouse strains C57BL/6 and 
BALB/c. Inbred mice are ideally suited to study the inheritance of an epigenetic mark like 
DNA methylation, because they have a distinct genetic background, which allows for 
reproducible mating conditions between two inbred mouse strains. To study the 
inheritance of an epigenetic mark in the F1 generation, one needs to define regions that 
are epigenetically different in cells of both strains. However, systematic screens for 
epigenetic differences in mice have not been performed and only a handful of 
epigenetically variable regions have been studied so far89. In the present study, we 
performed a combined genetic and epigenetic profiling of strain- specific differences in 
inbred mice. Therefore the MCIp procedure was further advanced to compare methylation 
profiles of a defined cell type (bone marrow-derived macrophages) from two inbred mouse 
strains (C57BL/6 & BALB/c) that represent prototypic models for Th1- or Th2- dominated 
immune responses148,149. We chose to analyze macrophages, because they may actually 
contribute to some immune-related phenotypic differences in these strains and they can 
                                               
B
 submitted publication: Schilling,E., El-Chartouni,C. & Rehli,M. Allele-specific DNA methylation in 
mouse strains is mainly determined by cis-acting sequences 
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be grown under identical conditions from bone-marrow progenitors. It was planned to use 
tiling arrays for comparative methylation profiling. However, although possible, the 
coverage of the whole genome is very expensive due to the high amounts of arrays 
needed. To circumvent this problem, the analysis was restricted to regions where genes 
showed differences in their mRNA expression profile in bone marrow-derived 
macrophages (BMMs) from the two inbred mouse strains, because epigenetic differences 
are likely to occur in such regions. Gene expression analyses using microarrays of 
untreated BMMs as well as IL-4 treated BMMs were previously performed in our lab. 
Microarray hybridizations were performed in two independent biological replicates. The 
results are summarized in Figure 5.11A. With few exceptions, differential gene 
expression was already detected in untreated BMM. However, some genes were shown 
to be differentially regulated by IL-4 and are therefore included in the list of differentially 
expressed genes. In total, 311 hits (probes), representing 311 genes or transcripts were 
identified, which showed at least five-fold differences between strains. The array results 
were controlled on a single gene level by quantitative reverse transcriptase-(RT)-PCR for 
a number of representative genes. Quantitative PCR results are shown in Figure 5.11B. 
All chosen examples validated the microarray results, indicating that the generated list 
contains few, if any, false positives. 
5.2.2 Design of custom tiling array 
Based on the expression analysis, the set of 311 differential probes was further reduced 
by removing those which are redundant or covering invalidated transcripts, resulting in a 
final set of 165 known genes showing significantly different gene expression between 
C57BL/6 and BALB/c BMM. Based on the transcriptome analysis, a custom tiling 
microarray was designed using the eArray software from Agilent. Assuming that 
epigenetically differentially regulated regions were not only located within the promoter 
sequence itself, the tiling array was designed to cover whole regions around differentially 
expressed transcripts. Depending on the genetic neighborhood about 50 kb downstream 
and upstream of a specific gene were covered with partially overlapping microarray 
probes. Regions containing repeats were excluded by the eArray software in order to 
minimize cross-hybridization effects. In total, the custom designed 240k Array covered 28 
mega bases of the mouse genome and contained 181 genomic segments, with a median 
size of 110 kb. These genomic regions contained more than 500 proximal promoter 
regions and at least 800 genes, which included a number of well known and 
immunologically relevant genes like Plau, Marco, Ltb and Ill1b (see a complete list in 
Table 12.2, page 173). The tiling array also contained 16 randomly chosen control regions 
that were either equally expressed or not expressed at all in both cell types. 
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Figure 5.11 Expression profiling of BMM from two inbred mouse strains. (A) BMM from 
BALB/c and C57BL/6 strains were left untreated or treated with IL-4 for 4 h or 18 h. Expression 
analysis was performed using Mouse Whole Genome arrays (Agilent) to identify genes that are 
differentially expressed in either strain. Shown is a hierarchical clustering of 311 probes that show 
at least five-fold differences in median normalized signals between untreated (0 h) or IL-4 treated 
(4 h, 18 h) BMM. Gene ontology (GO) terms enriched in either of the two gene clusters are shown 
on the right. Numbers in brackets indicate: genes in cluster/genes in cluster with specific GO 
term/total genes/total genes with specific GO term. (B) Validation of differential gene expression in 
untreated macrophages using qRT-PCR. Results for all genes (GOI, genes of interest) were 
normalized for Hprt1 expression. Data represent mean values ± SD of at least four independent 
qPCR analyses from at least two independent experiments. The top two rows contain genes 
indentified as higher expressed in BALB/c, while the lower two rows show genes which are higher 
expressed in C57BL/6 mice. 
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5.2.3 MCIp “mirror-image” procedure 
The general MCIp procedure is described in the methods section and was further 
improved for a novel application in section 5.1. Here I separated genomic DNA from 
macrophages from both mice strains into unmethylated (CpG) and methylated (mCpG) 
pools and co-hybridized the two unmethylated or the two methylated DNA pools onto 
locus-wide tiling array. As enriched DNA from one strain in the methylated fraction should 
be depleted in the unmethylated fraction, the signal intensities from CpG and mCpG pool 
hybridizations should complement themselves and, in addition, serve as an internal 
control. This “mirror-image” approach thereby allows the identification of differentially 
methylated regions (DMR), which is supported by reducing false positive hits. In addition, 
the stringency of hybridization was increased by a combination of a higher incubation 
temperature (67°C) and by adding formamide (15%) to the hybridization reaction mix. 
These modified reaction conditions were expected to additionally reduce 
crosshybridization events (nonspecific binding), which possibly give rise to misleading 
results. I used large scale MCIp (4 µg of each DNA) in order to get sufficient amount of 
gDNA for subsequent labeling and microarray hybridization. Prior to labeling, the 
separation of CpG methylation densities of individual MCIp fractions was controlled by 
qPCR using primers covering an imprinted region of Mest and a genomic region lacking 
CpG‟s within a range of 1000 bp (empty_mm). The methylated and unmethylated alleles 
of Mest are separated in BMM's from each mouse strain and elute in the low salt fractions 
and high salt fractions, respectively. The region defined by the empty_mm primers 
(negative control) eluted in the low salt fraction of the fractionation due to the complete 
absence of CpGs (data not shown). After defining a threshold at a salt concentration of 
500 mM, the fractions containing mainly unmethylated DNA (CpG pool) or methylated 
DNA (mCpG pool) were pooled. Subsequently the samples were directly labeled for 
microarray hybridization. C57BL/6 samples were labeled with Alexa-Fluor-5 and BALB/c 
samples using Alexa-Fluor-3. Efficiency of labeling was controlled with UV-spectroscopy 
and samples were hybridized on our custom design Agilent 240k microarrays as follows: 
 
1) C57BL/6 (CpG pool) repl. 1 versus BALB/c (CpG pool) repl. 1 
2) C57BL/6 (mCpG pool) repl. 1 versus BALB/c (mCpG pool) repl. 1 
3) C57BL/6 (CpG pool) repl. 2 versus BALB/c (CpG pool) repl. 2 
4) C57BL/6 (mCpG pool) repl. 2 versus BALB/c (mCpG pool) repl. 2 
 
Image-data was extracted with Agilent feature extraction software and imported to 
Microsoft Excel for further analysis. Because the signal intensities were biased in 
correlation to their GC content (higher GC content lowered the average signals), the 
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probes were GC normalized. In general, the replicates for each pool correlated well within 
individual hybridizations (r²=0.84 CpG pools and r²=0.85 for mCpG pools). However, the 
analysis is additionally complicated by the fact that the sequence of microarray probes 
corresponds to only one strain‟s genome (the reference genome of C57BL/6) and 
sequence variants between mouse strains can additionally influence the hybridization 
efficiency of microarray probes. Since the extent of genetic variation between both strains 
at the investigated loci was largely unknown, it was necessary to analyze genetic 
variations between both mouse strains at first (see next paragraph). Utilizing the fact that 
essentially the entire genome of both strains was analyzed in two halves (CpG pool and 
mCpG pool), the two independent microarray results were re-combined to obtain a virtual 
comparative hybridization (vCGH) of both strains. Figure 5.12 illustrates the whole 
procedure and explains the workflow.  
 
 
Figure 5.12 Simultaneous detection of epigenetic and genetic differences using MCIp. The 
experimental workflow is presented schematically. (A) Fragmented genomic DNA from bone 
marrow-derived macrophages of either mouse strain is fractionated using a MBD2-Fc column and 
separated into methylated (mCpG) and unmethylated (CpG) DNA pools. (B) Both DNA pools are 
fluorescently labeled and compared between mouse strains by co-hybridization on a locus-specific 
microarray using stringent conditions. (C) Array results are combined in a virtual CGH analysis to 
detect copy number variations (CNVs) and sequence polymorphic regions that are removed (D) 
from further analysis. (E) Differentially methylated regions are detected by analyzing remaining 
array probes for diametrically opposed enrichment behaviour between both hybridizations (e.g. a 
region that is relatively enriched in the unmethylated pool of BALB/c and shows reverse enrichment 
behaviour in the methylated pool is considered hypomethylated in BALB/c). 
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5.2.4 Virtual CGH to detect genetic differences 
As mentioned above, the two genomes of both mouse strains were virtually compared. 
For this, the signal intensities of both independent experiments and both genome pools 
(from CpG pool and mCpG pool) at each individual probe were added up for each strain. 
Next, the log10 ratios of cumulative signal intensities (C57BL/6 / BALB/c) were plotted 
against their chromosomal localization. Probes hybridizing to genomic DNA of both strains 
to the same extent should exhibit a log10 ratio of cumulative signal intensities close to 
zero. Unbalanced hybridization behavior in the vCGH with a log10 ratio of cumulative 
signal intensities >0.15 as compared to the surrounding probes was used as a threshold 
for detecting genetic differences between strains. Figure 5.13A illustrates that 15.1% of 
all microarray probes (34096) demonstrated preferential hybridization with gDNA from 
C57BL/6 macrophages. In addition, the majority of known SNPs (13535) overlapped with 
probe sequences showing unequal hybridization behavior, whereas all other probes 
associated with relatively few SNPs (2801). A representative set of regions (9 regions) 
that were indicative of sequence variations were sequenced for both strains and it was 
found that every affected probe contained at least one, but more often two or three 
sequence variations including SNP and microdeletions or –insertions: An example of 
sequence alignment is shown in Figure 5.13B (the complete list of sequence alignments 
can be found in the appendix section). In addition, it was also found, that the sequence 
variation was generally higher in genes that showed differential expression in 
macrophages of both strains (Figure 5.13A, gray dots) than in control genes (either 
equally expressed or not expressed; Figure 5.13A, black dots). Furthermore a number of 
regions where vCGH signals indicated copy number variations (CNV) were also 
indentified. Two regions (Nlrp1b and A430090E18Rik) appear to be deleted in BALB/c, 
two regions (Chia/Chi3l3/Chi3l4 and 2610305D13Rik) seem to be duplicated in C57BL/6 
and five regions (Btbd9/Glo1/Dnahc8/Glpr1, CD244, Ifi202b, Tmem14a and Gbp1/Gbp2) 
appear at least duplicated in BALB/c. I validated gene duplications for three locations 
using quantitative real-time PCR (Figure 5.13C). Some of the larger CNV‟s were 
previously identified using standard CGH approaches150 suggesting that vCGH analysis 
correctly identified genetic alterations between both mouse strains. All probes with 
underlying genetic differences were removed before microarray results were further 
analyzed for differential DNA methylation.  
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Figure 5.13 Detection of sequence variation using virtual CGH. (A) The histogram shows a 
CGH-like representation of combined signal intensities from separate hybridizations of methylated 
and unmethylated DNA pools. Control loci (in black) show relatively few C57BL/6-enriched signals. 
Two regions (Nlrp1b and A430090E18Rik, in red) are deleted in BALB/c, two regions 
(Chia/Chi3l3/Chi3l4 and 2610305D13Rik; in dark red and orange, respectively) are duplicated in 
C57BL/6 and five regions (Btbd9/Glo1/Dnahc8/Glpr1, CD244, Ifi202b, Tmem14a and Gbp1/Gbp2; 
in blue or green) appear at least duplicated in BALB/c. Genomic locations are provided for 
individual regions. The signs > and < indicate that the affected regions extended over the analyzed 
area. (B) Sequences of an exemplary region where several probes (boxed in gray) showed 
C57BL/6-enriched signals. Compared to the reference strain, BALB/c contains several nucleotide 
exchanges (highlighted in red). (C) QPCR-validation of three copy number variations 
(Chia/Chi3l3/Chi3l4, three amplicons; Btbd9/Glo1/Dnahc8/Glpr1, five amplicons, Gbp1/Gbp2, one 
amplicon) detected by vCGH. Regions where no sequence variations were seen have been chosen 
as controls (control 1-3; Camk2b, Chst10, Marco).  
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5.2.5 Detection of DMR by microarray 
The vCGH-corrected datasets were further analyzed to identify differentially methylated 
regions. All probes indicating sequence variations were excluded (34096). A 
representative scatter plot of vCGH-corrected comparative microarray hybridizations from 
unmethylated (CpG) and methylated pools (mCpG) is shown in Figure 5.14, where 
microarray probes showing the expected complementary behavior are colored in red 
(hypomethylated in C57BL/6 BMM) and blue (hypomethylated in BALB/c BMM). Next, 
hypomethylation scores were calculated by subtracting the log10 signal intensity ratios of 
the CpG pool hybridization from those of the mCpG pool hybridization of the same 
experiment. Hypomethylation scores were then analyzed using a sliding window 
approach. The window included five probes with a maximal distance of 500 bp between 
two neighboring probes. A cumulative hypomethylation score of the five probes >1.5 (in 
both replicate experiments) or >1.3 (if the value for each of the five probes was >0.15 in 
both replicate experiments) was used as a threshold for detecting hypomethylation in 
C57BL/6. A cumulative hypomethylation score of the five probes <-1.5 (in both replicate 
experiments) or <-1.3 (if the value for each of the five probes was <-0.15 in both replicate 
experiments) was used as a threshold for detecting hypomethylation in BALB/c.  
 
 
 
Figure 5.14 Sequence regions with strain-specific CpG methylation. (A) Scatter plots of 
normalized signal intensities from independent hybridizations of methylated (mCpG) and 
unmethylated (CpG) DNA pools. Probes in differentially methylated regions (colored in red and 
blue) show the expected intensity distribution (enriched in one pool and depleted in the other one). 
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In total, 435 regions with lineage-specific CpG methylation that were associated with 171 
genes were identified. Table 5.2 contains a list of 32 selected mouse strain-specific DMR. 
The genomic location (Build 36 assembly by NCBI, mm8) of the „core‟ region of the DMR 
is given along with information on the associated (neighboring) gene, its relative position 
to this gene, its methylation status and BMM expression data (if available) for the 
associated gene. Microarray expression data was median-normalized to the untreated 
C57BL/6 BMM (0 h) sample (data for 4h and 18h treatments is not shown). The call status 
of individual probes in each sample is given in brackets behind the relative expression 
values (P, present; A, absent). As expected, DNA methylation at proximal promoter 
regions correlated with lower gene expression levels in all but one cases (except 
Slc13a3), whereas no significant correlation between methylation and transcription state 
was evident at promoter distal sites. In addition, a remarkable number (about 90%) of the 
identified DMR contained probes that showed unbalanced hybridization behavior in the 
vCGH, suggesting that the large majority of DMR are associated with genetic variations.  
 
Table 5.2 Annotated list of selected mouse strain-specific DMR 
Center of DMR 
(Mouse assembly mm8) 
Gene symbol Position 
relative to 
gene 
De-
methylated 
in 
BMM 
BALB/c 
(0h) 
BMM 
C57BL/6 
(0h) 
chrX:119220336-119220381 3110007F17Rik prom C57BL/6 0.0515 (A) 0.992 (P) 
chr6:5333111-5334506 Asb4 distal C57BL/6 0.0642 (P.A) 0.997 (P) 
chr4:46594578-46596131 Coro2a intra C57BL/6 0.209 (P) 0.997 (P) 
chr4:46610429-46610801 Coro2a intra C57BL/6 0.209 (P) 0.997 (P) 
chr4:46620908-46622454 Coro2a intra C57BL/6 0.209 (P) 0.997 (P) 
chr7:4064078-4064123 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr7:4073211-4073587 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr7:4073898-4074764 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr7:4081211-4081948 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr4:147309756-147309900 Frap1 intra C57BL/6 1.22 (P) 0.998 (P) 
chr7:4468706-4470122 Isoc2b prom C57BL/6 0.188 (P) 0.987 (P) 
chr7:4476223-4476274 Isoc2b distal C57BL/6 0.188 (P) 0.987 (P) 
chr5:53010351-53010409 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53012858-53013017 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53013951-53014431 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53026418-53026767 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53049276-53049634 Pi4k2b intra BALB/c 7.234 (P) 0.999 (P) 
chr5:53058948-53058993 Pi4k2b distal BALB/c 7.234 (P) 0.999 (P) 
chr5:53061668-53062228 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53063596-53064069 Pi4k2b distal BALB/c 7.234 (P) 0.999 (P) 
chr7:37961808-37962602 Pop4 distal BALB/c 0.1 (P) 0.999 (P) 
chr2:118921263-118922015 Ppp1r14d prom C57BL/6 1.414 (A) 0.996 (A) 
chr9:102967337-102967700 Rab6b distal C57BL/6 0.0133 (A) 0.988 (P) 
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Center of DMR 
(Mouse assembly mm8) 
Gene symbol Position 
relative to 
gene 
De-
methylated 
in 
BMM 
BALB/c 
(0h) 
BMM 
C57BL/6 
(0h) 
chr9:102971565-102971612 Rab6b intra BALB/c 0.0133 (A) 0.988 (P) 
chr11:3092678-3093978 Sfi1 prom BALB/c 16.38 (P) 0.974 (P) 
chr2:165163847-165163893 Slc13a3 intra BALB/c 0.0413 (P.A) 0.999 (P) 
chr2:165165074-165165182 Slc13a3 prom BALB/c 0.0413 (P.A) 0.999 (P) 
chr18:58681880-58682279 Slc27a6 intra C57BL/6 8.848 (P) 0.997 (A) 
chr18:58686133-58686695 Slc27a6 intra C57BL/6 8.848 (P) 0.997 (A) 
chr2:118931167-118931543 Spint1 intra C57BL/6 0.0282 (P) 0.839 (P) 
chr2:118933687-118934010 Spint1 intra C57BL/6 0.0282 (P) 0.839 (P) 
chr7:29692014-29692149 Zfp568 prom C57BL/6   
Complete list is shown in the appendix section 12.3. 
5.2.6 Correlation between genetic variability and 
differential methylation status 
As described earlier, the number of probes demonstrating unbalanced hybridization 
behavior (34096) was substantially larger that the number of known variations. This 
suggested that sequences of both strains are far more variable at the studied genomic 
regions than previously published SNP data151 suggests. This is in line with an earlier 
study, suggesting that the published SNP data only captures a fraction of the variation 
found in the laboratory mouse152. To analyze if genomic intervals investigated in this study 
were enriched for genetic variation as compared to the whole genome, which could 
produce a bias towards cis-dependent DMR, we calculated the distribution of known SNP 
across all genomic loci on the microarray.  
The distribution of known SNP markedly varied across all interrogated regions with 15-
20% of all regions having comparably low or high SNP densities (less than 2/10000 or 
more than 15/10000, respectively; a diagram is provided in Figure 5.15A). The average 
SNP density (1 SNP every 1200 bp) on our array was approximately two times higher as 
compared to the whole genome (1 SNP every 2500 bp), suggesting that differentially 
expressed genes tend to contain more polymorphisms. Furthermore, we studied 
correlations between genetic variability and differential methylation status. According to 
the classifications provided by the Perlegen-study151, eighty of the genomic intervals 
contained DMR of intersubspecific origin and sixty six intervals contained DMR of 
intrasubspecific origin. Thirty two regions were predicted to be of the same haplotype. 
However, the majority of DMR in the latter class were also associated with probes 
showing unbalanced hybridization behavior in the vCGH, suggesting that most of them 
actually are of intrasubspecific origin (Figure 5.15B). In total, about 90% of the identified 
DMR contained probes that showed unbalanced hybridization behaviour in the vCGH. 
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DMR and SNP count per region correlated (r2=0.59) suggesting a link between DMR 
occurrence and genetic variation between both strains. A corresponding diagram and a 
box plot on DMR/SNP correlation are provided in Figure 5.15C and Figure 5.15D. 
 
 
 
Figure 5.15 Correlation of DMR and genetic variation. (A) The bar graph shows the distribution 
of SNP-densities across all genomic loci on the microarray (bin size 10 SNP/100000 bp). (B) The 
origin of each DMR was determined using the Mouse Ancestry Mapper and Mouse Haplotype 
Block Viewer provided by Perlegen Sciences (mouse.perlegen.com). The first column indicates 
classifications for individual DMR. For regions that were either not classified or predicted to be of 
the same haplotype the number of DMR showing unbalanced hybridisation behaviour are given in 
brackets. The second column indicates how many loci were associated with either type of 
classification. (C) Numbers of DMR/100kb were plotted against SNP counts per 100 kb for all loci 
present on the array. (D) The box plot shows the distribution of DMR counts conditional on the SNP 
counts at corresponding loci. The red lines denote medians, boxes the interquartile ranges, and 
whiskers the 5th and 95th percentiles. The total numbers of loci within each SNP-density group are 
given in brackets. 
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5.2.7 MALDI-TOF mass spectrometry: Validation of 
microarray data 
5.2.7.1 Method characteristics 
To validate and quantify methylation differences at the resolution of single CpGs, a 
representative set of DMR (from Table 5.2, page 92) was chosen to be analyzed by 
MALDI-TOF mass spectrometry. This method is based on matrix assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) measurement of 
bisulfite converted DNA using the EpiTYPER platform (Sequenom, San Diego, USA). 
Bisulfite treatment generates methylation dependent sequence variations, which can be 
measured using MALDI-TOF mass spectrometry. Moreover this procedure enables one to 
analyze multiple CpGs in one amplicon and to compare their methylation status between 
individual samples. Unlike classic methods for assessing methylation events at individual 
sites in the genome, EpiTYPER quantitatively assesses methylation ratios simultaneously 
across multiple CpG sites over multiple samples (see methods section for more details). 
5.2.7.2 Genomic DNA sequences in C57BL/6 and BALB/c 
Since many sequence variations were detected between both mouse strains, it was 
necessary to obtain the precise genomic DNA sequences at the desired loci prior to 
primer design for MALDI-TOF analysis. Initially a set of 22 regions was chosen based on 
the MCIp microarray results and underlying genomic DNA was sequenced from two male 
individuals of both strains. DNA sequencing indicated that DMRs were often associated 
with strain-specific insertions of CpG-containing repetitive sequences, not overlapping 
with microarray probes, which were likely methylated and responsible for the observed 
methylation pattern. Thus, four regions were excluded from further analysis, mainly 
because of large indels (insertion-deletion polymorphisms). The complete lists of 
sequence alignments between C57BL/6 and BALB/c are attached in the appendix section 
(see section 12.4, page 187). The residual 18 regions (see Table 5.3, page 100) were 
analyzed on the EpiTYPER platform. With one exception (Eps8l1), all of the analyzed 
regions contained sequence variations between mice strains. Four representative 
sequence alignments, including 1600021P15Rik (A), Coro2a (B), 3110007F17Rik (C) and 
Zfp568 (D) genes, are presented Figure 5.16 on the following two pages. All four 
examples exhibited single nucleotide exchanges within BALB/c sequences as compared 
to the C57BL/6 reference strain (13 in (A), 3 in (B), 21 in (C) and 12 in (D)). The latter two 
regions additionally contained small deletions (two in 3110007F17Rik) or insertions (one 
in Zfp568) within the sequenced BALB/c regions.   
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A) 
1600021P15Rik 
chr16:28,833,612-28,834,468 
C57BL/6   ----------------------GTAGTCAACAATGTGTTGACAGAATGTTTCCCCAGAGAACGGAGGGGACCCAAGCACACAGCTCTCCCTCCTTTGTGC 
BALB/c    ----------------------GTAGTCAACAATGTGTTGACAGAATGTTTCCCCAGAGAACGGAGGGGACCCAAGCACACAGCTCTCCCTCCTTTGTGC 
 
C57BL/6   TCAGGCTGCTACACTGATCTCAGCTTGGGAGGAGGAAGTATGGCGGTTGAGGGAAAAGGTTTCACATGGAGAGCGCCTAATATCCTGTGTACCTCAGATA 
BALB/c    TCAGGCTGCTACACTGATCTCAGCTTGGGAGGAGGAAGCATGGCGGTTGAGGGAAAAGGTTTCCCATGGAGAGCGCCTAATATCCTGTGTACCTCAGATA 
 
C57BL/6   ATACACACATAACCACTGCTGGGCTTTAACGGAAGCCTATACTCTTAGCTTTGCCCTTCATAAACTTAGCTTTGTCCTTAGAGATCTTTAGGACCTACAA 
BALB/c    ATACACACACAACCACTGCTGGGCTTTAACGGAAGCCTATACTCTTAGCTTTGCCCTTCATAAACTTAGCTTCGTCCTTAGAGATCTTTAGGACCTACAA 
 
C57BL/6   CAGGCTATGGAATGATGAAGCTAACACGATCTGTCCGGCCCCAGGGCCGTGTTCTCCCATCTCACTGCATCCTCACTTCTTCCGTGACAACTCTATCTCT 
BALB/c    CAGGCTATGGAATGATGAAGCTAACACGGTCTGTCCGGCCCCAGGGCCGTGTTCTCCCATCTCACTGCATCCTCACTTCTTCCGTGACAACTCTCTCTCT 
 
C57BL/6   CCCGTGCAGCCACAGAAGGATGGCTACTGTTTACCTCAGACAACGGAACTTAACACAGGAACTACAGATTTTGCCTAAACCACAGCTAAAAGACAAATCT 
BALB/c    CCCGTGCAGCCACAGAAGGATGGCTACTGTTTACCTCAGACAACGGAGCTTAACACAGGAACTACAGATTTTGCCTAAACCACAGCTAAAAGCCAAATCT 
 
C57BL/6   GCCAAGCCAGCTTTGTTCCCATTAGCAAAATTTAGCAACAGCACTATTCCTTAGTCACCAAAACTCTATGTCAACAATCACCTGAGCACGAGTCTTTCAT 
BALB/c    GCCAAGCCAGCTTTGTTCCCATTAGCAAAATTTAGCAACAGCACTATTCCTTAGTCACCAAGACTCTATGTCAACAATCACCTGAGCACGAGTCTTTCAT 
 
C57BL/6   ATTTGGGGAAATTTCTCACATTAGGTTATCTTGGGCCACTGTGGGAACTGCCATAGATTGTCATCAATGACAAACATCCAACAAACAGCCCAAGTTCTGA 
BALB/c    ATTTGGGGAAATTTCTCACATTAGGGTGTCTTGGGCCACTGTGGGAACTGCCATAGATTGTCATCAATGACAAACATCCAACAAACAGCCCAAGTTCTGA 
 
C57BL/6   ACAAAAACAAAATCAGTAATATTAGCAAGATCTGTTGAGGACCTCTCAAATCTCCACTGAACTGTGTTCCAGACATGCAAAAGAGAAACAACAGCATATC 
BALB/c    ACAAAAACAAAATCAGTAATATTAGCAAGATCTGTTGAGGCCCTCTCAAATCTCCACTGAACTGTGTTCCAGACATGCAAAAGAGAAACAACAGCATATC 
 
C57BL/6   CGTGAAGGGCATCTTTGGGATGTTAAGTAGTGGGAAACATCAGACATTGGTCACTAACAATTAGAAATTCATAACTGAC--------------------- 
BALB/c    CGTGAAGGGCATCTTTGGGATGTTAAGTAGTGGGAAACATCAGACACTGGTCACTAACAATTAGAAATTCATAACTGAC--------------------- 
 
 
B) 
Coro2a 
chr4:46,621,090-46,622,106 
C57BL/6   ---------------------------------------------GTTCGGTCGATTCGGTTTTGGGGATGGAACTCTGCCGACTGAGCTGCACCCTAGC 
BALB/c    ---------------------------------------------GTTCGGTCGATTCGGTTTTGGGGATGGAACTCTGCCGACTGAGCTGCACCCTAGC 
 
C57BL/6   TGCTAAGCACCCCATTCTTGGAATTAGGATTCCTGGCTGGTTTGTTGTGTGGCCTTTACCAGGCACACCCCCTCCTGGGACAGGTGATTATATGCCCATA 
BALB/c    TGCTAAGCACCCCATTCTTGGAATTAGGATTCCTGGCTGGTTTGTTGTGTGGCCTTTACCAGGCACACCCCCTCCTGGGACAGGTGATTATATGCCCATA 
 
C57BL/6   GAATACGAGCGTTGGATGAGATAGACGGTTTCTAGACTGCCCCTAGAATAAGGGCCTGGGATGAGATGGTTTCTAGAGACCCTTTCAGGTCAGAGAATCC 
BALB/c    GAATACGAGCGTTGGATGAGATAGACGGTTTCTAGACTGCCCCTAGAATAAGGGCCTGGGATGAGATGGTTTCTAGAGACCCTTTCAGGTCAGAGAATCC 
 
C57BL/6   ACAACTCCACAGTACATTTTTAAAGTTCGGGATGACTTTGTAATAATCAGGACCTGCCTGCTCATGCGCCATCACTGTAGCCTCCCAGATCACAAACGTT 
BALB/c    ACAACTCCACAGTACATTTTTAAAGTTCGGGATGACTTTGTAATAATCAGGACCTGCCTGCTCATGCGCCATCACTGTAGCCTCCCAGATCACAAACGTT 
 
C57BL/6   CCCAATGACAGGGGACTCAGGTGGTACTTAGGCTTTCGAGCTGGCGCTGGGCTCTGGCAGCCACACTTATACTTAGTCTCCCTTTATGAGGGGATAATAA 
BALB/c    CCCAATGACAGGGGACTCAGGTGGTACTTAGGCTTTCTAGCTGGCGCTGGGCTCTGGCAGCCACACTTATACTTAGTCTCCCTTTATGAGGGGATAATAA 
 
C57BL/6   CACTCATTTGCAGCGAAGCTCCAGGTTGGGGCCACAGGGCAAGGTCCCCTGCCACACTGCTTTGGCCCTGGCAACGCACAGCACCCTATGATGCCCACCC 
BALB/c    CACTCATTTGCAGCGAAGCTCCAGGTTGGGGCCACAGGGCAAGGTCCCCTGCCACAGTGCTTTGGCCCTGGCAACGCACAGCACCCTATGATGCCCACCC 
 
C57BL/6   AGCCCTCTGCCTGTACACTTAGATGACGTAGGGCTCACTACCGGCGCTGGCCTGGGGAAAGGGAAGGGTCTCCTCTTTTAGCCTTAAGAAAGTCCTTGGG 
BALB/c    AGCCCTCTGCCTGTACACTTAGATGACGTAGGGCTCACTACCGGCGCTGGCCTGGAGAAAGGGAAGGGTCTCCTCTTTTAGCCTTAAGAAAGTCCTTGGG 
 
C57BL/6   TGAGGGAGAGGGAGACAGGCGATCAGGAGGTGCTGAGCCTGTTCCTTAGTGGGGACAGATGTCAGGAAATGAGGCAGAAGTGTCCAGAGATGGGCTTAAG 
BALB/c    TGAGGGAGAGGGAGACAGGCGATCAGGAGGTGCTGAGCCTGTTCCTTAGTGGGGACAGATGTCAGGAAATGAGGCAGAAGTGTCCAGAGATGGGCTTAAG 
 
C57BL/6   CCTTTCTCTCCCTCCACATCCCTCAAGAGATGTCTGGAGGCGAGGGACGTGTAAGGACACATTCCTGTGCTGAGGCACAGGTGGTTATGAACAAGTCCCT 
BALB/c    CCTTTCTCTCCCTCCACATCCCTCAAGAGATGTCTGGAGGCGAGGGACGTGTAAGGACACATTCCTGTGCTGAGGCACAGGTGGTTATGAACAAGTCCCT 
 
C57BL/6   GGAGCATTCGCAGAAGAGCAGGCTCTGAGACAGAAGGGCCACATGCTAGCTAAGGGACACTATCAGGATTGCAGCCACAGTGGGACCAGATTCCCCAGTT 
BALB/c    GGAGCATTCGCAGAAGAGCAGGCTCTGAGACAGAAGGGCCACATGCTAGCTAAGGGACACTATCAGGATTGCAGCCACAGTGGGACCAGATTCCCCAGTT 
 
C57BL/6   TCGCTAGTGAGAGTCCCCATCTCGAGAAGAATGCAACATAAGACCT-CATCAAAAGGCATCT-------------------------------------- 
BALB/c    TCGCTAGTGAGAGTCCCCATCTCGAGAAGAATGCAACATAAGACCT-CATCAAAAGGCATCT-------------------------------------- 
 
Figure 5.16 DNA sequences of 4 selected DMRs in C57BL/6 and BALB/c. Regions that were 
selected as possible targets for methylation analysis using MALDI-TOF MS. Genomic DNA was 
amplified by PCR and directly sequenced. Differences between BALB/c and the reference strain 
C57BL/6 are marked as follows: deletions or insertions (relative to C57BL/6) are in red lettering; 
single nucleotide polymorphisms are boxed in blue (BALB/c). The Figure is continued on the next 
page showing two more examples. The complete list of sequence alignments is shown in the 
appendix section (see section 12.4, page 187).  
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C) 
3110007F17Rik 
chrX:119,220,163-119,220,873 
C57BL/6   ------------------TCTCGTTCAGCTGTTCTACCCACTGGTCTAGCTCCTTGGTGAATGCCTTGTCGTCTATGGCGGTGAGCTGCTCATCTCCGCC 
BALB/c    ------------------TCTCGTTCAGCTGTTCTACCCACTGGTCTAGCTCCTTGGTGAATGCCTTGTCGTCTGTGGCGGTGAGCTGCTCATCTCCGCC 
 
C57BL/6   GCCTCCCCCTCCGCTGATCCCCTGGCGGGACCGCTAAGCTGCAGAGAGCGCAGCCCGCGCCCCGCCCAAGCCCAGCCATTATCTTCGGGTCCCTGCTGTT 
BALB/c    GCCTCCCCCTCCGCTGATCCCCTGGCGGGACCGCTAAGCTGCAGAGAGCGCAGCCCGCGCCCTGCCCAAGCCCAGCCATTATCTTCGGGTCCCTGCTGTT 
 
C57BL/6   TGCCTCTAAGTCTGTGGCGGTTCCGTAGCTGTAGTGCCTGGCGGCCCCAGCCCCGCCCACGCGCTTCTGTCGCACCGCCCCCTGCGCTGTTGTCAGAGCG 
BALB/c    TGCCTCTAAGTCTGTGGCGGTTCCGTAGCTGTAGTGCCTGGCGGCCCCAGCCCCGCCCACGAGCTTCTGTCGCACCGCCCCCTGCGCTGTTGTCAGAGCG 
 
C57BL/6   CGGGACACAGTGAGGGAGGGGGGAATGGGCGAGCGGTCGCGCCGTTGGGAGGAGCAGTCCGGACCCATGCCCGTGCAGGCAGGACATGGGGAGAGCACGC 
BALB/c    CGGGACACAGTGAGGGAGGGGGGAATGGGCGAGCGGTCGCGCCATTGGGAGGAGCAGTCCGGACCCCTGCCCGTGCAGGCGGGACGTGGGGAGAGCACGC 
 
C57BL/6   AGCGACAGGCATCTGGCTTTCTGAGCCCTGGGATTTGGTGAGCGAACACTCGGAGTGGGATGGTTCGGCGCGCGCTGAGACCCGCTATCCCGGCCCCCGC 
BALB/c    AGCGACAGGCATCTGGCTTTCTGAGCCCTGGGATTTGGCGAGCGAACACTCGGAGTGGGA-----------------AGACCCGCTATCCCGGCCCCCGC 
 
C57BL/6   CCACCTTTCCCAGCGGGCCTTTCCAGCGGTCCCGGGGCGGTCTTGGTGTACTGCCATGGTGGGTGGAGGTGCGCTTGGGGCCTGGTCGCTGGCCAGGGGG 
BALB/c    CCACCTTTCCCAGCGGGCCTTTCCAGCCGTCCCAGGGCGGTCGAGGTGTACCGCCATGGTGG----AGGTGCGCTTGGGGCCTGGTCGCTGGCCAGGGGG 
 
C57BL/6   GGCAGTCCCCCGCCGACCCCAGCCTGGCCCTGCCCGCGAGCCCGCCACCAGAGCACGGGACGCAGGAAAAGGGGGCGGGGAATGACGCGCGGGTGGAGGA 
BALB/c    GGCAGTCCCCAGCCGACCCCAGCCTGGCCCTGCCCGCGCGCCGGCCGCCAGAGCACTGGACGCAGGAAAAGGGGACGGGGAATGACGCGCGGGTGGAGGA 
 
C57BL/6   GTTTTCGCTGTGCGCCGCCAGCACAGTTG----------------------------------------------------------------------- 
BALB/c    GTTTTCACTGTGCGCCGCCAGCACAGTAG----------------------------------------------------------------------- 
 
 
D) 
Zfp568 
chr7:29,691,813-29,692,926 
C57BL/6   -------------------------------------GCTATTCTAAGA-CAGAGGTCTTATCTCAGCCTTTAGGGAGCTCGCCCAGGCCTGGTGGTTTT 
BALB/c    -------------------------------------GCTATTCTAAGAACGGAGGTCTTATCTCAGCCTTTAGGGAGCTCGCCCAGGCCTGGTGGTTTT 
 
C57BL/6   ACTGCAGCTTGAAAGAAAGTAAGGCTTGCGGGCATGCAGTAAGATGGGGGCGGCCGTCCAATACCTGGGATCACTCTGGGCTCGGCACAAAGGAAAGCCC 
BALB/c    ACTGCAGCTTGAAAGAAAGTAAGGCTTGCGGGCATGCAGTAAGATGGGGGCGGCTGTCCAATACCTGGGATCACTCTGGGCTCGGCACAAAGGAAAGCCC 
 
C57BL/6   GGCTCTTTGTGGTTTGTAGTGCATTCTTTGCCTCTTTTGGGTAACTGACCTGGCAATGGGTAAAACTGGGAGTAGACATAAAAAAATTGTGACCCTCCAG 
BALB/c    GGCTCTTTGTGGTTTGTAGTGCATTCTTTGCCTCTTTTGGGTAACTGACCTGGCAATGGGTAAAACTGGGAGTAGACATAAAAAAATTGTGACCCTCCAG 
 
C57BL/6   GTCTTTCTTGGCCAGGCCAGAGATCATTACCAGCCTTGTCCCCATTATCCATCCTGCGTAGAGAATGGAGATTAGGAGAGAACTGGCACCCTGACCAATT 
BALB/c    GTCTTTCTTGGCCAGGCCAGAGATCATTACCAGCCTTGTCCCCATTATCCATCCTGCGTAGAGAATGGAGATTAGGAGAGAACTGGCACCCTGACCAATT 
 
C57BL/6   TGCGAATCTAAACCTCACCTCAGAGATTGTTCCCAGGAGCAGAGTTCTGAAGTCACAACCACTCGGGTGACAGGAGCCCCATGGTTACATGCAAGATGCC 
BALB/c    TGCGAATCTAAACCTCACCTCAGAGATTGTTCCCAGGAGCAGAGTTCTGAAGTCACAACCACTCGGGTGACAGGAGCCCCATGGTTACATGCAAGATGCC 
 
C57BL/6   ACATAGAGGTAGGCACAGTCTT------------------------------------------------------------------------------ 
BALB/c    ACATAGAGGTAGGCACAGTCTTTTTTTTGTTTGTTTGTTTGTTTTTTGTTTTTTTTTGTTTGTTTTTGTTTTTTTGAGACAGGGTTTCTCTGTATAGCCC 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    TGGCTGTCCTGGAACTCACTCTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCGCCTGCCTCTGCCTCCCGAGTGCTGAGATTAAAGGCGTGCGCCACC 
 
C57BL/6   -------------------------ACACTTAAGCCACAACTCCACAACGACCAGACATTTCATGTCCTCATAGAAAAGCTATCAGAATGTATTACAAAC 
BALB/c    ACGCCCGGCTGGTAGGCACAGTCTTACACTTAAGCCACAACTCCACAACGACCAGACATTTCATGTCCTCATAGAAAAGCTATCAGAATGTATTACAAAC 
 
C57BL/6   AACCACAAAAACTATTCCAGGGCACTGCGTCCGCCCAGTCGCAAGGCTCCTGCCGAGAGGCTGGACAGGCCACTAGCCTTTCTGGGAAATGTAGTCCACA 
BALB/c    AACCACAAAAACTATTCCAGGGCACTGCGTCCGCCCAGTCGCAAGGCTCCTGCCGAGAGGCTGGACAGGCCACTAGCCTTTCTGGGAAATGTAGTCCACA 
 
C57BL/6   AAGGGACAGCCACCTAGCGCCCCCAGCGCCTCCTCTGGTTGTTCCGGAAAAGACCGTCCCCGCAGCTGCTCACGTCCAGCGCTGCTTCGCCGGCGGCGTC 
BALB/c    AAGGGACAGCCACCTAGCGCCCCCAGCGCCTCCTCTGGTTGTTCCGGAAAAGACCGTCCCCACAGCTGCTCACGTCCAGCGCTGCTTCGCCGCCGGCGTC 
 
C57BL/6   ACCGTCTCGCCGCGCTAATGGGCTCAGCCACCTCGGCGCCTTCGGCCATGACTCCTGTCCCTAGCACAGGAAACGCCAGCCGAGCTCTGACCGGAAGTTG 
BALB/c    ACCGTCTCGCGGCGCTAATGGGCTCAGCCACCTCCGCGCCTTCGGCCATGACTCCTGTCCCTAGTACAGGAAACGCCAGCGGAGCTCTGACCGGAAGTTG 
 
C57BL/6   GGTCGGGCCGCGGGTCCTTCTGGGAGCACCTGTGCTCTGGGACATAACGGGCGCGCGCTGCCGCCCGAGTGGAGGGGCTGGCCGTGCGTGGCCCGCATGC 
BALB/c    GGTCGGGCCGCGGGTCCTTCTGGGAGCACCTGTGCTCTGGGACATAACGGGCGCGCGCTGCTGCCCGAGTGGAGGGGCTGGCCGTGCGTGGCCCGCATGC 
 
C57BL/6   CGCGTCTCTGAGGTTGCGTCTCGGGAGGTTTTGGCTGGTGGCGCTGCGGGGACCTCTCCACGGGAGAGGCACGGGTGGTCCGGTTTGCGCCGGCCGTGGG 
BALB/c    CGCGTCTCTGAGGTTGAGTCTCGGGAGGTTTTGGCTGGTGACGCTGCGGGGACCTCTCCACGGGAGAGGCACGGGTGGTCCGGTTTGCGCCGGCCGTGGG 
 
C57BL/6   CTTCGGGCTGGGCGCGGGCTCTCGGGGGGCTCGGAGTATCCCGGGTCACAGCTTT--------------------------------------------- 
BALB/c    CTTCGGGCTGGGCGCGGGCTCTCGGGGGGCTCGGAGTATCCCGG-TCACAGTTTT--------------------------------------------- 
 
Figure 5.16 continued from previous page. 
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5.2.7.3 Validation of DMR by combination of bisulfite and MALDI-TOF MS 
The validation panel primarily focused on sequences showing no repeat variations. First, 
an initial round of MALDI-TOF MS analysis for the 18 selected DMRs was performed 
using gDNA from two male mice of each strain (C57BL/6 and BALB/c). Six of these 18 
DMRs resided within the promoter region of the associated gene (3110007F17Rik, 
Isoc2b, Ppp1r14d, Rab6b, Slc13a3 and Zfp568), Asb4 and Pi4k2b reside in regions distal 
to the promoter and the remaining 10 DMRs are associated with intragenic sequences. 
Genomic sequencing of the Sfi1 promoter region indicated the presence of an additional 
pseudogene (ps) of unknown chromosomal localization. This pseudogene differed slightly 
in sequence and was present in both strains, according to the equal PCR sequencing 
results from both strains. Specific primers for both possible Sfi1 regions (endogenous 
copy and pseudogene) were designed in order to discriminate between them.  
In total I designed 60 primer pairs for the amplification of bisulfite-treated DNA. Five 
primer pairs were specific only for the underlying sequence of C57BL/6 and four primer 
pairs were specific for BALB/c sequences. The remaining 51 primer pairs resided in 
regions where no sequence polymorphism was detected within the primer binding sites 
between the two strains. This ensures an unbiased amplification of both alleles (C57BL/6 
or BALB/c derived) independent of their origin. Data for the validation set is summarized in 
Table 5.3 and four examples are shown and described in Figure 5.17. (The complete 
MALDI-TOF MS data will be available online within the supplementary information of the 
corresponding publication).  
All four examples shown, exhibited a similar degree of methylation difference between the 
strains as detected by the microarray experiment. Thus, the MALDI-TOF analysis proved 
that the microarray experiment correctly identified DMRs. Thirteen out of eighteen regions 
showed „true‟ methylation differences. In the remaining five cases, the differential MCIp 
enrichment behavior resulted from an increased number of methylated CpGs in one 
strain, either due to the presence of SNPs (Pi4k2b, Ppp1r14d, Spint1) or due to the 
insertion of methylated sequences in one strain (Pop4, Zfp568). Alleles with higher 
numbers of methylated CpG lead to a stronger binding to the MBD-Fc column during the 
MCIp procedure and therefore appear as stronger methylated in the microarray data.  
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Figure 5.17 Validation of strain-specific CpG methylation by MALDI-TOF MS of bisulfite 
treated DNA. Four examples of DMRs detected by the MCIp-microarray approach and validation 
using MALDI-TOF MS of bisulfite treated DNA: (A) 1600021P15Rik, (B) Eps8L1, (C) Pdgfrb and 
(D) Coro2a (C and D are shown on next page). MCIp results are presented in the upper panels. 
Shown are the following tracks (from top to bottom) that were generated using the UCSC Genome 
Browser: repetitive regions as identified by the RepeatMasker program, single nucleotide 
polymorphisms from the dbSNP (NCBI database for genomic variation) build 126 (both in black), 
hypomethylation scores for BMM of both mouse strains (defined as the difference product of log10 
signal intensity ratios of both hybridizations; shown in green), vCGH signals indicating the presence 
of genetic variation at probe level (in brown) as well as gene structures (in light blue) and the 
position of amplicons (Epityper Ampl.; in blue) that were designed for MALDI-TOF MS analysis of 
bisulfite treated DNA. The relative position of CpGs within amplicons is indicated below by small 
lollipops (with the upward orientation representing C57BL/6, and the downward orientation 
representing BALB/c). Sequence variations are highlighted in red and blue, black bars mark the 
position of exons and gray lollipops are not analyzed by the MS due to system restrictions 
(explained in the methods section). Methylation levels of individual CpGs in the indicated cell types 
(two individuals for each strain) are shown color-coded. The scale ranges from pale yellow (0% 
methylation) to dark blue (100% methylation), strain-specifically absent CpGs are coloured black, 
non-detectable CpGs are marked in gray. 
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Figure 5.17 continued from previous page. 
 
 
Table 5.3 MCIp-detected DMR validation set and germ line methylation 
Genomic Region 
(Mouse Assembly mm8) 
 
Associated 
Gene 
 
Distance 
from TSS 
(in kB) 
MCIp 
indicated 
Demethylation 
in 
Bisulfite-MS analysis  
(Nos. of amplicons) 
 
Methylation 
status in sperm 
  (C57 – BALB) 
chr16: 28833304-28834357 1600021P15Ri
k 
15.6 C57BL/6 confirmed DMR (2) mCpG - mCpG 
chrX: 119220336-119220381 3110007F17Rik -0.1 C57BL/6 confirmed DMR (5) CpG - CpG 
chr6: 5333111-5334506 Asb4 -6.6 C57BL/6 confirmed DMR (6) CpG - CpG 
chr4: 46620908-46622454 Coro2a 1.3 C57BL/6 confirmed DMR (4) mCpG - mCpG 
chr7: 4064078-4064123 Eps8l1 0.2 BALB/c confirmed DMR (3) CpG - CpG 
chr4: 147309756-147309900 Frap1 17.4 C57BL/6 confirmed DMR (3) mCpG - mCpG 
chr7: 4468706-4470122 Isoc2b -0.2 C57BL/6 confirmed DMR (6) CpG - CpG 
chr18: 61190864-61191597 Pdgfrb 20.7 BALB/c confirmed DMR (2) mCpG - CpG 
chr5: 53026418-53026767 Pi4k2b -3.2 C57BL/6 one additional mCpG in BALB/c (2) mCpG - mCpG 
chr7: 37961808-37962602 Pop4 18.2 BALB/c methylated insertion in C57BL/6 (2) m-CpG - ND 
chr2: 118921263-118922015 Ppp1r14d -0.3 C57BL/6 two additional mCpGs in BALB/c (2) mCpG - mCpG 
chr9: 102968600-102969350 Rab6b -0.9 BALB/c confirmed DMR (2) CpG - CpG 
chr11: 3092678-3093978 Sfi1 0.1 BALB/c confirmed DMR* (5) mCpG - CpG 
chr2: 165163847-165165182 Slc13a3 -0.1 BALB/c confirmed DMR (3) CpG - CpG 
chr18: 58681880-58682279 Slc27a6 0.5 C57BL/6 confirmed DMR (2) CpG - CpG 
chr18: 58686133-58686695 Slc27a6 4.8 C57BL/6 confirmed DMR (2) CpG - CpG 
chr2: 118931167-118931543 Spint1 2.5 C57BL/6 two additional mCpGs in BALB/c (4) mCpG - mCpG 
chr7: 29692014-29692149 Zfp568 -0.6 C57BL/6 methylated insertion in BALB/c (4) CpG - CpG 
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5.2.8 Analysis of gender differences  
Since the initial screen included only male mice, it was also of interest to look at gender 
specific methylation differences. To address this issue BMM of female individuals of each 
strain were examined as well. In addition, DNAs with different grades of methylation (0%, 
33%, 66% and 100% methylation, generated by mixing SssI-methylated DNA and 
unmethylated DNA produced in the appropriate ratios; see methods section for more 
details) were analyzed to test if the procedure yields reliable and accurate results in the 
data analysis. To accomplish this and for all following MassARRAY experiments the initial 
set was reduced to 24 amplicons. Since some primer pairs amplified the same region, but 
on different DNA strands, it was possible to exclude one or several pairs without losing 
information. In addition, other regions, originally covered by several primer pairs, were 
restricted to fewer primer pairs, especially when removed primer pairs were redundant in 
the methylation level as investigated with the remaining primer pairs.  
We analyzed genomic DNA from BMM of three different female individuals of each strain 
and also included a third male per strain in order to limit possible individual differences. 
For correlation analysis the complete dataset was reduced to all autosomal CpG units that 
were measured in all samples. The comparison of Bisulfite/MALDI-TOF MS analysis of 
methylation patterns in males and females suggested that the DMRs were equally 
detected on autosomes of both genders. A correlation matrix for this calculation is 
illustrated in Figure 5.18. All three biological replicates of each strain and gender were 
highly similar for the analyzed regions. (median r2>0.97). Moreover, both genders also 
correlated well within one strain (median r2>0.97).  
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Figure 5.18 Correlation matrix of MALDI-TOF MS detected methylation ratios in BMM. The 
complete dataset was reduced to all autosomal CpG units that were measured in all BMM samples 
of three males and females of each strain. Correlation was calculated using the „coefficient of 
determination‟ function in Excel 2007 and colored according to a three-color-scale ranging from the 
lowest value (red) to the highest value (dark blue).  
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5.2.9 Analysis of the influence of the BMM culture system 
To exclude the possibility that the observed differences in methylation are due to an 
influence of the artificial in vitro BMM culture system, spleen samples of each mouse were 
additionally prepared and analyzed. Concordantly, the genomic DNA derived from the 
spleen samples from three individuals per strain and gender was evaluated. In the 
following, the methylation data for the reduced set of 24 amplicons (female samples were 
only measured in the reduced set) were used to calculate correlation matrixes. Of note, 
the correlation analysis involved only autosomal CpG units, which were measured in all 
samples. This correlation showed, that the three biological replicates of each cell or tissue 
type were highly similar (see Figure 5.18 for BMM; data not shown for spleen) for the 
analyzed regions. Moreover, as shown in Figure 5.19 both spleen and BMM also 
correlated well within the same strain (median r2>0.93), suggesting that the observed 
patterns are not a cell culture-induced artifact.  
 
 
 
Figure 5.19 Correlation matrix of MALDI-TOF MS detected methylated ratios in BMM and 
spleen. The complete dataset was reduced to all autosomal CpG units that were measured in all 
samples. Individual male or female methylation data was averaged (n=3 in each case) and 
correlation was calculated using Excel 2007 and colored according to a three-color-scale ranging 
from the lowest value (red) to the highest value (dark blue). 
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5.2.10 Comparison of somatic cells with germ line 
cells 
It is still unclear how epigenetic states are inherited to the next generation. The 
inheritance of 5-methylcytosine marks itself could provide a conceivable possibility. To 
investigate this it was important to access the level of methylation in reproductive cells as 
well, because a prerequisite for this option is, that reproductive cells show similar 
differential patterns like non-reproductive cells. Accordingly, I assessed how methylation 
patterns differed between somatic and germ line cells. Germ line cells were prepared from 
testis and analyzed by mass spectrometry using the full initial amplicon set. Assuming that 
testis mainly contains germ line cells or cells committed to the germ line lineage, the 
amount of germ line cells within the testis preparations was determined. Therefore, a 
single-gene MCIp was performed followed a by real-time PCR with two independent 
genomic DNA preparations for each tissue (BMM, spleen and testis) and strain. But in this 
case the MCIp process differed in that the genomic DNA was digested with MseI 
restriction endonuclease instead of shearing by ultrasonication. This resulted in a more 
stable DNA fragment length, which generally leads to a more distinct distribution pattern 
during column fractionation. As judged by the predominantly unmethylated status (95-
85%) of the maternally imprinted Snrpn alleles in these samples (see Figure 5.20), the 
testis samples were prepared to mainly contain germ line cells (70-90%).  
 
When comparing germ line with somatic tissues, it appeared that the majority (16/18) of 
the validated DMR only acquired differential DNA methylation in somatic cells (BMM, 
spleen) but showed similar methylation states in the testis (containing mostly germ line 
cells) of both strains. Table 5.3 (page 100) shows that six of the analyzed regions were 
methylated in testis samples of both strains and nine regions were unmethylated. Only 
two DMRs (Pdgfrb and Sfi1) also appeared in germ line. The methylation status for Pop4 
in BALB/c was not measurable, since the DMRs resulted from a methylated insertion in 
the other strain. Thus, the differential patterns are more likely established after fertilization 
and DNA methylation itself is unlikely to be the inherited mark.  
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Figure 5.20 Real-time PCR results for a maternally imprinted gene. MCIp elution profiles are 
schematically represented as bar charts. During the small scale MCIp procedure increasing 
concentrations of NaCl were used to elute the DNA into different fractions, which were analyzed by 
real-time PCR for the distribution of both alleles of the maternal imprinted gene Snrpn. The results 
are shown relative to the amount of input-DNA (1.0; 100%). Normalized results of somatic tissues 
(BMM and spleen) were averaged for both parental strains shown separately in (A) BALB/c and (B) 
C57BL/6. In germ line cells (testis) mainly the unmethylated allele was found, whereas in somatic 
tissues both the methylated and unmethylated versions of the allele were present. 
 
5.2.11 Inheritance of DNA methylation patterns in F1-
hybrid animals 
Since germ line cells lack the differential methylation pattern seen in somatic cells, the 
question arose, how these methylation differences are inherited to F1 hybrids. In order to 
investigate this question, the degree of CpG methylation at selected loci was compared 
between of F1 hybrids and their wild-type parents. I produced F1 hybrid offspring in both 
possible mating combinations (C57BL/6 sires or BALB/c sires). For each mating 
combination at least two litters, containing two individuals of both genders minimum, were 
produced, grown to the age of 6 to 8 weeks and independently analyzed. Genomic DNA 
from bone marrow-derived macrophages (BMM), spleen and germ line (testis) was 
prepared as described for both parental strains and the methylation status was measured 
by MALDI-TOF mass spectrometry using the reduced amplicon set (24 amplicons).  
5.2.11.1 Methylation pattern of DMRs in F1-hybrid mice 
As mentioned above most primer pairs used to amplify bisulfite-treated DNA were not 
specific for one of the parental strains. However some primer pairs were indeed 
specifically designed for one parental strain (for example, primer pairs for 3110007F17Rik 
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and Zfp568). In addition, some amplicons contained single nucleotide polymorphisms 
(SNP) located between the primer binding sites within the remaining amplicon sequence. 
These SNP‟s had no impact on PCR reactions, but sometimes resulted in altered 
fragment mixtures after fragmentation of cRNA during the MassARRAY application. 
Therefore I analyzed F1-hybrid animals with both possible genomic DNA sequences, 
derived from C57BL/6 and BALB/c parental mice, and averaged the methylation data at 
the level single CpG units, in order to eliminate a possible influence of fragment 
composition on the methylation data. If SNPs resulted in additional CpG sites, the 
methylation data for this CpG site was obtained only from the analysis with the underlying 
parental sequence. Three examples of DMR, corresponding to two genes (Slc27a6 and 
Zfp568) are shown in Figure 5.21. 
 
 
 
Figure 5.21 Inheritance of strain-specific methylation patterns in F1 hybrids. This figure 
illustrates two examples for allelic inheritance of strain-specific methylation patterns in (A) Slc27a6 
and (B) Zfp568. In the top panels, hypomethylation scores for BMM of both strains are displayed as 
described in Figure 5.17. Averaged methylation levels of individual CpGs were determined by 
MALDI-TOF analysis at the indicated DMRs in BMM, spleen, and testis and are shown color coded 
for parental strains and F1 hybrids. Data are mean values of 2-4 individual samples. 
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Figure 5.22 Inheritance of a X-linked DMR in F1-hybrid mice. Example of allelic inheritance of 
strain-specific methylation patterns in the 3110007F17Rik gene on the X-chromosome. In the top 
panels, hypomethylation scores for BMM of both strains are displayed as described in Figure 5.17. 
Gender-specific averaged methylation levels of individual CpGs were determined by MALDI-TOF 
analysis at the indicated DMRs in BMM, spleen, and testis and are shown color coded for parental 
strains and F1 hybrids. Data are mean values of 2-4 individual samples. Methylation in this region 
is only seen in male BALB/c animals and male F1-hybrids derived from a BALB/c mother.  
  
Results 
 
108 
The first example (Slc27a6) given in Figure 5.21A exhibited two DMRs where the 
methylation status in F1-hybrid mice ranged between the levels seen in the parental 
strains. The differentially methylated region in the promoter of Zfp568 (Figure 5.21B) 
resided within a BALB/c-specific insertion. F1-hybrid mice, although harboring both 
parental alleles, contained only methylated CpG‟s within the parental BALB/c-specific 
insertion and not on the C57BL/6-derived allele.  
Another DMR example is located at the 3110007F17Rik gene, which is located at the X-
chromosome. In parental strains this region is methylated in BALB/c and unmethylated in 
C57BL/6 males. Figure 5.22 illustrates, that methylation of the X-chromosomal gene in 
F1-hybrid males is only seen if the corresponding mother is of BALB/c origin (transmitting 
the methylated allele). However this phenomenon was only evident in males. In females 
the methylation was more similar between all F1 individuals analyzed, which is likely due 
to the presence of the second X-chromosome. Random X-inactivation, occurring in female 
cells, leads to an altered DNA methylation creating a different methylation pattern as 
compared to males. 
5.2.11.2 Impact of mating combination or offspring gender 
The next question to be addressed was how the various F1-hybrid animals differed, first in 
terms of mating combination (C57BL/6 or BALB/c sire) and in gender. Initially, I compared 
the DNA methylation profiles of the different F1 individuals within a mating combination 
and gender and found that all F1 samples were methylated to a highly similar extent as 
measured for single CpG units (complete MassARRAY data is not shown due to space 
limitations but will be available online in the supplementary part of the corresponding 
publication). However, an exception was observed at the Isoc2b promoter were the 
methylation levels in F1 hybrids were considerably more variable (ranging from 15-45% in 
individual F1 mice). In a next step, the methylation levels for each gender within a mating 
combination were averaged at single CpG units and correlation ratios were calculated as 
described above (section 5.2.8). The corresponding complete correlation matrix is given in 
Figure 5.23. The matrix shows that averaged methylation levels in F1 animals were highly 
similar between samples of the somatic tissues with only a minor, if any, difference 
between mating combination (median r2>0.95 for BMM and median r2>0.96 for spleen). 
The same was apparent when comparing the two possible offspring gender within or 
between mating combinations. Hence, the methylation levels for individual CpG units of 
individual F1-hybrid mice were averaged for following comparisons to parental strains.  
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Figure 5.23 Correlation matrix of MALDI-TOF MS detected methylation ratios in parental 
strains and F1-hybrid mice. The complete dataset was reduced to all autosomal CpG units that 
were measured in all samples. Individual male or female methylation data was averaged and the 
number of individuals used is indicated in brackets (top lane). Correlation was calculated using 
Excel 2007 and colored according to a three-color-scale ranging from the lowest value (red) to the 
highest value (dark blue). 
 
5.2.11.3 Comparison of mean methylation levels between parents and 
offspring  
Most DMRs exhibited a methylation pattern in F1 mice as seen at the Slc27a6 gene (see 
Figure 5.21A), where offspring methylation levels were not comparable to one of the 
parental strains, but ranged in between the parental levels indicating an intermediate 
methylation status. To explore if this observation is a common phenomenon, the averaged 
methylation levels of parental BMM and spleen data were compared by plotting against 
averaged CpG methylation ratios of F1 hybrids derived from both mating combinations 
(C57BL/6 or BALB/c sires). In eight out of eleven DMRs analyzed by MALDI-TOF 
(1600021P15Rik, Asb4, Coro2a, Pdgfrb, endogenous Sfi, Slc13a3, Slc27a6, and Zfp568), 
methylation patterns in F1 hybrids were almost identical to the average methylation levels 
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seen in parental strains (r2>0.97) (see Figure 5.24). The remaining three DMRs (Sfi1 
pseudogene, Isoc2b, and Eps8l1) were slightly different and either acquired (Sfi1 
pseudogene) or lost methylation (Isoc2b, Eps8l1) in F1 hybrids relative to their parental 
strains. However, it was obvious that at the investigated loci neither one of the parental 
methylation levels was completely reconstituted in F1 animals, which would be the case if 
one parental methylation pattern is inherited dominantly. The simplest and most plausible 
explanation for this pattern is that the methylation level of each allele is inherited 
independently. During the MassARRAY application both parental alleles were not 
analyzed separately, since primer pairs did not discriminate between parental alleles. 
Hence, the methylation status of parental alleles in F1-mice was averaged. Given this 
situation I wondered if both parental alleles exhibited the same level of methylation in F1-
hybrid animals or if, as a second possible alternative, individual methylation status of 
parental alleles was maintained.  
 
 
Figure 5.24 Methylation ratios of wildtype mice versus F1 hybrids. Averaged CpG methylation 
ratios of parental (A) BMM or (B) spleen (n=3 for each strain and tissue) are plotted against 
averaged CpG methylation ratios of F1 hybrids derived from C57BL/6 (top, n=5) or BALB/c 
(bottom, n=4) sires. In eight out of eleven DMR analyzed by MALDI-TOF, methylation patterns in 
F1 hybrids are almost identical to the average methylation level in parental strains (r
2
>0.97; marked 
in black). Three DMR (Sfi1 pseudogene, Isoc2b, and Eps8l1, marked in red, green and blue, 
respectively) either acquired (Sfi1 pseudogene) or lost methylation (Isoc2b, Eps8l1) in F1 hybrids 
relative to parental strains. 
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5.2.11.4 Allele-specific bisulfite sequencing of DMRs 
To address if parental alleles maintained their own methylation pattern in F1-hybird 
animals I performed traditional bisulfite sequencing, since the MS analysis did not 
discriminate between the two different parental alleles. I chose DMR regions where a 
characteristic sequence difference remained after bisulfite-treatment of genomic DNA and 
analyzed the tissue where the greatest methylation difference between parental strains 
was observed. In total, six regions were analyzed; four containing single nucleotide 
polymorphisms (Coro2a, Isoc2b, 1600021P15Rik and Asb4) and two regions harboring 
small insertions in parental C57BL/6 (Slc27a6) or BALB/c (Pdgfrb) sequences. Besides 
two male F1-hybrid animals (one from each mating combination) I also included two male 
individuals from each parental strain. Genomic DNA, derived from BMMs (or testis in case 
of Pdgfrb) was treated with sodium-bisulfite, similar to the MassARRAY experiments (see 
methods section 4.5.3, page 57). PCR products of these five regions were generated 
using the same primer pairs, specific to bisulfite-treated DNA as well as the same PCR 
conditions which have been used in the MassARRAY experiments. PCR-products were 
then cloned into the pCR®2.1TOPO-vector and transfected in E. coli. Insert-containing 
plasmids, derived from single colonies were further purified and sequenced. Sequencing 
results for five amplicons are shown in Figure 5.25. The figure illustrates that in the 
parental strains the genes Coro2a, Isoc2b, Asb4, 1600021P15Rik and Slc27a6 were 
methylated in BALB/c, whereas Pdgfrb was methylated in C57BL/6. This observation was 
in line with the microarray and MassARRAY results. In F1-hybrid animals the methylation 
pattern within one animal was mixed, with some sequences being methylated and some 
unmethylated. Both F1-mice used showed the same methylation distribution pattern 
between individually cloned sequences and were, therefore, combined to one pool. 
Furthermore, since I restricted this analysis to amplicons, which can be traced back to 
their strain origin, I was able to determine the strain parentage of a specific amplicon 
within the F1-mice. Hence, alleles of Coro2a, Pdgfrb, Asb4, 1600021P15Rik and Slc27a6 
that derived from C57BL/6 exhibited a very similar methylation pattern as seen in the 
parental strain. The same was observed for alleles, which can be traced back to the 
BALB/c origin. However, the Isoc2b gene uniquely showed a different pattern, where both 
alleles within F1-hybrid animals contained unmethylated as well as methylated 
sequences. This pattern was obvious in both F1-mice examined in this experiment. 
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Figure 5.25 Strain-specific methylation patterns are mainly controlled in cis. Allele-specific 
bisulfite sequencing of DMRs in Coro2a (A, controlled in cis), Pdgfrb (B, controlled in cis), Isoc2b 
(C, controlled in trans), 1600021P15Rik (D, controlled in cis), Asb4 (E, controlled in cis) and 
Slc27a6 (F, controlled in cis) (D-F are shown on the next page). The genomic position of CpGs 
within the amplicons is shown at the top. Sequence variations used to distinguish the different 
parental alleles are marked in blue for C57BL/6 and in red for BALB/c. Individual CpGs are 
represented by either white (unmethylated) or black (methylated) squares. Lines of squares 
represent independently sequenced clones derived from two independent sample preparations, 
derived from reciprocal crosses. 
 
 
Taken together, in 5 (out of 6) regions the allelic methylation patterns in F1 hybrids were 
established essentially as observed on the parental alleles, suggesting that DNA-
methylation at these sites is largely controlled in cis by the local genetic sequence. 
Amongst the studied regions, only at the Isoc2b promoter, a mixed DNA methylation 
pattern was observed with some sequences being unmethylated and others methylated 
independent of their origin. Therefore the differential pattern must be controlled in trans, 
for example through a yet unknown strain-specific epigenetic modifier.  
In summary it became obvious, that allele-specific DNA methylation in mouse strains is 
mainly determined by local cis-acting sequences.  
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Figure 5.25 continued from previous page.  
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6 Discussion 
Epigenetic phenomena in general and DNA methylation in particular play a major role in 
the regulation of gene expression. The latter mechanism contributes to both the shaping 
of cellular phenotypes within an organism and the establishing of interindividual 
differences between organisms. In addition, differences in DNA methylation can not only 
be observed in transformed cells or other non-cancer diseases, but also at very different 
levels in various tissue types and developmental stages. In this work, I have established 
methods to study the contribution of differential DNA methylation to cell type-specific gene 
expression as well as the occurrence of differentially methylated regions between 
individuals (inbred mice strains).  
6.1 Mapping DNA methylation 
In the past years epigenetic modifications such as DNA methylation have been intensively 
studied. Several methodologies have been developed to map DNA methylation, each of 
which having its own advantages and disadvantages as highlighted in the introduction. As 
part of this thesis, methyl-CpG immunoprecipitation (MCIp)110 was modified and utilized to 
map DNA methylation both on single-gene level and on a global scale by combination with 
quantitative real-time PCR or microarrays, respectively. MCIp is based on the 
recombinant antibody-like MBD2–Fc fusion protein that was originally designed by our lab 
to globally detect disease-related hypermethylation in CpG islands on a global level110. A 
crucial step for accurate DNA methylation mapping is the sample pretreatment. Sanger 
sequencing of bisulfite treated genomic DNA, which is the standard method, provides the 
best resolution, because it maps methylated cytosines at single base-pair resolution. 
Large-scale bisulfite-DNA sequencing has been successfully initiated153,154, but is very 
laborious and resource-intensive. Alternative, less direct methods have been developed to 
map DNA methylation on a global scale. Approaches based on methylation-sensitive 
restriction enzymes enrich fragment due to digestion of methylated118,119 or unmethylated 
DNA116,155 followed by size fractionation. However, the restriction enzyme-based 
enrichment methods lack sensitivity and do not cover all CpGs due to their dependence of 
restriction sites7. Other methods have been developed which use protein affinity to enrich 
methylated or unmethylated sequences. Methylated DNA fragments are affinity purified 
with either an anti-m5C antibody (methylated DNA immunoprecipitation; MeDIP) or by 
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using MBD affinity purification (MAP, using the MBD domain for binding of methylated 
DNA)107,123. Both methods gave comparable results120, but require a relatively high density 
of DNA methylation such as methylated CGIs7. A method to enrich unmethylated DNA 
using CxxC affinity purification (CAP, with x being any residue) was also recently 
published126 but is also insensitive to regions with low CpG content7. In contrast, MCIp can 
divide the bulk of genomic DNA fragments into separate fractions of increasing 
methylation density. Therefore, during the MCIp procedure, not only the methylated DNA 
can be enriched, but also unmethylated DNA is recovered without sample loss. This 
allows the simultaneous analysis of the whole range of DNA methylation density, including 
both hyper- and hypomethylated DNA.  
Samples enriched by either of these techniques can be globally analyzed using DNA 
microarrays or by direct large-scale sequencing techniques. The latter, such as 454 
sequencing (Roche) or Solexa bisulfite sequencing (Illumina), are relatively fast and 
cheap and have been used in a number of publications156-158. However, these readout 
techniques are still resource intensive and analysis cannot be restricted to distinct regions. 
Microarrays are cheaper and more flexible, since one can either use custom-designed or 
pre-designed commercially available tiling arrays, depending on the genomic regions of 
interest. However, compared to large-scale sequencing approaches, microarrays receive 
data with only moderate resolution.  
During this thesis, the MCIp-on-chip application (MCIp combined with microarray readout) 
originally designed by our lab to globally detect disease-related hypermethylation in CpG 
islands110 was further developed to a novel application. This work was designed as a pilot 
study to demonstrate the applicability of this method for mapping of cell type-specific 
hypomethylation. To overcome resolution restrictions and to validate the microarray 
analysis, the methylation levels were additionally quantified for some regions using single-
gene MCIp and the standard bisulfite sequencing approach as a MCIp-independent 
approach. In summary, our data showed a good correlation between tissue-specific gene 
expression and promoter hypomethylation. Hence, the MCIp-on-chip was successfully 
applied to a novel application and seems to be a reliable method to detect cell type-
specific hypomethylation.  
Furthermore, by using MCIp I successfully fractionated genomic DNA into methylated and 
unmethylated pools, which has recently been performed by our group in another study as 
well159. In their study, Schmidl and colleagues were able to identify and functionally 
characterize differentially methylated regions between two different human T-cell 
populations. In the present study the performance of this “mirror image” approach was 
improved by using more stringent hybridization conditions to identify differentially 
methylated regions (DMRs) in specific, selected genomic intervals. Since the "mirror 
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image" data correlated well with the MassARRAY results, this elaborate approach seems 
to be a reliable method for locus-wide comparative methylation analysis. With the pre-
selection of differentially expressed genes and the downstream high-throughput analysis 
of selected CpGs by mass spectrometry, this work systematically identified DMRs and 
yielded new insights in individual (allele-specific) DNA methylation. Moreover, the vCGH 
analysis allowed the identification of genomic alternations, such as copy number 
variations (CNV) or deletions. Some of the larger CNV‟s, which have been validated in this 
thesis by qRT-PCR, were previously identified using standard comparative genomic 
hybridization approaches (CGH)150. Standard CGH approaches utilize genomic DNA 
without pre-treatment steps (like MCIp), to screen for genetic changes (gains or losses) on 
a regular basis160,161. The fact that these copy number variations between the two mice 
strains were correctly identified strongly suggests that the MCIp technique fractionated 
genomic DNA without sample loss like in MAP or MeDIP.  
Taken together, the MCIp technique seems to be a reliable methodology to map 
differential DNA methylation at the level of both hypo- and hypermethylation.  
6.2 Cell type-specific promoter methylation 
Entire organisms incorporate a huge variety of differentiated and specialized cells. Every 
cell of a multicellular organism contains essentially the same genome but only a small 
proportion of all available genes are actively transcribed, whereas all remaining genes are 
silent. It is widely accepted that methylation of the promoter region is related to gene 
silencing. However, experimental evidence on this topic tends to be unclear. Initially, 
theoretical models were proposed by Riggs or Holliday and Pugh, based on DNA 
methylation to explain X chromosome inactivation162 and other events in cell differentiation 
during development163. Although those early studies proposed that DNA methylation could 
have a role in regulating development, following studies of DNA methylation in known 
tissue-specific genes during development did not support a major role for DNA 
methylation. Studies by Warnecke and Clark36 found that the tissue-specific expression of 
the skeletal α-actin gene in the adult mouse did not correlate with the methylation state of 
the promoter. Walsh and Bestor35 investigated the methylation status of seven tissue-
specific genes and found no correlation with tissue-specific expression. However, more 
recent publications systematically comparing differential methylation patterns on a 
genome-wide level came to different conclusions. De Bustos and colleagues for example 
received very different methylation profiles from diverse organs, suggesting the existence 
of tissue-specific epigenetic modification patterns across human chromosome 1164. The 
results of another study utilizing MeDIP to analyze 16 different human tissues, including 
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sperm, indicates that tissue specific DNA methylation, including CpG islands, is relatively 
common165. These studies are in line with several others by Song, associating tissue-
specific differentially methylated regions with differential gene expression166,167. In 
addition, a study by Eckhardt identified cell type specific methylation using bisulfite 
sequencing across chromosomes 6, 20 and 22 across various tissues, which inversely 
correlated with transcription153. Similar results were also shown by a methylation 
sequencing study of 13 transcription factors suggesting that epigenetic remodelling of 
transcription factor genes is a frequent mechanism during hematopoietic development168. 
Recently Straussman and colleagues investigated the methylation of human CGIs in 
various tissues and found that some CpG-rich regions, which are constitutively 
unmethylated during early embryogenesis, gain tissue-specific methylation at later 
developmental steps169.  
 
Concordant to these publications, we found in our analysis a correlation between tissue-
specific hypomethylation and tissue-specific gene expression. This was most obvious in 
monocytes, with 76% of hypomethylated genes belonging to the hematopoietic system. 
Among the different tissue types used in this study, the monocyte sample was the most 
homogenous cell population with purity of up to 90%. Tissues are generally composed of 
different, specialized cell types, likely resulting in mixed gene expression and methylation 
patterns. This was also demonstrated by bisulfite sequencing, where fully methylated 
sequences were found among, usually unmethylated, germ line-derived sequences 
(testis). These sequences are likely derived from contaminating somatic cells, since testis 
contains various levels of cells from spermatocytes to sperm as well as the surrounding 
mesenchymal cell population. The same is true for the brain sample, which is also derived 
from a more heterogeneous cell population than purified monocytes. It is therefore 
difficult, if not impossible, to correlate tissue-specific methylation or expression patterns 
for all genes, because both signatures may be determined by independent cell 
populations within the tissue. However, the amount of genes that showed a restricted 
expression pattern in testis, monocytes or brain within each group of hypomethylated 
genes, led to the result that the number of genes expressed in a certain tissue was 
significantly enriched in the hypomethylated group of the same tissue. This observation is 
in line with recent studies164,166,167 and suggests that tissue-specific DNA hypomethylation 
correlates significantly with tissue-specific transcription. 
It is currently believed that tissue-specific variations in DNA methylation largely occur in 
CpG-depleted promoters, whereas most CpG island promoters remain unmethylated in all 
tissues137. Recently it was shown, that CpG island promoters are preferentially 
unmethylated independent of their expression state and that low density CpG promoters 
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(LCP) are mainly methylated without precluding gene expression122,170. However, an 
exception of this general rule was recently provided by Shen and colleagues who 
identified a class of normally methylated CGI promoters in normal blood comprising 4% of 
known CGI promoters171. Moreover, Straussman and colleagues showed that CGI-like, 
constitutively unmethylated regions, which seem to be formed during early 
embryogenesis, undergo de novo methylation in a tissue-specific manner and have a 
dynamic role in development169. Our study contrasts the suggestion that especially LCP 
associated genes are not influenced in their expression by DNA methylation, because we 
showed that tissue-specific DNA hypomethylation correlates significantly with tissue-
specific transcription, not only at CGI genes. Our results were recently supported by a 
study, which demonstrated that 'weak' CpG islands associated with specific 
developmentally regulated genes undergo aberrant hypermethylation in vitro172. It has also 
been reported that CpG-poor promoters are more prone to demethylation occurring in 
cancerous cells leading to the activation of oncogenes155. The greater flexibility in 
methylation states of regions with low CpG density may therefore contribute to the 
diversity of methylation states that underlies heterogeneity of cell types. 
 
The present study also showed that hypomethylated promoters were associated with 
classical CpG islands in every cell type analyzed. However, strikingly more 
hypomethylated promoters were associated with CpG islands in testis than in somatic 
tissues. This observation is in line with the previously postulated general absence of 
tissue-specific variation in somatic CpG island methylation137. Notably, a study by Weber 
suggests that de novo methylation of CGIs in somatic cells preferentially occurs at germ 
line-specific genes as well as promoters with an intermediate CpG frequency122. The 
marked association of testis-specific hypomethylation with CpG island promoters in our 
analysis extends earlier studies reporting the somatic methylation of individual, so-called 
cancer-testis antigens, which are generally controlled by CpG-rich promoters147,173-175. 
These studies favor a model, in which DNA methylation is the primary silencing 
mechanism for a unique subset of germ line- and tumor-specific genes with a CpG-rich 
promoter. In line with this a recent study demonstrated tissue-specific de novo methylation 
of CpG-rich regions, which are normally unmethylated during early embryogenesis and 
gain methylation upon development169.  
 
Interestingly, when comparing the percentage of hypomethylated promoters that are 
associated with Alu repeats138,139, we found a significant higher incidence of Alu repeats 
near hypomethylated promoters in testis as compared to the other two tissues. 
Oligonucleotide probes on the microarray do not directly correspond to repetitive 
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sequences. However, they may be located next to repeats and detect their methylation 
status. This observation is in line with previous studies indicating that Alu repeats in testis 
may be in general less methylated than those in somatic cells52,176,177. It was also reported 
that a significant number of all human genes may be controlled by Alu-associated CpG 
islands178 and that Alu elements exhibit tissue-specific methylation patterns, which was 
recently shown for different brain regions179. However, little information on the positions of 
hypomethylated Alu repeats is available. Our results represent a further indication for a 
role of Alu repeats in testis-specific gene regulation. It was reported that the chromosomal 
density of Alu repeats is around three times higher on chromosome Y than on 
chromosome X and over two times higher than the average density for all human 
autosomes180. In line with this it was demonstrated, that treatment of lymphoid tumor cells 
with a specific anti-cancer drug (clofarabine) induces, as a side effect, both 
hypomethylation of Alu repeats and expression of cancer-testis antigens181. Recently it 
was shown by two publications that demethylated regions are associated with repetitive 
sequences such as LTR repeats by analyzing purified spermatogenic cells182 or testis 
samples167. Moreover, it was published that some repetitive elements are activated and 
transcribed during spermatogenesis and therefore primarily passed through the paternal 
germ line176,180. During activation, these Y-linked Alu repeats have been shown to be 
hypomethylated due to the activity of a specific Alu repeat-binding protein (SABP) which 
protects element CpG dinucleotides from methyl-transferase enzyme activity183. This 
demethylation process may additionally affect nearby genes and activate their expression. 
For example, it was demonstrated in Arabidopsis thaliana that the expression of a 
flowering time gene correlates with the methylation status of a nearby SINE-like 
transposable element184. 
 
In the present study genes with cell type-specifically hypomethylated promoters were 
generally found on all chromosomes. However, an accumulation of testis-specific 
hypomethylation that has not been observed previously was detected on the Y 
chromosome, on which several of the annotated genes appeared hypomethylated 
compared to both somatic tissues and, as described earlier, on the X chromosome146.  
Besides the large number of testis-specific gene promoters that demonstrated 
hypermethylation in somatic tissues, a large group of testis-specific genes was also 
detected that did not exhibit a differential methylation status in any of the studied tissues. 
This suggests that only a subgroup of testis-specific genes is affected by somatic 
hypermethylation. In addition, we also noted that copies of Y-linked genes like DAZL 
(chromosome 3) or VCX (chromosome X) that share almost identical promoter regions 
with their gene homologues on chromosome Y (DAZ and VCY, respectively) also show 
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somatic hypermethylation, whereas homologous genes that are regulated by different 
promoter sequences, like RBMX (chromosome X) or TSPYL5 (chromosome 8), show a 
different methylation profile compared to their Y-chromosome homologues RBMY1A1 and 
TSPY1. This indicates that a sequence-dependent (promoter-specific) mechanism 
establishes the hypermethylation in somatic tissues. The SYBL1 genes on both X and Y 
chromosomes appear to represent an exception in having almost identical promoters but 
being solely methylated on the Y chromosome143,185. Based on the methylation 
characteristics of SYBL1, the existence of Y-chromosome inactivation resembling the 
well-known X-chromosome inactivation in females was previously proposed143. However, 
according to the methylation pattern of all other Y-chromosome genes that were analyzed 
in the present study, this kind of phenomenon appears to be restricted to the short 
pseudo-autosomal region at the outmost end of the long arm of the Y-chromosome, which 
is flanked by a large heterochromatic region. 
Taken together, these observations suggest the presence of sequence-specific regulatory 
mechanisms controlling either the specific demethylation of some promoters in 
testis/germ-line cells or their methylation in somatic tissues. Common cis-acting 
sequences responsible for this phenomenon are unknown so far and the attempt to 
associate specific DNA motifs with either group of promoters failed. The methylation of 
CpG islands in lymphocytes was recently shown to correlate with DNA sequence, repeats, 
and predicted DNA structure using bioinformatics scoring and prediction methods, 
suggesting that multiple factors may predispose CpG islands for DNA methylation186. A 
number of other bioinformatic attempts, however, indentified specific nucleotide 
sequences187,188 that correlated with methylated or unmethylated CGI in cancer samples 
but failed to identify consensus sites for known transcription factors. Only one recent study 
identified SP1 to be associated with unmethylated CGI169. However, an independent 
study, done by our lab, recently obtained evidence that the methylation states of CGI in 
normal and cancer cells correlates with combinatorial binding of specific cis-acting factors 
(unpublished data).  
Insulator proteins such as CTCF and Boris/CTCFL may also be involved in regulatory 
mechanisms controlling gene expression. An insulator is a DNA sequence that can act as 
a barrier to the influences of neighboring cis-acting elements and for example prevents 
gene activation when located between an enhancer and a promoter189. Normally, CTCF 
and BORIS are expressed in a mutually exclusive pattern that correlates with re-setting of 
methylation marks during male germ cell differentiation190. Recent studies have shown, 
that the testis-specific nuclear protein and the CTCF paralog BORIS/CTCFL190 can initiate 
the demethylation of the cancer-testis antigens MAGE-A1191 and NY-ESO-1192 in normal 
somatic cells, suggesting that this transcription factor may be involved in the testis-specific 
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demethylation of at least some of the somatically methylated promoters. Moreover, De 
Smet and colleagues gained evidence, that the site-specific hypomethylation of MAGE-A1 
in tumor cells relies on a transient process of demethylation followed by a persistent local 
inhibition of remethylation due to the presence of transcription factors141. Another report 
indicates that E2F6 may be essential for the long-term somatic silencing of certain male-
germ-cell-specific genes193. In addition, Storre et al. suggests a molecular mechanism for 
the stable transcriptional silencing of meiotic genes in somatic cells by E2F6194. In line 
with this, a recent work indicates that E2F6 possesses a broad ability to bind to and 
regulate the meiosis-specific gene population195. Taken together, the above observations 
favor a model in which specific cis-acting sequences control promoter methylation at the 
level of somatic hypermethylation rather than by testis-specific demethylation.  
 
The coexistence of DNA methylation and transcription in a certain tissue was also 
detected in this study. Transcription may indeed proceed in the presence of DNA 
methylation at those sites. However, there are a number of possibilities that may also 
explain these observations, including alternative promoter usage, tissue heterogeneity or 
simply false-positive microarray signals. It is clear that the presented pilot study provides 
only an initial and limited view of the human methylation landscape, although it is clearly in 
line with several other recent reports. Interindividual methylation variability, which might in 
addition be necessary to understand the role of DNA methylation in gene regulation, has 
not been addressed in this study. Moreover, only differences in dominant cell types within 
the tissue samples analyzed may be detected in these experiments, because tissues are 
composed of different cell types.  
6.3 Allele-specific DNA methylation in mice 
As detailed previously, epigenetic processes are fundamental for the differentiation and 
development of multicellular organisms by controlling chromatin accessibility and 
transcription38. Although phenotypic variation between individuals is mainly driven by 
genetic traits, there is also evidence that epigenetic mechanisms may contribute to inter-
individual phenotypic differences in mammals89. Examples for epigenetic differences 
between individuals are comparatively rare and mostly, but not exclusively, confined to the 
level of DNA methylation, which represents a relatively stable epigenetic modification that 
can often be measured in an allelic context. There is well-documented evidence that 
epigenetic states can be inherited across generations. For example, agouti viable yellow 
(Avy) mice display inheritance of yellow fur as a result of incomplete erasure of the 
methylation signal associated with a retrotransposon insertion96,97, and kinked-tail mice 
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transmit phenotype through multiple generations due to the loss of the silent epigenetic 
state at the Axin gene196 as well as a heritable white-tail phenotype associated with Kit-
specific microRNAs197. It was also reported, that allelic variation at certain epigenetic 
modifier genes in mice, like DNA methyl-transferases or chromatin remodeling factors 
may influence the inheritance of CpG methylation patterns in trans98,99. Differences at the 
level of DNA methylation have also been demonstrated in supposedly genetically 
identical, monozygotic twins that are acquired during the lifetime of each individual 
through largely unknown mechanisms90,91.  
In addition to trans-regulation, there are several reports demonstrating that DNA 
sequence variants associate with specific epigenetic states. Differential methylation states 
of individual alleles were first described for the in c-Ha-ras-1 gene in human cells198,199 
More recently, a study by Murrell for example showed that loss of imprinting of the IGF2 
gene, which is frequently observed in Beckwith-Wiedemann syndrome (BWS), correlated 
with loss of maternal allele-specific methylation (LOM) for certain haplotypes94. This 
observation was supported by another study, showing that variation in DNA methylation of 
the IGF2/H19 locus is amongst others mainly determined by single nucleotide 
polymorphisms (SNPs) in cis93. In addition, Flanagan demonstrated allele-specific 
methylation patterns in the CDH13 gene92, and Yamada reported a CGI, which is 
methylated in an allele-specific but parental-origin-independent (non-imprinted) manner200. 
Along this line, a recent study in humans identified several cases of allele-specific DNA-
methylation at non-imprinted gene loci95, where the methylation status of each allele was 
likely controlled in cis by the local DNA sequence. 
Taken together, the published data suggests that three types of inheritance of DNA 
methylation patters may exist in vivo: methylation patterns at non-imprinted loci may be 
inherited across generations based on genetic mechanisms (in cis and in trans) or based 
on epigenetic mechanisms (e.g. inheritance of DNA methylation, or other epigenetic 
marks).  
 
As part of this thesis a broad analysis of differential DNA methylation in two inbred mouse 
strains was performed utilizing a modified protocol of DNA methylation-dependent 
genome fractionation (MCIp) in combination with locus-wide tiling arrays. Stringent 
hybridization conditions for microarray analyses of CpG-methylated and unmethylated 
genome fractions allowed the simultaneous detection of several hundred differentially 
methylated regions (DMRs). In addition, previously unrecognized strain-specific sequence 
variations that track with the large majority of DMRs were detected. The microarray results 
were validated by DNA sequencing (to confirm sequence variations) and a combination of 
bisulfite treatment of genomic DNA and mass spectrometry (to confirm CpG methylation 
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differences). The results suggest that the chosen approach is highly reproducible and 
correctly identified both DMRs and DNA sequence variations.  
 
Why were inbred mice chosen as model organisms to investigate allele-specific DNA 
methylation? The house mouse is one of the most successful mammals and the premier 
research animal in mammalian biology. A strain is defined as inbred when it has been 
mated brother versus sister for 20 or more consecutive generations. Such inbred strains 
are therefore isogenic (genetically identical) allowing offspring to posses both genetic and 
phenotypic uniformity. Each inbred strain has a unique genotype and consequently a 
unique phenotype. The normal pigmented C57BL strain was originally derived by Little in 
1921, whereas the strain BALB/c, which is albino and small in size, originated in 1923 by 
McDowell. C57BL is probably the most widely used of all inbred strains. Its sub strain 
C57BL/6, which developed before 1937, alone accounts for more than 14% of occasions 
on which an inbred strain is used.  
Concerning immunology various differences between these two strains are known. The 
C57BL/6-BALB/c model has been intensively used to study the immunopathogenesis of 
several intracellular infections such as listeriosis201, leihsmaniasis202,203, yersiniosis204,205 
and mycobacterial infections206,207. For example, the BALB/c strain is highly susceptible to 
the infection of Leishmania major, in contrast to resistant C57BL/6208,209. Susceptible mice 
as BALB/c fail to control parasite proliferation and develop progressive lesions and 
systemic disease, which is associated with Th2 response manifested by high levels of IL-
4, IL-13, IL-10 and antibody production. In contrast, resistant C57BL/6 mice develop IL-
12-driven, interferon-gamma (INF-gamma) dominated Th1 response that promotes 
healing and parasite clearance210,211. It is likely that epigenetical differences are found in 
immune-cells derived from the two inbred stains especially in regions containing genes 
which are differentially expressed without or upon stimulation. Macrophages are widely 
distributed immune system cells and beyond that involved in all stages of the immune 
response. They were chosen because they actually contribute to the clearance of an 
intracellular pathogen. The leishmanial parasites for example live inside the macrophage, 
but the macrophage is also the host‟s major effector cell in the elimination of this 
pathogen212. Macrophages can be phenotypically polarized by the local cytokine pattern to 
trigger specific functional programs. Polarized macrophages are broadly classified in two 
main groups: classically activated macrophages (or M1), and alternatively activated 
macrophages (or M2). M1 exhibit potent microbicidal properties and promote strong Th1 
responses, whilst M2 support Th2-associated effector functions. An activation of 
inappropriate effector mechanisms can lead to enhanced pathogen growth, rather than 
effective pathogen clearance. For example, classically activated macrophages protect 
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from L. major (Th1 response) in C57BL/6 mice, because they contribute to the clearance 
of the bacterium. On the contrary, in susceptible BALB/c mice, macrophages with a 
wound-healing phenotype (Th2 response) allow for its persistence210,211. It is also 
important, that macrophages can be grown in vitro, without possible environmental 
impacts.  
 
Both mice strains used in this study (C57BL/6 and BALB/c) belong to the most widely 
studied inbred mice. Especially the underlying genetic background of the C57BL/6 strain 
has been sequenced in detail and serves as the reference sequence for murine genetic 
research. It was conceivable that differences between inbred mice strains are present. In 
particular, since it was proposed that the genomes of inbred strains are a mosaic of 
regions of different sub specific origins. The fine structure of such mosaic variation was 
described by Wade, reporting extremely high variation spanning one-third of the genome 
and low variation in the remaining part213. This bimodal distribution was thought to 
represent regions having different, or the same, sub specific origins, respectively. 
Following studies raised questions about the haplotype structure214,215, the effect of 
ascertainment biases in subspecific assignment216,217 and the contributions of 
intersubspecific versus intrasubspecific variation218. In addition, the presence of 
substantial intrasubspecific variation, ancestral polymorphisms and secondary 
introgression after the divergence of the subspecies was reported218,219. Frazer and 
colleagues recently identified 8.3 million SNPs by resequencing of 15 different mouse 
strains indicating that modern inbred strains are composed of at least four mus musculus 
substrains (domesticus, molossinus, musculus and castaneus)151. In contrast to the 
mosaic model, another recent work found that most of the genome has intermediate levels 
of variation of intrasubspecific origin152. However the true extent of genetic differences 
between these two specific mice strains still remains elusive.  
 
In order to account for both, the reported genetic differences between strains and the 
unbalanced hybridization behavior seen in our experiments, we applied the virtual CGH 
analysis. The amount of microarray probes showing preferential hybridization only with the 
reference strain (C57BL/6) was unexpectedly high (>15%) in the present experiments. 
Although the analysis focused on regions where differential gene expression was 
observed, a huge number of array probes were affected. Subchromosomal alterations 
such as copy number variations (CNV) were seen and validated during the virtual CGH 
analysis. These findings were in line with a recently published study, which identified 
some of the larger CNV's as well using standard CGH approaches150. In addition to these 
large scale variations a huge number of smaller alterations were observed including 
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insertions and deletions within one strain and single nucleotide polymorphisms (SNPs). 
The accumulation of these sequence variations correlated well with probes exhibiting 
unequal hybridization behavior. Since probes were designed according to the genomic 
sequence of the reference strain C57BL/6, the affected ones were only conspicuous for 
BALB/c. Most previously known SNPs, as identified by Frazer151, correlated with affected 
probes. In addition, a large number of previously unknown SNPs were found in exemplary 
sequenced regions showing unequal hybridization behavior. The genomic sequencing 
data yielded also that the position of a number of repetitive elements was altered in 
BALB/c as compared to C57BL/6. However, it is unclear if the BALB/c strain contains 
more or less repetitive elements in general.  
Taken together, it is therefore conceivable that the genetic backgrounds of these two 
mouse strains vary to a greater extent than previously known and expected. These 
variations may in part contribute to the differential immune answer in both strains.  
 
After correction by vCGH our experiments defined a large number of allele-specific 
methylation events. In the following a representative set of these genomic regions were 
traced in the germ line of parental animals. Interestingly, most DMRs that were studied in 
detail, were only differentially methylated within the somatic tissues studied (BMM and 
spleen) and showed equal levels of methylation in the male germ line, suggesting that the 
observed differences are established post-fertilization and DNA methylation itself is not 
inherited across generations.  
Furthermore, the exemplary mass spectrometry validation of DMRs and allele specific 
examination of DNA methylation in F1 Hybrids using traditional sequencing of bisulfite 
treated genomic DNA suggests, that the propensity for acquiring DNA methylation during 
development mainly depended on the local sequence context in cis. It is formally possible 
that another, yet uncharacterized epigenetic mark at these sites determines the allelic 
methylation status in a heritable fashion. However, since a common association of DMRs 
with sequence variations was found, it is much more likely that the establishment of 
differential methylation patterns during embryonic development may involve cis-acting 
regulators, including sequence-specific DNA-binding proteins or other sequence-
dependent regulatory mechanisms. Several publications accentuate the contribution of 
cis-acting regulators as observed in this thesis. The findings of this work are in line with a 
number of previous studies linking allelic DNA-methylation and genetic variation which 
were already discussed in the beginning of this chapter92-95,200 and share an obvious 
corollary with the recent observation that the genetic sequence is largely responsible for 
directing species-specific transcription in mice carrying the human chromosome 21220. 
Moreover, investigating the same human chromosome, Zhang and colleagues very 
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recently indentified three cases of allele-specific DNA methylation showing strong 
sequence dependence similar to our results221. However, our analysis contrasts a lately 
published study that did not find significant variation in DNA methylation between inbred 
or outbred mice and concluded that the impact of DNA polymorphisms on DNA 
methylation would not seem to be common91. The reasons for the deviant findings are not 
clear but may relate to the different technologies and readout systems used in each study. 
For example, the above study used a CpG island microarray covering 2176 unique CpG 
island regions of the mouse genome that are likely more conserved, frequently contain 
gene promoters and are often unmethylated. Based on our findings that differential DNA 
methylation is associated with genetic variation and promoter-distal sites, we would 
predict that the microarray platform utilized by Kaminski et al. is less likely to detect allele-
specific DNA methylation than the considerably larger and locus-wide microarray used in 
our study. 
It is conceivable that trans-acting mechanisms contribute to the epigenetic status of a 
specific region as well. It has recently been published that the absence or functional 
inactivation of the few known epigenetic modifiers that mediate DNA methylation in trans 
show profound developmental abnormalities222. However, our data suggests, that only a 
relatively small proportion of strain-specific DMRs (like the ones identified in Isoc2b, Sfi1 
pseudogene, or Eps8l1) depend dominantly on trans-acting mechanisms.  
Taken together, the presented findings suggest that genetic variability has a major impact 
on epigenetic variability, likely due to its influence on the propensity of individual alleles to 
become methylated (or demethylated) during development. This relationship is likely not 
restricted to early embryonic development in mice, but may also apply to other 
developmental (including disease- and age-related) processes in mammals. For example 
Zhang et al. demonstrated allele-specific DNA methylation in human samples as well221. In 
essence, the results imply that any given DNA sequence (at a non-imprinted locus) may 
carry intrinsic information that recruits cis-acting factors and determines its DNA 
methylation status during mammalian development. 
 
What is the relevance of the present findings? The systematic screening of the human 
genome for genetic variants that affect gene regulation was thought to advance the 
fundamental understanding of phenotypic diversity and lead to the identification of alleles 
that modify disease risk. It becomes more and more obvious, that the allele-specific 
expression of genes is, for instance, controlled by cis-acting factors (such as DNA 
polymorphisms and methylation) in the flanking DNA sequence and trans-acting 
modulators (such as transcription factors) that are themselves regulated by other genetic 
(developmental or environmental) factors. Recently a study showed that genetics may be 
an important factor that influences global chromatin states by using allele-specific ChiP 
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(chromatin immunoprecipitation)223. These allelic differences in chromatin may provide an 
explanation for the observed allelic variation in gene expression224. Evidence for the 
medical importance of cis-acting polymorphisms has been provided by positional cloning 
of susceptibility genes for common diseases such as stroke225 and type 2 diabetes226. The 
polymorphisms in these examples were not associated with protein coding or splice-site 
variations. However, diverse cis-acting mechanisms might also be important for malignant 
diseases. Successful epigenetic control of gene expression is necessary and aberrant 
DNA methylation, which has been recognized as an important feature in cancer formation, 
leads to the altered gene expression seen in almost all human cancers. Originally only 
genome-wide DNA hypomethylation was linked with cancer and was the focus of tumor 
research37,227,228. But during the mid 1980s regional hypermethylation of specific cancer-
associated gene promoter sites attracted greater attention and the focus relocated to the 
participation of hypermethylation to cancer formation229-231. The present study strongly 
suggests, that individual alleles can exhibit different probabilities to become methylated 
(regulated in cis). Interestingly, a recent study investigated the regulation of allele-specific 
expression (ASE) by cis-acting elements in acute lymphoblastic leukemia (ALL)232. They 
found that allele-specific CpG site methylation is one of the factors that regulate allele-
specific gene expression in ALL cells. Besides, an independent study, done by our lab, 
recently obtained evidence of allele-specific methylation of certain CGIs in acute myeloid 
leukemia (AML) samples (unpublished data). However, further studies are certainly 
required, in order to shed more light on a possible connection between cis-acting 
mechanisms and cancer formation.  
 
Taken together, this study describes the first comprehensive identification of allele-specific 
DNA-methylation in mice, and provides a resource for further mechanistic studies. The 
findings presented in this thesis imply that the genetic context of a specific region is 
strongly regulating the epigenetic status in terms of DNA methylation. It seems that 
genetic variability has a major impact on epigenetic variability and that this variability 
contributes to the shaping of different individual phenotypes. However, this might not only 
have an impact for early developmental steps, but also for disease-related processes in 
mammals.  
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6.4 Outlook 
This pilot study enabled the detection of cell type-specific differences in promoter DNA 
methylation with a reasonable resolution. Hence, the study presents a novel application of 
the MCIp methodology that may fill previous methodical gaps allowing the reliable 
detection of hypomethylated DNA fragments on a genome-wide level. It is also clear that 
this study provides only an initial and limited view of the human methylation landscape. 
Since tissues are composed of different cell types, we likely detected differences in 
dominant cell types. Further analysis would certainly benefit when purified cell populations 
are used. In addition, matched methylation and expression profiling data will be necessary 
to completely understand the relationship between DNA methylation and gene expression. 
Our studies concentrated on promoters so far. In the literature, there is rising data on 
distribution and dynamics of DNA methylation off-side promoter regions. For example, 
Eckhardt et al. reported that tissue-specific DNA methylation patterns are not only found in 
promoters but also in conserved intergenic elements, leading the authors to propose that 
DNA methylation regulates the activity of distant enhancers153. In line with this a recent 
study done by our lab showed that cell type-specific methylation differences mainly occur 
in promoter off-side regions of low CpG content (no CGIs)159. This study concentrated on 
specific T-cell subsets, but the conclusions very likely apply to other cell types as well and 
would be interesting to study on more diverse cell types or tissues. In addition, a 
combined analysis of DNA methylation and chromatin marks may lead to the identification 
of promoter distal regions with enhancer/silencer activity.  
On the other hand the present study demonstrated that genetic sequence variations 
contribute to epigenetic regulation in a cis-acting manner. The relevance of these findings 
for human disease-related research is stated above. For years, much effort has been 
made to understand epigenetic reasons for malignant growth as well as other non-
cancerous human diseases, but the interpretation of disease-related DNA methylation 
pattern was and is certainly very difficult and additionally complicated by the occurrence of 
normal cell developmental processes as well as age-related processes. Moreover, there 
are other determinants as well, such as the local genetic context regulating the 
methylation pattern in cis. Other determinates might regulate DNA methylation in a trans-
acting manner. In general the true extent of contribution from genetic determinants such 
as sequence polymorphisms to epigenetic patterns is currently unknown. Hence, 
comparative DNA methylation profiling is interesting for other model systems as well, 
which could be easily achieved with this approach. In principal, all disease processes 
could be analyzed regarding allele-specific DNA methylation differences. Allele-specific 
DNA methylation may also have an impact on psychological and behavioral issues as well 
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as disease- and cancer-related issues. For instance, individual phenotypical differences 
between twins could be addressed using our methodology. An in-depth investigation of 
human allele-specific methylation will likely contribute to the identification of distinct 
epialleles, which are not only involved in individual phenotypical characteristics but may 
also affect different individual disease susceptibility and probability to develop cancer. As 
a first step one could investigate the occurrence of allele-specific DNA methylation in 
human cell lines. However, CGH-microarray-based detection has limited ability to 
measure allelic DNA methylation and bisulfite sequencing, though less limited in this 
regard, requires extensive resources when applied genome-wide. MCIp in combination 
with SNP arrays for example may provide an opportunity to identify specific alleles, which 
are more prone to DNA methylation. Data on allelic methylation asymmetry will likely be 
useful for fine mapping and interpreting associations of (noncoding) SNPs to complex 
genetic diseases.  
In our analysis we also gained evidence that the DNA methylation of some regions might 
be regulated by a certain strain-specific epigenetic modifier (in trans). The identification of 
the factor being responsible for the epigenetic control of for example the Isoc2b gene 
promoter in parental strains can provide interesting information about the epigenetic 
regulation of such particular regions. A useful tool in to search for such a factor might be a 
methodology called marker-assisted backcrossing. Backcrossing leads to offspring with a 
genetic identity which is closer to that of one parent. By screening for F2-offspring 
individuals with either F1-like or parental-like patterns one might be able to clarify the 
location of genomic regions harboring the modifier possibly leading to its identification.  
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7 Summary 
Epigenetic mechanisms such as histone modifications and DNA methylation extend the 
information of the underlying genomic DNA sequence. Understanding cell type-specific 
epigenetic codes on a global level is a major challenge after the sequencing of the human 
genome has been completed. In addition, differences in epigenetic patterns between 
individuals may contribute to phenotypic variation and disease susceptibility. However, 
little is known about the extent of such variation or how different epigenetic patterns are 
established. In the present thesis, I applied and modified the methyl-CpG 
immunoprecipitation (MCIp) method to globally map DNA methylation. This method is 
based on a recombinant, methyl-CpG-DNA binding protein (MBD2-Fc), which is used to 
fractionate genomic DNA depending on its methylation status.  
During this thesis the MCIp-method was on the one hand modified and established for a 
novel application. This study was designed as a pilot project to establish the MCIp 
approach for comparative hypomethylation analysis. To study cell-type-specific DNA 
methylation differences, the MCIp procedure was used in combination with oligonucleotide 
promoter microarrays (MCIp-on-chip) to identify differences in promoter hypomethylation 
of coding and non-coding genes in human tissues. Forty-four identified tissue-specifically 
methylated promoters were independently validated using bisulfite sequencing or single 
gene MCIp, confirming the results obtained by the MCIp microarray approach. A 
comparison of the obtained tissue methylation profiles with corresponding gene 
expression data indicated a significant association between tissue-specific promoter 
methylation and gene expression, not only in CpG-rich promoters. The data also 
highlighted the exceptional epigenetic status of germ line cells in testis, where many 
testis-specific promoters were demethylated as compared to somatic tissues. Somatic 
hypermethylation particularly affected many CpG-rich promoters of testis-specific genes 
e.g. in ampliconic areas of the Y-chromosome. 
In order to analyze individual (allele-specific) DNA methylation the MCIp-on-chip method 
was on the other hand further improved to the “mirror image” procedure. The “mirror 
image” approach was used to analyze the methylation profiles of immune cells from two 
inbred mice strains (C57BL/6 and BALB/c) that represent prototypic models for Th1- or 
Th2-dominated immune responses. Using MCIp the genomes of bone marrow-derived 
macrophages were fractionated into methylated and unmethylated genome pools and 
separately analyzed by microarray at 181 genomic regions (covering 28 Mb of mouse 
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genome) that were selected based on differential gene expression between both mouse 
strains. The combined analysis of hypo- and hypermethylated profiles allowed the 
identification of several hundred differentially methylated regions, but also uncovered 
several copy number variations as well as many single nucleotide polymorphisms (SNPs) 
or micro- and macro-deletions/insertions. By using DNA sequencing and mass 
spectrometry it was shown for a subset of regions that specific allelic methylation patterns 
in somatic cells were maintained in F1- hybrid animals, regardless of their status in germ 
line cells. A common association with sequence polymorphisms suggests that the 
genomic context at these differentially methylated regions determines their 
developmentally regulated methylation in cis. 
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8 Deutsche Zusammenfassung 
Epigenetik im Allgemeinen und DNA Methylierung im Speziellen, erweitern den 
Informationsgehalt der zugrundeliegenden genomischen DNA-Sequenz. Nachdem das 
menschliche Genom weitgehend sequenziert wurde, ist insbesondere das Verständnis 
von zelltypspezifischen epigenetischen Kodierungen in genomweiter Hinsicht die nächste 
zu bewältigende Herausforderung. Darüber hinaus sind unterschiedliche epigenetische 
Muster auch im Verdacht, sowohl zu unterschiedlichen individuellen phänotypischen 
Ausprägungen, als auch zu der individuellen Anfälligkeit für bestimmte Krankheiten 
beizutragen. Allerdings ist über das Ausmaß solcher Unterschiede und deren Etablierung 
sehr wenig bekannt. In dieser Arbeit wurde die Methyl-CpG Immunpräzipitations (MCIp)-
Methode verwendet, um die DNA Methylierung unter zwei Aspekten zu untersuchen. Die 
Methode basiert auf einem rekombinanten, methyl-CpG-DNA bindenden Protein (MBD2-
Fc), mit dessen Hilfe genomische DNA hinsichtlich ihres Methylierungsgrades fraktioniert 
werden kann.  
Zunächst wurde die MCIp Methode während dieser Arbeit modifiziert und für eine neue 
Anwendung etabliert. Diese Studie war als Pilotprojekt angelegt um die Verwendung der 
MCIp Methode zur vergleichenden Analyse der DNA Hypomethylierung zu etablieren. Um 
zelltypspezifische DNA Methylierungsunterschiede untersuchen zu können, wurde die 
MCIp Methode mit Promotor Microarrays kombiniert, um gewebespezifische Unterschiede 
in der Hypomethylierung von Promotoren codierender und nicht codierender Gene zu 
analysieren. Daraufhin wurden 44 als gewebespezifisch methyliert identifizierte 
Promotoren mit Microarray-unabhängigen Methoden validiert. Hierzu wurde sowohl die 
MCIp-Methode zum Nachweis der Methylierung an Einzelgenen als auch die 
Sequenzierung von Natriumbisulfit-behandelter genomischer DNA angewendet. Nach 
Validierung der Arrayergebnisse wurden die resultierenden gewebsspezifischen 
Methylierungsmuster mit der Expression der entsprechenden Gene verglichen. Es stellte 
sich heraus, dass nicht nur in stark CpG-haltigen Promotoren die gewebespezifische 
Methylierung und die Expression signifikant miteinander korrelierten. Sondern auch, dass 
Keimbahnzellen aus dem Hodengewebe, ein im Vergleich zu somatischen Zellen, 
außergewöhnliches epigenetisches Muster aufwiesen. So waren im Besonderen, stark 
CpG-haltige Promotoren hodenspezifischer Gene von somatischer Hypermethylierung 
betroffen. Diese Gene waren vor allem in ampliconischen Bereichen des Y-Chromosoms 
zu finden. Die kombinierte Anwendung von MCIp, zur Probenvorbehandlung, und 
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Microarrays, als globales Auslesesystem, ermöglichten in diesem Projekt die 
unverfälschte und unvoreingenommene Analyse gewebespezifischer 
Promotormethylierung.  
Um individuelle (allele-spezifische) DNA Methylierungsunteschiede untersuchen zu 
können, wurde die MCIp-on-chip zur „mirror image“ Anwendung weiterentwickelt. Damit 
wurden in einem zweiten Projekt Immunzellen zweier Maus-Inzuchtstämme (C57BL/6 und 
BALB/c), die ein prototypisches Model für die Th1- oder Th2-dominierte Immunantwort 
darstellen, analysiert. Hierbei wurde die MCIp-Methode verwendet, um die Genome von 
murinen Knochenmarksmakrophagen in einen methylierten und einen unmethylierten Teil 
aufzutrennen. Die jeweiligen korrespondierenden DNA-Pools beider Mausstämme wurden 
auf einen spezifisch hergestellten Microarray hybridisiert. Da epigenetische Unterschiede 
vermehrt in Bereichen differentieller Genexpression zwischen Knochenmarks-
makrophagen beider Mausstämme zu erwarten sind, wurden zunächst 181 dieser 
Regionen ausgewählt und für das Arraydesign herangezogen. Insgesamt wurden damit 
28 Mb des murinen Genoms abgedeckt. Die kombinierte Analyse der hypo- und 
hypermethylierten Teilbereiche ermöglichte die Identifizierung von mehreren hundert 
unterschiedlich methylierten Regionen. Ferner wurden auch verstärkt genetische 
Variationen, wie Unterschiede in der Genkopiezahl, Insertionen und Deletionen im Mikro- 
und Makromaßstab, sowie Einzelnukleotid-Polymorphismen zwischen beiden 
Mausstämmen festgestellt. Anschließend wurde eine ausgewählte Anzahl von Regionen 
mittels MALDI-TOF Massenspektrometrie und Sequenzierung von Natriumbisulfit-
behandelter DNA eingehender untersucht. Dabei zeigte sich, dass die 
Methylierungsmuster elterlicher Allele im Wesentlichen auch in F1-Tieren, unabhängig 
vom Methylierungsgrad dieser Regionen in Keimbahnzellen, beibehalten wurden. Dieses 
Phänomen war häufig mit Sequenz-unterschieden zwischen den Allelen assoziiert. Dies 
führte zu der Annahme, dass die entwicklungsspezifische Methylierung dieser Regionen 
maßgeblich durch die lokale genetische Sequenz in cis reguliert wird. 
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10 Abbreviations 
°C Grad Celsius 
µg Microgram 
µl Microliter 
5mC 5-methylcytosine 
A Adenine 
AA Acrylamide 
ALL Acute lymphoblastic leukemia 
APS Ammonium persulfate 
AS Antisense 
ASE Allele-specific expression 
BMM Bone-marrow derived macrophages 
bp Base pair 
BSA Bovine serum albumine 
C Cytosine 
CAP CxxC affinity purification 
cDNA Copy DNA 
CGH Comparative genome hybridisation 
CGI CpG-island 
CIAP Calf intestinal alkaline phosphatase 
CNV Copy number variation 
CpG Cytosine/Guanine dinucleotide 
cRNA Copy RNA 
CTCF CCCTC-binding factor 
C-terminal Carboxyterminal 
(d) CTP (deoxy) Cytosine triphosphate 
DEPC Diethylpyrocarbonate 
DMF Dimethylformamide 
DMR Differentially methylated region 
DNA Deoxyribonucleic acid 
Dnmt DNA-methyltransferase 
dNTP Deoxyribonucleotide 
EDTA Ethylenediaminetetraacetic acid 
EtBr Ethydiumbromide 
F1 F1 generation 
G Guanine 
g Rotational force or gram 
GC Guanine/Cytosine 
Abbreviations 
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gDNA Genomic DNA 
GE Gene expression 
GO Gene ontology 
h Hour 
HELP HpaII-tiny fragment Enrichment by Ligation-mediated PCR 
hg Human genome 
i.a. Inter alia 
ICR Inprinting control region 
IP Immunopreciptitation 
k Kilo 
kb Kilo base 
kDa Kilo Dalton 
l Liter 
LB Lysogeny broth 
M Molar 
M1/M2 classically/alternatively activated macrophage 
mA Milli Ampere 
MALDI_TOF MS Matrix-assisted laser desorption/ionisation time-of-flight 
mass spectrometry 
MBD Methyl-binding domain 
MB-PCR Methyl-binding PCR 
MCIp Methyl-CpG-immunoprecipitation 
mCpG Methylated CpG dinucleotide 
MeCP2 Methyl CpG binding protein 2 
MeDIP Methylated DNA immunoprecipitation 
mg Milligram 
min Minute 
ml Milliliter 
mM Millimolar 
mm Mus musculus 
MNC Mononuclear cells 
mRNA Messenger RNA 
MS Mass spectrometry 
MSP Methyl-specific PCR 
n Number 
NaCL Sodium chloride 
NaHSO3 Sodium bisulfite 
NCBI National Center for Biotechnology Information 
ng Nanogram 
NGS Next generation sequencing 
nos Numbers 
N-ternimal Aminoternimal 
OD Optical density (Absorbance) 
Abbreviations 
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PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
ps Pseudogene 
qPCR Quantitative PCR 
rCSF Recombinant colony stimulating factor 
RLGS Restriction landmark genomic scanning  
RNA Ribonucleic acid 
rpm Rotations per minute 
RT Room temperature 
RT-PCR Reverse transcription PCR 
s Second 
S Sense 
SAM S-Adenosyl-Methionine 
SAP Shrimp Alkaline Phosphatase  
SD Standard diviation 
SDS Sodium dodecyl sulfate 
SINE Short interspersed element 
SNP Single nucleotide polymorphism 
SOC Rich bacterial growth media 
SSPE Sodium chloride, sodium phosphate, EDTA buffer 
T Thymine 
TAE Tris-acetate buffer with EDTA 
TBS Tris buffered saline 
TE Tris EDTA buffer 
TEMED Tetramethylethylenediamine 
TFBI/II Media for competent cells 
Th1/Th2 Type 1/Type 2 helper T cell 
Tm Melting temperature 
TRD Transcriptional repression domain 
U Unit or Uracil 
UCSC University of California, Santa Cruz 
UPD Uniparental contribution of one chromosome pair 
vCGH Virtual comparative genome hybridisation 
w/v Weigth per volume 
Xic X-inactivation center 
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Appendix I – Tissue-specific methylated promoters (section 12.1; page 154) 
Table 12.1 contains all tissue-specific differentially methylated promoters. Genomic 
locations are based on the Build 35 assembly by NCBI and the Human Genome 
Sequencing Consortium (hg17). The distance of probes to transcription start sites (TSS) 
of corresponding genes is indicated as well as the CpG index (+/- 350 bp). The tissue 
where this promoter is demethylated is shown in the last column.  
 
Appendix II – Differentially expressed loci (section 12.2; page 173) 
Table 12.2 lists all gene loci that were selected for the locus-wide tiling array. Genomic 
locations are based on the Build 36 assembly by NCBI and the Mouse Genome 
Sequencing Consortium (mm8). Randomly chosen control loci are boxed in light green.  
 
Appendix III – Annotated list of mouse strain-specific DMR (section 12.3; page 177) 
Table 12.3 contains the complete list of mouse strain-specific DMR discovered in this 
study. The genomic location (Build 36 assembly by NCBI, mm8) of the  „core‟ region of the 
DMR is given along with information on the associated (neighboring) gene, its position 
relative to this gene, its methylation status and BMM expression data (if available) for the 
associated gene. Microarray expression data was median-normalized to the C57BL/6 
BMM sample (data for 4h and 18h treatments is not shown). The call status of individual 
probes in each sample is given in brackets behind the relative expression values (P, 
present; A, absent; M, marginal).  
 
Appendix IV – sequence alignments (section 12.4; page 187) 
This supplement contains DNA sequence alignments of 34 selected regions in C57BL/6 
and BALB/c. Regions were randomly selected from the vCGH data (A-I), or as possible 
targets for methylation analysis using MALDI-TOF MS (J-AH). Genomic DNA was PCR 
amplified and directly sequenced. All sequences were deposited with GenBank 
(accession numbers: FJ751937-FJ752004). Differences between BALB/c and the 
reference strain C57BL/6 are marked as follows: deletions or insertions (relative to 
C57BL/6) are in red lettering; single nucleotide polymorphisms are boxed in blue 
(BALB/c). Variations between the published reference sequence and the C57BL/6 
sequence used in this study were only observed in a fragment that represents a 
pseudogene or duplication of the Sfi1 locus (in AC). Genomic locations are based on the 
Build 36 assembly by NCBI and the Mouse Genome Sequencing Consortium (mm8). 
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12.1 Appendix I – Tissue-specific methylated 
promoters 
Table 12.1 Microarray-detected differentially methylated gene promoter 
Probe Location 
(NCBI Built 35) 
Gene Name TSS-Distance 
of Probe 
CpG-Index 
(+/- 350 bp) 
demethylated 
in 
chr13:113156292-113156352 ADPRHL1 -482 29 brain 
chr15:027001096-027001156 APBA2 -18 17 brain 
chr15:027001215-027001265 APBA2 96 16 brain 
chr18:053550053-053550112 ATP8B1 -45 11 brain 
chr1:006380184-006380236 BACH -71 23 brain 
chr19:010471818-010471874 BC002417 -107 16 brain 
chr12:049926071-049926129 BC003379 61 12 brain 
chrX:141018179-141018224 BC005891 -521 21 brain 
chr20:018070821-018070881 BC007537 -112 11 brain 
chr1:001204306-001204358 BC007625 -158 32 brain 
chr12:127824516-127824576 BC009492 -371 22 brain 
chr16:083581862-083581922 BC017702 -453 25 brain 
chr9:094602320-094602379 BC020194 75 12 brain 
chr18:013672133-013672193 BC022410 -57 9 brain 
chr10:050401989-050402049 BC028954 130 11 brain 
chr7:112018428-112018488 BC030804 -262 8 brain 
chr7:112018654-112018714 BC030804 -488 9 brain 
chr21:041670735-041670795 BC035293 128 15 brain 
chr17:007226637-007226691 BC035782 -211 14 brain 
chr14:090821721-090821781 BC035914 8 24 brain 
chr12:039507992-039508052 BC036569 -258 13 brain 
chr8:001794402-001794449 BC040474 98 27 brain 
chr8:021966477-021966533 BC052805 -596 15 brain 
chr17:024426164-024426224 BC058075 -477 21 brain 
chr16:002319879-002319939 BC062779 -211 12 brain 
chr2:135822033-135822093 BC064616 -123 11 brain 
chr20:041626880-041626940 BC065511 -349 17 brain 
chr1:200471739-200471799 BC069650 102 13 brain 
chr14:089112094-089112145 BC069658 -245 20 brain 
chr14:089112268-089112328 BC069658 -66 16 brain 
chr1:032054426-032054486 BC070182 -369 14 brain 
chr14:020580502-020580555 BC074960 -434 13 brain 
chr1:034990667-034990712 BC093838 -252 18 brain 
chr17:019126986-019127046 BC093972 64 26 brain 
chr17:040238543-040238600 BC096213 140 19 brain 
chr17:041395305-041395363 BC098281 -185 15 brain 
Appendix I 
 
155 
Probe Location 
(NCBI Built 35) 
Gene Name TSS-Distance 
of Probe 
CpG-Index 
(+/- 350 bp) 
demethylated 
in 
chr10:011401728-011401788 C10orf31 95 13 brain 
chr11:030558663-030558723 C11orf8 -77 9 brain 
chr11:030558830-030558890 C11orf8 -244 6 brain 
chr11:030559065-030559125 C11orf8 -479 8 brain 
chr14:066725463-066725523 C14orf54 -405 11 brain 
chr5:034079089-034079144 C1QTNF3 -42 12 brain 
chr22:042144979-042145035 C22orf1 -401 14 brain 
chr8:011025219-011025279 C8orf16 -94 13 brain 
chr1:019491575-019491635 CAPZB -54 15 brain 
chr22:048538819-048538879 CCDS14080.1 -23 26 brain 
chr1:010443963-010444008 CORT -251 20 brain 
chr1:010444106-010444166 CORT -100 18 brain 
chr1:010444380-010444438 CORT 173 22 brain 
chr22:023919940-023919992 CRYBB3 -412 14 brain 
chr10:126706348-126706408 CTBP2 65 25 brain 
chr10:035934088-035934148 CX40.1 -225 14 brain 
chrX:019744390-019744450 CXorf23 -339 9 brain 
chr2:228323317-228323377 DKFZp547H025 46 9 brain 
chr8:001436591-001436651 DLGAP2 -354 14 brain 
chr8:001436801-001436854 DLGAP2 -148 23 brain 
chr20:001224333-001224385 ENST00000217276 -58 24 brain 
chr16:012516793-012516846 ENST00000219090 -68 14 brain 
chr2:105383785-105383845 ENST00000258449 -519 13 brain 
chr16:000337079-000337137 ENST00000262320 2 19 brain 
chr16:000337208-000337268 ENST00000262320 -128 18 brain 
chrX:110171873-110171933 ENST00000262836 -573 6 brain 
chrX:110172089-110172149 ENST00000262836 -357 6 brain 
chr3:102987196-102987254 ENST00000273347 95 11 brain 
chr5:138238070-138238126 ENST00000274711 47 9 brain 
chr5:138238643-138238699 ENST00000274711 -526 16 brain 
chr12:001007477-001007535 ENST00000299183 176 16 brain 
chr16:015640655-015640715 ENST00000300014 -32 14 brain 
chr18:070475055-070475115 ENST00000309902 -246 12 brain 
chr12:016644843-016644903 ENST00000320122 188 8 brain 
chr16:011677271-011677316 ENST00000329565 -37 31 brain 
chr15:089569526-089569586 ENST00000330276 -547 11 brain 
chr15:089569658-089569718 ENST00000330276 -415 10 brain 
chr8:043077295-043077355 ENST00000331373 -523 11 brain 
chr6:012826568-012826628 ENST00000332995 71 12 brain 
chr10:123770911-123770971 ENST00000334433 -499 19 brain 
chr10:123771372-123771432 ENST00000334433 -38 20 brain 
chr4:154549026-154549086 ENST00000338700 -86 15 brain 
chr2:198773879-198773939 ENST00000341860 -132 10 brain 
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chr2:198774045-198774098 ENST00000341860 30 11 brain 
chr2:198774190-198774249 ENST00000341860 178 12 brain 
chr10:123343655-123343715 ENST00000346997 -364 21 brain 
chr6:118994211-118994271 ENST00000359516 -1 15 brain 
chr11:131035896-131035956 ENST00000360508 -157 13 brain 
chr11:131036065-131036125 ENST00000360508 -326 10 brain 
chr1:040591855-040591915 ENST00000361584 83 8 brain 
chr17:026673154-026673214 EVI2A -341 8 brain 
chr17:077910023-077910083 FLJ35767 -359 18 brain 
chr17:032806792-032806852 FLJ39647 -275 13 brain 
chr17:032806919-032806979 FLJ39647 -148 8 brain 
chr20:014266631-014266691 FLRT3 -391 12 brain 
chr15:089212954-089213014 FURIN 96 9 brain 
chr6:010693856-010693916 GCNT2 -94 16 brain 
chr6:024597559-024597619 GPLD1 189 12 brain 
chrX:013594808-013594864 GPM6B 135 14 brain 
chrX:013595126-013595186 GPM6B -185 18 brain 
chrX:013595243-013595303 GPM6B -302 15 brain 
chrX:013595385-013595445 GPM6B -444 11 brain 
chr19:052113811-052113857 GRLF1 62 17 brain 
chr6:114490978-114491038 HS3ST5 -306 8 brain 
chr3:035760481-035760539 hsa-mir-128b -462 9 brain 
chr3:035760665-035760725 hsa-mir-128b -277 13 brain 
chr3:035760825-035760885 hsa-mir-128b -117 12 brain 
chr3:035761037-035761087 hsa-mir-128b 90 14 brain 
chr9:094927591-094927651 hsa-mir-24-1 -237 35 brain 
chr7:130019996-130020056 hsa-mir-29b-1 -473 12 brain 
chr17:076714638-076714698 hsa-mir-338 -324 34 brain 
chr3:054937590-054937641 HT017 -503 17 brain 
chr11:128242463-128242523 KCNJ1 -15 11 brain 
chr17:065612388-065612448 KCNJ16 -171 8 brain 
chr17:065612548-065612600 KCNJ16 -15 10 brain 
chr19:048977667-048977725 KCNN4 -447 15 brain 
chr13:044666706-044666766 KCTD4 116 13 brain 
chr19:039483115-039483175 KIAA0354 -73 15 brain 
chrX:116888523-116888583 KLHL13 182 8 brain 
chr4:038886645-038886705 KLHL5 50 10 brain 
chr21:044817499-044817551 KRTAP10-4 -508 16 brain 
chr21:044817830-044817890 KRTAP10-4 -173 23 brain 
chr12:016652579-016652639 LMO3 -318 9 brain 
chr4:054265227-054265282 LNX 41 14 brain 
chr12:123298434-123298494 LOC144347 -125 18 brain 
chr16:006367728-006367788 LOC440337 -6 12 brain 
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chr1:024473419-024473474 LOC90529 -191 10 brain 
chr5:138238877-138238935 LRRTM2 2 16 brain 
chr19:051850046-051850102 MGC15476 -320 22 brain 
chr7:077621227-077621287 MGC34774 48 7 brain 
chr19:014913135-014913195 OR7C2 -135 12 brain 
chr11:123816664-123816719 OR8B8 -500 14 brain 
chr11:123686382-123686442 OR8D1 -540 7 brain 
chr11:057703393-057703453 OR9Q1 -69 10 brain 
chr11:057703574-057703634 OR9Q1 112 13 brain 
chr11:066478359-066478419 PC 67 14 brain 
chr10:050402588-050402648 PGBD3 -286 12 brain 
chr10:050402894-050402954 PGBD3 -592 10 brain 
chr6:012825817-012825877 PHACTR1 29 10 brain 
chr20:057729122-057729182 PHACTR3 -507 15 brain 
chr20:057729238-057729298 PHACTR3 -391 13 brain 
chr20:057729743-057729791 PHACTR3 108 11 brain 
chr5:067557608-067557666 PIK3R1 -580 18 brain 
chr5:067557770-067557830 PIK3R1 -417 17 brain 
chr5:067557898-067557949 PIK3R1 -294 16 brain 
chr5:067558297-067558357 PIK3R1 110 13 brain 
chr5:146415567-146415627 PPP2R2B 74 10 brain 
chr12:010972575-010972635 PRH2 -495 7 brain 
chr6:150304060-150304115 RAET1E 124 8 brain 
chr16:024765142-024765187 SLC5A11 112 17 brain 
chr11:066245697-066245757 SPTBN2 -281 18 brain 
chr12:011031222-011031282 TAS2R50 -526 8 brain 
chr15:055299101-055299161 TCF12 185 19 brain 
chr10:114033350-114033410 TECTB -102 17 brain 
chr20:002224396-002224456 TGM3 -248 13 brain 
chr20:030184552-030184603 TM9SF4 102 10 brain 
chr9:097366024-097366079 TMOD1 60 9 brain 
chr2:233559949-233560002 UNQ830 -523 12 brain 
chr9:134034396-134034456 WDR5 -41 21 brain 
chr7:020030099-020030159 7A5 124 5 monocyte 
chr7:020030479-020030539 7A5 -256 6 monocyte 
chr12:021981417-021981477 ABCC9 -572 7 monocyte 
chr11:100367624-100367684 AD031 -366 6 monocyte 
chr1:111758594-111758651 ADORA3 -470 9 monocyte 
chr6:031691579-031691630 AIF1 -163 12 monocyte 
chr6:031691863-031691918 AIF1 123 12 monocyte 
chr9:072797308-072797368 ALDH1A1 185 12 monocyte 
chrY:006785869-006785929 AMELY -470 6 monocyte 
chr10:090601872-090601932 ANKRD22 -406 9 monocyte 
Appendix I 
 
158 
Probe Location 
(NCBI Built 35) 
Gene Name TSS-Distance 
of Probe 
CpG-Index 
(+/- 350 bp) 
demethylated 
in 
chr7:036537529-036537589 AOAH -294 7 monocyte 
chr11:043289816-043289876 API5 -262 36 monocyte 
chr2:143720458-143720518 ARHGAP15 -206 7 monocyte 
chr2:143720760-143720820 ARHGAP15 96 6 monocyte 
chrX:011043676-011043733 ARHGAP6 48 9 monocyte 
chrX:011044130-011044190 ARHGAP6 -408 7 monocyte 
chrX:135589041-135589096 ARHGEF6 -45 13 monocyte 
chrX:135589230-135589279 ARHGEF6 -231 8 monocyte 
chrX:135589371-135589431 ARHGEF6 -378 6 monocyte 
chrX:135589508-135589568 ARHGEF6 -515 6 monocyte 
chr14:075058388-075058448 BATF -118 15 monocyte 
chr18:030427081-030427137 BC005300 -210 8 monocyte 
chr1:150176015-150176069 BC005928 64 16 monocyte 
chr4:185725651-185725698 BC015803 -300 21 monocyte 
chr17:004284158-004284210 BC023646 169 17 monocyte 
chr3:100102558-100102603 BC029658 144 51 monocyte 
chr12:069317856-069317916 BC051329 -425 5 monocyte 
chr12:010953076-010953136 BC069376 58 5 monocyte 
chr18:065765813-065765860 BC074787 -185 7 monocyte 
chr18:065766196-065766256 BC074787 -575 5 monocyte 
chr6:136214703-136214763 BC075082 -70 12 monocyte 
chr22:021478281-021478341 BC089414 -515 9 monocyte 
chr15:031147428-031147482 BC103692 70 23 monocyte 
chr15:031148053-031148113 BC103692 -558 13 monocyte 
chr10:098021115-098021175 BLNK 171 6 monocyte 
chr4:068253333-068253393 BRDG1 152 6 monocyte 
chr20:011846702-011846762 BTBD3 168 6 monocyte 
chr16:020610453-020610511 BUCS1 -403 5 monocyte 
chr14:057030226-057030286 C14orf105 67 6 monocyte 
chr14:057030420-057030480 C14orf105 -127 10 monocyte 
chr1:244038040-244038100 C1orf150 -421 14 monocyte 
chr1:111728804-111728864 C1orf162 189 16 monocyte 
chr20:012937751-012937810 C20orf38 -66 8 monocyte 
chr20:012937957-012938011 C20orf38 138 8 monocyte 
chr21:033107724-033107784 C21orf62 114 8 monocyte 
chr13:048873355-048873415 CAB39L 115 7 monocyte 
chr13:048873633-048873685 CAB39L -159 7 monocyte 
chr16:054158083-054158143 CAPNS2 29 6 monocyte 
chr11:104411424-104411484 CASP1 -387 5 monocyte 
chr2:201873017-201873077 CASP10 -313 14 monocyte 
chr11:104385097-104385157 CASP5 -218 5 monocyte 
chr16:046823116-046823176 CCDS10732.1 187 9 monocyte 
chr17:031441416-031441463 CCL3 161 9 monocyte 
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chr17:029669941-029670001 CCL8 -207 5 monocyte 
chr3:032967875-032967935 CCR4 -164 11 monocyte 
chr3:114176584-114176640 CD200R1 15 7 monocyte 
chr19:040511691-040511744 CD22 -234 18 monocyte 
chr1:157646127-157646187 CD244 -439 11 monocyte 
chr2:204396677-204396737 CD28 4 14 monocyte 
chr17:070131477-070131537 CD300LE -111 11 monocyte 
chr17:070221099-070221148 CD300LF -420 18 monocyte 
chr1:157494697-157494757 CD48 -69 9 monocyte 
chr1:111127601-111127659 CD53 -184 10 monocyte 
chr1:111127777-111127837 CD53 -7 10 monocyte 
chr12:009804656-009804716 CD69 78 5 monocyte 
chr12:009805014-009805074 CD69 -280 7 monocyte 
chr3:123279253-123279306 CD86 -160 8 monocyte 
chr3:123279385-123279441 CD86 -26 9 monocyte 
chr1:199930587-199930642 CHIT1 -181 7 monocyte 
chr1:243907508-243907568 CIAS1 147 12 monocyte 
chr12:009913629-009913689 CLEC2B 66 11 monocyte 
chr12:009913853-009913913 CLEC2B -158 8 monocyte 
chr12:009914031-009914091 CLEC2B -336 8 monocyte 
chr12:008167453-008167513 CLEC4A -11 6 monocyte 
chr12:008557410-008557470 CLEC4D 38 8 monocyte 
chr13:045577337-045577397 CPB2 -198 5 monocyte 
chr14:024115709-024115769 CTSG -433 7 monocyte 
chrX:128639251-128639301 CXorf9 -218 19 monocyte 
chr4:101094606-101094666 DAPP1 -531 8 monocyte 
chrX:110461445-110461503 DCX -23 6 monocyte 
chrX:110461689-110461749 DCX -168 5 monocyte 
chr20:000016400-000016455 DEFB125 65 5 monocyte 
chrX:031933072-031933121 DMD 147 6 monocyte 
chrX:031933269-031933320 DMD -51 7 monocyte 
chr18:030544384-030544444 DTNA 169 7 monocyte 
chr13:040454715-040454775 ELF1 -327 8 monocyte 
chr4:101796439-101796499 EMCN -112 5 monocyte 
chr19:006838564-006838624 EMR1 13 6 monocyte 
chrX:030637639-030637699 ENST00000288422 -215 7 monocyte 
chr3:065999103-065999154 ENST00000295884 -105 60 monocyte 
chr12:025096774-025096830 ENST00000312137 38 11 monocyte 
chr18:064656299-064656359 ENST00000319445 -589 7 monocyte 
chr12:054149628-054149688 ENST00000327335 168 5 monocyte 
chr3:174804847-174804907 ENST00000360119 -213 6 monocyte 
chr19:060077475-060077534 FCAR 144 11 monocyte 
chr1:158364610-158364658 FCGR2C -66 6 monocyte 
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chr2:150541171-150541231 FLJ32955 12 7 monocyte 
chr15:036776061-036776113 FLJ35695 -3 6 monocyte 
chr20:014266338-014266394 FLRT3 -96 9 monocyte 
chr7:113648765-113648825 FOXP2 -431 7 monocyte 
chr19:056947246-056947293 FPR1 -307 5 monocyte 
chr5:161426705-161426765 GABRG2 -559 9 monocyte 
chr11:022652630-022652690 GAS2 -270 5 monocyte 
chr3:113334829-113334875 GCET2 -45 7 monocyte 
chr3:113334974-113335034 GCET2 -197 7 monocyte 
chr7:149702231-149702290 GIMAP4 155 13 monocyte 
chr12:074160760-074160820 GLIPR1 -10 14 monocyte 
chr14:104602606-104602660 GPR132 166 15 monocyte 
chr14:104602823-104602876 GPR132 -50 17 monocyte 
chrX:078232777-078232837 GPR174 194 8 monocyte 
chr13:098708452-098708511 GPR18 148 7 monocyte 
chr19:040631908-040631954 GPR43 -525 21 monocyte 
chr5:054433851-054433911 GZMA -348 7 monocyte 
chr3:122862799-122862859 HCLS1 -424 6 monocyte 
chr12:053177919-053177979 HEM1 170 6 monocyte 
chr17:053763603-053763663 hsa-mir-142 45 25 monocyte 
chr21:025867811-025867871 hsa-mir-155 -322 7 monocyte 
chr21:025868007-025868067 hsa-mir-155 -126 6 monocyte 
chrX:065021531-065021588 hsa-mir-223 -174 6 monocyte 
chr7:136044799-136044859 hsa-mir-490 -340 6 monocyte 
chrX:138731834-138731886 hsa-mir-505 50 5 monocyte 
chrX:138731949-138732009 hsa-mir-505 -69 5 monocyte 
chr19:010311120-010311167 ICAM3 157 19 monocyte 
chr16:021571336-021571392 IGSF6 100 8 monocyte 
chr19:018058713-018058773 IL12RB1 -46 15 monocyte 
chr2:113601343-113601394 IL1RN 0 10 monocyte 
chr16:028425706-028425755 IL27 -74 17 monocyte 
chrX:070114605-070114665 IL2RG -211 10 monocyte 
chrX:070114819-070114873 IL2RG -422 9 monocyte 
chr2:218815979-218816033 IL8RB -245 10 monocyte 
chr21:034806400-034806460 KCNE1 13 14 monocyte 
chrX:086578760-086578815 KLHL4 -174 9 monocyte 
chrX:086578936-086578995 KLHL4 4 10 monocyte 
chr3:184755993-184756047 KLHL6 90 16 monocyte 
chr19:059568434-059568489 LAIR1 -181 18 monocyte 
chr19:059705722-059705776 LAIR2 -75 17 monocyte 
chr13:045654201-045654261 LCP1 164 11 monocyte 
chr4:159800755-159800815 LGR7 52 10 monocyte 
chr19:059777016-059777064 LILRA2 -30 13 monocyte 
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chr11:033870368-033870419 LMO2 19 8 monocyte 
chr12:053534187-053534247 LOC118430 -370 6 monocyte 
chr19:007647597-007647647 LOC199675 109 17 monocyte 
chr7:092493734-092493794 LOC253012 -243 5 monocyte 
chr12:090007918-090007978 LUM 62 7 monocyte 
chr6:006533842-006533894 LY86 -64 14 monocyte 
chrX:138450602-138450662 MCF2 -260 6 monocyte 
chr12:045896156-045896216 MGC16044 -132 14 monocyte 
chr12:045896307-045896367 MGC16044 19 14 monocyte 
chr4:109171932-109171992 MGC26963 -71 6 monocyte 
chr2:232651796-232651841 MGC42174 -80 70 monocyte 
chr12:014929893-014929953 MGP 172 7 monocyte 
chr12:014930158-014930218 MGP -93 7 monocyte 
chr12:014930491-014930551 MGP -426 8 monocyte 
chr4:010362701-010362752 MIST 32 9 monocyte 
chr1:046771745-046771805 MKNK1 63 14 monocyte 
chr11:102156587-102156647 MMP10 -63 5 monocyte 
chr4:091173153-091173212 MMRN1 -47 7 monocyte 
chr11:019038698-019038758 MRGPRX2 76 7 monocyte 
chr11:059580353-059580411 MS4A3 -294 9 monocyte 
chr11:059580782-059580842 MS4A3 136 10 monocyte 
chr11:059804592-059804648 MS4A4A -94 6 monocyte 
chr11:059707157-059707217 MS4A6A 63 5 monocyte 
chr8:016094406-016094466 MSR1 159 5 monocyte 
chr17:005428634-005428680 NALP1 -107 13 monocyte 
chr19:059019379-059019433 NALP12 -1 22 monocyte 
chr16:003567563-003567608 NOD3 -295 23 monocyte 
chr15:074091620-074091680 NRG4 190 10 monocyte 
chr15:074092059-074092119 NRG4 -249 7 monocyte 
chr11:059920331-059920391 NYD-SP21 -194 6 monocyte 
chr11:007917489-007917547 OR10A3 125 6 monocyte 
chr11:006870334-006870394 OR2D2 -57 7 monocyte 
chr11:055096329-055096389 OR4C16 180 6 monocyte 
chr15:100163532-100163587 OR4F6 114 6 monocyte 
chr14:019598158-019598212 OR4L1 142 5 monocyte 
chr11:004748193-004748253 OR51F1 -500 5 monocyte 
chr11:056137660-056137720 OR5M1 -136 5 monocyte 
chr11:123695081-123695141 OR8D2 192 5 monocyte 
chr11:007684730-007684790 OVCH2 -243 6 monocyte 
chrY:001699759-001699804 P2RY8 46 35 monocyte 
chr6:136214016-136214076 PDE7B -480 5 monocyte 
chr7:106099744-106099804 PIK3CG -100 12 monocyte 
chr7:106099890-106099950 PIK3CG 46 13 monocyte 
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chr2:068503807-068503867 PLEK -237 8 monocyte 
chr13:037070784-037070844 POSTN 60 6 monocyte 
chr7:113153060-113153120 PPP1R3A -75 5 monocyte 
chr20:004669765-004669825 PRNT -481 11 monocyte 
chr19:000646594-000646650 PRSSL1 -161 39 monocyte 
chr22:036002457-036002517 PSCD4 -436 12 monocyte 
chr2:158126089-158126148 PSCDBP -6 11 monocyte 
chr2:158126252-158126312 PSCDBP -170 10 monocyte 
chr1:195339670-195339730 PTPRC -181 6 monocyte 
chr1:195339927-195339987 PTPRC 76 6 monocyte 
chr1:189276226-189276286 RGS1 -257 8 monocyte 
chr1:189276641-189276701 RGS1 158 7 monocyte 
chr14:020429033-020429091 RNASE3 -339 7 monocyte 
chrX:105742642-105742702 RNF128 -540 5 monocyte 
chr21:035343526-035343586 RUNX1 -91 12 monocyte 
chr5:076181489-076181549 S100Z -62 18 monocyte 
chr16:020682896-020682956 SAH 114 6 monocyte 
chr21:014840611-014840671 SAMSN1 -106 5 monocyte 
chr2:165886060-165886120 SCN3A -30 6 monocyte 
chr2:165886326-165886386 SCN3A -296 7 monocyte 
chr1:166412892-166412952 SELL -537 6 monocyte 
chr20:001548843-001548895 SIRPB1 -239 8 monocyte 
chr1:157430268-157430328 SLAMF1 -356 9 monocyte 
chr2:219072069-219072118 SLC11A1 -328 14 monocyte 
chr2:219072566-219072612 SLC11A1 53 15 monocyte 
chr7:122434066-122434126 SLC13A1 -120 5 monocyte 
chr13:085271470-085271530 SLITRK6 -16 6 monocyte 
chr13:085271744-085271804 SLITRK6 -290 5 monocyte 
chr16:029581461-029581521 SPN -309 17 monocyte 
chr13:032678432-032678492 STARD13 -319 7 monocyte 
chr11:059390799-059390859 TCN1 -235 5 monocyte 
chr9:117546051-117546111 TLR4 -56 13 monocyte 
chr1:169751629-169751682 TNFSF18 58 5 monocyte 
chr1:169751799-169751859 TNFSF18 -116 5 monocyte 
chr1:169752037-169752097 TNFSF18 -354 6 monocyte 
chr1:074412639-074412699 TNNI3K -436 5 monocyte 
chr1:074412830-074412890 TNNI3K -245 5 monocyte 
chr3:190831478-190831538 TP73L -409 9 monocyte 
chr6:041277331-041277391 TREML2 -459 11 monocyte 
chr21:044597502-044597562 TRPM2 -379 19 monocyte 
chr11:002279235-002279289 TSPAN32 -556 30 monocyte 
chr11:002279412-002279472 TSPAN32 -376 27 monocyte 
chr11:063730212-063730262 URP2 -544 19 monocyte 
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chr11:063730360-063730409 URP2 -397 17 monocyte 
chr6:133076944-133077004 VNN1 -93 10 monocyte 
chrX:065042712-065042769 VSIG4 166 5 monocyte 
chrX:065043147-065043205 VSIG4 -270 5 monocyte 
chrX:048298024-048298072 WAS -410 11 monocyte 
chrX:048298366-048298413 WAS -69 18 monocyte 
chrX:048298583-048298629 WAS 148 17 monocyte 
chr20:043691414-043691474 WFDC10A -354 7 monocyte 
chr10:102212516-102212567 WNT8B -246 6 monocyte 
chr20:055628978-055629038 ZBP1 -73 16 monocyte 
chr1:226001750-226001795 ABCB10 -595 61 testis 
chrX:070581435-070581495 ACRC 184 42 testis 
chr9:108697985-108698034 ACTL7B -244 14 testis 
chr8:039815105-039815165 ADAM2 -199 30 testis 
chr8:039815434-039815494 ADAM2 -528 15 testis 
chr15:083160423-083160483 ALPK3 -461 24 testis 
chr15:083160861-083160921 ALPK3 -23 33 testis 
chr17:057023731-057023791 ANAC -416 12 testis 
chr8:041774538-041774583 ANK1 -263 53 testis 
chr12:050567855-050567909 ANKRD33 -128 35 testis 
chr1:062497498-062497558 ANKRD38 -424 29 testis 
chr4:165476253-165476311 ANP32C 186 27 testis 
chr14:030564711-030564756 AP4S1 90 57 testis 
chr2:021179003-021179051 APOB -430 20 testis 
chr2:131507983-131508043 ARHGEF4 58 38 testis 
chr7:116661739-116661799 ASZ1 -275 44 testis 
chr7:116662038-116662098 ASZ1 -574 17 testis 
chr3:184453274-184453334 B3GNT5 -442 27 testis 
chr10:013427520-013427580 BC000941 -526 25 testis 
chr2:010813651-010813711 BC012142 128 7 testis 
chr10:065052808-065052868 BC018658 -335 18 testis 
chr6:007930830-007930890 BC028580 -476 17 testis 
chr1:150561140-150561185 BC029792 190 77 testis 
chr3:040404320-040404380 BC029869 -190 19 testis 
chr4:156019738-156019798 BC031053 171 29 testis 
chr11:093940419-093940473 BC031060 117 30 testis 
chr20:005399468-005399528 BC031676 -354 18 testis 
chr17:069781533-069781582 BC033013 -432 33 testis 
chr10:102737912-102737961 BC033762 -364 21 testis 
chr19:047039558-047039603 BC034629 54 11 testis 
chr19:047039753-047039807 BC034629 -146 16 testis 
chr19:047039869-047039920 BC034629 -260 21 testis 
chr19:047039984-047040031 BC034629 -373 22 testis 
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chr8:028230883-028230931 BC034758 185 26 testis 
chr1:061831723-061831783 BC034822 -185 43 testis 
chrY:013453945-013454005 BC034942 -174 20 testis 
chr2:175409928-175409988 BC038989 -165 30 testis 
chr10:051774291-051774351 BC042899 -226 24 testis 
chr19:061039769-061039823 BC050326 -285 21 testis 
chr19:061039875-061039927 BC050326 -180 21 testis 
chr19:061039998-061040043 BC050326 -61 17 testis 
chr2:024309223-024309283 BC050462 -369 48 testis 
chrX:042394092-042394138 BC056673 -449 30 testis 
chr11:032772794-032772839 BC062749 -39 25 testis 
chr11:032773245-032773305 BC062749 -498 17 testis 
chr5:156209712-156209772 BC066922 -384 38 testis 
chr2:147178392-147178452 BC068242 -570 34 testis 
chr14:090771094-090771141 BC069592 30 29 testis 
chr19:058486091-058486151 BC071665 114 43 testis 
chr4:123211791-123211850 BC093682 53 39 testis 
chr20:044519568-044519613 BC100775 99 22 testis 
chr10:005397209-005397263 BC100867 182 29 testis 
chrX:027586080-027586140 BC101308 -179 28 testis 
chrX:027586324-027586375 BC101308 60 21 testis 
chr12:050004544-050004596 BIN2 -365 46 testis 
chr5:000944836-000944882 BRD9 -456 34 testis 
chr1:092126698-092126758 BRDT -424 33 testis 
chr1:092127055-092127115 BRDT -67 37 testis 
chr4:015380379-015380435 BST1 -502 17 testis 
chr10:014856735-014856789 C10orf45 140 21 testis 
chr10:014857023-014857081 C10orf45 -150 16 testis 
chr10:014857215-014857274 C10orf45 -342 13 testis 
chr10:050176694-050176739 C10orf71 -476 14 testis 
chr10:050177017-050177077 C10orf71 -145 24 testis 
chr10:050177136-050177196 C10orf71 -26 27 testis 
chr10:050177316-050177361 C10orf71 146 25 testis 
chr11:064619729-064619778 C11orf2 -505 36 testis 
chr12:089851642-089851694 C12orf12 -247 26 testis 
chr2:119633051-119633111 C1QL2 -386 43 testis 
chr20:016502637-016502697 C20orf23 -589 32 testis 
chr20:006052697-006052757 C20orf42 -536 18 testis 
chr5:134236976-134237036 C5orf14 -319 7 testis 
chr6:028334561-028334615 C6orf194 -488 18 testis 
chr6:168216888-168216935 C6orf54 -598 22 testis 
chr8:090982710-090982770 C8orf1 -528 29 testis 
chr8:050146829-050146889 C8orf22 -600 22 testis 
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chr9:083466971-083467024 C9orf103 -522 33 testis 
chr9:111636628-111636676 C9orf84 126 30 testis 
chr19:051609001-051609054 CCDC8 -346 39 testis 
chr17:017421192-017421252 CCDS11187.1 -171 20 testis 
chr20:055532659-055532710 CCDS13459.1 -17 16 testis 
chr20:055532860-055532918 CCDS13459.1 -222 22 testis 
chr20:044179812-044179867 CD40 -473 35 testis 
chr16:054424364-054424416 CES1 186 38 testis 
chr14:073775463-073775511 CHX10 -440 13 testis 
chr13:094883687-094883747 CLDN10 -141 25 testis 
chr13:094883826-094883886 CLDN10 -2 26 testis 
chr3:139211273-139211331 CLDN18 -401 23 testis 
chr21:034962950-034963003 CLIC6 -581 30 testis 
chr7:093667928-093667975 COL1A2 -572 26 testis 
chr10:101831460-101831506 CPN1 101 22 testis 
chr13:036578196-036578256 CSNK1A1L -425 15 testis 
chr13:036578320-036578380 CSNK1A1L -549 16 testis 
chrX:119491377-119491437 CUL4B 124 18 testis 
chrX:017998934-017998994 CXorf20 -304 38 testis 
chr10:135229354-135229406 CYP2E1 -367 13 testis 
chr5:055069906-055069963 DDX4 -598 38 testis 
chr5:055070131-055070191 DDX4 -371 19 testis 
chr14:100262518-100262576 DLK1 -458 62 testis 
chr1:053636513-053636573 DMRTB1 -549 13 testis 
chr1:053636683-053636743 DMRTB1 -379 17 testis 
chr1:053636834-053636894 DMRTB1 -228 23 testis 
chr19:047040866-047040916 DMRTC2 28 51 testis 
chr6:038798487-038798547 DNAH8 -358 23 testis 
chr6:038798726-038798779 DNAH8 -123 28 testis 
chr6:038798990-038799050 DNAH8 145 20 testis 
chr17:069789351-069789407 DNAI2 134 27 testis 
chr2:027409437-027409497 DNAJC5G -472 15 testis 
chr2:027409633-027409682 DNAJC5G -282 28 testis 
chr3:110517996-110518051 DPPA2 31 33 testis 
chr3:110518270-110518330 DPPA2 -246 33 testis 
chr12:007755184-007755244 DPPA3 -141 15 testis 
chr12:007755506-007755557 DPPA3 176 20 testis 
chrX:044459214-044459274 DUSP21 -259 16 testis 
chr13:049164091-049164151 EBPL -509 37 testis 
chr1:062372292-062372341 ECAT11 -240 32 testis 
chr10:011823894-011823954 ECHDC3 -464 44 testis 
chr11:034492005-034492057 ELF5 -125 22 testis 
chr7:072887099-072887144 ELN -47 39 testis 
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chr19:012335763-012335819 ENST00000242804 -346 18 testis 
chr19:048602268-048602315 ENST00000253435 78 27 testis 
chr3:115438395-115438445 ENST00000308095 191 22 testis 
chr3:115438598-115438643 ENST00000308095 -9 33 testis 
chr8:088955150-088955195 ENST00000319675 143 46 testis 
chr14:088086735-088086791 ENST00000328736 -44 25 testis 
chr1:024486962-024487022 ENST00000337248 -99 33 testis 
chr22:016607778-016607838 ENST00000342111 -313 34 testis 
chr9:096879787-096879842 ENST00000343150 66 12 testis 
chr10:014412406-014412461 ENST00000358621 -326 17 testis 
chr5:145297403-145297463 ENST00000359120 -199 12 testis 
chr16:023632406-023632466 ERN2 -114 31 testis 
chr3:033293599-033293659 FBXL2 -308 39 testis 
chr12:004425224-004425284 FGF6 -213 25 testis 
chr2:070929759-070929819 FIGLA -359 41 testis 
chr2:070929932-070929992 FIGLA -532 22 testis 
chr6:035765221-035765274 FKBP5 -555 24 testis 
chr19:004197644-004197696 FLJ10374 -437 24 testis 
chr5:014634305-014634365 FLJ11127 -596 27 testis 
chr2:127679908-127679968 FLJ16008 -365 18 testis 
chr13:035687166-035687226 FLJ20449 -520 37 testis 
chr12:014612434-014612494 FLJ22662 -406 29 testis 
chr12:014612584-014612644 FLJ22662 -556 33 testis 
chr4:189401781-189401829 FLJ25801 -248 13 testis 
chr4:189401950-189402010 FLJ25801 -423 15 testis 
chr12:053153513-053153572 FLJ32942 72 27 testis 
chr22:027492745-027492805 FLJ33814 -485 26 testis 
chr11:006474809-006474866 FLJ35709 -269 33 testis 
chr11:006475069-006475115 FLJ35709 -14 33 testis 
chr16:065393596-065393648 FLJ35894 -598 21 testis 
chr12:038305834-038305894 FLJ40126 -387 25 testis 
chr12:038306039-038306099 FLJ40126 -182 27 testis 
chr3:128394059-128394110 FLJ40141 -587 20 testis 
chr3:128394789-128394849 FLJ40141 148 32 testis 
chr7:055676401-055676461 FLJ44060 20 19 testis 
chrX:146767996-146768055 FMR1NB -369 26 testis 
chr7:151090966-151091017 GALNTL5 -167 19 testis 
chr9:076303158-076303218 GCNT1 -511 31 testis 
chr13:019615417-019615468 GJA3 -15 32 testis 
chr12:102946927-102946987 GLT8D2 -575 14 testis 
chrX:009543990-009544046 GPR143 -365 20 testis 
chr19:050787372-050787432 GPR4 155 11 testis 
chr2:105316635-105316685 GPR45 -57 22 testis 
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chr12:121740032-121740085 GPR81 -49 30 testis 
chr12:121740456-121740516 GPR81 -477 22 testis 
chr3:142979453-142979513 GRK7 -257 16 testis 
chr3:142979636-142979688 GRK7 -78 28 testis 
chr1:042299954-042299999 GUCA2A -488 17 testis 
chr12:047009081-047009135 H1T2 79 18 testis 
chrX:103074934-103074994 H2BFWT -563 13 testis 
chr2:172603958-172604018 HAT1 -493 37 testis 
chr11:057180646-057180706 HEAB -529 23 testis 
chr6:026126370-026126430 HIST1H1A -405 30 testis 
chr6:026216289-026216349 HIST1H1T 24 28 testis 
chr6:026216516-026216576 HIST1H1T -203 23 testis 
chr6:026216688-026216748 HIST1H1T -375 16 testis 
chr6:025834843-025834893 HIST1H2AA -99 35 testis 
chr6:025835017-025835072 HIST1H2AA -275 33 testis 
chr6:026355415-026355475 HIST1H4G -261 35 testis 
chr1:147506201-147506261 HORMAD1 194 43 testis 
chr14:100418478-100418527 hsa-mir-127 -567 42 testis 
chr14:100418684-100418741 hsa-mir-127 -357 35 testis 
chr14:100418906-100418957 hsa-mir-127 -138 33 testis 
chr19:058982557-058982617 hsa-mir-371 -154 25 testis 
chr19:058983199-058983249 hsa-mir-373 -547 41 testis 
chr19:058983592-058983652 hsa-mir-373 -149 34 testis 
chr19:058916941-058917001 hsa-mir-520g -261 10 testis 
chrX:069064911-069064958 HSHIN6 -427 28 testis 
chr3:185300293-185300347 HTR3E -348 30 testis 
chr5:158690481-158690530 IL12B -446 12 testis 
chr6:137407996-137408056 IL20RA -35 36 testis 
chr9:136610397-136610457 INPP5E -334 54 testis 
chr9:005175919-005175973 INSL6 -328 42 testis 
chr1:223232075-223232122 ITPKB -168 76 testis 
chr14:062638206-062638266 KCNH5 101 24 testis 
chr3:180467656-180467707 KCNMB3 -141 20 testis 
chr16:076380089-076380134 KIAA1576 128 70 testis 
chr17:049254827-049254872 KIF2B -411 14 testis 
chr17:049255007-049255067 KIF2B -223 22 testis 
chr17:036725541-036725601 KRTAP17-1 -98 29 testis 
chr12:050981310-050981369 KRTHB6 -576 14 testis 
chr12:050981695-050981751 KRTHB6 -192 33 testis 
chr12:050981838-050981890 KRTHB6 -51 46 testis 
chr18:019706520-019706573 LAMA3 -457 16 testis 
chr15:098902835-098902895 LASS3 -417 23 testis 
chr2:074642598-074642647 LBX2 -524 46 testis 
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chr11:018433626-018433686 LDHAL6A -350 31 testis 
chr4:041824665-041824715 LOC285429 -13 29 testis 
chr5:118993002-118993062 LOC340069 -120 12 testis 
chr5:118993224-118993284 LOC340069 102 23 testis 
chr3:140222658-140222718 LOC389151 -222 38 testis 
chr3:140222811-140222871 LOC389151 -375 24 testis 
chr12:031836914-031836974 LOC440093 -502 14 testis 
chr6:112775022-112775082 LOC442247 -172 13 testis 
chr6:112775289-112775349 LOC442247 95 17 testis 
chr14:106330981-106331033 LOC90925 -170 8 testis 
chrX:114346898-114346958 LUZP4 -372 24 testis 
chrX:114347357-114347414 LUZP4 85 30 testis 
chr1:163689893-163689953 MAEL -253 39 testis 
chrX:027585180-027585240 MAGEB10 -571 10 testis 
chrX:027585295-027585355 MAGEB10 -456 15 testis 
chrX:027585574-027585634 MAGEB10 -177 27 testis 
chrX:027585816-027585867 MAGEB10 60 31 testis 
chr5:034020679-034020735 MATP -170 14 testis 
chr4:156059682-156059742 MGC27016 -392 31 testis 
chr19:047040294-047040351 MGC42718 26 39 testis 
chr13:023781149-023781205 MGC48915 -538 23 testis 
chr16:054070000-054070055 MMP2 -576 22 testis 
chr10:127454430-127454477 MMP21 -73 31 testis 
chr11:004965548-004965608 MMP26 -421 20 testis 
chr3:110319810-110319870 MORC1 -182 44 testis 
chr3:110320025-110320081 MORC1 -395 27 testis 
chr3:110320179-110320239 MORC1 -551 12 testis 
chr22:024462570-024462625 MYO18B -76 32 testis 
chr22:024462774-024462822 MYO18B 125 32 testis 
chr2:105926618-105926665 NCK2 -181 29 testis 
chr2:105926928-105926988 NCK2 136 22 testis 
chr19:060109208-060109254 NCR1 -88 22 testis 
chr22:028323597-028323657 NF2 -491 42 testis 
chr14:076807728-076807782 NGB -347 31 testis 
chr20:035582479-035582532 NNAT -515 39 testis 
chr1:202023046-202023106 NUAK2 -536 17 testis 
chrX:108585183-108585230 NXT2 52 14 testis 
chr9:006317882-006317942 NYD-SP25 -462 14 testis 
chr9:006318029-006318089 NYD-SP25 -315 19 testis 
chr9:006318143-006318200 NYD-SP25 -203 21 testis 
chr9:006318527-006318587 NYD-SP25 183 23 testis 
chr19:015779866-015779917 OR10H1 -44 21 testis 
chr11:057752890-057752942 OR10Q1 7 36 testis 
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chr11:057753340-057753400 OR10Q1 -447 29 testis 
chr9:104411064-104411120 OR13C8 89 9 testis 
chr9:122591290-122591350 OR1L6 -252 14 testis 
chr9:122591559-122591619 OR1L6 17 15 testis 
chr1:243941631-243941691 OR2B11 -336 16 testis 
chr1:244425915-244425966 OR2L13 -593 31 testis 
chr11:057714609-057714666 OR9Q2 99 23 testis 
chr4:140559484-140559544 OSAP -530 28 testis 
chrX:119032158-119032209 OTEX -454 12 testis 
chrX:119032301-119032354 OTEX -598 13 testis 
chr20:002999795-002999852 OXT -442 19 testis 
chr1:017320543-017320597 PADI3 -328 18 testis 
chrX:049163752-049163805 PAGE1 -175 22 testis 
chrX:055129478-055129538 PAGE5 -303 28 testis 
chr7:139216973-139217033 PARP12 -298 20 testis 
chr5:140481779-140481834 PCDHB4 42 27 testis 
chr9:122670999-122671059 PDCL -565 45 testis 
chr2:170377235-170377295 PHOSPHO2 34 27 testis 
chr8:022188432-022188485 PIWIL2 -342 27 testis 
chr15:019336639-019336686 POTE15 5 42 testis 
chrY:000272912-000272964 PPP2R3B -348 58 testis 
chr9:101437406-101437463 PPP3R2 -596 14 testis 
chr22:021226443-021226499 PRAME -221 28 testis 
chr22:021226692-021226751 PRAME -471 20 testis 
chr18:021967526-021967586 PSMA8 -257 36 testis 
chr14:051803708-051803768 PTGDR -442 26 testis 
chrY:022010829-022010879 RBMY1A1 -519 27 testis 
chrY:022011049-022011104 RBMY1A1 -297 41 testis 
chrY:022011196-022011241 RBMY1A1 -155 40 testis 
chrY:022034356-022034405 RBMY1A1 -534 26 testis 
chrY:022034590-022034645 RBMY1A1 -297 41 testis 
chrY:022379013-022379063 RBMY1A1 -265 40 testis 
chrY:022379305-022379352 RBMY1A1 -555 23 testis 
chrY:022402554-022402604 RBMY1A1 -265 40 testis 
chrY:022402846-022402893 RBMY1A1 -555 23 testis 
chrY:022035074-022035134 RBMY1D 175 38 testis 
chrY:022378632-022378685 RBMY1E 100 38 testis 
chrY:022402173-022402226 RBMY1E 100 38 testis 
chrY:022667088-022667141 RBMY1F 100 39 testis 
chrY:022667499-022667554 RBMY1F -312 42 testis 
chrY:022667706-022667751 RBMY1F -514 30 testis 
chrY:022792588-022792640 RBMY1F -520 30 testis 
chrY:022792785-022792845 RBMY1F -319 37 testis 
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chr17:009749337-009749382 RCV1 50 27 testis 
chr13:097627971-097628018 RNF113B -474 21 testis 
chr13:024235857-024235913 RNF17 -453 25 testis 
chr13:024236016-024236076 RNF17 -292 31 testis 
chr17:058239951-058239996 RNF190 -546 20 testis 
chr20:055399371-055399431 RNPC1 -468 60 testis 
chrX:095944828-095944886 RPA4 -194 22 testis 
chrX:095944984-095945044 RPA4 -37 25 testis 
chr20:049852955-049853015 SALL4 -564 13 testis 
chr2:119998637-119998697 SCTR -531 34 testis 
chr15:041879150-041879209 SERINC4 -553 16 testis 
chr18:059295290-059295350 SERPINB5 122 23 testis 
chr7:134870010-134870061 SLC13A4 153 18 testis 
chr7:134870181-134870240 SLC13A4 -22 18 testis 
chr7:134870420-134870476 SLC13A4 -260 16 testis 
chr5:140664281-140664334 SLC25A2 -511 39 testis 
chr4:129008782-129008842 SLC25A31 -366 33 testis 
chr15:043331195-043331251 SLC28A2 -502 26 testis 
chr19:054520595-054520655 SLC6A16 -339 34 testis 
chr19:054520701-054520761 SLC6A16 -445 28 testis 
chr3:150287495-150287555 SMARCA3 -510 36 testis 
chr5:157012185-157012243 SOX30 -208 27 testis 
chr17:028342640-028342695 SPACA3 -327 8 testis 
chr20:055337931-055337991 SPO11 -276 36 testis 
chrX:047812424-047812478 SSX5 2 18 testis 
chr7:023522820-023522873 STK31 -286 37 testis 
chr7:023523231-023523281 STK31 74 48 testis 
chr15:072282580-072282640 STRA6 -365 17 testis 
chr1:115109205-115109265 SYCP1 -261 25 testis 
chr2:047507506-047507566 TACSTD1 -581 31 testis 
chr9:032625452-032625500 TAF1L 191 30 testis 
chrX:100354018-100354063 TAF7L 150 32 testis 
chrX:100354217-100354269 TAF7L -53 25 testis 
chr14:054977244-054977293 TBPL2 -252 37 testis 
chr18:042816199-042816259 TCEB3B -243 18 testis 
chr6:035217605-035217665 TCP11 -531 36 testis 
chrX:069911419-069911479 TEX11 139 28 testis 
chrX:069911757-069911817 TEX11 -199 17 testis 
chr11:111542733-111542787 TEX12 -544 14 testis 
chr11:111543010-111543067 TEX12 -266 31 testis 
chr11:111543401-111543446 TEX12 119 35 testis 
chr17:054124266-054124322 TEX14 121 27 testis 
chr17:054124532-054124591 TEX14 -146 36 testis 
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chrX:132077792-132077852 TFDP3 74 52 testis 
chr7:093165110-093165170 TFPI2 -424 35 testis 
chrY:003490121-003490181 TGIF2LY -335 18 testis 
chrY:003490590-003490650 TGIF2LY 134 28 testis 
chr3:197553427-197553477 TM4SF19 102 21 testis 
chr21:010013262-010013309 TPTE -494 57 testis 
chr6:030238601-030238661 TRIM15 -340 15 testis 
chr11:005573297-005573357 TRIM6 -595 15 testis 
chr4:166256899-166256947 TRIM61 -500 20 testis 
chr4:123212030-123212090 TRPC3 156 17 testis 
chr5:135721032-135721092 TRPC7 -90 23 testis 
chrY:009217882-009217927 TSPY1 -529 38 testis 
chrY:009218125-009218180 TSPY1 -281 43 testis 
chrY:009258493-009258538 TSPY1 -530 36 testis 
chrY:009258675-009258726 TSPY1 -345 40 testis 
chrY:009278839-009278884 TSPY1 -529 38 testis 
chrY:009279082-009279137 TSPY1 -281 43 testis 
chrY:009917685-009917730 TSPY1 -529 38 testis 
chrY:009917928-009917983 TSPY1 -281 43 testis 
chrY:009937968-009938013 TSPY1 -529 38 testis 
chrY:009938211-009938266 TSPY1 -281 43 testis 
chrY:009958298-009958343 TSPY1 -529 38 testis 
chrY:009958541-009958596 TSPY1 -281 43 testis 
chrY:006157316-006157372 TSPY2 -284 41 testis 
chrY:009238215-009238260 TSPY2 -532 38 testis 
chrY:009238458-009238513 TSPY2 -284 42 testis 
chr2:054394979-054395026 TSPYL6 -7 37 testis 
chr13:018654238-018654291 TUBA2 -328 37 testis 
chr17:016224925-016224984 UBB -137 49 testis 
chr7:129186948-129187008 UBE2H -238 36 testis 
chr7:129187262-129187322 UBE2H -552 22 testis 
chr1:064380995-064381055 UBE2U -485 22 testis 
chr1:064381614-064381674 UBE2U 134 26 testis 
chr10:005396663-005396723 UCN3 -282 21 testis 
chr19:059259113-059259173 UNQ3033 -124 32 testis 
chr3:120374655-120374715 UPK1B -429 11 testis 
chr11:017522705-017522756 USH1C -191 53 testis 
chr15:048626028-048626088 USP50 -44 10 testis 
chr15:048626269-048626329 USP50 -285 15 testis 
chrY:014536716-014536766 VCY -218 23 testis 
chrY:014605985-014606035 VCY -218 23 testis 
chr14:096332954-096333014 VRK1 -452 32 testis 
chr8:088955364-088955411 WDR21C 25 43 testis 
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Probe Location 
(NCBI Built 35) 
Gene Name TSS-Distance 
of Probe 
CpG-Index 
(+/- 350 bp) 
demethylated 
in 
chr8:088955576-088955636 WDR21C -194 43 testis 
chrX:027759211-027759256 WDR42B -10 24 testis 
chrX:027759401-027759461 WDR42B -208 20 testis 
chr17:046267562-046267618 WFIKKN2 -248 35 testis 
chrX:052724088-052724138 XAGE5 -135 22 testis 
chrX:073306853-073306913 ZCCHC13 -162 32 testis 
chr16:070080829-070080881 ZNF19 -113 32 testis 
chr16:070081172-070081226 ZNF19 -457 13 testis 
chr19:057182391-057182449 ZNF350 -529 24 testis 
chr2:027717601-027717646 ZNF512 80 40 testis 
chr19:009470707-009470767 ZNF560 -458 27 testis 
chrX:022050692-022050752 ZNF645 6 22 testis 
chr17:035277376-035277431 ZPBP2 -591 29 testis 
chr17:035277492-035277552 ZPBP2 -472 42 testis 
chr19:061431564-061431617 ZSCAN5 -119 27 testis 
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12.2 Appendix II – Differentially expressed 
loci 
Table 12.2 Genomic regions selected for C57BL/6-BALB/c DMR screening 
Gene Symbol Genomic Location (mm8 Assembly) Region Size 
Tmem14a/Gsta3 chr1:21175070-21265070 90000 
Prim2 chr1:33353488-33657701 304213 
Chst10 chr1:38765658-38877701 112043 
2810022L02Rik/Kctd18 chr1:57667722-57937906 270184 
Serpinb10 chr1:109300970-109410970 110000 
Marco chr1:122250969-122380969 130000 
Ctse/5430435G22Rik chr1:133440969-133560969 120000 
Qscn6 chr1:157505088-157615088 110000 
Rfwd2 chr1:161011546-161236546 225000 
Cd244/Ly9/SlamF7 chr1:173372619-173530408 157789 
Gm1313 chr1:175248822-175352711 103889 
Ifi202b chr1:175779250-175898466 119216 
Usp6nl chr2:6194226-6411092 216866 
Ssb chr2:69633467-69703643 70176 
Gchfr chr2:118831229-118890830 59601 
Spint1 chr2:118890918-118975954 85036 
Tmem87a chr2:120020705-120135705 115000 
Sord chr2:121881280-121980778 99498 
Il1b chr2:129006032-129112561 106529 
Slc13a3 chr2:165061308-165201402 140094 
Col20a1 chr2:180896703-180996948 100245 
Postn chr3:54409054-54528961 119907 
5830417I10Rik chr3:88835975-88948905 112930 
Chi3l3/Chi3l4 chr3:106245610-106405138 159528 
D3Bwg0562e chr3:117261149-117402880 141731 
Ank2 chr3:126874104-127524104 650000 
Dkk2 chr3:131974607-132167610 193003 
Gbp1 chr3:142392233-142606562 214329 
Ifi44/H28 chr3:151618310-151734422 116112 
Coro2a chr4:46525228-46668228 143000 
Ptprd chr4:75330613-76115327 784714 
2310009E04Rik chr4:95005807-95450953 445146 
A430090E18Rik chr4:111680177-111848400 168223 
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Tie1 chr4:117945964-118024781 78817 
Zfp69 chr4:120394772-120485053 90281 
4732473B16Rik chr4:132702209-132797015 94806 
C1qb chr4:136111222-136201253 90031 
Padi4 chr4:139981584-140156279 174695 
Fblim1 chr4:140812020-140903161 91141 
2610305D13Rik chr4:146416268-146536308 120040 
Angptl7 chr4:147289080-147394262 105182 
Prdm16 chr4:153079925-153530673 450748 
Mmel1 chr4:153676058-153769691 93633 
Abhd1 chr5:31199647-31249676 50029 
A930005I04Rik chr5:35197772-35279696 81924 
Pi4k2b chr5:52979822-53082588 102766 
Uchl1 chr5:66906028-67016369 110341 
9430027B09Rik(AK020441) chr5:67638314-67688271 49957 
Pkd2 chr5:104676856-104787118 110262 
Ccl24 chr5:135819207-135907670 88463 
4921520G13Rik chr5:144115000-144185000 70000 
Sgce chr6:4578612-4747100 168488 
Ppp1r9a chr6:4803428-5166532 363104 
Asb4 chr6:5290427-5433021 142594 
Smo chr6:29650513-29741369 90856 
3321401G04Rik chr6:42564846-42689678 124832 
Atp6v0e2 chr6:48440201-48490384 50183 
Magi1 chr6:93590731-94299367 708636 
Dppa3 chr6:122556043-122635890 79847 
Klrk1 chr6:129547265-129609534 62269 
Klra21 chr6:130010920-130173550 162630 
Dusp16 chr6:134629170-134807675 178505 
Pde6h chr6:136890719-136977679 86960 
Eps8l1 chr7:4031936-4102329 70393 
Isoc2b(0610042E07Rik) chr7:4398047-4511485 113438 
Gpr77 chr7:15363248-15438676 75428 
Ryr1 chr7:28673943-28873741 199798 
Zfp74 chr7:29604551-29703741 99190 
Dmkn chr7:30449165-30523818 74653 
Pop4 chr7:37931908-38030436 98528 
Rcn3 chr7:44922955-44993196 70241 
Kcnj14 chr7:45664509-45712789 48280 
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Snrpn chr7:59811452-60379127 567675 
Hddc3 chr7:80189650-80259610 69960 
Mesdc2 chr7:83718442-83817717 99275 
Dgat2 chr7:98998855-99094905 96050 
Trim12/A530023O14Rik chr7:104137416-104293705 156289 
Thumpd1 chr7:119488373-119552914 64541 
Crym chr7:119938287-120028137 89850 
Il21r chr7:125344625-125452718 108093 
H19 chr7:142330097-142530245 200148 
Tspan32 chr7:142765081-142859034 93953 
Cd209a chr8:3703397-3798930 95533 
Gdf15 chr8:73530382-73585445 55063 
Cyp4f18 chr8:74880471-74985606 105135 
Arl2bp chr8:97536235-97583551 47316 
Slc7a5 chr8:124717240-124823762 106522 
Pgbd5 chr8:127225139-127370026 144887 
Thy1 chr9:43744379-43829574 85195 
Amica1 chr9:44804941-44888846 83905 
Ttc12 chr9:49144191-49278455 134264 
Snf1lk chr9:50599125-50804125 205000 
9830163H01Rik chr9:51776244-51870405 94161 
Mns1 chr9:72187100-72307141 120041 
Rab6b chr9:102930224-103076420 146196 
Camp chr9:109684793-109736865 52072 
Vill chr9:118883109-118950024 66915 
Cck chr9:121308523-121394360 85837 
Ppp1r14c chr10:6820000-7032000 212000 
Lats1/Zc3h12d chr10:7350392-7600392 250000 
Ltb chr17:34786107-34829107 43000 
Dscr1l1 chr17:43214106-43541106 327000 
Guca1a chr17:46836242-46881242 45000 
Fzd8 chr18:9162918-9264975 102057 
Colec12 chr18:9657675-9927990 270315 
Slc27a6 chr18:58631609-58780715 149106 
Pdgfrb chr18:61145715-61235715 90000 
Kcnk7 chr19:5680000-5725000 45000 
Best1(Vmd2) chr19:10002219-10098259 96040 
Gcnt1 chr19:17343162-17489863 146701 
Tjp2 chr19:24112607-24341607 229000 
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Ankrd15 chr19:25257607-25550607 293000 
Ppp1r2 chr19:30554873-30641507 86634 
D19Ertd652e chr19:47803821-48003821 200000 
3110007F17Rik chrX:119170503-119310237 139734 
Casp8* chr1:58,690,040-58,841,559 151519 
Ly96 chr1:16,633,670-16,740,819 107149 
Cebpb chr2:167,330,172-167,421,592 91420 
Psma7 chr2:179,920,784-180,011,810 91026 
Creb3 chr4:43,546,778-43,630,964 84186 
S100pbp chr4:128,620,129-128,730,786 110657 
Clec4a2 chr6:123,039,011-123,150,618 111607 
Cebpa chr7:34,778,063-34,880,686 102623 
Tmem34 chr8:80,452,004-80,556,693 104689 
Egr2 chr10:66,883,235-66,987,541 104306 
Lrp1 chr10:126,895,143-127,065,000 169857 
Nef2 chr12:57,562,909-57,680,019 117110 
Jarid2 chr13:44,691,875-44,981,947 290072 
Cebpd chr16:15,755,864-15,853,123 97259 
Mapk1 chr16:16,850,945-17,023,015 172070 
Psmb9 chr17:33,752,387-33,837,618 85231 
* Control loci are boxed in light green. 
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12.3 Appendix III – Annotated list of mouse 
strain-specific DMR 
Table 12.3 Annotated list of all mouse strain-specific DMR 
Center of DMR  
(Mouse assembly mm8) 
Gene Symbol Position  
relative to 
 Gene 
Demethylated  
in 
BMM BALB/c 
(0h) 
BMM 
C57BL/6 
(0h) 
chr1:33428882-33429004 Prim2 intra C57BL/6 0.0513 (P) 0.998 (P) 
chr1:33476141-33476727 Prim2 intra C57BL/6 0.0513 (P) 0.998 (P) 
chr1:33499231-33499713 Prim2 intra C57BL/6 0.0513 (P) 0.998 (P) 
chr1:33585109-33585169 Prim2 intra BALB/c 0.0513 (P) 0.998 (P) 
chr1:33600588-33600898 Prim2 intra C57BL/6 0.0513 (P) 0.998 (P) 
chr1:38834245-38834666 Chst10 intra C57BL/6 35.28 (P) 1 (P) 
chr1:57749504-57749558 2810022L02Rik intra BALB/c 10.77 (P) 0.999 (A) 
chr1:58749011-58749071 Casp8 intra BALB/c 0.996 (P) 0.998 (P) 
chr1:58777847-58778072 Casp8 intra C57BL/6 0.996 (P) 0.998 (P) 
chr1:109401592-109402066 Serpinb8 distal C57BL/6 1.48 (P) 0.995 (P) 
chr1:122290855-122291258 Marco distal BALB/c 0.0779 (P) 1 (P) 
chr1:122308958-122309018 Marco intra C57BL/6 0.0779 (P) 1 (P) 
chr1:122371709-122371770 Marco distal C57BL/6 0.0779 (P) 1 (P) 
chr1:133539104-133539235 5430435G22Rik intra BALB/c 0.0695 (P) 0.995 (P) 
chr1:133540665-133540799 5430435G22Rik intra C57BL/6 0.0695 (P) 0.995 (P) 
chr1:133553009-133553065 Slc26a9 distal BALB/c 0.561 (A) 0.991 (P) 
chr1:133559814-133559910 Slc26a9 distal BALB/c 0.561 (A) 0.991 (P) 
chr1:157549961-157550607 Qsox1 intra C57BL/6 9.433 (P) 0.992 (P) 
chr1:157554929-157555080 Qsox1 intra C57BL/6 9.433 (P) 0.992 (P) 
chr1:157577435-157577492 Qsox1 distal BALB/c 9.433 (P) 0.992 (P) 
chr1:161072415-161072474 Rfwd2 intra BALB/c 0.0874 (P) 0.987 (P) 
chr1:161132832-161133097 Rfwd2 intra C57BL/6 0.0874 (P) 0.987 (P) 
chr1:161154201-161154255 Rfwd2 intra BALB/c 0.0874 (P) 0.987 (P) 
chr1:161173713-161173898 Rfwd2 intra C57BL/6 0.0874 (P) 0.987 (P) 
chr1:161181010-161181534 Rfwd2 intra C57BL/6 0.0874 (P) 0.987 (P) 
chr1:161220409-161220798 Rfwd2 distal BALB/c 0.0874 (P) 0.987 (P) 
chr1:173418157-173418737 Cd244 intra BALB/c 0.122 (P) 0.987 (P) 
chr1:173424681-173424758 Ly9 distal BALB/c 0.851 (P) 0.995 (P) 
chr1:173434392-173434437 Ly9 intra C57BL/6 0.851 (P) 0.995 (P) 
chr1:173472612-173472668 Slamf7 intra BALB/c 0.17 (P) 0.999 (P) 
chr1:173480500-173480622 Slamf7 intra BALB/c 0.17 (P) 0.999 (P) 
chr1:173509929-173510843 Cd48 distal C57BL/6 0.953 (P) 0.999 (P) 
chr1:173521917-173521962 Cd48 intra BALB/c 0.953 (P) 0.999 (P) 
chr10:6828900-6829688 Iyd distal C57BL/6 1.207 (A) 0.996 (A) 
chr10:7018786-7019486 Ppp1r14c distal C57BL/6 0.0184 (A) 1 (P) 
chr10:7456811-7457022 BC013529 distal C57BL/6 0.781 (P) 0.993 (P) 
chr10:7465903-7466014 BC013529 intra BALB/c 0.781 (P) 0.993 (P) 
chr10:7554662-7554765 Zc3h12d intra C57BL/6 0.0925 (P) 0.999 (P) 
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Center of DMR  
(Mouse assembly mm8) 
Gene Symbol Position  
relative to 
 Gene 
Demethylated  
in 
BMM BALB/c 
(0h) 
BMM 
C57BL/6 
(0h) 
chr10:7556446-7556491 Zc3h12d intra BALB/c 0.0925 (P) 0.999 (P) 
chr10:8453154-8453214 Sash1 intra BALB/c 1.302 (P) 0.994 (P) 
chr10:8499529-8500702 Sash1 intra BALB/c 1.302 (P) 0.994 (P) 
chr10:8516559-8516781 Sash1 intra BALB/c 1.302 (P) 0.994 (P) 
chr10:8533747-8533799 Sash1 intra C57BL/6 1.302 (P) 0.994 (P) 
chr10:8565556-8566318 Sash1 intra BALB/c 1.302 (P) 0.994 (P) 
chr10:8569257-8569687 Sash1 intra C57BL/6 1.302 (P) 0.994 (P) 
chr10:8600425-8600804 Sash1 distal BALB/c 1.302 (P) 0.994 (P) 
chr10:18209707-18210091 Nhsl1 distal C57BL/6 1.503 (P) 0.966 (P) 
chr10:18262232-18262290 Hebp2 distal C57BL/6 21.81 (P) 1 (P) 
chr10:18264292-18264337 Hebp2 distal C57BL/6 21.81 (P) 1 (P) 
chr10:84777151-84777599 Btbd11 distal BALB/c 0.151 (A) 0.96 (P) 
chr10:84813063-84813163 Btbd11 distal C57BL/6 0.151 (A) 0.96 (P) 
chr10:85015114-85015305 Btbd11 intra C57BL/6 0.151 (A) 0.96 (P) 
chr10:85038563-85039091 Btbd11 intra BALB/c 0.151 (A) 0.96 (P) 
chr10:85073454-85073867 Btbd11 intra BALB/c 0.151 (A) 0.96 (P) 
chr10:85077536-85077897 Btbd11 intra C57BL/6 0.151 (A) 0.96 (P) 
chr10:88105615-88105792 Spic intra BALB/c 6.522 (P) 0.991 (P) 
chr10:92874018-92874212 Lta4h distal C57BL/6 1.032 (P) 1 (P) 
chr10:92886703-92886763 Lta4h intra BALB/c 1.032 (P) 1 (P) 
chr10:92893443-92893580 Lta4h intra BALB/c 1.032 (P) 1 (P) 
chr10:92894786-92895269 Lta4h intra C57BL/6 1.032 (P) 1 (P) 
chr10:92900457-92900512 Lta4h intra BALB/c 1.032 (P) 1 (P) 
chr10:92912661-92912967 Lta4h intra C57BL/6 1.032 (P) 1 (P) 
chr10:92916395-92916703 Hal distal C57BL/6 1293 (P) 0.997 (P.A) 
chr10:92931309-92931538 Hal intra C57BL/6 1293 (P) 0.997 (P.A) 
chr10:92947751-92947804 Hal distal C57BL/6 1293 (P) 0.997 (P.A) 
chr10:93014816-93014876 Ccdc38 intra C57BL/6 1.207 (A) 0.996 (A) 
chr10:104598765-104598953 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
chr10:104626764-104627103 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
chr10:104634539-104634758 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
chr10:104635908-104635968 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104671761-104672161 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
chr10:104706006-104706340 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104747765-104747995 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104759614-104759674 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
chr10:104789057-104789197 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104839643-104839694 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
chr10:104840547-104840607 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104840635-104840749 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104842784-104842934 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
chr10:104883498-104883558 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104927384-104927444 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104951824-104951878 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104968996-104969374 Tmtc2 intra C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:104976330-104976386 Tmtc2 intra BALB/c 0.0226 (P.A) 0.993 (P) 
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Center of DMR  
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Gene Symbol Position  
relative to 
 Gene 
Demethylated  
in 
BMM BALB/c 
(0h) 
BMM 
C57BL/6 
(0h) 
chr10:105001660-105002240 Tmtc2 distal C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:105014390-105014549 Tmtc2 distal C57BL/6 0.0226 (P.A) 0.993 (P) 
chr10:122672434-122672816 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr10:122708405-122708511 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr10:122710469-122710529 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr10:122822800-122823015 Fam19a2 intra BALB/c 69.92 (P) 0.996 (A) 
chr10:122827614-122827671 Fam19a2 intra BALB/c 69.92 (P) 0.996 (A) 
chr10:122849206-122849328 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr10:122858308-122858831 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr10:122859610-122860125 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr10:122868108-122868477 Fam19a2 intra BALB/c 69.92 (P) 0.996 (A) 
chr10:122904978-122905047 Fam19a2 intra BALB/c 69.92 (P) 0.996 (A) 
chr10:122957032-122957347 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr10:123131977-123132288 Fam19a2 intra BALB/c 69.92 (P) 0.996 (A) 
chr10:123135244-123135391 Fam19a2 intra C57BL/6 69.92 (P) 0.996 (A) 
chr11:3092678-3093978 Sfi1 prom BALB/c 16.38 (P) 0.974 (P) 
chr11:3128842-3128985 Eif4enif1 intra C57BL/6 1.48 (P) 0.957 (P) 
chr11:5857646-5857691 Ykt6 intra C57BL/6 1.141 (P) 0.973 (P) 
chr11:5911639-5911781 Camk2b intra BALB/c 0.0639 (A) 0.992 (P) 
chr11:5932196-5932242 Camk2b intra C57BL/6 0.0639 (A) 0.992 (P) 
chr11:46600295-46600496 Havcr1 intra C57BL/6 0.19 (A) 0.806 (P) 
chr11:46707379-46707893 Timd4 distal BALB/c 8.529 (P) 0.967 (P.A) 
chr11:88799550-88799596 Coil intra BALB/c 0.682 (P) 0.999 (P) 
chr11:88801073-88801240 Coil intra BALB/c 0.682 (P) 0.999 (P) 
chr11:88804568-88804628 Coil intra BALB/c 0.682 (P) 0.999 (P) 
chr11:90494121-90494462 Tom1l1 intra BALB/c 6.307 (P) 0.998 (P) 
chr11:90523839-90524032 Tom1l1 distal C57BL/6 6.307 (P) 0.998 (P) 
chr11:90527633-90527930 Tom1l1 distal BALB/c 6.307 (P) 0.998 (P) 
chr11:90538382-90538517 Tom1l1 distal BALB/c 6.307 (P) 0.998 (P) 
chr11:90543530-90543948 Tom1l1 distal C57BL/6 6.307 (P) 0.998 (P) 
chr11:90546847-90546916 Tom1l1 distal BALB/c 6.307 (P) 0.998 (P) 
chr12:15770109-15770577 Trib2 distal C57BL/6 0.0942 (A) 0.891 (P) 
chr12:15784239-15784299 Trib2 distal BALB/c 0.0942 (A) 0.891 (P) 
chr12:15823593-15823638 Trib2 intra BALB/c 0.0942 (A) 0.891 (P) 
chr12:15826824-15826870 Trib2 intra BALB/c 0.0942 (A) 0.891 (P) 
chr12:45187434-45187920 Nrcam distal C57BL/6 42.4 (P) 0.942 (P) 
chr12:45213241-45213388 Nrcam intra C57BL/6 42.4 (P) 0.942 (P) 
chr12:79919494-79919852 6330442E10Rik intra C57BL/6 0.944 (P) 0.998 (P) 
chr12:79968891-79969672 Plekhh1 intra C57BL/6 5.628 (P) 0.998 (P) 
chr12:79994386-79994739 Plekhh1 intra C57BL/6 5.628 (P) 0.998 (P) 
chr12:79995677-79995722 Plekhh1 intra BALB/c 5.628 (P) 0.998 (P) 
chr12:80002205-80002717 Pigh intra BALB/c 1.281 (P) 0.998 (P) 
chr13:56269324-56269539 Neurog1 distal C57BL/6 0.756 (P) 0.979 (P) 
chr13:56313994-56314118 Cxcl14 distal BALB/c 17.13 (P) 0.952 (P) 
chr13:56347924-56348198 Cxcl14 distal C57BL/6 17.13 (P) 0.952 (P) 
chr13:62858842-62859176 Fbp2 intra C57BL/6 1.207 (A) 0.996 (A) 
Appendix III 
 
180 
Center of DMR  
(Mouse assembly mm8) 
Gene Symbol Position  
relative to 
 Gene 
Demethylated  
in 
BMM BALB/c 
(0h) 
BMM 
C57BL/6 
(0h) 
chr13:67930408-67930468 Zfp459 distal BALB/c 7.655 (P) 0.937 (P.A) 
chr13:76579670-76579730 Ttc37 intra C57BL/6 1.925 (P) 0.939 (P) 
chr13:109314064-109314489 Ercc8 intra BALB/c 1.302 (P) 0.998 (P) 
chr13:109326652-109326712 Elovl7 distal BALB/c 0.0586 (A) 0.996 (P) 
chr13:109416087-109416140 Elovl7 distal C57BL/6 0.0586 (A) 0.996 (P) 
chr14:19624572-19624712 Plau prom C57BL/6 20.23 (P) 0.974 (P) 
chr14:50788103-50788154 Ear6 distal C57BL/6 0.863 (A) 0.996 (A) 
chr14:50809903-50810041 Mett11d1 intra C57BL/6 1.097 (P) 1 (P) 
chr14:50884020-50884348 E130112L23Rik distal BALB/c 1.953 (P) 0.99 (P) 
chr14:51053374-51053423 Rpgrip1 intra BALB/c 0.21 (P) 1 (P) 
chr14:51060437-51060883 Rpgrip1 intra C57BL/6 0.21 (P) 1 (P) 
chr14:51081511-51082058 Rpgrip1 intra BALB/c 0.21 (P) 1 (P) 
chr14:51104658-51105062 Supt16h intra C57BL/6 0.652 (P) 0.999 (P) 
chr14:65636120-65636251 Adra1a intra BALB/c 5.283 (P) 0.999 (P) 
chr14:65651727-65652060 Adra1a intra BALB/c 5.283 (P) 0.999 (P) 
chr14:65710648-65711641 Adra1a distal C57BL/6 5.283 (P) 0.999 (P) 
chr14:78033582-78034116 1190002H23Rik intra C57BL/6 0.0526 (P) 0.994 (P) 
chr14:78037674-78038068 1190002H23Rik distal BALB/c 0.0526 (P) 0.994 (P) 
chr14:78042149-78042203 1190002H23Rik distal BALB/c 0.0526 (P) 0.994 (P) 
chr15:74776186-74776280 Ly6e distal C57BL/6 1.38 (P) 0.982 (P) 
chr15:74783393-74783628 Ly6e intra C57BL/6 1.38 (P) 0.982 (P) 
chr15:74790167-74790537 Ly6e distal C57BL/6 1.38 (P) 0.982 (P) 
chr15:90288150-90288496 Cpne8 distal C57BL/6 39.53 (P) 0.924 (P) 
chr15:90314666-90314836 Cpne8 distal C57BL/6 39.53 (P) 0.924 (P) 
chr15:90335420-90335501 Cpne8 intra C57BL/6 39.53 (P) 0.924 (P) 
chr15:90478475-90478535 Cpne8 intra C57BL/6 39.53 (P) 0.924 (P) 
chr16:28833304-28834357 1600021P15Rik intra C57BL/6 8.062 (P) 0.998 (P) 
chr16:38842237-38842369 Igsf11 intra BALB/c 0.314 (P.A) 0.984 (P) 
chr16:38873534-38873736 Igsf11 intra BALB/c 0.314 (P.A) 0.984 (P) 
chr16:38944175-38944451 Igsf11 intra C57BL/6 0.314 (P.A) 0.984 (P) 
chr16:85665872-85665932 Adamts1 distal C57BL/6 30.23 (P) 0.987 (P.A) 
chr17:3293172-3293498 Tiam2 intra C57BL/6 0.0958 (P) 0.979 (P) 
chr17:3334336-3334651 Tiam2 intra C57BL/6 0.0958 (P) 0.979 (P) 
chr17:3353108-3353259 Tiam2 intra C57BL/6 0.0958 (P) 0.979 (P) 
chr17:3355433-3355486 Tiam2 intra BALB/c 0.0958 (P) 0.979 (P) 
chr17:3359059-3359104 Tiam2 intra BALB/c 0.0958 (P) 0.979 (P) 
chr17:3360576-3360633 Tiam2 intra C57BL/6 0.0958 (P) 0.979 (P) 
chr17:3486560-3486832 Tfb1m intra C57BL/6 1.298 (A) 0.984 (A) 
chr17:3489017-3489250 Tfb1m intra C57BL/6 1.298 (A) 0.984 (A) 
chr17:3505060-3505778 Tfb1m intra C57BL/6 1.298 (A) 0.984 (A) 
chr17:30301717-30302316 Btbd9 intra C57BL/6 11.81 (P) 0.995 (P) 
chr17:30462176-30462337 Dnahc8 intra C57BL/6 4.678 (P) 0.996 (P) 
chr17:33787792-33788060 Psmb9 distal C57BL/6 0.992 (P) 0.994 (P) 
chr17:33914667-33915150 H2-Eb1 intra C57BL/6 1.578 (P) 0.997 (P) 
chr17:33917083-33917555 H2-Eb1 intra C57BL/6 1.578 (P) 0.997 (P) 
chr17:33948318-33948367 H2-Ea distal C57BL/6 319.1 (P) 0.996 (A) 
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chr17:34637963-34638443 Msh5 intra C57BL/6 56.31 (P) 0.994 (P) 
chr17:43287601-43287829 Rcan2 intra C57BL/6 17.43 (P) 0.996 (A) 
chr17:43292477-43292537 Rcan2 intra C57BL/6 17.43 (P) 0.996 (A) 
chr17:43295716-43295900 Rcan2 intra C57BL/6 17.43 (P) 0.996 (A) 
chr17:43343826-43344046 Rcan2 intra BALB/c 17.43 (P) 0.996 (A) 
chr17:43395146-43395209 Rcan2 intra BALB/c 17.43 (P) 0.996 (A) 
chr17:43417114-43417163 Rcan2 intra C57BL/6 17.43 (P) 0.996 (A) 
chr17:43475365-43475425 Rcan2 intra BALB/c 17.43 (P) 0.996 (A) 
chr17:43485699-43486569 Rcan2 intra BALB/c 17.43 (P) 0.996 (A) 
chr17:43490290-43490887 Rcan2 intra BALB/c 17.43 (P) 0.996 (A) 
chr18:9209850-9210313 Fzd8 distal C57BL/6 5.553 (P) 0.937 (P) 
chr18:9214393-9214977 Fzd8 intra C57BL/6 5.553 (P) 0.937 (P) 
chr18:58681880-58682279 Slc27a6 intra C57BL/6 8.848 (P) 0.997 (A) 
chr18:58686133-58686695 Slc27a6 intra C57BL/6 8.848 (P) 0.997 (A) 
chr19:5687110-5687363 Pcnxl3 intra BALB/c 1.089 (P) 0.995 (P) 
chr19:10054676-10054898 Best1 intra BALB/c 0.111 (P) 0.997 (P) 
chr19:10059640-10059975 Best1 intra C57BL/6 0.111 (P) 0.997 (P) 
chr19:17402472-17402791 Gcnt1 intra C57BL/6 0.0663 (P) 0.994 (P) 
chr19:17411445-17411968 Gcnt1 intra BALB/c 0.0663 (P) 0.994 (P) 
chr19:17417594-17417742 Gcnt1 intra BALB/c 0.0663 (P) 0.994 (P) 
chr19:17424366-17424594 Gcnt1 prom C57BL/6 0.0663 (P) 0.994 (P) 
chr19:24146132-24146183 Tjp2 distal BALB/c 0.0519 (P) 0.974 (P) 
chr19:24221222-24221543 Tjp2 intra C57BL/6 0.0519 (P) 0.974 (P) 
chr19:24229262-24229401 Tjp2 intra BALB/c 0.0519 (P) 0.974 (P) 
chr19:24310167-24310227 Tjp2 distal C57BL/6 0.0519 (P) 0.974 (P) 
chr19:24331447-24331788 Fxn intra BALB/c 0.85 (P) 0.999 (P) 
chr19:24337430-24337560 Fxn intra BALB/c 0.85 (P) 0.999 (P) 
chr19:25277140-25278032 Ankrd15 distal BALB/c 20.66 (P) 0.912 (P.A) 
chr19:25346036-25346164 Ankrd15 intra C57BL/6 20.66 (P) 0.912 (P.A) 
chr19:25390590-25390638 Ankrd15 intra C57BL/6 20.66 (P) 0.912 (P.A) 
chr19:25499075-25499142 Ankrd15 intra BALB/c 20.66 (P) 0.912 (P.A) 
chr19:25499563-25499613 Ankrd15 intra BALB/c 20.66 (P) 0.912 (P.A) 
chr19:47809044-47809476 6330577E15Rik intra BALB/c 1.013 (P) 1 (P) 
chr19:47919990-47920050 Gsto2 intra BALB/c 0.946 (P) 0.996 (P) 
chr19:47932361-47932413 Gsto2 intra BALB/c 0.946 (P) 0.996 (P) 
chr19:47956327-47956551 Itprip intra C57BL/6   
chr19:47958144-47958529 Itprip intra C57BL/6   
chr19:47961787-47962003 Itprip intra BALB/c   
chr2:118831692-118831737 1200015F23Rik intra C57BL/6 1.389 (P) 0.968 (P) 
chr2:118870105-118870259 Dnajc17 intra C57BL/6 1.771 (P) 0.982 (P) 
chr2:118921263-118922015 Ppp1r14d prom C57BL/6 1.414 (A) 0.996 (A) 
chr2:118931167-118931543 Spint1 intra C57BL/6 0.0282 (P) 0.839 (P) 
chr2:118933687-118934010 Spint1 intra C57BL/6 0.0282 (P) 0.839 (P) 
chr2:120043669-120043809 Vps39 intra BALB/c 1.379 (P) 1 (P) 
chr2:121917801-121918164 Sord distal C57BL/6 0.147 (P) 0.971 (P) 
chr2:129008854-129009320 Il1a distal C57BL/6 1.584 (A) 0.996 (A) 
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chr2:129060442-129060527 Il1b intra BALB/c 10.84 (P) 0.997 (P) 
chr2:129084712-129085352 Il1b distal C57BL/6 10.84 (P) 0.997 (P) 
chr2:129095204-129095388 Il1b distal C57BL/6 10.84 (P) 0.997 (P) 
chr2:165163847-165163893 Slc13a3 intra BALB/c 0.0413 (P.A) 0.999 (P) 
chr2:165165074-165165182 Slc13a3 prom BALB/c 0.0413 (P.A) 0.999 (P) 
chr2:180916370-180916541 9230112E08Rik distal C57BL/6 0.995 (P) 0.992 (P) 
chr2:180924755-180925097 9230112E08Rik distal C57BL/6 0.995 (P) 0.992 (P) 
chr3:54505131-54505191 Postn distal BALB/c 2.843 (P) 1 (P.A) 
chr3:117362502-117362562 D3Bwg0562e distal BALB/c 20.58 (P) 0.996 (A) 
chr3:117363368-117363427 D3Bwg0562e distal BALB/c 20.58 (P) 0.996 (A) 
chr3:117378454-117378604 D3Bwg0562e distal BALB/c 20.58 (P) 0.996 (A) 
chr3:117390058-117390183 D3Bwg0562e distal BALB/c 20.58 (P) 0.996 (A) 
chr3:126918409-126918466 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:126932154-126932803 Ank2 intra BALB/c 6.139 (P) 0.999 (P.A) 
chr3:126961500-126961737 Ank2 intra BALB/c 6.139 (P) 0.999 (P.A) 
chr3:126964886-126964946 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:126990100-126990231 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:126997578-126997623 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127002910-127003059 Ank2 intra BALB/c 6.139 (P) 0.999 (P.A) 
chr3:127058579-127058783 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127064288-127064344 Ank2 intra BALB/c 6.139 (P) 0.999 (P.A) 
chr3:127115515-127116082 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127144143-127144203 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127144544-127144604 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127152673-127152718 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127157369-127157422 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127161553-127161690 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127181064-127181574 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127183561-127183610 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127204193-127204468 Ank2 intra BALB/c 6.139 (P) 0.999 (P.A) 
chr3:127220202-127220609 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127228341-127228401 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127234728-127235174 Ank2 intra BALB/c 6.139 (P) 0.999 (P.A) 
chr3:127242061-127242747 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127260837-127261164 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127261581-127261716 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127308653-127309047 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127347726-127347863 Ank2 intra C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127384454-127384514 Ank2 intra BALB/c 6.139 (P) 0.999 (P.A) 
chr3:127401141-127401603 Ank2 prom C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127443926-127443972 Ank2 distal C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:127474127-127474259 Ank2 distal BALB/c 6.139 (P) 0.999 (P.A) 
chr3:127492535-127492881 Ank2 distal C57BL/6 6.139 (P) 0.999 (P.A) 
chr3:131987012-131987072 Dkk2 distal BALB/c 8.107 (P) 0.99 (A) 
chr3:142400177-142400232 Gbp5 distal BALB/c 1.205 (P) 1 (P) 
chr3:142401448-142401499 Gbp5 distal BALB/c 1.205 (P) 1 (P) 
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chr3:142548523-142548645 Gbp2 distal C57BL/6 0.743 (P) 1 (P) 
chr4:46555277-46556225 Trim14 intra C57BL/6 1.145 (P) 0.995 (P) 
chr4:46594578-46596131 Coro2a intra C57BL/6 0.209 (P) 0.997 (P) 
chr4:46610429-46610801 Coro2a intra C57BL/6 0.209 (P) 0.997 (P) 
chr4:46620908-46622454 Coro2a intra C57BL/6 0.209 (P) 0.997 (P) 
chr4:46645788-46645910 Tbc1d2 intra C57BL/6 1.5 (P) 0.993 (P) 
chr4:46661251-46661373 Tbc1d2 intra C57BL/6 1.5 (P) 0.993 (P) 
chr4:66324635-66324996 Tlr4 intra C57BL/6 1.542 (P) 0.994 (P) 
chr4:75614171-75614231 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:75643880-75643940 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:75666515-75667215 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:75709451-75709627 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:75749082-75749313 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:75762858-75763384 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:75781594-75781862 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:75852063-75852194 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:75857675-75858015 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:75903639-75904077 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:75909398-75909566 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:75970799-75971683 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:75998019-75998274 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:76002246-76002407 Ptprd intra C57BL/6 44.94 (P) 0.996 (A) 
chr4:76014633-76014693 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:76042627-76042753 Ptprd intra BALB/c 44.94 (P) 0.996 (A) 
chr4:95020698-95021255 Fggy distal C57BL/6 0.15 (P) 0.98 (P) 
chr4:95049158-95049994 Fggy prom C57BL/6 0.15 (P) 0.98 (P) 
chr4:95071653-95071921 Fggy intra BALB/c 0.15 (P) 0.98 (P) 
chr4:95074879-95075609 Fggy intra C57BL/6 0.15 (P) 0.98 (P) 
chr4:95255640-95255700 Fggy intra C57BL/6 0.15 (P) 0.98 (P) 
chr4:95281652-95281871 Fggy intra BALB/c 0.15 (P) 0.98 (P) 
chr4:117954421-117954479 Mpl intra BALB/c 0.664 (A) 0.939 (P) 
chr4:117998531-117998591 Tie1 distal BALB/c 13.28 (P) 0.958 (A) 
chr4:118000679-118000739 Tie1 distal C57BL/6 13.28 (P) 0.958 (A) 
chr4:136116934-136117007 Ephb2 distal BALB/c 0.583 (A) 0.983 (P.A) 
chr4:136120484-136120813 Ephb2 distal BALB/c 0.583 (A) 0.983 (P.A) 
chr4:136127607-136127655 Ephb2 distal BALB/c 0.583 (A) 0.983 (P.A) 
chr4:136157517-136157754 C1qb prom C57BL/6 0.146 (P) 0.995 (P) 
chr4:136160301-136161004 C1qb distal BALB/c 0.146 (P) 0.995 (P) 
chr4:136188412-136188847 C1qa distal BALB/c 0.383 (P) 0.999 (P) 
chr4:139992658-139992703 Rcc2 intra C57BL/6 1.033 (P) 0.999 (P) 
chr4:140001888-140002184 Padi6 intra BALB/c 0.781 (A) 0.992 (P.A) 
chr4:140037365-140037761 Padi4 intra BALB/c 0.0265 (P) 0.989 (P) 
chr4:140053810-140053855 Padi4 distal C57BL/6 0.0265 (P) 0.989 (P) 
chr4:140066734-140066816 Padi3 intra BALB/c 0.443 (P.A) 0.999 (P) 
chr4:140075656-140075701 Padi3 intra C57BL/6 0.443 (P.A) 0.999 (P) 
chr4:140086347-140087247 Padi1 intra C57BL/6 0.756 (P) 0.999 (P) 
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chr4:140088960-140089479 Padi1 intra BALB/c 0.756 (P) 0.999 (P) 
chr4:140098544-140098705 Padi1 intra C57BL/6 0.756 (P) 0.999 (P) 
chr4:140100052-140100287 Padi1 intra C57BL/6 0.756 (P) 0.999 (P) 
chr4:140102179-140102439 Padi1 intra C57BL/6 0.756 (P) 0.999 (P) 
chr4:140117495-140117765 Padi1 prom BALB/c 0.756 (P) 0.999 (P) 
chr4:140150659-140150706 Padi1 distal BALB/c 0.756 (P) 0.999 (P) 
chr4:140834500-140834615 Fblim1 distal BALB/c 0.126 (P) 0.991 (P) 
chr4:140848488-140848640 Fblim1 distal BALB/c 0.126 (P) 0.991 (P) 
chr4:140887217-140887262 Tmem82 intra C57BL/6 1.56 (P) 1 (P) 
chr4:140902197-140902509 Slc25a34 intra BALB/c 0.779 (P) 0.99 (P) 
chr4:146455519-146455683 2610305D13Rik distal C57BL/6 0.0885 (A) 0.989 (P) 
chr4:147309756-147309900 Frap1 intra C57BL/6 1.22 (P) 0.998 (P) 
chr4:147344719-147345290 Angptl7 prom BALB/c 71.66 (P) 0.998 (A) 
chr4:153165776-153166060 Prdm16 intra BALB/c 0.0185 (A) 0.988 (P) 
chr4:153374889-153374938 Prdm16 intra C57BL/6 0.0185 (A) 0.988 (P) 
chr4:153377867-153377925 Prdm16 intra C57BL/6 0.0185 (A) 0.988 (P) 
chr4:153397287-153397825 Prdm16 intra C57BL/6 0.0185 (A) 0.988 (P) 
chr4:153416659-153417244 Prdm16 intra BALB/c 0.0185 (A) 0.988 (P) 
chr4:153521279-153522015 Actrt2 distal C57BL/6 0.524 (A) 0.84 (P.A) 
chr5:31235102-31235151 Preb intra BALB/c 0.987 (P) 0.996 (P) 
chr5:35229612-35229843 A930005I04Rik distal C57BL/6 0.143 (P) 0.999 (P) 
chr5:53010351-53010409 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53012858-53013017 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53013951-53014431 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53026418-53026767 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53049276-53049634 Pi4k2b intra BALB/c 7.234 (P) 0.999 (P) 
chr5:53058948-53058993 Pi4k2b distal BALB/c 7.234 (P) 0.999 (P) 
chr5:53061668-53062228 Pi4k2b distal C57BL/6 7.234 (P) 0.999 (P) 
chr5:53063596-53064069 Pi4k2b distal BALB/c 7.234 (P) 0.999 (P) 
chr5:66959934-66959982 Uchl1 intra C57BL/6 0.0211 (P) 0.998 (P) 
chr5:67640239-67640299 Slc30a9 distal BALB/c 1.548 (P) 0.99 (P) 
chr5:67676687-67677026 Slc30a9 distal BALB/c 1.548 (P) 0.99 (P) 
chr5:67680207-67680368 Slc30a9 distal C57BL/6 1.548 (P) 0.99 (P) 
chr5:104720508-104721242 Pkd2 intra C57BL/6 25.9 (P) 1 (P) 
chr5:104725504-104725800 Pkd2 intra C57BL/6 25.9 (P) 1 (P) 
chr5:104733382-104733438 Pkd2 intra C57BL/6 25.9 (P) 1 (P) 
chr6:5104955-5105188 Ppp1r9a intra C57BL/6 10.8 (P) 0.988 (P) 
chr6:5333111-5334506 Asb4 distal C57BL/6 0.0642 (P.A) 0.997 (P) 
chr6:29688651-29688794 Smo intra C57BL/6 7.301 (P) 0.984 (P) 
chr6:29716478-29716561 4631427C17Rik distal BALB/c 1.345 (P) 0.827 (P) 
chr6:93630855-93630915 Magi1 distal C57BL/6 9.72 (P) 1 (P.A) 
chr6:93691281-93691444 Magi1 intra BALB/c 9.72 (P) 1 (P.A) 
chr6:93694981-93695577 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:93704332-93704392 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:93713202-93713457 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:93735273-93735333 Magi1 intra BALB/c 9.72 (P) 1 (P.A) 
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chr6:93755446-93756328 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:93768673-93769578 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:93814158-93814213 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:93823430-93823772 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:94029111-94029381 Magi1 intra C57BL/6 9.72 (P) 1 (P.A) 
chr6:94085475-94085534 Magi1 intra BALB/c 9.72 (P) 1 (P.A) 
chr6:94115136-94115260 Magi1 intra BALB/c 9.72 (P) 1 (P.A) 
chr6:122566409-122566463 Apobec1 intra C57BL/6 2.923 (P) 1 (P) 
chr6:122593442-122593497 Dppa3 intra C57BL/6 0.0522 (P) 0.998 (P) 
chr6:122599007-122599338 Dppa3 distal BALB/c 0.0522 (P) 0.998 (P) 
chr6:129559721-129559770 Klrd1 intra BALB/c 0.785 (P) 0.99 (P) 
chr6:134647920-134648332 Loh12cr1 intra BALB/c 0.551 (P) 1 (P) 
chr6:134652859-134653242 Loh12cr1 intra C57BL/6 0.551 (P) 1 (P) 
chr6:134666768-134667057 Loh12cr1 intra C57BL/6 0.551 (P) 1 (P) 
chr6:134684992-134685037 Dusp16 intra BALB/c 6.056 (P) 0.989 (P) 
chr6:134711215-134711398 Dusp16 intra BALB/c 6.056 (P) 0.989 (P) 
chr6:134723586-134723979 Dusp16 intra C57BL/6 6.056 (P) 0.989 (P) 
chr6:136898012-136898210 Arhgdib intra C57BL/6 0.933 (P) 0.997 (P) 
chr6:136920044-136920089 Pde6h intra BALB/c 0.125 (A) 0.999 (P) 
chr6:136962558-136962606 Pde6h distal C57BL/6 0.125 (A) 0.999 (P) 
chr6:136920044-136920089 Pde6h intra BALB/c 0.125 (A) 0.999 (P) 
chr6:136962558-136962606 Pde6h distal C57BL/6 0.125 (A) 0.999 (P) 
chr7:4064078-4064123 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr7:4073211-4073587 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr7:4073898-4074764 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr7:4081211-4081948 Eps8l1 intra BALB/c 0.0861 (A) 0.979 (P) 
chr7:4468706-4470122 Isoc2b prom C57BL/6 0.188 (P) 0.987 (P) 
chr7:4476223-4476274 Isoc2b distal C57BL/6 0.188 (P) 0.987 (P) 
chr7:15421071-15421190 C5ar1 distal BALB/c 0.37 (P) 0.998 (P) 
chr7:28818237-28818282 Ryr1 intra BALB/c 13.91 (P) 1 (P) 
chr7:28863980-28864027 1110006G06Rik intra BALB/c 1.008 (P) 1 (P) 
chr7:29665315-29665376 Zfp74 intra BALB/c 1.336 (P) 0.999 (P) 
chr7:29692014-29692149 Zfp568 prom C57BL/6   
chr7:37961808-37962602 Pop4 distal BALB/c 0.1 (P) 0.999 (P) 
chr7:80210572-80210730 Unc45a intra C57BL/6 2.327 (P) 0.999 (P) 
chr7:99033917-99034043 Dgat2 intra C57BL/6 11.39 (P) 0.99 (P) 
chr7:99037518-99037643 Dgat2 intra BALB/c 11.39 (P) 0.99 (P) 
chr7:99064892-99065884 Dgat2 distal C57BL/6 11.39 (P) 0.99 (P) 
chr7:119504588-119504967 Thumpd1 distal C57BL/6 0.01 (A) 0.996 (P) 
chr7:119506866-119506918 Thumpd1 distal BALB/c 0.01 (A) 0.996 (P) 
chr7:119994863-119995241 Abca14 prom C57BL/6 1.207 (A) 0.996 (A) 
chr7:120010482-120010849 Abca14 intra BALB/c 1.207 (A) 0.996 (A) 
chr7:125348874-125348919 Il4ra intra BALB/c 1.04 (P) 0.999 (P) 
chr7:125398313-125398366 Il21r intra C57BL/6 0.724 (P) 0.99 (P) 
chr7:142430532-142430685 Igf2 distal BALB/c 1.098 (M.A) 0.923 (P) 
chr8:73561622-73562051 Gdf15 distal C57BL/6 0.0791 (P) 0.988 (P) 
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chr8:124746984-124747033 Slc7a5 distal BALB/c 3.167 (P) 0.998 (P) 
chr8:124747942-124748185 Slc7a5 distal BALB/c 3.167 (P) 0.998 (P) 
chr8:124755205-124755348 Slc7a5 distal BALB/c 3.167 (P) 0.998 (P) 
chr8:124757601-124757653 Slc7a5 distal C57BL/6 3.167 (P) 0.998 (P) 
chr8:124758800-124759357 Slc7a5 distal BALB/c 3.167 (P) 0.998 (P) 
chr8:124760437-124760974 Slc7a5 distal BALB/c 3.167 (P) 0.998 (P) 
chr8:124768035-124768493 Slc7a5 intra C57BL/6 3.167 (P) 0.998 (P) 
chr8:124774258-124775049 Slc7a5 intra C57BL/6 3.167 (P) 0.998 (P) 
chr8:124798597-124798956 BC048644 intra C57BL/6   
chr8:124823004-124823197 Car5a intra C57BL/6 0.693 (A) 0.973 (P.A) 
chr8:127227407-127227452 Galnt2 intra BALB/c 1.505 (P) 0.999 (P) 
chr8:127276982-127277478 Pgbd5 intra BALB/c 0.0115 (A) 1 (P) 
chr8:127283682-127283870 Pgbd5 intra C57BL/6 0.0115 (A) 1 (P) 
chr8:127301989-127302034 Pgbd5 intra C57BL/6 0.0115 (A) 1 (P) 
chr8:127317898-127318260 Pgbd5 intra BALB/c 0.0115 (A) 1 (P) 
chr8:127359130-127359175 Pgbd5 distal C57BL/6 0.0115 (A) 1 (P) 
chr8:127361009-127361074 Pgbd5 distal C57BL/6 0.0115 (A) 1 (P) 
chr8:127364656-127364799 Pgbd5 distal BALB/c 0.0115 (A) 1 (P) 
chr9:49187501-49188250 Ttc12 distal C57BL/6 7.06 (P) 0.998 (P) 
chr9:49192161-49192634 Ttc12 intra C57BL/6 7.06 (P) 0.998 (P) 
chr9:49237091-49237345 Ttc12 intra BALB/c 7.06 (P) 0.998 (P) 
chr9:50769119-50769184 Snf1lk2 distal C57BL/6 1.375 (P) 0.966 (P) 
chr9:51783122-51783240 Rdx distal C57BL/6 0.971 (P) 1 (P) 
chr9:51850201-51850259 Rdx distal C57BL/6 0.971 (P) 1 (P) 
chr9:51851802-51851859 Rdx distal C57BL/6 0.971 (P) 1 (P) 
chr9:72207341-72207401 BC065403 intra BALB/c   
chr9:102967337-102967700 Rab6b distal C57BL/6 0.0133 (A) 0.988 (P) 
chr9:102971565-102971612 Rab6b intra BALB/c 0.0133 (A) 0.988 (P) 
chrX:119220336-119220381 3110007F17Rik prom C57BL/6 0.0515 (A) 0.992 (P) 
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A  
md_1  
chr8: 124,744,953-124,745,822 
 
C57BL/6   ---------------------------------GAATGCCTAGGAGGGAA-CGCCCAGATGGTCAAGGAGTACTGACACGTCCTACGTCACTGTACACTG 
BALB/c    ---------------------------------GAGATGCTAGGAGGGAA-CGCCCAGATGGTCAAGGAGTACTGACACGTCCTACGACACTGTACACCG 
 
C57BL/6   AGCATCACACAGTGCATGGGGACCGTGGCTGCTCTCAGCAGGTGGCAGAGCAGGGCCAAGAGGGAATCAAAATCTTAACCTCCTTCATGAACCAGAAGTA 
BALB/c    AGCATCACACGGTGCATGGGGACCGTGGCTGCTCTCAGCATGTGGCAGAGT------------GAATCAAAATCTTAACCTCCTTCATGAACCAGAAGTA 
 
C57BL/6   GCAATGGAAAAGAAATTCCAGGGAGGA-TGGGAGGTGGTGGCAGGCTCAGCATGGGCTGGGGGACATGGCGGCTCTCTCCCTCTGTCCTCCCTTACATAT 
BALB/c    GCAATGGAAGAGAAATTCCAGGGAGGACTGGGAGGTGGTGGCAGGCTCAGCCTGGGCTGGGGGACATGGCGGCTCTCTCCCTCTGTCCTCCCTTCCATAT 
 
C57BL/6   GGC----------CCCCCCTGGTCTGCACCTCTGTGCTCTAACTACCCCGGGGACCTTTCTGTTCTTACATGTCACTAATCAGAAAATTGGGCTGGAGAG 
BALB/c    GGCGGCGCCCCCCCCCCCCCCGTCTGCACCTCTGTGCTCTAACTGCCCCAGGGACCTTTCTGTTCTTACATGCCACTAATCAGAAAATTGGGCTGGAGAG 
 
C57BL/6   ATGGCTCACAGTTAAGAGAACTGGCTGCTCTTCCACAGGACCCAGTGTTAATTCCCAGCGCCCACAGGAAGCTCACAACCATCTGTAACTCTAGCACTAG 
BALB/c    ATGGCTCACAGTTAAGAGAACTGGCTGCTCTTCCACAGGACCCAGTGTTAATTCCCAGCGCCCACAGGAAGCTCACAACCATCTGTAACTCTAGCACTAG 
 
C57BL/6   GGGAATCCAATGCCCTTAGTGCCCGGCGAACGCATGATGCACAGGCATATATGCAGACAAATCCCCCATGCACATAAAGAATGGGGAGGAAGAGGAGGGG 
BALB/c    GGGA-TCCAATGCCCTTAGTGCCCGGCATACGCATGATGCACAGGCATATATGTAGACAAATCCCCCATGCACATAAAGAATGGGGAGGAAGAGGAGGGG 
 
C57BL/6   GGGCAAGGGGA-GGAGAAGGGGAGGGGGATAGGGAGGAGGAAGAGAAAGAAGAAGGGGAAGGAAGAAGAGGAGGGGGAGAGAAAAAGGAGGGGGAAGAGG 
BALB/c    GTGCAAGGGGAAGGAGAAGGGGAGGGGGATAGGGAGGAGGAAGAGAAAGAAGAAGGGGAAGGAAGAAGAGGAGGGGGAGAGAAAAAGGAGGGGGAAGAGG 
 
C57BL/6   AAGAGAAGGAAGAGAAGAGAAAGAAGAAGAGGAGGAGGAGG------GGAAGGAGGAGGAAATGGAAAAAAAAAAAACTCTTTGGGTCCCAAAGTCAGAT 
BALB/c    AAGAGAAGGAAGAGAAGAGAAAGAAGAAGAAGAGGAGGAGGAGGAGGGGAAGGAGGAGGAAATGGAAAA--CAAAACCTCTTTGGGTCCCAAAGTCAGAT 
 
C57BL/6   ACTTTCCATAGACCCCAACTGTATAACAAGACAGAGCCAGGTGTCAAGAAGAGCAGAGCCCAGGGCCACAGCACCAATGACGAGAGCTTGTGAGACACAC 
BALB/c    ACTTTCCAGAGACCCCAACTATATAACAAGACAGAGCCAGGTGTCAAGAAGAGCAGAGCCCAGGGCCACAGCACCAATGACGAGAGCTTGTGAGACACAC 
 
C57BL/6   TCACCTGCCACAGACTCACCA 
BALB/c    TCATCTGCCACAG-CTCACCA 
 
B 
md_3  
chr7:59,714,748-59,715,117 
 
C57BL/6   ---------------------------------CTGAATT-ACTCTGTACACTTACTTTCTTAATGCCACATTGGAATCCCCTTTCCTGTATTATAAGTA 
BALB/c    ---------------------------------CTGAATT-ACTCTGTACACTTACTTTCTTAATGCCACATTGGAATCCCCTTTCCTGTATTATAAGTA 
 
C57BL/6   TCAAAGTGTCAAAACACGTATTTACCGGTTCCTCCTATCCCTTTAGAAACTGGGAGGTGCAAATCACCATTATCTGTTGTGATTTCCCTCTGAAAAAAAT 
BALB/c    TCAAAGTGTCAAAACACATATTTACCTGTTCCTCCTATCCCTTTAGAAACTGGGAGCTGCAAATCACCATTATCTGTTATGATTTTCCTCTGAAAATGAT 
 
C57BL/6   CTGCATGTTAACTCTCAAGTGCTTTTATCCCTTCCCATCATTAATTATATTCACAGCAAGGCACAATATAATTTTAATTCCTTTAGGAATATTATTATTG 
BALB/c    CTGCATGTTAACTCTCAAGTGCTTTTATCCCTTCC-ATCACTAATTATATTCACAGCAAGGCACAATATAATTTCAATTCCTTTAGGAATATTATTTTTA 
 
C57BL/6   TGCAACACCCATATACCAAAATAAATGTTCTTTTTTTCTGTCTGCCTTTAATTTCCACACACCTTTAATCCACAATACTGTCTGTTCTTTGAAATATTAA 
BALB/c    TGCAACACCCATGTACCAAAATAAATGTTCTTTTTTTCTGTCTGCCTTTAATTTCCACACACGTTTAATCCACAATACTGTCTGTTCTTTGAAATATTAA 
 
C57BL/6   TGT 
BALB/c    TGT 
 
C 
md_4  
chr7:104,152,267-104,153,014 
 
C57BL/6   ---------------------------------ATCTTTCAG--TTTCAAATTCTTTCTTATCTGCCATCAGCCTTTGCAGAACTACCTGCAGCTGCTCC 
BALB/c    ---------------------------------ACCTTTCGA--TTTC-AATTCTTTCTTGTCTGCCATCAGCCTTTGCAGAACTACCTGCAGCTGCTCC 
 
C57BL/6   TGTAAGAAAGGAATTGTAGCAGAGTCAAGCTGTGTGCTTAGTAGGACTGTTGTTCTATCCAAAGGCCAAAACCTTCTGGAAAGATAGAAAGCTAAGGATT 
BALB/c    TGTAAGAAAGGAATTGTAGCAGAGTCAAGCTGTGTGCTTAGTAGGACTGTTGTTCTATCCAAAGGCCAAAACCTTCTGGAAAGATAGAAAGTTAAGGATT 
 
C57BL/6   TCTACCTTTCTTTTAAAGGATTGTGATATGAATTCTTTACATAACAATTATATACACATATAGTTTTAATCTATTATGAATAAGTAGATAAGAAACTTTT 
BALB/c    TCTACCTTTCTTTTAAAGGATTGTGATATGAATTCTTTACATAACAATTATATACACATATAGTTTTAATCTATTATGAATAAGTAGATAAGACACTTTT 
 
C57BL/6   GGAAACAAGGCAAACAGGGACAAAATCAACTTGGTCTGGAAAGTTTACAGAAACCCAGGGAATGGCAACTAGAGTCTAGGAGTAGGAAGAAAATAATAAG 
BALB/c    GAAATGAAGGCAAACAGGGACAAAATCAACTTGGTCTGGGAAGTTTACAGAAACCCAGGGAATGGCAACTAGAGTCTAGGAGTAGGAAGAAAATAATAAG 
 
C57BL/6   GGATAGCCATGTACTTGGAAAAAGATTCCCCATCTTCTTTCAAAAAGGTGGTCTCAAGCCATGCCAGGTATGTAGATATCAGAGAATAATTTGCAACTTG 
BALB/c    GAATAACCATCTACTTGGAAAAGGATTCCCCATCTTCTATCCAAATGGTGGTCTCAAGCCATGCCAGGTATGTAGATATCAGAGAATAATTTGCAACTTG 
 
C57BL/6   CAGCCATCAGTTTTCTCCTTCAGTGGTCTGGTTTCTGAGTTCAGACTCAGGCCGATATACTTGGCAACAAGCCATTGAGGCATTGTTCCCAACACTCATC 
BALB/c    CAGCCATCAGTTCTCTCCTTCAGTGGTCTGGTTTCTGATTTCAGACTCAGGCCGTTATACTTGGCAACAAGCCATTAAGGCATTGCTCCCAACCCTCATC 
 
C57BL/6   TTACTTACTTTGACAACTAAAGAATAATCAGAGCTTTTCTTGGACATAAAACCTCAACAGTATACAACAAACTGTAAAAACACTTGCTCTTGTTCTAGAG 
BALB/c    TTATTTACTTTGACACGTAAAGTATAATCAGAGCTTTTCGTGGACATAAAATCTCAACAGTATACAACAAACTGTAAAAACACTTGCTATTGTTCTAGAG 
 
C57BL/6   TTTGTCGCCCCTGGTAGATTCTCTTAGGATTAAGCTCAATGGATAGTCCCATTCTTTCAGGCCTCAGAAGGTAACAGGATG 
BALB/c    TTTGTCACCCTTGGTAGATTATCTTAGGATTAAGCTCAATGGATAGTCCCATTCTTTCAAGCCTCAGAAGGTAACAGGATG 
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D 
md_5  
chr7:29,621,365-29,622,278 
 
C57BL/6   -----------------------------------------------------AGCCTCAGGTGATCTCTTTATTGGAGCAAGGCAAAGAGCCCTGGATG 
BALB/c    -----------------------------------------------------AGCCTCAGGTGATCTCTTTATTGGAGCAAGGCAAAGAGCCCTGGATG 
 
C57BL/6   ATTGGTAAAGAGCTTACAAGAGGCCTGTGCTCGGGTAAGTGAGAAGCATTGCGCAGAGCGGTGCCCACGGGGACAACTCGCTGGTAATCCAGGAAACTGC 
BALB/c    ATTGGTAAAGAGCTTACAAGAGGCCTGTGCTCGGGTAAGTGAGAAGCATTGCGCAGAGCGGTGCCCACGGGGACAACTCGCTGGTAATCCAGGAAACTGC 
 
C57BL/6   ACCTTTCCCATGTTATTTTGTTTTTTTTTTTTTTTTTTATTTTTTTTTTTTTTAAAAATTTTTTTTTTTTTTATTTGAAAGTACACTGTAGCTGTCTTCA 
BALB/c    ACCTTTCCCATGTTATTTTGTTTT---------------------------------------------------------------------------- 
 
C57BL/6   GACACTCCAGAAGAGAGAGTCAGATCTCCTTACGGATGGTTGTGAGCCACCATGTGGTTGCTGGGATTTGAACTCCTGACCTTCGGAAGAGCAGTCGGGT 
BALB/c    ---------------------------------------------------------------------------------------------------- 
 
C57BL/6   GCTCTTACCCACTGAGCCATCTCACCAGCCCGTTATTTTGTTTTAAAGAGTATTTCCTAATGTTATGTAGACGAGTGCTCTGTCTGCATGTACACCTGCG 
BALB/c    --------------------------------------------AAAGAGTATTTCCTAATGTTATGTAGACGAGTGCTCTGTCTGCATGCACACCTGCG 
 
C57BL/6   TGCCAGAAGAGAACATCAACTCCCATTATAGATGGCTGTGAGCCACCATGTGGTTGCTGGAAAGTGACCTCTTAACAGCTGAGCCATCTCTCCTGCCCAT 
BALB/c    TGCCAGAAGAGAACATCAACTCCCACTATAGATGGCTGTGAGCCACCATGTGGTTGCTGGAAAGTGACCTCTTAACAGCTGAGCCATCTCTCCTGCCCAT 
 
C57BL/6   TGGTTGTTATTTTGTAAGCTTCTGCCAAAAACTTGGGTCTAAGTGAGAAAAGCAAGTTCTTTTTTTAAAAAAAG-AGCATTATTATTATTATTATTTTGT 
BALB/c    TGGTTGTTATTTTGTAAGCTTCTGCCAAAAACTTAGATCTAAGTGAGAAAAGCAAGTTCTTTTTTTAAAAAGAGCATTATTATTATTATTATTATTTTGT 
 
C57BL/6   TTCATGTATTGATTGATTGATTGATTGATTGCATGGGGCGAATTGGGGGGGGTCAAAGGACAACTGTGAGAGTTCGTTTTCTCTGTGCATGGTGTTGGTC 
BALB/c    TTCATGTATTGATTGATTGATTGATTGATTGCATGGGGCGAGTTGGGGGGG-TCAAAGGACAACTGTGAGAGTTCGTTTTCTCTGTGCATGGTGTTGGCC 
 
C57BL/6   TGGGGATCAGACTCAGGTCATCATTGGTTTTGTTTTCACATAGGAACGGTTTTATAACTGGCTTATCAGTCTTTACCTTCTCTTGTCCATCCAGAGGTCG 
BALB/c    TGGGGATCAGACTCAGGTCATCATTGGTTTTGTTTTCACATAGGAACGGTTTTATAGCTGGCTTCTCAGTCTTTACCTTCTCTTGTCCATCCAGAGGTCG 
 
C57BL/6   GATGCCTAAAATCCCAACCTCCTAACAACCTGAGTTACCCTCTGGTGACCAGGCTCAATACTAGAGCT 
BALB/c    GATGCCTAAAATCCCAACCTCCTAACAACCTGAGTTACCTTCTGGTGACCGGGCTCAATACTAGAGCT 
 
E 
Tbc1d2  
chr4:46,658,967-46,659,728 
 
C57BL/6   ----------------------------------TTGA-GCAGGTTAACAACAGCAAAGTGGCTGCAAAGTGATCGGTTTTGCTGCTGAAGCCTTCTTGG 
BALB/c    ----------------------------------TTGATGCAGGGTTACAACAGCAAAGTGGCTGCAAAGTGATCGGTTTTGCTGCTGAAGCCTTCTTGG 
 
C57BL/6   AGACTCTTCACGAACACGCAGGCCACAGGTGACTCTGTATCTGATAAGCCATTTTAAAAAAAGAGTCTGAAATGTACCAAAAACTTGATGTGCCAAGGTG 
BALB/c    AGACTCTTCACGAACACGCAGGCCACAGGTGACTCTGTATCTGATAAGCCATTT-AAAAAAAGAGTCTGAAATGTACCAAAAACTTGATGTGCCAAGGTG 
 
C57BL/6   TCTATCCTAGGGTCATGTATAGTACCTTAAAGTGGAAATAACTTTTCCTAGGTTTCTGTTGCTGTTGTTGTTTTATTTTTATCATGTGTATGTATGTATT 
BALB/c    TCTATCCTAGGGTCATGTACAGTACCTTAAAGTGGAAATAACTTTCCCCAGGTTTCTGTTGCTGTTGTTGTTTTATTTTTATCATGTGTATGTATGTATT 
 
C57BL/6   GGAGGGAGCATATATAATGTTTGTTCACATGTGTATGAACACACATGCACATGCATGTGCTATGTGTGGTGCCCAGAGGTTGATGTCAGATTTCTTCTTG 
BALB/c    GGAGGGAGCATATATAATGTTTGTTCACATGTGTATGAACACACATGCACATGCATGTGCTATGTGTGGTGCCCAGAGGTTGATGTCAGATATCTTCTTG 
 
C57BL/6   ACCACTCTGCTTTACTTACTGACACAGGTGCTCTAGCTGAGCCCAGAGCTCGCTGATTAGGACAGTCTGTTTATCCAGCTTGCTCTGCATCTCCTGTCTC 
BALB/c    ACCACTCTGCTTTACTTACTGACACAGGTTCTCTAGCTGAGCCCAGAGCTCGCTGATTAGGACAGTTTGTTTATCCAGCTTGCTCTGCATCTCCTATCTC 
 
C57BL/6   TGCCTCCCCAGGAA-----GAGCACAAGGTACCATGCCCACCTGGCTTTCCCATGCACTCTGGGGAAATCTGCATGCTGTTTCTCAGGCTTGCATGGCAA 
BALB/c    TGCCTCCCCAGGAATACCTGAGCACAAGGTACCACGCCCACCTGGCTTTCCCATGCACTCTGGGGAAATCTGCATGCTGTTTCTCAGGCTTGCATGGCAA 
 
C57BL/6   TCCTTTATCTATGGAGCCATCTCTCTAGACATCCTCCTTTTTTGGGGGGGGGGGGGTAGAGTCTCACTAAATTACTCAGACCTGGCCTGGATCTTGAAAT 
BALB/c    TCCTTTATCTATGGAGCCATCTCTCTAGACATCCCCCTTTTTTGGGGGGG------CAGAGTCTCACTAAATTACTCATACCTGGCCTGGATCTTGAAAT 
 
C57BL/6   CCATATTCCAGCGCTCAAGAACCTAGGATTACAGGTGCACACCACCAAGCCCGGCCAGAAATGAAGACTTGACAGCCCAGGAGGAGGCTGGGTAAAGCAA 
BALB/c    CCATATTCCAATGCTCAAGAACCTAGGATTACAAGTGCACACCACAAAGCCCGGCTGGAAATGAAGACTTGACAGCCCAGGAGGAGGCTGGGTAAAGCAA 
 
C57BL/6   GA 
BALB/c    GA 
 
F 
Cd48  
chr1:173,518,415-173,518,932 
 
C57BL/6   ------------------------------------------------------CTCCCCTCTGCGACGCTGGTGGTCTCTGCCCAGTCACAGCCTCTCC 
BALB/c    ------------------------------------------------------CTCCCCTCTGCGACGCTGGTGGTCTCTGCCCAGTCACAGCCTCTCC 
 
C57BL/6   TTACTCCCCACAGGCAACAGCAGATTCGGCCTCAGTGCTCAAAGTGCACTGCTGAAAAATCCATTCTTTTAAGCCAAGCTATTTTTCTTGTTGATCTCTA 
BALB/c    TTACTCCCCACAGGCGACAGCAGATTCGGCCTCAGTGCTCAAAGTGCACTGCTGAAAAATCCATTCTTTTAAGCCAAGCTATTTTTCTTGTTGATCTCTA 
 
C57BL/6   GTGGGTAGGAGAATTTGAAATCTCATTCCATGTGGTGTGATGGTAGTGGTCTGCTTTCCTGTTGTGTATGGTAATTCGTGAAATAGAGAAAAAACAGAAA 
BALB/c    GTGGGTAGGAGAATTTTAAATCTCATTCCATGTGGTGTGATGGTAGTG-----CTTTCCTGTTGTGTATGGTAATTCGTAAGATAGAGAAAAAACAGAAA 
 
C57BL/6   AACCTCATACGACTTCCGGTTTTGGGTTTTGCTTCCTGATTGAAGGGCAGGCGCCCTGACTTCTCTTACAGTTGTCTCCAGTGTTCTGGGGAAGCTTCTC 
BALB/c    AACCTCATACAACTTCCGGGTTTGGGTTTTGCTTCCTGATTGAAGGGCAGGCGCCCTGCCTTCTCTTACAGTTGTCTCAAGTGTTTCGGGGAAGCTTCTC 
 
C57BL/6   TAAGTATTATGTGCTTCATAAAACAGGGATGGTGTCTGGTCCTGGAACTGCTACTGCTGCCCTTGGGAACTGGATTTCAAGGTAGCTTCCTCCAAGTGTC 
BALB/c    TAAGTATTATGTGCTTCAGAAAACAGGGATGGTGTCTGGTCCTGGAACTGCTACTGCTGCCCTTGGGAACTGGATTTCAAGGTAGCTTCCACCAAGTGTC 
 
C57BL/6   CGGCTGTGCACTGAAGGCATGGCCAGCTGGGAAAGGGGAGGTGGGATGTAGCTCAACCCTGGAAATGAGCAT 
BALB/c    CGGCTGTGCACTGAAGGCATGGCCAGCTGGGAAAGGGGAGGTGTGATGTAGCTCAACCCTGGAAATGAGCAT 
Appendix IV 
 
189 
G 
Tmtc2  
chr10:104,969,448-104,970,451 
 
C57BL/6   -------------------TTTGTTGTTCTGTTAAATGTGCTGGCCTTCAAACTCCTGAGGACTTTGCTGTTTCTGCCTCCCATCTTCTCAGGGAAGTAG 
BALB/c    -------------------TTTGTTGT-CTGTTAA-TGTGTGG--CTTCAAATTCCTGAGGACTTGGT--GTTCTGCCTCCCATCTTCTCAGGGAAGTAG 
 
C57BL/6   TCCTTCATTGAGGATTCAAGAGGATTTACAGACATTCATGTTATGCTT-TTTTTTTTTTTCTGTAGGTCTGGAAGATGCAAATTTAGGTCCTCAGGCTTG 
BALB/c    TCCTTCAT-GAGGATTCAAGAGGATTTACAGACATTCATGTTATACTTCTTTTTTTTTTTCTGTAGTTCTGGAAGATGCAAATTTAGGTC-TCAGGCTTG 
 
C57BL/6   GGTACCAAGTGCTTCTATCCACTGAACCCTCCCTCCACCCAGCTTCAAGGAAATATTTTTAAGGTTTCCTAACAAAATAAAGCAAAATTGAAAACTATGT 
BALB/c    GGTACCAAGTGCTTCTATCCACTGGAACCTTCCTTCCACCAGCTTCAAGGAAATATTTTTAAGGTTTCCTAACAAAATAAAGCAAAATTAAAAACTATGT 
 
C57BL/6   TGATTTTTTTTTTGCTAGGGTTATGTAAGAAGAGAGAATATCCATTGAGACAACACTTCCATCAAATTGGCCTGTAAATAAGTCTGTGGGAGGCATTTTC 
BALB/c    TGATTTTTTTT--GCTAGGGTTATGTAAGAAGAAAGAATATCCATTGAGACAACACTTCCATCAAATTGGCCTGTAAATAAGTCTGTGGGAGGCATTTTC 
 
C57BL/6   TTGGTTAAAAGTTGATGTGGGAGGGCTCAGCCCATTGCAGGTGCTATCACACATAGGCTAGTGGTCCTGGATGCTATAAGAGGAGGTTATGCAAGCCATC 
BALB/c    TTGGTAAAAAGTTGATGTGGGAGGGTCCAGCCCATTGTAGGGGCTATCACACATAGGCTAGTGGTCCTGGATGCTATAAGAGTAGGTTACACAAGCCATC 
 
C57BL/6   AAGAGCTTGCCTTGTAAGCAGCACTCTCCCAGGTCTTCTACAGAAGTTCTGTCTCCAGGTACCTGCCTTGAATTCCTGTCCTGACTTCCTTCAGTGATGG 
BALB/c    AAGAGCTTGCCTTGTAAGCAGCACTCTTCCAGGTCTTCTACAGAAGTTCTGTCTCCAGGTCCCTGCCTTGAATTCCTGTCCTGACTTCCTTCAGTGATGG 
 
C57BL/6   ACTGTGACGTGAAAATATAAACCAAATAAACCCTCTCCAAGTTGCTTTTGATCAGAAGGCTTTACCATAGCAAGTGAAAATGAACAAGGACATGTACCTA 
BALB/c    ACAGTGACGTGAAAATATAAACCAAATAAACCCTCTCCAAGTTGCTTTTGGTCAGAAGGCTTCACCATAGCAAGTGAAAATGAACAAGGACATGGACCTA 
 
C57BL/6   CATTGATCCCATTTTTATAAACTTGTTGCTTCTAAGAAAAATTGCAAATGTATTGTGAAGATCTCCCCAGAAAGGGCGATTAGTCATCAAAAGCAGAGAT 
BALB/c    CATTGATCCCATTTTTATAAACGTGTTGCTTCTAAGAAAAATTGCAAATGTATTGTGAAAATCTCCCCAGAAAGGGCGATTAGTCATCAAAAGCAGAGAT 
 
C57BL/6   TTGACAAAAACAACAACAACAAACAAACAAACAAAAACAACAACAACAACAAACTTTTTT------AACTGATCACACCACCTAGCACAGAGGCACAAGT 
BALB/c    TTGACAAAAACAACAACAACAAACAAACAAACAAAAACAACAACAAAAAAAACCCTTTTTTCCTTTAACTGATCACACCACCTAGCACAGAGGCACACGT 
 
C57BL/6   TCATAGGC-AGGACCATGTTTCATTTGACAAACCAGGAATTCAGACTTGAGAGCAGTCTAGGCCACACCTCCTACCTTACCTCTCACAGATACCACAAAG 
BALB/c    TCATAGGCGAGGACCGTGTTTCATTTGACAA-CCAGGAATTCAGACTTGAGAGCAGTCTAGGCCACGCCCCCTACCCTACCTCTCACAGATACCACAAAG 
 
C57BL/6   TGACCTACTGGTTGAATCAAGAAACAAAAGC 
BALB/c    TGACCTACTGGT-GAATCGAGAAC--GAAGC 
 
H 
Pgbd5  
chr8:127,300,507-127,300,973 
 
C57BL/6   -------------------------------------CACTCTACCCACAGCTT-CTCAACAAATGCCCCTCACAAAACAAGCTTTCTATCTTTCAATTT 
BALB/c    -------------------------------------CATCTCCAGCACAGTTTTCTCAACAAACACCCCTT-CAAAACAAGCTTTCTACCTTTCAATTT 
 
C57BL/6   CCCTGTCTTCATTTTGACCAAGCC-TTGGTTAGGGCCAC-TCCACAC-TCAGGCATGGAAGGCATGCCTTACACTGACCAAGACCAAGCCATGCCCAATC 
BALB/c    CCCTGCCTTCATTTTGACCAAGCCATTGGTTAGGGCCACCTCCACACATCAGGCATGGAAGGCATGCCTTACACTGACCAAGACCAAGCCATGCCCAGTC 
 
C57BL/6   GCCCATTAAGCGCCCACAGGAATGAACTCTAGCTTTGACCCTACACTCTCAGACTGACCTGAGAATTAAAGCTGGTCACTGCCCTCTCAGAGCCCGGTCT 
BALB/c    GCCCATTAAGCGCCCACAGGAATGAACTCAAGCTTTAACCCTACGCTCTCAGACTGACCTGAGAATTAAAGCCGGTCACTGCCCTCTCAGAGCCCGGTCT 
 
C57BL/6   CCCTGCAGAAAACACCCAAAGAAGG------ACCCTGAAGGTGTCGGTCGGATCAGGTTGAAGAGTGGCACGAGCCAAGTGGTCCCTAATGTTCTAACGT 
BALB/c    CCCTGCAGAAAACACCCAAAGGAGAGAGCCTAATCTGAAGATGTCGGTCGGATCAGGTTGAAGAGTGTCACGAGCCAAGTGGTCCCTAATGTTCTAACAT 
 
C57BL/6   CTTTCTGTAAACCCAGTGGTTCCCTGCAACTTCACGTACCCGTGAGCCTCCTTAAAAGTCTAGAGACCAGTTGGTTGTGGTCCCAGGATCCAGGAATCAC 
BALB/c    CTTTCTGTAAACCCAGTGGTTCCCTGCAACTTCACGTACCCATGACCCTCCTTAAAAGTCTAGAGGCCAGTTGGTTGTGGTCCCAGGATCCAGGAATCAT 
 
C57BL/6   ACTCTACCAGGATC 
BALB/c    ACTCTAACAGGATC 
 
I 
Tmtc2  
chr9:49,224,882-49,225,570 
 
C57BL/6   ----------------------------------AAAGGAGAAGAAGGTACTAGGAAAGACCAGTGAATCGCTGGGACTAATGTGAGACAATTAGGAAGA 
BALB/c    ----------------------------------AAAGGAGAAGAAGGTACTAGGAA-GACCAGTGAATCGCTGGGACTAATGTGAGTCAATTAGGAAGA 
 
C57BL/6   AAAAGAAATAGCAAGAGAATTTAATACTGGGCTTCCAGGAACAGAGCTTTAAGTCACTAGCCAACTCTAGTAATTTATGGACGGCTTATCAGGAGTTGTA 
BALB/c    AAAAGAAATAGCAAGAGAATTTAATACCGGGCTTCCAGGAACAGAGCTTTAAGTCACTAGCCAACTCTAGTAATTTATGGACGGCTTATCAGGAGTTGTA 
 
C57BL/6   TGCTTTGCTGAGTATCAGGGAAAGTGGTGAATAAAAAACAAAATCCTTTTGTTTTGTTTGAAAAGCTTGTGATCTTGTGTGGGAGACAAACGTTAACACA 
BALB/c    TGCTTTGCTGAGTATCAGGGAAAGTGGTGAATAAAAAACAAAATCCTTTTGTTTTGTTTGAAAAGCTTGTGATCTTGTGTGGGAGACAAACGTTAACACA 
 
C57BL/6   AGCAGCTCTGAGATTCCTAAAACAGAAGCCTTCAGCTGTCTCCCTGCCTCTCTTCACTGTGTTGTCTACGCAGATTGGCATTCATAGACTGTCCTTTAGA 
BALB/c    AGCAGCTCTGAGATTCCTAAAACAGAAGCCTTCAGCTGTCTCCCTGCCTCTCTTCACTGTGTTGTCTACCCAGATTGGCAATCATAGACTGTCCTTTAGA 
 
C57BL/6   GGGATCACTCTACCCTCACACCCCACCTAAACAGATAAATTTGTTCACCTCACTCCAATTTCAGATCAATCTAATTATCCATATCTAGCAGCCTTGACTA 
BALB/c    GGGATCACTCTACCCTCACACCCCACCTAAACAGATAAATTTGTTCACCTCACTCCAATTTCAGATCAATCTAATTATCCATATCTAGCAGCCTTGACTA 
 
C57BL/6   GGGAGGCTAAACATTGATGAAGAAAAATGGATAAATATCTGGGGGGGGGGGGACTTACTGGTCTGTCAGTGACCCTCACTCTCCCAGATCCTTTACTATG 
BALB/c    GGGAGGCTAAACATTGATGAAGAAAACTGGATAAATATCTGTGGGGGG---AACTTACTGGTCTGTCAGTGACCCTCACTCTCCCAGATCCTCTACTATG 
 
C57BL/6   TCATCCTAGGTAGTCTATTATCCTCTCAAACACTTTCAAGTTTTGGACAATCTAAACCTGACGATTCCAAATAGAGGATTCTGCTTATTCATTCGGTGAG 
BALB/c    TCATCCTAGGTAGTCTATTATCCTCTCAAACACTTTCAAGTTTTGGACAATCTAAACCTGACGATTCCAAATAGAGGATTCTGCTTATTCATTCGGTGAG 
 
C57BL/6   GAAAGGGATGGTGTTAAGAAAGAG 
BALB/c    GAAAGGGATGGTGTTAAGAAAGAG 
Appendix IV 
 
190 
J 
1600021P15Rik  
chr16:28,833,612-28,834,468 
 
C57BL/6   ----------------------GTAGTCAACAATGTGTTGACAGAATGTTTCCCCAGAGAACGGAGGGGACCCAAGCACACAGCTCTCCCTCCTTTGTGC 
BALB/c    ----------------------GTAGTCAACAATGTGTTGACAGAATGTTTCCCCAGAGAACGGAGGGGACCCAAGCACACAGCTCTCCCTCCTTTGTGC 
 
C57BL/6   TCAGGCTGCTACACTGATCTCAGCTTGGGAGGAGGAAGTATGGCGGTTGAGGGAAAAGGTTTCACATGGAGAGCGCCTAATATCCTGTGTACCTCAGATA 
BALB/c    TCAGGCTGCTACACTGATCTCAGCTTGGGAGGAGGAAGCATGGCGGTTGAGGGAAAAGGTTTCCCATGGAGAGCGCCTAATATCCTGTGTACCTCAGATA 
 
C57BL/6   ATACACACATAACCACTGCTGGGCTTTAACGGAAGCCTATACTCTTAGCTTTGCCCTTCATAAACTTAGCTTTGTCCTTAGAGATCTTTAGGACCTACAA 
BALB/c    ATACACACACAACCACTGCTGGGCTTTAACGGAAGCCTATACTCTTAGCTTTGCCCTTCATAAACTTAGCTTCGTCCTTAGAGATCTTTAGGACCTACAA 
 
C57BL/6   CAGGCTATGGAATGATGAAGCTAACACGATCTGTCCGGCCCCAGGGCCGTGTTCTCCCATCTCACTGCATCCTCACTTCTTCCGTGACAACTCTATCTCT 
BALB/c    CAGGCTATGGAATGATGAAGCTAACACGGTCTGTCCGGCCCCAGGGCCGTGTTCTCCCATCTCACTGCATCCTCACTTCTTCCGTGACAACTCTCTCTCT 
 
C57BL/6   CCCGTGCAGCCACAGAAGGATGGCTACTGTTTACCTCAGACAACGGAACTTAACACAGGAACTACAGATTTTGCCTAAACCACAGCTAAAAGACAAATCT 
BALB/c    CCCGTGCAGCCACAGAAGGATGGCTACTGTTTACCTCAGACAACGGAGCTTAACACAGGAACTACAGATTTTGCCTAAACCACAGCTAAAAGCCAAATCT 
 
C57BL/6   GCCAAGCCAGCTTTGTTCCCATTAGCAAAATTTAGCAACAGCACTATTCCTTAGTCACCAAAACTCTATGTCAACAATCACCTGAGCACGAGTCTTTCAT 
BALB/c    GCCAAGCCAGCTTTGTTCCCATTAGCAAAATTTAGCAACAGCACTATTCCTTAGTCACCAAGACTCTATGTCAACAATCACCTGAGCACGAGTCTTTCAT 
 
C57BL/6   ATTTGGGGAAATTTCTCACATTAGGTTATCTTGGGCCACTGTGGGAACTGCCATAGATTGTCATCAATGACAAACATCCAACAAACAGCCCAAGTTCTGA 
BALB/c    ATTTGGGGAAATTTCTCACATTAGGGTGTCTTGGGCCACTGTGGGAACTGCCATAGATTGTCATCAATGACAAACATCCAACAAACAGCCCAAGTTCTGA 
 
C57BL/6   ACAAAAACAAAATCAGTAATATTAGCAAGATCTGTTGAGGACCTCTCAAATCTCCACTGAACTGTGTTCCAGACATGCAAAAGAGAAACAACAGCATATC 
BALB/c    ACAAAAACAAAATCAGTAATATTAGCAAGATCTGTTGAGGCCCTCTCAAATCTCCACTGAACTGTGTTCCAGACATGCAAAAGAGAAACAACAGCATATC 
 
C57BL/6   CGTGAAGGGCATCTTTGGGATGTTAAGTAGTGGGAAACATCAGACATTGGTCACTAACAATTAGAAATTCATAACTGAC 
BALB/c    CGTGAAGGGCATCTTTGGGATGTTAAGTAGTGGGAAACATCAGACACTGGTCACTAACAATTAGAAATTCATAACTGAC 
 
K 
2310009E04Rik (Fggy)  
chr4:95,071,096-95,072,198 
 
C57BL/6   ------------------------------------------CCAGGCTACAAAGCTGAGGAGGAGTGGGCTGTCATAGAAGACAGCCTTTTACTTTAAG 
BALB/c    ------------------------------------------CCAGGCTACAAAGCTGAGGAGGAGTGGGCTGTCATAGAAGACAGCCTTTTATTTTAAG 
 
C57BL/6   AGGAAGAAAGATCCTGAATATGCTGAGAGAAGCCATAGAGAATCAGGTATTATTGTCATGTTGACTCCTTCCTTCCTGTACAAAATTTTCTCACCATCTT 
BALB/c    AGGAAGAAAGATCCTGAATATGCTGAGAGAAGCCATAGAGAATCAGGTATTATTGTCATGTTGACTCCTTCCTTCCTGTACAAAATTTTCTCACCATCTT 
 
C57BL/6   AGAGCATGTGGGAGACTTGCAGGACTATTCACTCTTATAGGAGCGGCGAATCTTTTCTGTTAATAAGACTGAAGTGCGCAGTACAGGCCTACTTGTTGCT 
BALB/c    AGAGCATGTGGGAGACTTGCAGGACTACTCACTCTTATAGGAGCGGCGAATCTTTTCTGTTAATAAGACCGAAGTGAGCAGTACAGGCCTACTTGTTGCT 
 
C57BL/6   TGTCCTCATCTCCCCTGCTTACCTAAACCGGATTACAATGTAACCAAAAACTAAATTGCATGAGGCTGGAACACATGAGCTCCCAGTAGAGTTCAAAGAT 
BALB/c    TGTCCTCATCTCCCCTTCTTACCTAAACCGGATTACAATGTAACCAAAAACTAAATTGCATGAGGCTGGAACACATGAGCTCCCAGTAGAGTTCAAAGAT 
 
C57BL/6   CACTGTTAAAAGAGGACACTGAGTTGAGTTTTCTCCCCTGGCCTGGGACTTACTTTCTGTAGGCTGTCACCAACGAAACTGAACCTGGAGGAGTGGTTCT 
BALB/c    CACTGTTAAAAGAGGACACTGAGTTGAGTTTTCTCCCCTGGCCTGGGACTTAATTTCTGTAGGCTGTCACCAACGAAACTGAACCTGGAGGAGTGGTTCT 
 
C57BL/6   TTAAGAAGCAGAATCTAAGGTAAGCCCCTCCATTTTCCAGGGATGTGGTGCTGTGAAGTAGTCATCACTGTGACTAAGTTATTTGAGGGGAAAG------ 
BALB/c    TTAAGAAGCAGAATCTAAGGTAAGCCCCTCCATTTTCCAGGGATGTGGTGCTGTGAAGTAGTCATCACTGTGACTAGGTTATTTGAGGGGAAAGAAAGGG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    AATACAGGGACAGCACAATTCCCTAGGGTTGTTTTTGAGCAGAGAGTTTGTAGCATTTACCCCCTTCTAGGGATGGCTGAAATAGTTTTGCAGAGAGCAG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    TCCCAGTTTCCAGGTCTCCCGCCTATCCTCATATGGCATTTGAATAAGCTTGTACATTTGCTAAACAATTAGCTGTGAAATCTATGACTTCCTGTGGTAC 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    ACTTCTCACAATATTTATACAGGCCATCATTTAGTGAACTGTATAAATATTTATGGCATGGAACAGCCTTTTGATCATAAATAGGGGCCAGGAGTCAGTG 
 
C57BL/6   -------------------GCTTGGTATTACCTGAGTTTTAAGGCATCTTGTAGCCTGAGATATTAGGTATGTCTCAGGACTTGTGCACAGCTTGAATTT 
BALB/c    TCGCCCATGCTGGGGACTGGCTTGGTATTACCTGAGTTTTAAGGCATCTTGTAGCCTGAGATATTAGGTATGTCTCAGGACTTGTGCACAGCTTGAATTT 
 
C57BL/6   CTCTTCATTATTTTTCTATCTCTTTGCCATTTATTTTTCTATCTCTTTGCCATCGAGAGGCCATGAGCTTATTTTTCCTGAATGCCCTCCTCTACAACTG 
BALB/c    CTCTTCATTATTTTTCTATCTCTTTGCCAT-----------------------CGAGAGGCCATGGGCTTATTTTTCCTGAATGCTCTCCTCTAAAACTG 
 
C57BL/6   TTTTTCTTTTTAGAGTATTCCTCTTTGCCCCAAAATAGTGAGTTGAAACCCAAGTTCCATTCCTCATTATTCATAAAGCAGGCTGTGGAATTTCCGTGAC 
BALB/c    TTTTTCTTTTTAGAGTATTCCTCTTTGCCCCAAAATAGTGAGTTGAAACCCAAGTTCCATTCCTCATTATTCATAAAGCAGGCTGTGGAATTTCCGTGAC 
 
C57BL/6   CTGACCTGGAATTATAGCCCCTCTGTTGCTGCTATGCTTTACCTAGTGCTGTCTTTGAATACCTCAGCTCATTTTCCTGAGAAATGGGGCTTCCACACTG 
BALB/c    CTGACCTGGAATTATAGCCCCTCTGTTGCTGCTATGCTTTACCTAGTGCTGTCTTTGAATACCTCAGCTCATTTTCCTGAGAAATGGGGCTTCCACACTG 
 
C57BL/6   CCTACTTGCTCAGCTAAAGATGAAATGAGATCATAGAGTCAGGTGGGCAGTTTGCTCAAGAAAGACCAGCTTTTGTGGCATTTGTTGTTTGTTATTGAAG 
BALB/c    CCTACTTGCTCAGCTAAAGATGAAATGAGATCATAGAGTCAGGTGGGCAGTTTGCTCAAGAAAGACCAGCTTTTGTGGCATTTGTTG----TTATTGAAG 
 
C57BL/6   TTGCAAAGGCTTTGATTTTCAGTTTTAGCTGAATGTTGTGGAAAGTGTCCGAAACTCACTACTGTATGCT 
BALB/c    TTGCAAAGGCTTTGATTTTCAGTTTTAGCTGAATGTTGTGGAAAGTGTCCGAAACTCACTACTGTATGCT 
Appendix IV 
 
191 
L 
2310009E04Rik (Fggy) 
chr4:95,074,498-95,075,968 
 
C57BL/6   --------------------------------------CATGCCTCTGGGAATGCCCGTGTTCTCCCTTCTAGCTTTCTGTAAGCACAGCTTATGATGCA 
BALB/c    --------------------------------------CATGCCTCTGGGA-TGCCCGTGTTCTCCCTTCTAGCTTTCTGTAAGCACAGCTTATGATGCA 
 
C57BL/6   TTCTCAAAGCGGACATCATCTACTGCATTTCTCAGAAAGGAACCCTGTTAAGTGACACATGATTGTACAAGCACAGACTGAGAAAGTCAAATAACTAAGG 
BALB/c    TTCTCAAAGCGGACATCATCTACTGCATTTCTCAGAAAGGAACCCTGTTAAGTGACACATGATTGTACAAGCACAGACTGAGAAAGTCAAATAACTAAGG 
 
C57BL/6   GATGGCTCTTTTCGCTTTTTTTT-CCTATTGGTTCACTGATAAAGGAGTTTACTTTAGAAAACCACCGCTGGAAACCAATTATATTGCAAGCACTGGAAG 
BALB/c    GATGGCTCTTTTCGCTTTTTTTTTCCTATGGGTTCACTGATAAAGGAGTTTACTTTAGAAAACCACCGCTGGAAACCAACTATATTGCAAGCACTGGAAG 
 
C57BL/6   GGAGTGGGGATGCAGCAATCAGTAACATCCCCTTTTCTCCAGGTTCAGTCCAATGAGGAGATGGACATACCACCAAAAACATGGTCCAGAGCGAACATTT 
BALB/c    GGAGTGGGGATGCAGCAATCAGTAACATCCCCTTTTCTCCAGGTTCCGTCCAATGAGGAGATGGACATACCACCAAAAACATGGTCCAGAGCGAACATTT 
 
C57BL/6   GAAATGAAAATACAGACACTGTACATATTGACAGCCTTTGTACATGTGCAAGAAAAGTGATAAGGTCCCCCTTAGAGAAGTAGAGGATGGAATTGGGAAG 
BALB/c    GAAATGAAAATACAGACACTGTACATATTGACAGCCTTTGTACATGTGCAAGAAAAGTGATAAGGTCCCCCTTAGAGAAGTAGAGGATGGAATTGGGAAG 
 
C57BL/6   GGAAGAGCAAGTGATGGGGGAGGACCTCCATCAGTGCAAAGCACAAGTATACTTCCAGGACTGTGGGAATATCTAGGATCCCAGTGGGCAGGGCCAGGGT 
BALB/c    GGAAGAGCAAGTGATGGGGGAGGACCTCCATCAGTGCAAAACACAAGTATACTTCCAGGACTGTGGGAATATCTAGGACCCCAGTGGGCAGGGCCAGGGT 
 
C57BL/6   AGCATTCATTCGGGTTAAGAAGCTCACAGAAAGTCTCACTTGAGGAAGACCTTAGGGTGTCTTATTCTATCTATTTCTATCTATTGTGATGATATACTGC 
BALB/c    AGCGTTCATTCGGGTTAAGAAGCTCACAGAAAGTCTCACTTGAGGAAGACCTTAGGCTGTCTTATTCTATCTATTTCTATCTATTGTGATGATATTCTGC 
 
C57BL/6   TGCCCCAAGAAAGAGTCTAGCACAGTAATCACTATGGTGTTCATCTGGCTTGACCCAGGATATCTGACTTGGGGTACTAGGACACAAAAGGACAGACAAA 
BALB/c    TGCCCCGAGAAAGAGCCTAGCACAGTAATCACTATGGTGTTCATCTGGCTTGACCCAGGATATCTGACATGGGGTACTAGGACACAAAAGGACAGACACA 
 
C57BL/6   CAGATACAAGTACAGGAAAGCCAGGACTGCATGGACCACACACACTCTGATAAAGATGCGCCATCAGAGTCTGCACTGTGCAGGTTGCAGTTATATATAG 
BALB/c    CAGATGCAAGTACAGGAAAGCCAGGACTGCATGGACCACACACACTCTGATAAAGATGCGCCATCAGAGTCGGCACTGTGCAGGTTGCAGTTATATATAG 
 
C57BL/6   TTGCAGGAGGAGCTGGGATTACTGTATAAATTTGCAAGAGATGGTGAGGTTATTCTATACACTTGTAGTGAGAGGCAGGGTTATTGTATACAGTTGTCCA 
BALB/c    TTGCAGGAGGAGCTGGGATTATTGTATAAAGTTGCAGAAGATGGTGAGGTTATTCTATACACTTGTAGTGAGAGGCAGGGTTATTGTATACAGTTGTCCA 
 
C57BL/6   AGAAGGCAGGACTATTATATATGTAGCTGAGCAAGGAGGCAGGCTTAGCTAATCTTGGTAGGGGAGTCTCTATAGGGGAACCGGCTCAGACTGTAAGCAT 
BALB/c    AGAAGGCAGGGCTATTATAGATGTAGCTGAGCAAGGAGGCAAGCTTAGCTAATCTTGGTAGGGGAGTCTCTATAGGGGAACCGGCTCAGACTGTAAGCAT 
 
C57BL/6   CTTGGATGAAGTTATTGCACTTGACCTATTTTTAAGGACCAGGGTAAGGTCTTGACTTTCCCATGGGTCTGAGGCATGTGGACATTAACATGGTCATACT 
BALB/c    CTTGGATGAAGTTATTGCACTTGACCTATTTTTAAGGACCAGGGTAAGGTTTTGACTTTCCCATGGGTCTGAGGCATGTGGACATTGACATGGTCATACT 
 
C57BL/6   CATGTCAAACAATCCATGTTCACTCAGGACTTCCTCTACTCCCTGTGAACCACTAAGAGCAAACAGGGAGGATGGGAATGACAACTCAACAGGTGTCTGG 
BALB/c    CATGTCAAACAATACATGTTCACTCAGGACTTCCTCTACTCCCTGTGAACCACTAAGAGCAAACAGGGAGGATGGGAATGACAACTCAACAGGTGTCTGG 
 
C57BL/6   GTTATTTAAAAATCTGCTTTTATTGGTTACTGGCTTAAAGAGAAGGTATCACTCCCAAGTGAATGAAAGAATGAAAGCTGGTACTCATGTTTATGTGAGC 
BALB/c    GTTATTTAAAAATCTGCTTTTATTGGTTACTGGCTTAAAGAGAAGGTATCACTCCCAAGTGAATGAAAGAATGAAAGCTGGTACTCATGTTTATGTGAGC 
 
C57BL/6   TCTCGAGGGGAAAAAAGTCAGGGACCCAGGGAGCCAGGAAGACCCACCTGCTGAGCCTGGGAGCCCTGTCATGCTCAGGGGAGGCTGTGAGCTTTATTAT 
BALB/c    TCTCGAGGGGAAAAAAGTCAGGGACCCAGGGAGCCAGGAAGACCCACCTGCTGAGCCTGGGAGCCCTGTCATGCTCAGGGGAGGCTGTGAGCTTTATTAT 
 
C57BL/6   TCTTGCTTCT 
BALB/c    TCTTGCTTCT 
 
M 
3110007F17Rik  
chrX:119,220,163-119,220,873 
 
C57BL/6   ------------------TCTCGTTCAGCTGTTCTACCCACTGGTCTAGCTCCTTGGTGAATGCCTTGTCGTCTATGGCGGTGAGCTGCTCATCTCCGCC 
BALB/c    ------------------TCTCGTTCAGCTGTTCTACCCACTGGTCTAGCTCCTTGGTGAATGCCTTGTCGTCTGTGGCGGTGAGCTGCTCATCTCCGCC 
 
C57BL/6   GCCTCCCCCTCCGCTGATCCCCTGGCGGGACCGCTAAGCTGCAGAGAGCGCAGCCCGCGCCCCGCCCAAGCCCAGCCATTATCTTCGGGTCCCTGCTGTT 
BALB/c    GCCTCCCCCTCCGCTGATCCCCTGGCGGGACCGCTAAGCTGCAGAGAGCGCAGCCCGCGCCCTGCCCAAGCCCAGCCATTATCTTCGGGTCCCTGCTGTT 
 
C57BL/6   TGCCTCTAAGTCTGTGGCGGTTCCGTAGCTGTAGTGCCTGGCGGCCCCAGCCCCGCCCACGCGCTTCTGTCGCACCGCCCCCTGCGCTGTTGTCAGAGCG 
BALB/c    TGCCTCTAAGTCTGTGGCGGTTCCGTAGCTGTAGTGCCTGGCGGCCCCAGCCCCGCCCACGAGCTTCTGTCGCACCGCCCCCTGCGCTGTTGTCAGAGCG 
 
C57BL/6   CGGGACACAGTGAGGGAGGGGGGAATGGGCGAGCGGTCGCGCCGTTGGGAGGAGCAGTCCGGACCCATGCCCGTGCAGGCAGGACATGGGGAGAGCACGC 
BALB/c    CGGGACACAGTGAGGGAGGGGGGAATGGGCGAGCGGTCGCGCCATTGGGAGGAGCAGTCCGGACCCCTGCCCGTGCAGGCGGGACGTGGGGAGAGCACGC 
 
C57BL/6   AGCGACAGGCATCTGGCTTTCTGAGCCCTGGGATTTGGTGAGCGAACACTCGGAGTGGGATGGTTCGGCGCGCGCTGAGACCCGCTATCCCGGCCCCCGC 
BALB/c    AGCGACAGGCATCTGGCTTTCTGAGCCCTGGGATTTGGCGAGCGAACACTCGGAGTGGGA-----------------AGACCCGCTATCCCGGCCCCCGC 
 
C57BL/6   CCACCTTTCCCAGCGGGCCTTTCCAGCGGTCCCGGGGCGGTCTTGGTGTACTGCCATGGTGGGTGGAGGTGCGCTTGGGGCCTGGTCGCTGGCCAGGGGG 
BALB/c    CCACCTTTCCCAGCGGGCCTTTCCAGCCGTCCCAGGGCGGTCGAGGTGTACCGCCATGGTGG----AGGTGCGCTTGGGGCCTGGTCGCTGGCCAGGGGG 
 
C57BL/6   GGCAGTCCCCCGCCGACCCCAGCCTGGCCCTGCCCGCGAGCCCGCCACCAGAGCACGGGACGCAGGAAAAGGGGGCGGGGAATGACGCGCGGGTGGAGGA 
BALB/c    GGCAGTCCCCAGCCGACCCCAGCCTGGCCCTGCCCGCGCGCCGGCCGCCAGAGCACTGGACGCAGGAAAAGGGGACGGGGAATGACGCGCGGGTGGAGGA 
 
C57BL/6   GTTTTCGCTGTGCGCCGCCAGCACAGTTG 
BALB/c    GTTTTCACTGTGCGCCGCCAGCACAGTAG 
Appendix IV 
 
192 
N 
Arhgdib 
chr6:136,897,634-136,898,449 
 
C57BL/6   ----------------------------------------TAATTATACAATCCATGACCTTAGGCAGCAGGGTACAGATGGTGCCTCACCCACCTAACC 
BALB/c    ----------------------------------------TAATTATACAATCCATGACCTTAGGCAGCAGG-TACAGATGGTGCCTCACCCACCTAACC 
 
C57BL/6   AGGAAGCCCTTTGCTCCTGACTGTGGGTGACAGCAATTGCATGTCTCCGTGGAGGCCTTGCCCTGACCCATCCCTACACGCACACACCTGCTACCACAGG 
BALB/c    AGGAAGCCCTTTGCTCCTGACTGTGGGTGACAGCAATTGCATGTCTCCGTGGAGGCCTTGCCCTGACCCAACCCTACACGCACACACCTGCTACCACAGG 
 
C57BL/6   GACATCTCCCAGCAGTGTTTTCTTGTACTTGGTTAGACTCTCGTCATCCTTGTCCATCTCCTGCAGCTCCTTCAAGGACTTCTGAGGGGGTGGCTTATAA 
BALB/c    GACATCTCCCAGCAGTGTTTTCTTGTACTTGGTTAGACTCTCGTCATCCTTGTCCATCTCCTGCAGCTCCTTCAAGGACTTCTGAGGGGGTGGCTTATAA 
 
C57BL/6   TTGAGCTTGCTGTCCAGGTCGTCGTCCGCCTCTTCCAGCTGTGGCTGTGCATCCTTCTCCGTCATCTTGATTGCTCTCTATTTCAGAGAGAGAATGATGG 
BALB/c    TTGAGCTTGCTGTCCAGGTCGTCATCCGCCTCTTCCAGCTGTGGCTGTGCATCCTTCTCCGTCATCTTGATTGTTCTCTATTTCAGAGAGAGAATGATGG 
 
C57BL/6   TTCATTAGGCGCTGGGGTTGCTACTGGTACCACCTTAGTGGAGATCTGTATTCATCGGTGATTTTCAAATTGTTCCTCAACACAGATATTCCATGAAATA 
BALB/c    TTCATTAGGCGCTGGGGTTGCTACTGGTACCACCTTAGTGGAGATCTGTATTCATCGGTGATTTTCAAATTGTTCCTCAACACATATATTCCATGAAATA 
 
C57BL/6   GATAGTATTTCCAGTCATTTCTCTGACTTGTCTTAATTTTTGCTTATAGAATAAAGCTATAAGAATGAACAGCTTTTCTGTGAGCCATGCACTACAGTGA 
BALB/c    GATAGTATTTCCAGTCATTTCTCTGACTTGTCTTAATTTTTGCTTATAGAATAAAGCTGTAAGAATGAACAGCTTTTCTGTGAGCCATGCACTACAGTGA 
 
C57BL/6   AGAAAGGTAACATAAACAATCCCAGCGATCGACCATTCTAGCTTAGCCC--------------------------------------------------- 
BALB/c    AGAAAGGTAACATAAACAATCCCAGCGATCGACCATTCTAGCTTAGCCCATTGCTATTCCCAGCGATCGACCATTCTAGCTTAGCCCATTGCTATTCCCA 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    GCGATCGACCATTCTAGCTTAGCCCCATTGCTATTCCCAGCGATCGACCATTCTAGCTTAGCCCATTGCTATTCCCAGCGATCGACCATTCTAGCTTAGC 
 
C57BL/6   -----------------------------------------CATTGCTATTCCCAGTATGCGCAATCTGAGTTTTGCTGACTTCTGGACACTGGTCAATT 
BALB/c    CCCATTGCTATTCCCAGCGATCGACCATTCTAGCTTAGCCCCATTGCTATTCCCAGTATGCGCAATCTGAGTTTTGCTGACTTCTGGACACTGGTCAATT 
 
C57BL/6   ATCTGTGGTCAAAAGGCTGGTTTCTTCTTATTAATGTATTCTTTCGTTGAATACTTATCAGACCTTAAAGGGGAACCCTGGGGAAAACAGACCTCTAATG 
BALB/c    ATCTGTGGTCAAAAGGCTGGTTTCTTCTTATTAACGTATTCTTTCCTTGAATACTTATCAGACCTTAAAGGGGAACCCTGGGGAAAACAGACCTCTAATG 
 
C57BL/6   CCTGCCTGGCGGGTATGAACGGTTCTGCTCCATGCTGTTAATCATAGCT 
BALB/c    CCTGCCTGGCGGGTATGAACGGTTCTGCTCCATGCTGTTAATCATAGCT 
 
O 
Asb4 
chr6:5,331,766-5,333,016 
 
C57BL/6   ---------------------------------CTGTCTCTTGGCTTCAGCCTGGTGGATCCCAGTAGCATACAGCAATAACTCAAGTCCATAGCCATTG 
BALB/c    ---------------------------------CTGTCTCTTGGCT-CAGCCTGGTGGATCCCAGTAGCATACAGCAATAACTCAAGTCCATAGCCATTG 
 
C57BL/6   AGTTATGGTATGTGGAGGCAGGGCTTCCAGCCAAGCCAGAAATGTATCAGATAGCTTTCAGCCAAGGCAATTTATTGTAGCATGTTGGTGTTTGTTCCTA 
BALB/c    AGTTATGGTATGTGGAGGCAGGGCTTCCAGCCAAGCCAGAAATGTATCAGATAGCTTTCAGCCAAGGCAATTTATTGTAGCATGTTGGTGTTTGTTCCTA 
 
C57BL/6   AGTCGCCTTTGCTGGTGACTGATGTACCATCCTTCTAACACTCCTGAAAACCTCATAGTCATGCTGAAGAAAGAAATTCACCCAGGAGAAACGCCAGACG 
BALB/c    AGTCGCCTTTGCTGGTGACTGATGTACCATCCTTCTAACACTCCTGAAAACCTCATAGTCATGCTGAAGAAAGAAATTCACCCAGGAGAAACGCCAGACG 
 
C57BL/6   GATCAGGAGTACAAGCTCCCCGCCCTTTTATGCCCTGGAGCTATCAAAGGCCACCTAGCAACATTATCAGACAGGGAAAGGAGGGCATATCTTTGATTTC 
BALB/c    GATCAGGAGTACAAGCTCCCCGCCCTTTTATGCCCTGGAGCTATCAAAGGCCACCTAGCAAGATTATCAGACAGGGAAAGGAGGGCATATCTTTGATTTC 
 
C57BL/6   TCAGTCTTGCCTGGGGCCTTGACTGACAGTAGCTGCTGTTTTAACCTCCATCTGTGTCTTCGTGCCTTTTTAGAAGGGACTCAGGAAAGCTTGCTCTGGC 
BALB/c    TCAGTCTTGCCTGGGGCCTTGACTGACAGTAGCTGCTGTTTTAACCTCCATCTGTGTCTTCATGCCTTTTTAGAAGGGACTCAGGAAAGCTTGCTCTGGC 
 
C57BL/6   ATTATGGGGAATATCATCAACCTAGGAGGAGAATTCTGAACATGAGATGCAAGCTTGTCTTGCTTTCCCACAGCCCAAAACAGACGTATATGACAGTGAG 
BALB/c    ATTATGGGGAATATCATCAACCTAGGAGGAGAATTCTGAACATGAGATGCAAGCTTGTCTTGCTTTCCCACAGCCCAAAACAGACGTATATGACAGTGAG 
 
C57BL/6   TATGGGAAATAAACATATAGAAGAAAACACGTCTAGTTCGTTTACAGAACGCTTCTTAATACCAGTGACGTAGGAGCAAAGGATCGTGGGTGGGCGGCTA 
BALB/c    TATGGGAAATAAACATATAGAAGAAAACACGTCTAGTTCGTTTACAGAACGCTTCTTAATACCAGTGACGTAGGAGCAAAGGATCGTGGGTGGGCGGCTA 
 
C57BL/6   CTCCTCCCTGACAAGCCTTAATTACTTTTATATTTATTAGACATACATCTTGAAATGATTCTATAGAATCATAGGCAAACCTATGGTAAAATTTCAGCAG 
BALB/c    CTCCTCCCTGACAAGCCTTAATTACTTTTATATTTATTAGACATACATCTTGAAATGATTCTATAGAATCATAGGCAAACCTATGGTAAAATTTCAGCAG 
 
C57BL/6   AGAAATTCATCCTCGAAGCAAAATTTAATCAGCAAGGATAATGGTTTATATGGATTAAAACACATTTTTAAAATCTGCGTTTGATTTCATCTAGACCTCG 
BALB/c    AGAAATTCATCCTCGAAGCAAAATTTAATCAGCAAGGATAATGGTTTATATGGATTAAAACACATTTTTAAAATCTGCGTTTGATTTCATCTAGACCTCG 
 
C57BL/6   TTTT-ATCTGCATTGGCTCATTTCTCCCATTTTTGAGAGATTTTGCAGCTGGTCTTTCAGGTTCATTTTTCAAGGAATACTGCCCTCATGCGGCCGGGTG 
BALB/c    TTTTTATCTGCATTGGCTCATTTCTCCCATTTTTGAGAGATTTTGCAGCTGGTCTTTCAGGTTCATTTTTCAAGGAATACTGCCCTCATGCGGCCGGGTG 
 
C57BL/6   TGCCAAGACCGCTCACTCTCTGATTCCCTCCAGAGGACGGTCTGTGTGGCTCTGTGAGAGAGAGCTTTTGCTGCTTGAGGCTGTGTCTGTGGGTTCCTTT 
BALB/c    TGCCAAGACCGCTCACTCTCTGATTCCCTCCAGAGGACGGTCTGTGTGGCTCTGTGAGAG----CTTTTGCTGCTTGAGGTTGTGTCTGTGGGTTCCTTT 
 
C57BL/6   CGAAAACATGAATCCTTAAAATGCTTGCCAGGGGATGCACTCTGGTGCAGCTTTTGACTCAATTATCTGCTTACTGCATCAATAACCAACACATGCAAAA 
BALB/c    CGAAAACATGAATCCTTAAAATGCTTGCCAGGGGATGCACTCTGGTGCAGCTTTTGACTCAATTATCTGCTTACTGCATCAATAACCAACACATGCAAAA 
 
C57BL/6   ATAATCAGTCGCTGATCATTTTACACACTCGGAAAGTCCTCACAAACCCGACTCCTTTAAAGTCAGTAGAACGCGTTAGCCTTG 
BALB/c    ATAATCAGTCGCTGATCATTTTACACACTCGGAAAGTCCTCACAAACCCGACTCCTTTAAAGTCAGTAGAACGCGTTAGCCTTG 
Appendix IV 
 
193 
P 
Asb4  
chr6:5,333,153-5,335,375 
 
C57BL/6   --------------------AGTGGAACAAACAACGGAGGTGGGCTCTGTACTTTCTTAAAAAGACAAGGTTTGACAAGATACTGTTTCTCAGCTCCAAT 
BALB/c    --------------------AGTGGAACAAACAACGGAGGTGGGCTCTGTACTTTCTTAAAAAGACAAGGTTTGACAAGATACTGTTTCTCAGCTCCAAT 
 
C57BL/6   TCAGCCGTTCTATAGCAAGAATATCTGTAAGCAGACAGAAAATATGCAACCCTTCTCTCCACTCTTCCCGGGTCCTGCAGCTTCATTTGCATGATACACT 
BALB/c    TCAGCCGTTCTATAGCAAGAATATCTGTAAGCAGACAGAAAATATGCAACCCTTCTCTCCACTCTTCCCGGGTCCTGCAGCTTCATTTGCATGATACACT 
 
C57BL/6   CCAAACAAATTCTCTGCAAGAATGTCGATTTTACATTATATCCAGGGAAATGCGCAAAGTGCTACCCCAAAAGGTAAAATCAAATCGATGAATCTTTGCA 
BALB/c    CCAAACAAATTCTCTGCAAGAATGTCGATTTTACATTATATCCAGGGAAATGCGCAAAGTGCTACCCCAAAAGGTAAAATCAAATCGATGAATCTTTGCA 
 
C57BL/6   ACTGGTAAACTGCTTCTTGGTTTCTGTGAACTCTGAGGGCTAAAGGGCATCCTGGGATCTTAGGAAAGAAGGCTTAGAAGCCTGCCATATTTCTTTCCCA 
BALB/c    ACTGGTAAACTGCTTCTTGGTTTCTGTGAACTCTGAGGGCTAAAGGGCATCCTGGGATCTTAGGAAAGAAGGCTTAGAAGCCTGCCATATTTCTTTCCCA 
 
C57BL/6   CATGAAGGGCAATTTTCTTCCCTAGCTATACTTTGCCTTCAAAAATTTGTCAGAGGTAAAGAAAGAATGCAAACGCTGCCTGGAGTACAATTGCGGGGTC 
BALB/c    CATGAAGGGCAATTTTCTTCCCTAGCTATACTTTGCCTTCAAAAATTTGTCAGAGGTAAAGAAAGAATGCAAACGCTGCCTGGAGTACAATTGCGGGGTC 
 
C57BL/6   AGTGTTCTGATTGAGACAGAATTATGGCGAATTATTCCCATGAGTTGATTTTGTGAAGTGTGTGCTGGTG-TGAGGGTGGAAATACAAGCCGGCGCTAGT 
BALB/c    AGTGTTCTGATTGAGACAGAATTATGGCGAATTATTCCCATGAGTTGATTTTGTGAAGTGTGTGCTGGTG-TGAGGGTGGAAATACAAGCCGGCGCTAGT 
 
C57BL/6   GTTTAAACAAGGCTGCAAGGGCAGTTGCTAGGAGACCCTGCACACAGCTGATGCCCCCACTGCGGGCTCAGACGTGCTTTGTCTGAAGAACCCGGCCTTT 
BALB/c    GTTTAAACAAGGCTGCAAGGGCAGTTGCTAGGAGACCCTGCACACAGCTGATGCCCCCACTGCGGGCTCAGACGTGCTTTGTCTGAAGAACCCGGCCTTT 
 
C57BL/6   CGCAGTCAAAGATGACATTAAATGTATAGTCTGTCAAAATTTAGGTGGAGGAAAAATTCAGGTGGACCAGGGCTCGGTTATTGCTTGTGTCAATCTAGCT 
BALB/c    CGCAGTCAAAGATGACATTAAATGTATAGTCTGTCAAAATTTAGGTGGAGGAAAAATTCAGGTGGACCAGGGCTCGGTTATTGCTTGTGTCAATCTAGCT 
 
C57BL/6   ATTCTGACGTCCATCACCCATTAAGGATGGGTTTTGAAAGGGAAAATATAGCATTGTGCCAGGAACCAAGAGCCTCCGGAAACGCTCAAGGGAATTTAGT 
BALB/c    ATTCTGACGTCCATCACCCATTAAGGATGGGTTTTGAAAGGGAAAATATAGCATTGTGCCAGGAACCAAGAGCCTCCGGAAACGCTCAAGGGAATTTAGT 
 
C57BL/6   TACAAATGCAGTTTGAATACCCCGATATGAAAGGCAGATGGTCTGGGTACCAGTTCCGGGAAGCAGGCGGCCCCAGCTAAGTAATCACTTCAATGTTCCA 
BALB/c    TACAAATGCAGTTTGAATACCCCGATATGAAAGGCAGATGGTCTGGGTACCAGTTCCGGGAAGCAGGCGGCCCCAGCTAAGTGATCACTTCAATGTTCCA 
 
C57BL/6   AATAGAGGACCTTGAGTCCACAAACAGAGACTTCTAAGAGGAAAGGCGCGCGAGTGTGATTTTAGATCCCGCCGTTTACAAACAACCATTTCAGTCATTT 
BALB/c    AATAGAAGACCTTGAGTCCACAAACAGAGACTTCTAAGAGGAAAGGCGCGCGAGTGTGATTTTAGATCCCGCCGTTTACAAACAACCATTTCAGTCATTT 
 
C57BL/6   GTGGGAACCGTTTAATAGACTTTTATGAGAAACACATAGGCTTCCAGTTTGTAATTTAGACCTTAGAGATGCATCGAACTCGAGAGCTGAAAGTGGCTTA 
BALB/c    GTGGGAACCGTTTAATAGACTTTTATGAGAAACACATAGGCTTCCAGTTTGTAATTTAGACCTTAGAGATGCATCGAACTCGAGAGCTGAAAGTGGCTTA 
 
C57BL/6   GAAGTTCCTCAAGCGCCCCCAACTGGTGGAAGGAGAAAACTGACCCGCTTTGTGGATAAGTGCAGTCTAAAAAAAACGTTGCTTTCTTGGTTTTCAGAAA 
BALB/c    GAAGTTCCTCAAGCGCCCCCAACTGGTGGAAGGAGAAAACTGACCCGCTTTGTGGATAAGTGCAGTCTAAAAAAAACGTTGCTTTCTTGGTTTTCAGAAA 
 
C57BL/6   CTCAGGCAAGACTACTTGCCTTTGTAAAATAGTATCACCCACCCTCTGCCAATGCTCAAGATATGATACCCGGTGAGGAGTAAAGTAGAGGAAAGAGGAA 
BALB/c    CTCAGGCAAGACTACTTGCCTTTGTAAAATAGTATCACCCACCCTCTGCCAATGCTCAAGATATGATACCCGGTGAGGAGTAAAGTAGAGGAAAGAGGAA 
 
C57BL/6   CATTTTGAATTTTGTGTTTTGAATATCAGTAGCACGGGAGCCAGAGACACAGTCAGTTAAGATTGCCTGTCTTCTCCAGGAGAGTCATGTTGTTCTGTGA 
BALB/c    CATTTTGAATTTTGTGTTTTGAATATCAGTAGCACGGGAGCCAGAGACACAGTCAGTTAAGATTGCCTGTCTTCTCCAGGAGAGTCATGTTGTTCTGTGA 
 
C57BL/6   GCATCGAGACCAGAATCATCCACAACTCTTTGTAGTGCTTTTCCGTGTACAAGCACATTCTGTGTATTAATTTTTTTCATTTGTTTCATAAAGTCTGACA 
BALB/c    GCATCGAGACCAGAATCATCCACAACTCTTTGTAGTGCTTTTCCGTGTACAAGCACATTCTGTGTATTAATTTTTTTCATTTGTTTCATAAAGTCTGACA 
 
C57BL/6   ATTGCTCTTACACGCTGGTGGTGAAACTAATAAGGATTTGATACAAGGTTTAGTTGTAACTCCACTACCCTACCTCCAAATAAGGAATAACTTCCTTGGC 
BALB/c    ATTGCTCTTACACGCTGGTGGTGAAACTAATAAGGATTTGATACAAGGTTTAGTTGTAACTCCACTACCCTACCTCCAAATAAGGAATAACTTCCTTGGC 
 
C57BL/6   CAGTGATCTCACAGAATAGCTAATTGAAATCTCAAAGTGGTTTGAATTTTTAATTTTGTTTGTTTTGTATTTATACTTCATAGCCAGGAAAAACAAAAAC 
BALB/c    CAGTGATCTCACAGAATAGCTAATTGAAATCTCAAAGTGGTTTGAATTTTTAATTTTGTTTGTTTTGTATTTATACTTCATAGCCAGGAAAAACAAAAAC 
 
C57BL/6   AAAACAAAAAAACCTCTGTACTTTTTTTGCTTTTTTATGAAAAAAAAAAAAAAAGAAACCCCATCAGCACTTCCCATGTTGGAGAAATTAGTATTACTAA 
BALB/c    AAAACAAAAAAACCTCTGTACTTTTTTTGCTTTTTTATGAAAAAAAAAAAAAA-GAAACCCCATCAGCACTTCCCATGTTGGAGAAATTAGTATTACTAA 
 
C57BL/6   CCCTGGTACATAGTAACTTTCGGAATGTTGTTCCAGGCAGCCTTGAGAGAACTGAGCTGGTTGGGTTCAAGAAACAGAAGGAAATAAAAATTACCCATCA 
BALB/c    CCCTGGTACATAGTAACTTTCGGAATGTTGTTCCAGGCAGCCTTGAGAGAACTGAGCTGGTTGGGTTCAAGAAACAGAAGGAAATAAAAATTACCCATCA 
 
C57BL/6   GTCCCACTCTTAAACTTTACTGCAAAGAGATGTCTTTAGAGAGATGGAACCCAGGGGCTGATATGGCTTCTTTGCATCCTCTTGGCAGAGCTTAGGGGCC 
BALB/c    GTCCCACTCTTAAACTTTACTGCAAAGAGATGTCTTTAGAGAGATGGAACCCAGGGGCTGACATGGCTTCTTTGCATCCTCTTGGCAGAGCTTAGGGGCC 
 
C57BL/6   CAGGACTTGTTGCTTTAGCCCACAAAGCTCTGTCCTTACAGAGAAAACCAGTCTCGATGTTCCCTCCCCTCCCCTTTTCCTTCGTTCTAGGAGATGCCAA 
BALB/c    CAGGACTTGTTGCTTTAGCCCACAAAGCTCTGTCCTTACAGAGAAAACCAGTCTCGATGTTCCCTCCCCTCCCCTTTTCCTTCGTTCTAGGAGATGCCAA 
 
C57BL/6   CCACCATGCGGGGAGGGTATTCAGACAGGCTCCTGGAGAGACTG 
BALB/c    CCACCATGCGGGGAGGGTATTCAGACAGGCTCCTGGAGAGACTG 
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194 
Q 
Cd48  
chr1:173,509,829-173,510,806 
 
C57BL/6   --------------------------------------------------GACATGAGCATTAAGGCCTCCCTCTGCACTGGTCCTCATAAGCCCTGCTT 
BALB/c    --------------------------------------------------GACATGAGCATTAAGGCCTCCCTCTGCACTGGTCCTCATAAGCCCTGCTT 
 
C57BL/6   GCCTGCAGGTGCTGCTGGCTTGCAGGTCAGCTGGATCTCAGCTGCTCTGAGCCTTCTGTCACCTTCTGCTCATTGGTTTGCTAGGTTGCTAGGAAACCGT 
BALB/c    GCCTGCAGGTGCTGCTGGCTTGCAGGTCAGCTGGATCTCAGCTGCTCTGAGCCTTCTGTCACCTTCTGCTCATTGGTTTGCTAGGTTGCTAGGAAACCGT 
 
C57BL/6   GTCCCAGGCTTCCATGCTGGGCTTGGCCTAAAGCCTAGTCTGCCTAAGTTTAGATTTCTAGCCCTACATTTGGTGAGCCGAATACTGTTAGACCACCTCA 
BALB/c    GTCCCAGGCTTCCGTGCTGGGCTTGGCCTAAAGCCTAGTCTGCCTAAGTTTAGATTTCTAGCCCTACATTTGGTGAGCTGAATACTGTTAGACCGCCTCA 
 
C57BL/6   ACTCGCCAGCTCCCAATAATGACTTTTTACTAGTTATAAAAGCTGAGGCCTTTTATCTGTTTTTT----------------------------------- 
BALB/c    ACTCGCCAGCTCCCAATAATGACTTTTTACTAGTTATAAAAGCTGAGGCCTTTTATCTGTTTTTTTTTTCTCTTTGTCTTGTCTTGTTTTCCTGTATAAA 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    AAAGATCCCAGTATAAATCAGGGAGGGAAGAAGACAGATACACCTGCCCTTTAGTGTAGAGCTAGGGGAGGGTAATGGGGGTGAACCTCGTAAGGAGAGG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    TGGGGACTTGTTATTTAAGGCTTAAAATATTCTCTGTAAAAAACGAGGATTCTCCACAGCCTTGGGGGAGACAGAGGCTGCCGCTTCAGTGAGGGTTTCT 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    CCACCAAGACTGGGAAAGGCAGCCCCTCTTCTCACTCTGCGTCGCTTTCCTCCTTGTGCAGGTAGGAGTGCTGCAGGGCTCGGAAGGCAGAGATTCGCTT 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    ATGTGGGTTAAAGGTCAGCATTTCCAGTAGCAGCTGCGCTCCAGACTCCTCCATCTCTGGCACCACTGACTGCACTGGCCGAGGCCCTCTGGGGGCAAAG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    GCTCCTCGAGGTAGAGATACCTCTCGAGGCCAGTCGTCTTCTGGAGGCAATCCAATGAGATCAAAGATTTTCCCCAACTGGTGGGCTTCAGAGTTTCCAC 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    AGAAGAGAGGCTTCCGACGGAACATCTCTGCAAAGATACAGCCAACGCTCCACATGTCCACGGGTGTTGCGTATGTAGACTGCAGAAGAACTTCAGGAGC 
 
C57BL/6   -----------------------------------------   -------------------------------------------------------- 
BALB/c    TCGGTACCAAAGCGTACCACCACAGGCGTGAGGCCATCTGG //GGAGTACACGACTCCTCACCGTCACATTGGAGTCAAAGGCTCCAGCTCCTAACAAG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    CCACTCACGAACTGTGCT-GATGGAAGGCCCCTCCAGCTGCTCCTCCATTAGGACTCTCACACTTCTTGAGGCCACAAAGTGGCCACTGTGGGGATCTCG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    GGTTTGTACACCGTCCCATAGGCACCGACACCAATTTCAGCCACGGGTTCATATCGAGTGGCAGCCATTCTCGAAGCAGGGGATCTTACGCTCGGCTAAG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    AGCTCTGGAGGTGGCCCTTTATCTGGGCCCGGGAGCCGGTTCCTGCGGCGCCATACACCGGGGATCGGTCCCGGGCAGCTGGACGCTTCGGGCCAGACCA 
 
C57BL/6   -------------------------ATGCAATGCAAATATTTACTCTTAATTCACATTGTCAAAATTTTTCAAGAAACAATCACAAAGGTTTATTTTAAA 
BALB/c    --TAGACACAGTTATCTGTTTTTTTATGCAATGCAAATATTTACTCTTAATTCACATTGTCAAAAATTTTCAAGAAACAATCACAAAGGTTTATTTTAAA 
 
C57BL/6   TGTGCTTTGTATCTTTGGCTTGTTCTCGACTAGCTTGTATAACTTAGTAACTCCACAGGTAGTCACTATGTCTGACTTTCTCCATGTCTGGCTGGAGCAT 
BALB/c    TGTGCTTTGTATCTTTGGCTTGTTCTCGACTAGCTTGTATAACTTAGTAACTCCACAGGTAGTCACTATGTCTGACTTTCTCCATGTCTGGCTGGAGCAT 
 
C57BL/6   TTCCCAGGCCTGATTCTTTCCCAGAGTTCCTATCTATACTCTGAAGTTTCACTTTTCTTCTCCTGTCCTGTTATAGACCATCAGATCTTTATTAAACCAA 
BALB/c    TTCCCAGGCCTGATTCTTTCCCAGAGTTCCTATCTATATTCTGAAGTTCCGCTTTTCTTCTCCTGTCCTGTTATAGACCATCAGATCTTTATTAAACCAA 
 
C57BL/6   TCAGAAGATGATGGAGAAAATGTTTACGAAATCTTTAGGCAGGTGTGATGATCCAATAAAAATAACAATACCAAGGTCAGGCCTGTAAACAGCTCTGCGG 
BALB/c    TCAGAAGATGATGGAGAAAATGTTTACGAAATCTTTAGGCAGGTGTGATGATCCAATAAAAGTAACAATACCAAGGTCAGGCCTGTAAACAGCTCTGCGG 
 
C57BL/6   GTAGGTAAACCAATATTTGAATAATACAAGGGTAACCTTTACACAGTGCACAAAAAGATTAACCCAACTGAGGAGGAGAGAGGAGGAAGGGAAGAAGGGT 
BALB/c    GTAGATAAACCAATATTTGAATAATACAAGGGTAACCTTTACACAGTGCACAAAAAGATTAACCCAACTGAGGAGGAGAGAGGAGGAAGGGAAGAAGGGT 
 
C57BL/6   AGAGACAAGAGCAGAGTGGGACAAAGGTGGCCTGCTAAATTGACTTTGGTATTAAAGGAGGAATCTGTGTAAATGAAAGAGCTGGATGAAAATCCAGTAC 
BALB/c    AGAGACAAGAGCGGAGTGGGACAAAGGTGGCCTGCTAAATTGACTTTGGTATTAAAGGAGGAATCTGTGTAAATGAAAGAGCTGGATGAGAATCCAGTAC 
 
C57BL/6   ATGAACACTGTCTGGTCTGTTTGCTTGGTTTAGTTTTGAGCCTCTCAGCATCCCTTCCTAGGTGTT-AGAAGTCCATCTCATCCCTGG 
BALB/c    ATGAACGCTGTCTGGTCTGTTTGCTTGGTTTAGTTTTGAGCCTCTCAGCATCTCTTCCTAGGTGTT-AGAAGTCCATCTCATCCCTGG 
Appendix IV 
 
195 
R 
Coro2a  
chr4:46,621,090-46,622,106 
 
C57BL/6   ---------------------------------------------GTTCGGTCGATTCGGTTTTGGGGATGGAACTCTGCCGACTGAGCTGCACCCTAGC 
BALB/c    ---------------------------------------------GTTCGGTCGATTCGGTTTTGGGGATGGAACTCTGCCGACTGAGCTGCACCCTAGC 
 
C57BL/6   TGCTAAGCACCCCATTCTTGGAATTAGGATTCCTGGCTGGTTTGTTGTGTGGCCTTTACCAGGCACACCCCCTCCTGGGACAGGTGATTATATGCCCATA 
BALB/c    TGCTAAGCACCCCATTCTTGGAATTAGGATTCCTGGCTGGTTTGTTGTGTGGCCTTTACCAGGCACACCCCCTCCTGGGACAGGTGATTATATGCCCATA 
 
C57BL/6   GAATACGAGCGTTGGATGAGATAGACGGTTTCTAGACTGCCCCTAGAATAAGGGCCTGGGATGAGATGGTTTCTAGAGACCCTTTCAGGTCAGAGAATCC 
BALB/c    GAATACGAGCGTTGGATGAGATAGACGGTTTCTAGACTGCCCCTAGAATAAGGGCCTGGGATGAGATGGTTTCTAGAGACCCTTTCAGGTCAGAGAATCC 
 
C57BL/6   ACAACTCCACAGTACATTTTTAAAGTTCGGGATGACTTTGTAATAATCAGGACCTGCCTGCTCATGCGCCATCACTGTAGCCTCCCAGATCACAAACGTT 
BALB/c    ACAACTCCACAGTACATTTTTAAAGTTCGGGATGACTTTGTAATAATCAGGACCTGCCTGCTCATGCGCCATCACTGTAGCCTCCCAGATCACAAACGTT 
 
C57BL/6   CCCAATGACAGGGGACTCAGGTGGTACTTAGGCTTTCGAGCTGGCGCTGGGCTCTGGCAGCCACACTTATACTTAGTCTCCCTTTATGAGGGGATAATAA 
BALB/c    CCCAATGACAGGGGACTCAGGTGGTACTTAGGCTTTCTAGCTGGCGCTGGGCTCTGGCAGCCACACTTATACTTAGTCTCCCTTTATGAGGGGATAATAA 
 
C57BL/6   CACTCATTTGCAGCGAAGCTCCAGGTTGGGGCCACAGGGCAAGGTCCCCTGCCACACTGCTTTGGCCCTGGCAACGCACAGCACCCTATGATGCCCACCC 
BALB/c    CACTCATTTGCAGCGAAGCTCCAGGTTGGGGCCACAGGGCAAGGTCCCCTGCCACAGTGCTTTGGCCCTGGCAACGCACAGCACCCTATGATGCCCACCC 
 
C57BL/6   AGCCCTCTGCCTGTACACTTAGATGACGTAGGGCTCACTACCGGCGCTGGCCTGGGGAAAGGGAAGGGTCTCCTCTTTTAGCCTTAAGAAAGTCCTTGGG 
BALB/c    AGCCCTCTGCCTGTACACTTAGATGACGTAGGGCTCACTACCGGCGCTGGCCTGGAGAAAGGGAAGGGTCTCCTCTTTTAGCCTTAAGAAAGTCCTTGGG 
 
C57BL/6   TGAGGGAGAGGGAGACAGGCGATCAGGAGGTGCTGAGCCTGTTCCTTAGTGGGGACAGATGTCAGGAAATGAGGCAGAAGTGTCCAGAGATGGGCTTAAG 
BALB/c    TGAGGGAGAGGGAGACAGGCGATCAGGAGGTGCTGAGCCTGTTCCTTAGTGGGGACAGATGTCAGGAAATGAGGCAGAAGTGTCCAGAGATGGGCTTAAG 
 
C57BL/6   CCTTTCTCTCCCTCCACATCCCTCAAGAGATGTCTGGAGGCGAGGGACGTGTAAGGACACATTCCTGTGCTGAGGCACAGGTGGTTATGAACAAGTCCCT 
BALB/c    CCTTTCTCTCCCTCCACATCCCTCAAGAGATGTCTGGAGGCGAGGGACGTGTAAGGACACATTCCTGTGCTGAGGCACAGGTGGTTATGAACAAGTCCCT 
 
C57BL/6   GGAGCATTCGCAGAAGAGCAGGCTCTGAGACAGAAGGGCCACATGCTAGCTAAGGGACACTATCAGGATTGCAGCCACAGTGGGACCAGATTCCCCAGTT 
BALB/c    GGAGCATTCGCAGAAGAGCAGGCTCTGAGACAGAAGGGCCACATGCTAGCTAAGGGACACTATCAGGATTGCAGCCACAGTGGGACCAGATTCCCCAGTT 
 
C57BL/6   TCGCTAGTGAGAGTCCCCATCTCGAGAAGAATGCAACATAAGACCT-CATCAAAAGGCATCT 
BALB/c    TCGCTAGTGAGAGTCCCCATCTCGAGAAGAATGCAACATAAGACCT-CATCAAAAGGCATCT 
 
S 
Eps8l1  
chr7:4,081,175-4,081,945 
 
C57BL/6   --------------------GCCCCAGCACCTAGAGTGCGCACTCCCTCCCTTCCCGGTTTCCCTCCTGCAGAGAAATTCTCCCAGATGCTTTGTGTCAA 
BALB/c    --------------------GCCCCAGCACCTAGAGTGCGCACTCCCTCCCTTCCCGGTTTCCCTCCTGCAGAGAAATTCTCCCAGATGCTTTGTGTCAA 
 
C57BL/6   TGAGGAGCTGCAGTCGCGCCTGGCGCAGGGCCGTTCGGGTCCCAGCCGGGTAACCCCGGGGCCCCGAGCCCAAGAGCCCCAGCTCAGCCCGCGCTCTGAG 
BALB/c    TGAGGAGCTGCAGTCGCGCCTGGCGCAGGGCCGTTCGGGTCCCAGCCGGGTAACCCCGGGGCCCCGAGCCCAAGAGCCCCAGCTCAGCCCGCGCTCTGAG 
 
C57BL/6   GCCTCGGTGGTCCGTGCCTGGCTGCAGACCAAGGGCTTTAGCTCCGGGTGAGTGGGGTCCCGCTGCTACTTTGCAGAGACAGATAACAGACCTGGAAGTC 
BALB/c    GCCTCGGTGGTCCGTGCCTGGCTGCAGACCAAGGGCTTTAGCTCCGGGTGAGTGGGGTCCCGCTGCTACTTTGCAGAGACAGATAACAGACCTGGAAGTC 
 
C57BL/6   AAGGTTTTAGTTGGTCTGGGGGTGGGAGCGGGGAAAACTGTAGGGCAATTTGCTACGCCCAAAGACAGGCTCTGATTGGAGACCACAGGGAAGAGCATTC 
BALB/c    AAGGTTTTAGTTGGTCTGGGGGTGGGAGCGGGGAAAACTGTAGGGCAATTTGCTACGCCCAAAGACAGGCTCTGATTGGAGACCACAGGGAAGAGCATTC 
 
C57BL/6   CTTTTCTGAAATCTGACACCTCCGGAGCCTGAGCCTCTCCGTCCCAACTTCCTTGCTTGAGAGCTCTGATTGGACAAGCAGCTAGGTGGGTGCGATGTGA 
BALB/c    CTTTTCTGAAATCTGACACCTCCGGAGCCTGAGCCTCTCCGTCCCAACTTCCTTGCTTGAGAGCTCTGATTGGACAAGCAGCTAGGTGGGTGCGATGTGA 
 
C57BL/6   TTGGTGAAGCTGAAGGGGCTTGAGCTGTGATGGCCCCTGCTGCCTTCTTAGGACTGTGGAGGCGCTCGGTGTGCTGACCGGCGCACAGCTCTTCTCGCTG 
BALB/c    TTGGTGAAGCTGAAGGGGCTTGAGCTGTGATGGCCCCTGCTGCCTTCTTAGGACTGTGGAGGCGCTCGGTGTGCTGACCGGCGCACAGCTCTTCTCGCTG 
 
C57BL/6   CAAAAGGAAGAGTTGCGGGCGGTGTGCCCCGAGGAAGGGGCGCGAGTGTACAGCCAAGTCACTGTGCAGCGCGCGCTGCTGGAGGTGAGAGAATCGCCCA 
BALB/c    CAAAAGGAAGAGTTGCGGGCGGTGTGCCCCGAGGAAGGGGCGCGAGTGTACAGCCAAGTCACTGTGCAGCGCGCGCTGCTGGAGGTGAGAGAATCGCCCA 
 
C57BL/6   GGCCCTGACGAGGCGAGGGGTGGGGCGCCCAGGACTCACATACTAAGGTCTTGATTTCTACCCCACCCTCAAGGACAGAGAAAAAGTATCA 
BALB/c    GGCCCTGACGAGGCGAGGGGTGGGGCGCCCAGGACTCACATACTAAGGTCTTGATTTCTACCCCACCCTCAAGGACAGAGAAAAAGTATCA 
Appendix IV 
 
196 
T 
Frap1  
chr4:147,344,467-147,345,448 
 
C57BL/6   --------------------------------------------AGGAGCTGTGAACTTGTTTCCAGTTGCGCCTATTAGATTATGGCCTGCCAGCCACT 
BALB/c    --------------------------------------------AGGAGCTGTGAACTTGTTCCCAGTTGCGCCTATTAGATTATGGCCTGCCAGCCACT 
 
C57BL/6   GGCTCAGCTCTATCAGCAGACAGGCAGAGTGGAAGACTTTCCCAACTCCTGTCTGAAGGTTATATAACACAGATTGAGGGTGAGGTAGCAAGAAAGAGTT 
BALB/c    GGCTCAGCTCTATCAGCAGACAGGCAGAGTGGAAGACTTTCCCAACTCCTGTCTGAAGGTTATATAACACAGACTGAGGGTGAGGTAGCAAGAAAGAGTT 
 
C57BL/6   GGACTGGAGACTGCTGAGCCAGGGAGGCTGGCTAAGGTAATGCATGCTGTTTACTCCAGGTCCTGGTTTATCTGGGCTGAGATGAGTCTTAACAGGGCTT 
BALB/c    GGACTGGAGACTGCTGAGCCAGGGAGGCTGGCTAAGGTAATGCATGCTGTTTACTCCAGGTCCTGGTTTATCTGGGCTGAGATGAGTCTTAACAGGGCTT 
 
C57BL/6   TGTCTGGCCATCATTCGGTGTTCTTCAAAATCCTGTTGAACCTGATCCTTGGGCGTCAGGTGGTTTGCATCTGTGGGGCTGTCTTCCTCTTTACACATTC 
BALB/c    TGTCTGGCCATCATTCGGTGTTCTTCAAAATCCTGTTGAACCTGATCCTTGGGCGTCAGGTGGTTTACATCTGTGGGGCTGTCTTCCTCTTTACACATTC 
 
C57BL/6   TCCTTCTAAAACGATCTTTCAACATTTACAAGGAGTTGTCATAGTTTGGGGCAGAGAGAAAGTCTCAGCCATGCCAGGCGTGGTCTGGGGTTGGTCATCC 
BALB/c    TCCTTCTAAAACGATCTTTCAACATTTACAAGGAGTTGTCATAGTTTGGGGCAGAGAGGAAGTCTCAGCCATGCCAGGCGTGGTCTGGGGTTGGTCATCC 
 
C57BL/6   ACACTTCTGTCAGGTTCTGTCTGGGCAGCAGTGAGTGGGCCTGACCTTTACCCAAGGCTCAGACTCAGAGAGAAGATTCCCTAGTACATGCAGATCAGAA 
BALB/c    ACACTTCTGTCAGGTTCTGTCTGGGCAGCAGTGAGTGGGCCTGACCTTTACCCAAGGCTCAGACTCAGAGAGAAGACTCCCTAGTACATGCAGATCAGAA 
 
C57BL/6   GGCTCGATTCCCTCTGTGCCTGCAGCGTGGTTTGCAGCTTGATGCTGGCCCCTATACCTACGTACACAGTGTCTGAGAAAACGGGGTGATGGCAGCTTTC 
BALB/c    GGCTCGATTCCCTCTGTGCCTGCAGCGTGGTTTGCAGCTTGATGCTGGCCCCTATAGCTACGTACACAGTGTCTGAGAAAACGGGGTGATGGCAGCTTTC 
 
C57BL/6   ATACCTTTAATTGAAGGGCACTGCTCTTCTGAAATCATGTAAAAGATGGAACTTTCCCTATAACTGTACAAAGGTCCCTCTGTCCTTATGGCAGGAGCTC 
BALB/c    ATACCTTTAAGTGAAGGGCACTGCTCTTCTGAAATCATGGAAAAGATGGAACTTTCCCTATAACTGTACAAAGGTCCCTCTGTCCTTATGGCAGGAGCTC 
 
C57BL/6   TGTCTGACTTTATAGTGTGGGTCCTACAGCTTTGCCTACCCTGATCCCTCAGAGTCTTTCCCAGATGGGTTTCTGGCTCCTCGGAAAGTGATTTCTGCTC 
BALB/c    TGTCTGACTTTATAGTGTGGGTCCTACAGCTTTGCCTACCCTGATCCCTCAGAGTCTTTCCCAGATGGGTTTCTGGCTCCTCGGAAAGTGATTTCTGCTC 
 
C57BL/6   AGACAGCTGGAGTTACTTAGCAGGGACCCATTTCTGAATATAAGCATTGGGTGCTCAGACAGACGACTGTCTGTTTCCTCTCACTCCTGTCTTTTTTGCC 
BALB/c    AGACAGCTGGAGTTACTTAGCAGGGACCCATTTCTGAATATAAGCATTGGGTGCTCAGACAGACGACTGTCTGTTTCCTCTCACTCCTGTCTTTTTTGCC 
 
C57BL/6   TCCTTGGGCACCAGGTTGTTACTAAC 
BALB/c    TCCTTGGGCACCAGGTTGTTACTAAC 
 
U 
Pdgfrb  
chr18:61,190,675-61,191,616 
 
C57BL/6   -----------------------------------------ACCTAGACTTCCCACCGAGCCTAGTTCATTCTCAACCCCTCAGTGCAGACCTTGACAGC 
BALB/c    -----------------------------------------ACCTAGACTTCCCACCGAGCCTAGTTCATTCTCAACCCCTCAGTGCAGACCTTGACAGC 
 
C57BL/6   CCCGTTGCCAGAGTCAACCTCTGCATTAGTTTGAAGTTCCCTTGCACCCTGTATATAATATAGACCCAGAATAGAAAACTTCAACTCCACTCCCAACCTC 
BALB/c    CCCGTTGCCAGAGTCAACCTCTGCATTAGTTTGAAGTTCCCTTGCACCCTGTATATAATATAGACCCAGAATAGAAAACTTCAACTCCACTCCCAACCTC 
 
C57BL/6   AGCTCTGACCCTAACACTATCAGTTAGGGTCAAATTCCATCCCTGTTTCCGTTCCAGTCAAAGCTTGCACTTCAGCTCTGTTGCCTAAAGAAACCGTGCC 
BALB/c    AGCTCTGACCCTAACACTATCAGTTAGGGTCAAATTCCATCCCTGTTTCCGTTCCAGTCAAAGCTTGCACTTCAGCTCTGTTGCCTAAAGAAACCGTGCC 
 
C57BL/6   CTAGTTTTTAGAAGCCCCCAGAAGGTGTTTATCTTGCATTTAGTCCGCGCTGGCCTCCAGGAACCCTCCACTAGAGATGGGCAGGATG--------CATT 
BALB/c    CTAGTTTTTAGAAGCCCCCAGAAGGTGTTTATCTTGCATTTAGTCCGCGCTGGCCTCCAGGAACCCTCCACTAGAGATGGGCAGGATGCACATTCTCATT 
 
C57BL/6   GGTGTCTGGGCATAACTCCGCCCACAGGGCCCGCCCCTAACTGTTGTACCTTCCGCAGAGAATGGCTACGTGCGGCTGCTGGAGACACTGGGAGATGTAG 
BALB/c    GGTGTCTGGGCATAACTCCGCCCACAGGGCCCGCCCCTAACTGTTGTACCTTCCGCAGAGAATGGCTACGTGCGGCTGCTGGAGACACTGGGAGATGTAG 
 
C57BL/6   AAATTGCTGAGCTGCACCGGAGTCGGACGCTGCGGGTGGTGTTCGAGGCTTATCCGATGCCTTCTGTCCTGTGGCTCAAGGACAACCGTACCTTGGGTGA 
BALB/c    AAATTGCTGAGCTGCACCGGAGTCGGACGCTGCGGGTGGTGTTCGAGGCTTATCCGATGCCTTCTGTCCTGTGGCTCAAGGACAACCGTACCTTGGGTGA 
 
C57BL/6   CTCCGGCGCTGGCGAGTTAGTTTTGTCTACTCGCAACATGTCTGAGACCCGGTGAGCACCAGTTAGTCCACTTATGTTGGAAGCTTCAAAGCTGCCAGGC 
BALB/c    CTCCGGCGCTGGCGAGTTAGTTTTGTCTACTCGCAACATGTCTGAGACCCGGTGAGCACCAGTTAGTCCACTTATGTTGGAAGCTTCAAAGCTGCCAGGC 
 
C57BL/6   AGCCTGGGGCCTTCAGTCACCAACAAACCTAGGACCTTCTTGTCTGAGAGCCTGTTGTGTGATGGACACATGCCAGGTACTAGGTATGATGCTCCTGCAG 
BALB/c    AGCCTGGGGCCTTCAGTCACCAACAAACCTAGGACCTTCTTGTCTGAGAGCCTGTTGTGTGATGGACACATGCCAGGTACTAGGTATGATGCTCCTGCAG 
 
C57BL/6   GAGCAACGCAGGCTGCTCTGCTCCTCCTAGTGGGGGTAGCAGACACTGACGACTTGGCCACTCAGAGGTTTAGTTAACCTTGTGATGAACAGAACCAGCA 
BALB/c    GAGCAACGCAGGCTGCTCTGCTCCTCCTAGTGGGGGTAGCAGACACTGACGACTTGGCCACTCAGAGGTTTAGTTAACCTTGTGATGAACAGAACCAGCA 
 
C57BL/6   GGTAATGGCCAAAAGCAAAAA-CACCGGATAGGAAGAGGATTTCCCCAAGGCTAGAGATCTGCAGACAGGCAAGAATGTGCCCCTCTGATGG 
BALB/c    GGTAATGGCCAAAAGCAAAAAACACCGGATAGGAAGAGGATTTCCCCAAGGCTAGAGATCTGCAGACAGGCAAGAATGTGCCCCTCTGATGG 
 
Appendix IV 
 
197 
V 
Isoc2b  
chr7:4,468,816-4,470,431 
 
C57BL/6   -------------------------------------------------------------------------ATGCTTTAGGGAGAGCGATACAGAGGA 
BALB/c    -------------------------------------------------------------------------ATGCTTTAGGGAGAGCGATACAGAGGA 
 
C57BL/6   GCACGTAATTGTGAGAGAAGCGGGGACCACAACTCCTGGAACCAGGAATTTCAGGCTGTGTGACCCTGGGTGAGTTTCCCTTCCTCTCTGGGTCTCTTTT 
BALB/c    GCACGTAATTGTGAGAGAAGCGGGGACCACAACTCCTGGAACCAGGAATTTCAGGCTGTGTGACCCTGGGTGAGTTTCCCTTCCTCTCTGGGTCTCTTTT 
 
C57BL/6   TTTCTCCAGGGTTAGCTCACTGGCGGGGTTGATGCAAAATTTGTCTCTAGAGAGGGTTGGGGACTCTCCCCGCGGGTCTATCCTGAGACCAAATGGAATG 
BALB/c    TTTCTCCAGGGTTAGCTCACTGGCGGGGTTGATGCAAAATTTGTCTCTAGAGAGGGTTGGGGACTCTCCCCGCGGGTCTATCCTGAGACCAAATGGAATG 
 
C57BL/6   CCATTCCAACCCCCGAACCCGACACCCTGCAAAGCTTCCGTTTCCCGGTCTGAATGACGGGATGGTGGGTTTGCAAACAGCCAGCAAGTAACGAACCGGA 
BALB/c    CCATTCCAACCCCCGAACCCGACACCCTGCAAAGCTTCCGTTTCCCGGTCTGAATGACGGGATGGTGGGTTTGCAAACAGCCAGCAAGTAACGAACCGGA 
 
C57BL/6   CTTACTCGAAGGTCCCAGGTTCGAGTTCGGGCCCCTTTTCCAAGAAGTCCCGTGACCTTTTCCCCGCTGGATTCCCACTGACCCCGTACTGGGCCTCCTT 
BALB/c    CTTACTCGAAGGTCCCAGGTTCGAGTTCGGGCCCCTTTTCCAAGAAGTCCCGTGACCTTTTCCCCGCTGGATTCCCACTGACCCCGTACTGGGCCTCCTT 
 
C57BL/6   TTTGCCCTTTGTAGACACGTAGTCAGAGCCGCGGGTCTACACCCCCGCGCCGAGCCAACCAATCGGCGTTCGCCTCACTCTGTTCTACTCCATCCTGTTA 
BALB/c    TTTGCCCTTTGTAGACACGTAGTCAGAGCCGCGGGTCTACACCCCCGCGCCGAGCCAACCAATCGGCGTTCGCCTCACTCTGTTCTACTCCATCCTGTTA 
 
C57BL/6   ATTCGATTGGTCTGAAGAAACTGGAGCAGGCGGAGAGACAGAGGGTAGGACCAATGAAAATCCACGGAGGGAGGGCCTTGGCTGAGAGCTCGGCTTCTAA 
BALB/c    ATTCGATTGGTCTGAAGAAACTGGAGCAGGCGGAGAGACAGAGGGTAGGACCAATGAAAATCCACGGAGGGAGGGCCTTGGCTGAGAGCTCGGCTTCTAA 
 
C57BL/6   CCCGGAAGGAGGGTGAAGAACGACCAGAGAGCTAGAGGCTCAATCTTGGCTAGTGTAGGGTTCATGGCACCATCCACTCCATCCGGGGCGACCGGGGAGA 
BALB/c    CCCGGAAGGAGGGTGAAGAACGACCAGAGAGCTAGAGGCTCAATCTTGGCTAGTGTAGGGTTCATGGCACCATCCACTCCATCCGGGGCGACCGGGGAGA 
 
C57BL/6   GGTGATGCTTTCTGTAACCTAGCTCTAGGAAGGCTGAAGCACGAGTATCGCCAGTTCGAGACTAGCCGGGACTGCGTGGTGAGACCCTGTCAACCAAAAC 
BALB/c    GGTGATGCTTTCTGTAACCTAGCTCTAGGAAGGCTGAAGCACGAGTATCGCCAGTTCGAGACTAGCCGGGACTGCGTGGTGAGACCCTGTCAACCAAAAC 
 
C57BL/6   AACAGCCGGGCATGGTGGCGCAAATGTTTAGTTCCAGTAATCATCATAAACCGATGATTTAGTTAATGGTTTAGTTCCAGTACTCAGGAGGCAGAGGCAG 
BALB/c    AACAGCCGGGCATGGTGGCGCTAATGTTTAGTTCCAGTAATCATCATAAACCGATGATTTAGTTAATGGTTTAGTTCCAGTACTCAGGAGGCAGAGGCAG 
 
C57BL/6   GCATAATTCTGACTCTACAACGCGAATTCCAGAATAGCCAGTACAACACGGAAGTAAGTCCTGTCTCGAAAACCCGAAAGTCAAACTAAGAAAACAAAAG 
BALB/c    GCATAATTCTGACTCTACAACGCGAATTCCAGAATAGCCAGTACAACACGGAAGTAAGCCCTGTCTCGAAAACCCGAAAGTCAAACTAAGAAAACAAAAG 
 
C57BL/6   AACAAGCCTCGTAAGACATTTTCCCCC-ACTGCTTGCCAGTTAGCTTTTTCTCCAGGAATTCAGGACTTGTCTCCTTGGGTGGTCTATATAGAAAACTGA 
BALB/c    AACAAGCCTCGTAAGACATTTTCCCCCCACTGCTTGCCAGTTAGCTCTTTCTCCAGGAATTCAGGACTTGTCTCCTTGGGTGGTCTATATAGAAAACTGA 
 
C57BL/6   CTCTGTACTTAGAAGTGGGGGTTAAGAGAGAGAGGATTACTTCATCCAGATATATAAACCTGGTATGGTGGCTCAGG-CCGGTAATCCCAGCGTTCTAGA 
BALB/c    CTCTGTACTTAGAAGTGGGGGTTAAGAGAGAGAGGATTACTTCATCCAGATATATAAACCTGGTATGGTGGCTCAGG-CCGGTAATCCCAGCGTTCTAGA 
 
C57BL/6   AGCTGAGGCCTTGAGTTCAATGAATAAGAAAACAAAAGCTGATTACGGTGGCTTAATACCCATGACCCCAAGTACTCAGAAGTGGAGACAGGAGGATTTC 
BALB/c    AGCTGAGGCCTTGAGTTCAATGAATAAGAAAACAAAAGCTGATTACGGTGGCTTAATACCCATGACCCCAAGTACTCAGAAGTGGAGACAGGAGGATTTC 
 
C57BL/6   TTCACCTTGAAGTTATGAGAAAAGGGCTAGGCATGGTGGCTAACGAGGACTGTAAACCCAGCACTTGGGAGGCTGAGTGTGGGTGAGGATCTTTTGGGGG 
BALB/c    TTCACCTTGAAGTTATGAGAAAAGGGCTAGGCATGGTGGCTAACGAGGACTGTAAACCCAGCACTTGGGAGGCTGAGTGTGGGTGAGGATCTTTTGGGGG 
 
C57BL/6   AGAGATATATATATACACAGAGTTCCAGGTTAGCCTGGGCCACAGAGTGTGACACTGTCGAACAAAGAAAAAGAAATAAGGCTGGAACTGTAGCTCAGGT 
BALB/c    AGAGATATATATATACATAGAGTTCCAGGTTAGCCTGGGCCACAGAGTGTGACACTGTCGAACAAAGAAAAAGAAATAAGGCTGGAACTGTAGCTCAGGT 
 
C57BL/6   GGCAGAGTCCTTGCCTGGCATGAATAAAGCCTTCGCTTTAGTGCCCAGCACTGTATGCATGGGGGTGGGGTGAGGGTGG-AGAGATGGGG 
BALB/c    GGCAGAGTCCTTGCCTGGCATGAATAAAGCCTTCGCTTTAGTGCCCAGCACTGTATGCATGGGGGTGGGGTGAGGGTGGGAGAGATGGGG 
 
W 
Pi4k2b  
chr5:53,026,310-53,027,151 
 
C57BL/6   ------------------------AAGGCCACACAAGATATTTTAGAACTGAGCTTGGATAAGGGCAGTAACAATAGCAGTTGTGGTTGGCATCTGGAAT 
BALB/c    ------------------------AAGGCCACACAAGATATTTTAGA-CTGAGCTTGGATAAGGGCAGTAACAATAGCAGTTGTGGTTGGCATCTGGAAT 
 
C57BL/6   GCCCTCCTCCGCCGGCTCACGCTTTGTTCCCAGGCTGCTGATGTGAGAGGTGGTACAGCCTTTAGGAAGATGGGTCTGGTGGGCAGAAGTATGTGACTCT 
BALB/c    GCCCTCCTCCGCCGGCTCACGCTTTGTTCCCAGGCTGCTGATGTGAGAGGTGGTACAGCCTTTAGGAAGATGGGTCTGGTGGGCAGAAGTATGTGACTCT 
 
C57BL/6   GGAGGTGACAGTGCCTTTGATATGGGACATGGCTTTTGCTCCATGTCTTTCCTAATGGGGGGGGGGAGGGGGGTGTCTCTGCCTCAGGCACCTCCTGTAA 
BALB/c    GGAGGTGACAGTGCCTTTGATATGGGACATGGCTTTTGCTCCATGTCTTTCCTAATGGGGGGGGG-AGGGGGGTGTCTCTGCCTCAGGCACCTCCTGTAA 
 
C57BL/6   GACCTTTTCCCACTCAGATGACTTGGAATTTCTGGAATCATAATTGAAAATGATCTTTCCTCTCCTGGGTTGTTTCCATCAGATGCTTTGGTCATGGTGG 
BALB/c    GACCTTTTCCCACTCAGATGACTTGGAATTTCTGGAATCATAATTGAAAATGATCTTTCCTCTCCTGGGTTGTTTCCATCAGATGCTTTGGTCATGATGG 
 
C57BL/6   CAAGAAAGGCGACCGACGTGCGATCCACGACCATTTGAAAATGCCGGTGAAATAAACCACCCCAAGTAAATAAAACCATAGACATCATCCCCAGATCTGT 
BALB/c    CAAGAAAGGCGAGCGACGTGCGATCCACGACCATTTGAAAATGCCGGTGAAATAAACCACCCCAAGTAAATAAAACCATAGACATCATCCCCAGATCTGT 
 
C57BL/6   GTTATAACTAACCGTGCTAATTTCTTCACTGGGAAGGAAAATGGTACTAGGTAGAAAATCAGACTTCTAAGAGGGAATAAAACAGGGGCTGGAGAGATGG 
BALB/c    GTTATAACTAACCGTGCTAATTTCTTCACTGGGAAGGAAAACGGTACTAGGTAGAAAATCAGACTTCTAAGAGGGAATAAAACAGGGGCTGGAGAGATGG 
 
C57BL/6   CTCAGCGAGTTAAGAGCACTGACTGCTCTTCAGAAGGTCCTGAGTTCAAATCCCAGCAACCACATGGTGGCTCACAACCAGATATGACGCCCTCTTCTGG 
BALB/c    CTCAGCGAGTTAAGAGCACTGACTGCTCTTCAGAAGGTCCTGAGTTCAAATCCCAGCAACCACATGGTGGCTCACAACCAGATATGACGCCCTCTTCTGG 
 
C57BL/6   TCTGTCTGAAGACAGCTACAGTGTACTTACATATAATGATAATGATGATGATAATAATAATAATAATTAATAAATAAAAGAGGTAATAAAACAGTACATT 
BALB/c    TCTGTCTGAAGACAGCTACAGTGTACTTACATATAATGATAATGATGATGATAATAATAATAATAATTAATAAATAAAAGAGGTAATAAAACAGTACATT 
 
C57BL/6   AGTAATTAGAGCCATCGTGTAATATTTATTTTAGGAAGAAGCTTCACAGGGAAAGGGAGGAGCATG 
BALB/c    AGTAATTAGAGCCATCGTGTAATATTTATTTTAGGAAGAAGCTTCACAGGGAAAGGGAGGAACATG 
Appendix IV 
 
198 
X 
Pop4  
chr7:37,961,843-37,962,567 
 
C57BL/6   --------------------------------------CTGTTTCTATCTCTTTGGGGCTGCTGCCAGCAGGCCTAGGCTTCCCTATGCACTGGTCTAGA 
BALB/c    --------------------------------------CTGTTTCTATCTCTTTGGGGCTGCTGCCAGCAGGCCTAGGCTTCCCTATGCACTGGTCTAGA 
 
C57BL/6   ATGCATGTCTCTCCTAGTAAGCCTTTCTGCCTTTAGGCCCTGGTTGTGGGTACACAAAGGTTCAAAGGGACAGAGATTGCGTTTCTGACACCGTGCTCAT 
BALB/c    ATGCATGTCTCTCCTAGTAAGCCTTTCTGCCTTTAGGCCCTGGTTGTGGGTACACAAAGGTTCAAAGGGACAGAGATTGCGTTTCTGACACCGTGCTCAT 
 
C57BL/6   GAGTACTGTTCCCATGCCTCATAACAATATCTGAGATGGCTGTGGTGGAATATAATATGCCTACAATCCTAGCATTTGGAAGGGTGAGGCAGAGAGATCC 
BALB/c    GAGTACTGTTCCCATGCCTCATAACAATATCTGAGATGGCTGTGGTGGAATATAATATGCCTACAATCCTAGCATTTGGAAGGGTGAGGCAGAGAGATCC 
 
C57BL/6   TGAGTTCCCAGATAGCCTGGTATATAGGGTAAGTTTCAGGCTAGCCTGTGCTGTAAAGCTAGAGACCCTATTTTAAAAAAAGAATCAAGCCGGGCGTGGT 
BALB/c    TGAGTTCCCAGATAGCCTGGTATATAGGGTAAGTTTCAGGCTAGCCTGTGCTGTAAAGCTAGAGACCCTATTTTAAAAAAAGAATCAA------------ 
 
C57BL/6   GGCGCACGCCTTTAATCCCAGCACTTGGGAGGCAGAGACAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAAAGAGAGTTCCGGGACAGCCAAGA 
BALB/c    ---------------------------------------------------------------------------------------------------- 
 
C57BL/6   CTATACAGAGAAACCCTGTCTCGAAAAACCAAAAAAAAAAAAAAAAAAAA----AAAGAATCAAAACTAATCAACTAATGAAAGATCAAAAAAGGCTGGG 
BALB/c    ----------------------------------------------------------------AACTAATCAACTAATGAAAGATCAAAAAAGGCTGGG 
 
C57BL/6   AGTATGGGTCATGGTCACAGGCTCAATGGTGTTCGTTTCCTTCCCGGCATTCAAACAAACAACAAAGAAAACCTTTCTTCTGTGCATCTTCAATGCTGAC 
BALB/c    AGTATGGGTCATGGTCACAGGCTCAATGGTGTTCGTTTCCTTCCCGGCATTCAAACAAACAACAAAGAAAACCTTTCTTCTGTGCATCTTCAATGCTGAC 
 
C57BL/6   CCTGGTCTAGGATGCAGATATTCCTCACAGGCCAGAGCCACCTCCTCACTGGCATATGTTCTT 
BALB/c    CCTGGTCTAGGATGCAGATATTCCTCACAGGCCAGAGCCACCTCCTCACTGGCATATGTTCTT 
 
Y 
Ppp1r14d  
chr2:118,921,131-118,922,245 
 
C57BL/6   -------------------------------------------TCTGTGGACGATGCCCTCCTTCTCTTCTCAGAAGCCCAGTGGACCTTCTTGTCTGGG 
BALB/c    -------------------------------------------TCTGTGGACGATGCCCTCCTTCTCTTCTCAGAAGCCCAGTGGACCTTCTTGTCTGGG 
 
C57BL/6   TTGTCTGTGCCAGGGCTGGGAGATGTACAGGAAGCAGGGCTTGAAGACAGCATGGAGAGATCAGACTGTGCAAGGTGCTGGGAGAAACTGCCAGTCTAGG 
BALB/c    TTGTCTGTGCCAGGGCTGGGAGATGTACAGGAAGCAGGGCTTGAAGACAGCATGGAGAGATCGGACTGTGCAAGGTGCTGGGAGAAACTGCCAGTCTAGG 
 
C57BL/6   CAAGAGAATAGAGGGAAATGAGGGGACAGAGAATGGAGGGAGAGGCCCACAAGGAAGAAAGGAGGTGGGAAGAGGGCCAAGGCTCTTGGGAGGGGCAGGG 
BALB/c    CAAGAGAATAGAGGGAAATGAGGGGACCGAGAATGGAGGGAGAGGCCCACAAGGAAGAAAGGAGGTGGGAAGAGGGCCAAGGCTCTTGGGCGGGGCAGGG 
 
C57BL/6   GTCAAAGATCAATAGGTCTCTAGTTAGTGCCGGGAATGAACTTCCTAGCCTCTCTCTGCCAGCCAGTGGCATTCAGAGCCATATCCCAGCCTCCATTCTG 
BALB/c    GTCAAAGATCAATAGGTCTCTAGTTAGTGCCGGGAATGAACTTCCTAGCCTCTCTCTGCCAGCCAGTGGCATTCAGAGCCGTATCCCAGCCTCCATTCTG 
 
C57BL/6   CAGCTGCTGGAGCCCACAGTAACATAAACCTCAAACAAGCAAATGTCAAGAGGCTAGCAAGCCTTGAGAAGAGGAAGAAGGAGCCTTTGAGTGCTGAAGG 
BALB/c    CAGCTGCTGGAGCCCACGGTAACATAAACCTCACACAAGCAAATGTCAAGAGGCTAGCAAGCCTTGAGAAGAGGAAGAAGGAGCCTTTGAGTGCTGAAGG 
 
C57BL/6   GTGTGGGGCTCCCACCTGTCTTCCGGGATAGCTCTAGACATACGGTGACTAGGCTCAATCAACTGAAGTCCCTCAGCATCCAATCTTCTAGGAACTAGAT 
BALB/c    GTGTGGGGCTCCCACCTGTTTTCCAGGATAGCTCTAGACATACGGTGACTAGGCTCAATCAACTGAAGTCCCTCAGCATCCGATCTTCTAGGAACTAGAT 
 
C57BL/6   AGTCTATTGCAGGCCTGAGCAGCTGTGGTCGGATAATTCTGGTTCCTGCAGGGGTAGGATTCCTCCTCAAGGTGAGGAGCCACCGAGGGCAATCTCAGCC 
BALB/c    AGTCTATTGCAGGCCTGAGCAGCTGTGGTCGGATAATTCCGGTTCCTGCGGTGGTAGGATTCCTCCTCACAGTGAGGAGCCACCGAGGGCAATCTCAGCC 
 
C57BL/6   AGTGGATAGAGTTCACAGATGGCTACTTCTGTCCTGTGTCTGGGTGTGTCTGGATATTGGCTTTGCTGCTGTGATTGTTAAAGGCAGATTTATGCAGCCT 
BALB/c    AGTGGATAGAGTTCATAGATGGCTACTTCTGTCCTGTGTCTGGGTGTGTCTGGATATTGGCTTTGCTGCTGTGATTGTTAAAGGCAGATTTATGCAGCCT 
 
C57BL/6   GGCCTACAAGACCTGTTGTCATTCTTAGAAGCCAAGTTTATGGTCATGTGACCCTCCCCTGATTCAGCTTCTTCCTGATAAAAGACACCTTCAGACCTGA 
BALB/c    GGCCTACAAGACCTGTTGTCATTCTTAGAAGCCAAGTTTATGGTCATGTGACCCTCCCCTGATTCAGCTTCTTCCTGATAAAAGACACCTTCAGACCTGA 
 
C57BL/6   CTTCACATAGGAATCCTGGACTGGTAAACAAGCTTGCCATTTAAAAGTACTTTCATTATTCAGTCCTTTATAAGAAAAAATTTAAATAACTTAATGTGGT 
BALB/c    CTTCACATAGGAATCCTGGACTGGTAAACAAGCTTGCCATTTAAAAGTACTTTCATTATTCAGTCCTTTATAAGAAAAAATTTAAATAACTTAATGTGGT 
 
C57BL/6   TCATTTTGTCTTGTTTTTCGTTTTAATGAACAGCTCAGAAAAACAGATAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA 
BALB/c    TCATTTTGTCTTGTTTTTCGTTTTAATGAACAGCTCAGAAAAAAAGATAGAA-GAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAG 
 
C57BL/6   AGAAAGGAAGGAAGG--AAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAG 
BALB/c    AGAGAGAGAGAGAGGGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAG 
Appendix IV 
 
199 
Z 
Rab6b  
chr9:102,967,555-102,969,590 
 
C57BL/6   ----------------------------------TATCGTGGGGGCTGTTGGATGAAGAGACACAGAAACTTCCTGTACTATTTTTTGAAACCTCTATGT 
BALB/c    ----------------------------------TATCGTGGGGGCTGTTGGATGAAGAGACACAGAAACTTCCTGTACTATTTTTTGAAACCTCTATGT 
 
C57BL/6   AGTCTAAAACTATTTCAGGCTTTAAAAACTGGACACATTTTTACTGAAAATGGTTTCAAAATTGGGGCAGACGATGGAATGCTAAGCAGACACGGGAACC 
BALB/c    AGTCTAAAACTATTTCAGGCTTTAAAAACTGGACACATTTTTACTGAAAATGGTTTCAAAATTGGGGCAGACGATGGAATGCTAAGCAGACACGGGAACC 
 
C57BL/6   AAAGGCTCTGCTCTATGCATCAACAGGAATCTTGGGAGTACAGCGAGAAGGGAAGAGCAAGTCAGAAGACAGGGTTTGAAATATGAATTCAAAAGACTCA 
BALB/c    AAAGGCTCTGCTCTATGCATCAACAGGAATCTTGGGAGTACAGCGAGAAGGGAAGAGCAAGTCAGAAGACAGGGTTTGAAATATGAATTCAAAAGACTCA 
 
C57BL/6   AGAGAAATGAAAGTGTTGAGAGTTTGGGTTTTCTGCCTTGGGGAAGGAGGAAAAGGGGGAGGGGATAAAAGAAGAATTAGAAGACAGGTGTGTGTTCACT 
BALB/c    AGAGAAATGAAAGTGTTGAGAGTTTGGGTTTTCTGCCTTGGGGAAGGAGGAAAAGGGGGAGGGGATAAAAGAAGAATTAGAAGACAGGTGTGTGTTCACT 
 
C57BL/6   GCGATATGATGTCTTTCCATGTTCCTCATCCAGAGAACACACTCATCAGGAAGGGCAGAAAGATGCCATGCAGAAGAAACTCTTTCTAGTGAGACTACCA 
BALB/c    GCGATATGATGTCTTTCCATGTTCCTCATCCAGAGAACACACTCATCAGGAAGGGCAGAAAGATGCCATGCAGAAGAAACTCTTTCTAGTGAGACTACCA 
 
C57BL/6   AAAAGAGGCTTATAGTGGCTCTTTTTATCTATCACATGGGAAATGCCTGATATCCCAGGACAGAATAAAGATGATCCCTTCCCCTAAGAGACAAAGGAAT 
BALB/c    AAAAGAGGCTTATAGTGGCTCTTTTTATCTATCACATGGGAAATGCCTGATATCCCAGGACAGAATAAAGATGATCCCTTCCCCTAAGAGACAAAGGAAT 
 
C57BL/6   GGCAAGGGTAAGGGAGAGACTTGGAAGAGAGCAGAAGCATTCTAAGGTTAGGATTCACATACAGCATGAAGACCATGCTGTGTAGCTCTGCCCAGACTGC 
BALB/c    GGCAAGGGTAAGGGAGAGACTTGGAAGAGAGCAGAAGCATTCTAAGGTTAGGATTCACATACAGCATGAAGACCATGCTGTGTAGCTCTGCCCAGACTGC 
 
C57BL/6   AGGAGCCAACCCAGCCGACTGAACCAGTACAGATGAGGAAATGCTGGGTGGAAGGTGTGACACCCCCCAACCCCCTGAATGCCTTGACCTCCACAGGCAG 
BALB/c    AGGAGCCAACCCAGCCGACTGAACCAGTACAGATGAGGAAATGCTGGGTGGAAGGTGTGACACCCCCCAACCCCCTGAATGCCTTGACCTCCACAGGCAG 
 
C57BL/6   GGAGGGGTGTGGCTTAGGAGTAGTTCTTTCACTGCTGGAGTGTCCAACTTCTAGCTACGGAGACACAACATTGCAATCTACAAACTTCACAATGTAAAAC 
BALB/c    GGAGGGGTGTGGCTTAGGAGTAGTTCTTTCACTGCTGGAGTGTCCAACTTCTAGCTACGGAGACACAACATTGCAATCTACAAACTTCACAATGTAAAAC 
 
C57BL/6   CAGGCAATGGGATCAACAACAATAAACAAAAACTTGCCCCAAAAAATGTAGAAACCCATCCAGTATCTCATAATGTTCTACATAAGATTACAATATTGTG 
BALB/c    CAGGCAATGGGATCAACAACAATAAACAAAAACTTGCCCCAAAAAATGTAGAAACCCATCCAGTATCTCATAATGTTCTACATAAGATTACAATATTGTG 
 
C57BL/6   TTGTGCTGAATTCAAAGCTATCCTGCAAGGCATATGGCCTGTGGACAGTGGGTCGGACACACCTGCCAAAACTTTCCTCAGCCCATGCTGGATCCCGAGA 
BALB/c    TTGTGCTGAATTCAAAGCTATCCTGCAAGGCATATGGCCTGTGGACAGTGGGTCGGACACACCTGCCAAAACTTTCCTCAGCCCATGCTGGATCCCGAGA 
 
C57BL/6   CAGCAACACACTCGGGGCAAAAGTAGGGTGGAGTCTGAGTTATCTTAGTCTGGTGCCCAATCTGGCATGCTTATATGCTCAGAGGGATGACCTCCGACTC 
BALB/c    CAGCAACACACTCGGGGCAAAAGTAGGGTGGAGTCTGAGTTATCTTAGTCTGGTGCCCAATCTGGCATGCTTATATGCTCAGAGGGATGACCTCCGACTC 
 
C57BL/6   CAGGGACTTCAAACCGAAGAAGACCACAAGAATAGAACAGTTACTCTGATTTGAGAGTAGTTTTAGAGGTTAATTCGAGCATTCAGCAACTGTTTCCTAA 
BALB/c    CAGGGACTTCAAACCGAAGAAGACCACAAGAATAGAACAGTTACTCTGATTTGAGAGTAGTTTTAGAGGTTAATTCGAGCATTCAGCAACTGTTTCCTAA 
 
C57BL/6   ACTCTAGGTGAAGTGGAACCTCAGCTGCTTCCATGGAGTTTCCTGTGAGGGCTCAATGTGCGGTGGGAGACTCTAGTGGGTACATTCGGGGTAAATTCAT 
BALB/c    ACTCTAGGTGAAGTGGAACCTCAGCTGCTTCCATGGAGTTTCCTGTGAGGGCTCAATGTGCGGTGGGAGACTCTAGTGGGTACATTCGGGGTAAATTCAT 
 
C57BL/6   AAGTGTCCCCTGGGAAATCCGTAGGCACGGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATTTCACTCCTGGCTTGCTTTGTGTAACATACACTACACA 
BALB/c    AAGTGTCCC-TGGGAAATCCGTAAGCACGGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATTTCACTCCTGGCTTGCTTTGTGTAACATACACTACACA 
 
C57BL/6   TTCCAAACAGTCCCAAACAAACATTCCCTGAATGGCCAGAGAAGGTCAAGACCAGCAAGTGGCTGGAGAGGAAGAGGGGAGGGGCTTTGTAAAGCCTCAA 
BALB/c    TTCCAAACAGTCCCAAACAAACATTCCCTGAATGGCCAGAGAAGGTCAAGACCAGCAAGTGGCTGGAGAGGAAGAGGGGAGGGGCTTTGTAAAGCCTCAA 
 
C57BL/6   TTAACCCGATGCCTTAGAGTGTACTGCTTGGGGACTGCGTTTAACCTTAGTCTGGCGTCTACTCCTTGCTCTCACGCTACTGTGTGTGCCCTGCAAACTT 
BALB/c    TTAACCCGATGCCTTAGAGTGTACTGCTTGGGGACTGCGTTTAACCTTAGTCTGGCGTCTACTCCTTGCTCTCACGCTACTGTGTGTGCCCTGCAAACTT 
 
C57BL/6   AGAGGTCGCTCTCTTATACTCTTGTAGCTCATTACCCGAATAAACCTAACTAGCAGGGCGCAGGAGTGTGGTTGGGCTGACGGTCTCAGGATCAAAAGAG 
BALB/c    AGAGGTCGCTCTCTTATACTCTTGTAGCTCATTACCCGAATAAACCTAACTAGCAGGGCGCAGGAGTGTGGTTGGGCTGACGGTCTCAGGATCAAAAGAG 
 
C57BL/6   GCAGGGCATTGTCTTTGGGTTAGTGGAGCTGTCTTCTACCAGGCAGGTTAGGTTTCAAACCCTAGTAGGCATATCCTGTAAGGGTGTCTTCTCTCTCACT 
BALB/c    GCAGGGCATTGTCTTTGGGTTAGTGGAGCTGTCTTCTACCAGGCAGGTTAGGTTTCAAACCCTAGTAGGCATATCCTGTAAGGGTGTCTTCTCTCTCACT 
 
C57BL/6   GGCCAGCTCCTCTGGGGACAACCACAGATCCCCTCCGCATGAAGAGTCTGAGCCTAGCTAGATAGGAGGTAAGCTAGAGGCCAGCAGGGGCCACCGAGGA 
BALB/c    GGCCAGCTCCTCTGGGGACAACCACAGATCCCCTCCGCATGAAGAGTCTGAGCCTAGCTAGATAGGAGGTAAGCTAGAGGCCAGCAGGGGCCACCGAGGA 
 
C57BL/6   GCCATACCCCAGGTCTGAGCCAGGTATCCGCACATCTTCCTACTCACCACCACACCACACACTGACCCTT 
BALB/c    GCCATACCCCAGGTCTGAGCCAGGTATCCGCACATCTTCCTACTCACCACCACACCACACACTGACCCTT 
Appendix IV 
 
200 
AA 
Slc13a3  
chr2:165,163,937-165,164,881 
 
C57BL/6   -------------------TAGAA---CGACATAGACTGATTCCTTTAT-TTCACCGTGAGCCTATGATGCGTTATCATATTCCCTCTTTCTGGGTAGGG 
BALB/c    -------------------TAGCA---CGACATAGACTGATTCCTTTATCTTCACCGTGAGCCTATGATGCGTTATCATATTCCCTCTTTCTGGGTAGGG 
 
C57BL/6   GGTACGCAAACCAAAGTTCAGAGAGGTTAAGTGACTGGCGACAGGTCACACAGTTGTTCTTCGGAAAGACTGTGAAGGGCTATATACCCCAGTAGCACCA 
BALB/c    GGTAAGCAAACCAAAGTTCAGAGAGGTTAAGTGACTGGCGACAGGTCACACAGTTGTTCTTCGGAAAGACTGTGAAGGGCTATATACCCCAGTAGCACCA 
 
C57BL/6   AGCAAGCCGTCAGAGCTCAAACTTTAGAAGAGTGGGAGGACCGAGAGAGGCAGACCAGGGAGAGGCAAGGAAGGGAGAAGGGGAGCGGGTGCTCCTAGGG 
BALB/c    AGCAAGCCGTCAGAGCTCAAACTTTAGAAGAGTGGGAGGACCGAGAGAGGCAGACCAGGGAGAGGCAAGGAAGGGAGAAGGGGAGCGGGTGCTCCTAGGA 
 
C57BL/6   GTAGGCAGGCTCAAGGCGGGAGGGTCTCGACCCGGGACCACCGTACCTTGGGCGGCAGGGCGAAGAGAATGGGCAGCAGAGCCAGCGGCACCAGCAGCAG 
BALB/c    GTAGGCAGGCTCAAGGCGGGAGGGTCTCGACCCGGGACCACCGTACCTTGGGCGGCAGGGCGAAGAGAATGGGCAGCAGAGCCAGCGGCACCAGCAGCAG 
 
C57BL/6   CACCAGGAGGCGCCGCGCGCTCCACACCTTCTTGGCCAGCGCCGCCAGCGCCGCCATCCGCGCGATCGCTGGAGACCAGGCGGCCCGACTGCCCCTCAGC 
BALB/c    CACCAGGAGGCGCCGCGCGCTCCACACCTTTTTGGCCAGCGCCGCCAGCGCCGCCATCCGCGCGATCGCTGGAGACCAGGCGGCCCGACTGCCCCTCAGC 
 
C57BL/6   GGCCGCCGGCAGGGACCTAAAGCCCCAAGGGACGGGGAGGAGCCATGCGGAACCGCCCCGGGCCGCGCCTCCTTGGTCTGGACAAGGAGCAGGGAAGGGG 
BALB/c    GGCCGCCGGCAGGGACCTAAAGCCCCAAGGGACGGGGAGGAGCCATGCGGAACCGCCCCGGGCCGCGCCTCCTTGGTCTGGACAAGGAGCAGGGAAGGGG 
 
C57BL/6   CCCCAGAGCACCCCACCCGCCCCCGCGCCCCACTCTGGACTCACGTGGGAAATGGGGCAAAGCCCAGGTGGGACTAAAGGCCTCAGCACCGTCATCCCAC 
BALB/c    CCCCAGAGCACCCCACCCGCCCCCGCGCCCCACTCTGGACTCACGTGGGAAATGGGGCAAAGCCCAGGTGGGACTAAAGGCCTCAGCACTGTCATCCCAC 
 
C57BL/6   TGTCCAACCCTGTAGGGACAGACCAAGCTACTGAGACCTCTAGTGACCGTGGTTGCAGCCTCTTCCAGACTTGGAGGTTGGTGGGGGGG----TTTAAGT 
BALB/c    TGTCCAACCCTGTAGGGACAGACCACGCTACTGAGACCTCTAGTGACCGTGGTTGCAGCCTCTTCCAGACTTGGAGGTTGGTGGGGGGGGGGGTTTAAGT 
 
C57BL/6   GAGATAGTGCTTCGTGCAAAGGGCCGGGTCACCTGTGGGTAGGAGCTTTCCCTTCTCAGTGACAGATGCCACAACCTGCTTGATATTGTGTGTGTTGGGA 
BALB/c    GAGATAGTGCTTCGTGCAAAGGGCCCGGTCACCTGTGGGTAGGAGCTTTCCCTTCTCAGTGACAGATGCCACAACCTGCTTGATATTGTGTGTGTTGGGA 
 
C57BL/6   CAGGCTCTTATTTAGCCCAAGCTGGCCTGCATCTCCCTATGCTGCTGAGGACAACCTTGAACTCCCATCCTCCTGC 
BALB/c    CAGGCTCTTATTTAGCCCAAGCTGGCCTGCATCTCCCTATGCTGCTGAGGACAACCTT-AACTCCC-TCCTCCTGC 
 
AB 
Sfi1  
chr11:3,092,948-3,093,861 
 
C57BL/6   ------------------------------------------AAACGCAACGTGAGCTCAGCTCCTTGCTTGGTCACTTGAGCTCAGTGTACCAACGAGC 
BALB/c    ------------------------------------------AAACGCAACGTGAGCTCAGCTCCTTGCTTGGTCACTTGAGCTCAGTGTACCAACGAGC 
 
C57BL/6   CCTACGCCCCGCCACACCCCTGAATCGAACGTGGATCTGCGCAGACTAGTAAGCGAAGCACGAGCTGGAGAATCACTCAGCGGAGCTCTCCACCAGGGGG 
BALB/c    CCTACGCCCCGCCACACCCCTGAATCGAACGTGGATCTGCGCAGACTAGTAAGCGAAGCACGAGCTGGAGAATCACTCAGCGGAGCTCTCCACCAGGGGG 
 
C57BL/6   AGAAGGATGCATAGACCCTGCAGAAACAGCGCGAGTGCAGCCGTGACTGCGAGCGACCTTACGCACGCCCTGCTCGCACTTCCACGCATGGACCAGAGCC 
BALB/c    AGAAGGATGCATAGACCCTGCAGAAACAGCGCGAGTGCAGCCGTGACTGCGAGCGACCTTACGCACGCCCTGCTCGCACTTCCACGCATGGACCAGAGCC 
 
C57BL/6   TTGTGGGTAGGCAGCATCTCCTGCACTTCTACAGAAGAAAGCAGAAGCCCCGACCAAGCCGTTCCAGGACAAAGTTCCTAGGAACGCGCGCTCCGCCAAC 
BALB/c    TTGTGGGAAGGCAGCATCTCCTGCACTTCTACAGAAGAAAGCAGAAGCCCCGACCAAGCCGTTCCAGGACAAAGTTCCTAGGAACGCGCGCTCCGCCAAC 
 
C57BL/6   TTCAAAACGCAAGGGCGAGCCAGTCAAAAGCTGGAGGCGCTAGGCCGGGCCTCGTACCTGAGGGAGGTGACTCCTCAGCAGACGCTAGACAGAGGTGGTA 
BALB/c    TTCAAAACGCAAGGGCGAGCCAGTCAAAAGCTGGAGGCGCTAGGCCGGGCCTCGTACCTGAGGGAGGTGACTCCTCAGCAGACGCTAGACAGAGGTGGTA 
 
C57BL/6   GCAAAGGGCCCCAGCCCAGAGTTTCCGGCCCTGCGCCGACGGCGGCTCCTCCCCCGTCTCCACGGCAACGCGACCCGCGCCGGAAGCTGCTCTGTCCAGC 
BALB/c    GCAAAGGGCCCCAGCCCAGAGTTTCCGGCCCTGCGCCGACGGCGGCTCCTCCCCCGTCTCCACGGCAACGCGACCCGCGCCGGAAGCTGCTCTGTCCAGC 
 
C57BL/6   TTAGTGCGCTCTGTCTTCCAGGAAACAGAGACTTCTCTCTAAGCTCGGCTTCCTACGGTTTTCTTGCCCTGAAGTTTCTGCGCTTCTGAGAAGCGGGTCA 
BALB/c    TTAGTGCGCTCTGTCTTCCAGGAAACAGAGACTTCTCTCTAAGCTCGGCTTCCTACGGTTTTCTTGCCCTGAAGTTTCTGCGCTTCTGAGAAGCGGGTCA 
 
C57BL/6   CTAGTTACAACTCCTGCATGGGACCGGTGTGAGACGGAAAAGTGTCTCTTTTCATTGCGTGGTGGCTCACGTCGGTAATCTCCGCATCAAACAGCCGAAT 
BALB/c    CTAGTTACAACTCCTGCATGGGACCGGTGTGAGACGGAAAAGTGTCTCTTTTCATTGCGTGGTGGCTCACGTCGGTAATCTCCGCATCAAACAGCCGAAT 
 
C57BL/6   CTTTAAAGAGAACTTTCAGAACAAAGTATGAAGTTTCATACTAAGAACAGTGAAAACTAGTGGGTGGGTGTCTGAAGACGAAAACCAAGGGGCAGGAGAT 
BALB/c    CTTTAAAGAGAACTTTCAGAACAAAGTATGAAGTTTCATACTAAGAACAGTGAAAACTAGTGGGTGGGTGTCTGAAGACGAAAACCAAGGGGCAGGAGAT 
 
C57BL/6   ATGACTCACCAGTTAAATGCACTTTTCATTCATCCAGACTCCCAATACCCACACGG 
BALB/c    ATGACTCACCAGTTAAATGCACTTTTCATTCATCCAGACTCCCAATACCCACACGG 
 
Appendix IV 
 
201 
AC 
Sfi1 (pseudogene or duplication)  
(location unknown) 
 
C57BL/6   -------------------------------------------------CAAATTAACCATGAAAAATCTCATCCTTGGGGCTGGAGAGATGGCTCAGTG 
BALB/c    -------------------------------------------------CAAATTAACCATGAAAAATCTCATCCTTGGGGCTGGAGAGATGGCTCAGTG 
 
C57BL/6   GTTAAGAGCACTGACTGCTCTTCCAGAGTTCCTGAGTTCAATTCCCAGCAACCACATGGTGGCTCACAACCATCTGTAATGGGATCTGATGCCCTCTTCT 
BALB/c    GTTAAGAGCACTGACTGCTCTTCCAGAGTTCCTGAGTTCAATTCCCAGCAACCACATGGTGGCTCACAACCATCTGTAATGGGATCTGATGCCCTCTTCT 
 
C57BL/6   GGTGTGTCTGAAGACAGCGACAGTGTACTCATATACATAAAATAAACAAATTGTTAAAAAAAAAAAAGAAAAGAAAAATCTCATCCTTGCAAGGCTAAGT 
BALB/c    GGTGTGTCTGAAGACAGCGACAGTGTACTCATATACATAAAATAAACAAATTGTTAAAAAAAAAAAAGAAAAGAAAAATCTCATCCTTGCAAGGCTAAGT 
 
C57BL/6   TTTTACTGATATATAATCTGCATTTAAGGCTGGAGATGGTTTAATTGTGCTTTTCCACCACAAAAAGAGCTCTAGGTTCAGTCATCAGCCCTGAATAGAA 
BALB/c    TTTTACTGATATATAATCTGCATTTAAGGCTGGAGATGGTTTAATTGTGCTTTTCCACCACAAAAAGAGCTCTAGGTTCAGTCATCAGCCCTGAATAGAA 
 
C57BL/6   CGGGGCATGGTGCCACACACCAGTAATCCCAGAGACAGGAGGATCTCTGCAAGCTTTTCTCTTTCTTTAAAATTTATGTATTCTGGAGCTGGAGAGATGG 
BALB/c    CGGGGCATGGTGCCACACACCAGTAATCCCAGAGACAGGAGGATCTCTGCAAGCTTTTCTCTTTCTTTAAAATTTATGTATTCTGGAGCTGGAGAGATGG 
 
C57BL/6   CTCAACAGTTAAAACCACTGATTGTTCCTTCAGAGATTCTGAGTTCAGTTCCCAGCAACCACATGGTGGCTCACAACCATCTATAATGGGATTCAATGCC 
BALB/c    CTCAACAGTTAAGACCACTGATTGTTCCTTCAGAGATTCTGAGTTCAGTTCCCAGCAACCACATGGGGGCTCACAACCATCTATAAGGGGATTCAATGCC 
 
C57BL/6   CTCTTCTGGTGTGTCTGGACAGCAACAGCGTACTCACATATATAAAATAAATCTTTTTTAAAATTTTAAGAATTATGTATTCTGTGTATGTATAGAAGTG 
BALB/c    CTCTTCTGGTGTGTCTGGACAGCAACAGCGTACTCACATATATAAAATAAATCTTTTTTAAAATTTTAAAAATTATGTATTCTGTGTATGTATAGAAGTG 
 
C57BL/6   CTTTGCCTACATGTGTGTACGAGTACCACATGAGTACATAGTTTCCTTGGAGGTCAAAAGAAGGTATCAGATTCCATGGAATTGGTGATATGAGCTTGAT 
BALB/c    CTTTGCCTACATGTGTGTACGAGTACCACATGAGTACATAGTTTCCTTGGAGGTCAAAAGAAGGTATCAGATTCCATGGAATTGGTGATATGAGCTTGAT 
 
C57BL/6   TTTTTTAATTCATTTTGGCCATATGTTTAGAAGCCTTTATACTCTTGTCAAAGTTTTCAAGACTCATCCCATATGGAGTCCTGACCTACAGTTTGAAAAG 
BALB/c    TTTTTTAATTCATTTTGGCCATATGTTTAGAAGCCTTTATACTCTTGTCAAAGTTTTCAAGACTCATCCCATATGGAGTCCTGACCTACAGTTTGAAAAG 
 
C57BL/6   CTGAGATCAGGGCTGGAGAAATACCCCAGCAGTTAACAACAGTACATGATATTCTAGCAGAGAAATGAAGTTTGGTTCCTACCACCCACAACCTGTAGTT 
BALB/c    CTGAGATCAGGGCTGGAGAAATACCCCAGCAGTTAACAACAGTACATGATATTCTAGCAGAGAAATGAAGTTTGGTTCCTACCACCCACAACCTGTAGTT 
 
C57BL/6   TCCAACCTCCTTTAACTACAGTTCCAAGGAATCCAATAAGAGATCGATCCAACACTCGTGGCTCCAAGAGAGCCTGTACAAATGCACATGTACCCCCACA 
BALB/c    TCCAACCTCCTTTAACTACAGTTCCAAGGAATCCAATAAGAGATCGATCCAACACTCGTGGCTCCAAGAGAGCCTGTACAAATGCACATGTACCCCCACA 
 
C57BL/6   AACACATAACTAAAAACAATAAAAGTAAATCTGTGTTGGGGGGGAGAGGGGCTGAAGTGATGGCTCAGCTGT---------------------------- 
BALB/c    AACACATAACTAAAAACAATAAAAGTAAATCTGTGTTGGGGGGGAGAGGGGCTGAAGTGATGGCTCAGCTGT---------------------------- 
 
C57BL/6   ----------TGAGGACGAATCAGATTCAGCTGACCGCTTTTCCAAAGTACCCAGATTAAGTTCCCATAACCCAGGGGTGGCTCACAATCACCTGGAACT 
BALB/c    ----------TGAGGACGAATCAGATTCAGCTGACCGCTTTTCCAAAGTACCCAGATTAAGTTCCCATAACCCAGGGGTGGCTCACAATCACCTGGAACT 
 
C57BL/6   CCAGTTCTGAGGTTCCAATGCCCTCGTCTGACCTCTCCATTTGGGCTTCTGAGGGCAACAGGCAAGCAAAAGGTACCCAGACATCCATGCACGCAAAACA 
BALB/c    CCAGTTCTGAGGTTCCAATGCCCTCGTCTGACCTCTCCATTTGGGCTTCTGAGGGCAACAGGCAAGCAAAAGGTACCCAGACATCCATGCACGCAAAACA 
 
C57BL/6   GCCACACACATAAATCTTTTTTTTTA-AATGTTTTTAAATAATCATGAATTGGAGGTTAGCCTGGATTCTGAGGCCAGTGTGAGCTAGCTTGTGTTATAG 
BALB/c    GCCACACACATAAATCTTTTTTTTTA-AATGTTTTTAAATAATCATGAATTGGAGGTTAGCCTGGATTCTGAGGCCAGTGTGAGCTAGCTTGTGTTATAG 
 
C57BL/6   AGACGCCAGAAATGGAGCCCAAAGCCTTCAGGACACCAGACAATCAGTCTACCTATGAGCTGGCATTTCAGGTGTGTTGTGAGCCACCAGTGGTGGACGC 
BALB/c    AGACGCCAGAAATGGAGCCCAAAGCCTTCAGGACACCAGACAATCAGTCTACCTATGAGCTGGCATTTCAGGTGTGTTGTGAGCCACCAGTGGTGGACGC 
 
C57BL/6   TGGGAGTCCAACTGGTATTGTCTCAAAAAGGAGTAAGGGTTTCTTAAGCGCTGAGCCATCTCTCTGGCTCCTTTAATAAATCATCTTTCTTTTTAAAAAT 
BALB/c    TGGGAGTCCAACTGGTATTGTCTCAAAAAGGAGTAAGGGTTTCTTAAGCGCTGAGCCATCTCTCTGGCTCCTTTAATAAATCATCTTTCTTTTTAAAAAT 
 
C57BL/6   ATTTAATATTAAATTTTAAACCATGATAACTTCAAATTACTTGATAATTACCAGGCAATCTAAAGCCCAGGGACTACAATTAAGACAGCATTTACAGCAC 
BALB/c    ATTTAATATTAAATTTTAAACCATGATAACTTCAAATTACTTGATAATTACCAGGCAATCTAAAGCCCAGGGACTACAATTAAGACAGCATTTACAGCAC 
 
C57BL/6   GGGTTGCACACGTTTTTCTGAAGCACTTTTCATGAACGACCCACTCTAAGAACAGGCACCTCAGCTGGTGCTTATTGTCATTTTCCAGGCTGATGCTCAA 
BALB/c    GGGTTGCACACGTTTTTCTGAAGCACTTTTCATGAACGACCCACTCTAAGAACAGGCACCTCAGCTGGTGCTTATTGTCATTTTCCAGGCTGATGCTCAA 
 
C57BL/6   GACCATCAGCTAACAGG-TGGCAAAGGTGCCACTCTCATTCAAACCTCGATACACCTTCAGGAACTACACCAGGAGAGGTTCCATGGTACAAACGCAACG 
BALB/c    GACCATCAGCTAACAGGCTGGCAAAGGTGCCACTCTCATTCAAACCTCGATACACCTTCAGGAACTACACCAGGAGAGGTTCCATGGTACAAACGCAACG 
 
C57BL/6   TGAGCTCAG--------------------------TGTACCAACGAGCCCTACGCCCAGCCACACCCCTGAATCGAACGTGGATCTGCGCAGACTAGTAA 
BALB/c    TGAGCTCAG--------------------------TGTACCAACGAGCCCTACGCCCAGCCACACCCCTGAATCGAACGTGGATCTGCGCAGACTAGTAA 
 
C57BL/6   GCGAAGCACGAGCTGGAGAATCACTCAGCGGAGCTCTCCACCAGGGGGAGAAGGATGCATAGACCCTGCAGAAACAGCGCGAGTGCAGCCGTGACTGCGA 
BALB/c    GCGAAGCACGAGCTGGAGAATCACTCAGCGGAGCTCTCCACCAGGGGGAGAAGGATGCATAGACCCTGCAGAAACAGCGCGAGTGCAGCCGTGACTGCGA 
 
C57BL/6   GCGACCTTACGCACGCCCTGCTCGCACTTCCACGCATGGACCAGAGCCTTGTGGGTAGGCAGCATCTCCTGCACTTCTACAGAAGAAAGCGGAAGCCCCG 
BALB/c    GCGACCTTACGCACGCCCTGCTCGCACTTCCACGCATGGACCAGAGCCTTGTGGGTAGGCAGCATCTCCTGCACTTCTACAGAAGAAAGCGGAAGCCCCG 
 
C57BL/6   ACCAAGCCGTTCCAGGACAAAGTTCCTAGGAACGCGAGCTCCGCCAACTTCAAAACACAAGGGCGAGCCAGTCAAAAGCTGGAGGCGCTAGGCCGGGCCT 
BALB/c    ACCAAGCCGTTCCAGGACAAAGTTCCTAGGAACGCGAGCTCCGCCAACTTCAAAACACAAGGGCGAGCCAGTCAAAAGCTGGAGGCGCTAGGCCGGGCCT 
 
C57BL/6   CGTACCTGAGGGAGGTGACTCCTCAGCAGACGCTAGACAGAGGTGGTAGCAAAGGGCCCCAGCCCAGAGTTTCCGGCCCTGCGCCGACGGCGGCTCCTCC 
BALB/c    CGTACCTGAGGGAGGTGACTCCTCAGCAGACGCTAGACAGAGGTGGTAGCAAAGGGCCCCAGCCCAGAGTTTCCGGCCCTGCGCCGACGGCGGCTCCTCC 
 
C57BL/6   CCCGTCTCCACGGCAACGCGGCCCGCGCCGGAAGCTGCTCTGTCTTGCTTAGTGCGCTCTGTCTTCCAGGAAACCGAGACTTCTCTCTAAGCTCGGCTTC 
BALB/c    CCCGTCTCCACGGCAACGCGGCCCGCGCCGGAAGCTGCTCTGTCTTGCTTAGTGCGCTCTGTCTTCCAGGAAACCGAGACTTCTCTCTAAGCTCGGCTTC 
 
C57BL/6   CTACAGTTTTCTTGCCCTGAAGTTTCTGCGCTTCTGAGAAGCGGGTCACTAGTTACAACTCCTGCATGGGACCGGTGTGAGACGGAAAAGTGTCTCTTTT 
BALB/c    CTACAGTTTTCTTGCCCTGAAGTTTCTGCGCTTCTGAGAAGCGGGTCACTAGTTACAACTCCTGCATGGGACCGGTGTGAGACGGAAAAGTGTCTCTTTT 
 
C57BL/6   CATTGCGTGGTGGCTCACGTCGGTAATCTCCGCATCAAACAGCCGAATCTTTAAAGAGAACTTTCAGAACAGAGTATGAAGTTTCAAACTAAGAACAGTG 
BALB/c    CATTGCGTGGTGGCTCACGTCGGTAATCTCCGCATCAAACAGCCGAATCTTTAAAGAGAACTTTCAGAACAGAGTATGAAGTTTCAAACTAAGAACAGTG 
 
C57BL/6   AAAACTAGTGGGTGGGTGTCTGAAGACGAAAACCAAGGGGCAGGAGATATGACTCACCAGTTAAATGCACTTTTCATTCATCCAGACTCCCAATACCCAC 
BALB/c    AAAACTAGTGGGTGGGTGTCTGAAGACGAAAACCAAGGGGCAGGAGATATGACTCACCAGTTAAATGCACTTTTCATTCATCCAGACTCCCAATACCCAC 
 
C57BL/6   ACGGTGGCTCTTAAAACAGTTGTGACTCCCAAGTCGCGCTCCCGTTTGACCTATATGCAAGCAAAACATTCATACTCAAAATTTTTAAAAAGATTAAACC 
BALB/c    ACGGTGGCTCTTAAAACAGTTGTGACTCCCAAGTCGCGCTCCCGTTTGACCTATATGCAAGCAAAACATTCATACTCAAAATTTTTAAAAAGATTAAACC 
 
C57BL/6   CAAGAAATATGGGTTTTGCCCTTTTACAAATGGTAATTTTGTAATCCAAAGATTTA 
BALB/c    CAAGAAATATGGGTTTTGCCCTTTTACAAATGGTAATTTTGTAATCCAAAGATTTA 
  
Appendix IV 
 
202 
AD 
Slc27a6  
chr18:58,681,397-58,682,391 
 
C57BL/6   --------------------------------------TTAGGCGGGGTTTTCAGAGGCAGCAAGAGGTGCTAAAGACATTCCCAGCTTGAAGCCCAGGG 
BALB/c    --------------------------------------TTAGGCGGGGTTTTCAGAGGCAGCAAGAGGTGCTAAAGACATTCCCAGCTTGAAGCCCAGGG 
 
C57BL/6   AGCTGCAAGGAGCCTGTTGGACAGCCGTGGAGGGTGGGTGCACTGAGCTGTGTTGGGCTCATTTCCAGCGCTGTGAGTGTTGTGAGTACAATAGCCCCCC 
BALB/c    AGCTGCAAGGAGCCTGTTGGACAGCCGTGGAGGGTGGGTGCACTGTGCTGTGTTGGGCTCATTTCCAGCGCTGTGAGTGTTGTGAGTACAATAGCTCCCC 
 
C57BL/6   CCCCCCCTCTTTTTTTAATCTAAGAAGACTCAGGGCTCTGCTCCACAACTGTCTAGCCCAATGCCCCAGGGCGTATCACCAGCGTTCTGTAGCTTTCTGG 
BALB/c    CCCCCCCTCTTTTTTTAATCTAAGAAGACTCAGGGCTCTGCTCCACAACTGTCTAGCCCAATGCCCCAGGGCTTATCACCAGCATTCTGAAGCTTTCTGG 
 
C57BL/6   GCGAAAACCTTTGATTTCTTTCATGGGATATACAAAGACATCTTGAGCCAGAACTACAGGTGCCAGCCTCTGAGCTTTCAGGACAGGAGTCTCCAGGGCA 
BALB/c    GCGAAAACCTTTGATTTCTTTCATGGGATATACAAAGACATCTTGAGCCAGAACTACAGGTGCCAGCCTCTGAGCTTTCAGGACAGGAGTCTCCGGGGCA 
 
C57BL/6   AAAAGAGGTGAAACTCTTGGAAAAGAAAGAGACACTGCTAGGACCCATCGGGTCTGCTGGAGGTCTGGGCACCCATGCTCCTGTCATGGCTCACAGGATT 
BALB/c    AAAAGAGGTGAAACTCTTGGAAAAGAAAGAGACACTGCTAGGACCCATCGGGTCTGCTGGAGGTCTGGGCACCCATGCTCCTGTCATGGCTCACAGGATT 
 
C57BL/6   GGGGGCTGGACTGCTCTCCCTGCATTTCCTGCAGAAACTTCTGTTCCCGTATTTCTGGGATGATTTCTGGTACTTGCTGAAGGTGGTGCGCTACGGAATT 
BALB/c    TGGGGCTGGACTGCTCTCCCTGCATTTCCTGCAGAAACTTCTGTTCCCGTATTTCTGGGATGATTTCTGGTACTTGCTGAAGGTGGTGCGCTACGGAATT 
 
C57BL/6   CAGATGGAGATGTACAAACTGAGGGGGGAGCTGGTCACGGTGCTGGATAAGTTCCTGAGCCACACCAGGAAGCAACCACGGAAAGCCTTCATCATTTATG 
BALB/c    CAGATGGAGATGTACAAACTGAGGGGGGAGCTGGTCACGGTGCTGGATAAGTTCCTGAGCCACGCCAGGAAGCAACCACGGAAAGCCTTCATCATTTATG 
 
C57BL/6   AGGGGGACGTCTACACCTACGAGGACGTGGACAAGAGGAGTAACAGAATAGCCCACGCTCTCCTGAACCACTCCTCGCTGAAAAGGGGGGACGTTGTGGC 
BALB/c    AGGGGGACGTCTACACCTACGAGGACGTGGACAAGAGGAGTAACAGAATAGCCCACGCTCTCCTGAACCACTCCTCGCTGAAAAGGGGGGACGTTGTGGC 
 
C57BL/6   TTTGTTGATGAGCAACGAGCCCGACTTCGTTCATGTGTGGTTTGGCCTGGCTAAACTGGGCTGCGTGGTGGCCTTCCTCAACTCCAACCTTCGCTTCGAT 
BALB/c    TTTGTTGATGAGCAACGAGCCCGACTTCGTTCATGTGTGGTTTGGCCTGGCTAAACTGGGCTGCGTGGTGGCCTTCCTCAACTCCAACCTTCGCTTCGAT 
 
C57BL/6   TCCCTCCTACACTGCATCAACACCTGTGAACCCACTGCCGTGGTGGTGGGCGGAGGTAGAGTATGGACTGTGGTCTGCTGTGCCCAAAGCAAACCAACCT 
BALB/c    TCCCTCCTACACTGCATCAACACCTGTGAACCCACTGCCGTGGTGGTGGGCGGAGGTAGAGTATGGACTGTGGTCTGCTATGCCCAAAGCAAACCAACCT 
 
C57BL/6   ATTTCCTGCCCTCCCCTTTCTATCCATACTTCC 
BALB/c    ATTTCCTGCCCTCCCCTTTCTATCCATACTTCC 
 
AE 
Slc27a6  
chr18:58,685,847-58,687,080 
 
C57BL/6   -------------------------------------CTTCAGTA-GGTTGCATAACCAGG-ATCAAAATCTCGACTTCTGATGTGAGGTCTTGATTTGA 
BALB/c    -------------------------------------CTTCAGTAAGGTTGCATAACCAGGGATCAAAATCTCGACTTCTGATGTGAGGTCTTGATTTGA 
 
C57BL/6   TCACAATCCAGCTATGTGGGGACCGTCAGTTACATTGCACACAGTTATAAAAAAGTATATATGTTCAGGCTCTATGAAAACACTACAAAATGGCAACATC 
BALB/c    TCACAATCCAGCTATGTGGGGACCGTCAGTTACATTGCACACAGTTATAAAAAAGTATATATGTTCAGGCTCTATGAAAACACTACAAAATGGCAACATC 
 
C57BL/6   AAGATACCAGGCTTTTAATACACACTAATTAGAAAAATGTGTACGATATTATTCTTCCAACAGAGCTGAAGACTCAAATATACTTGCAAAGGGGTCTCCT 
BALB/c    AAGATACCAGGCTTTTAATACACACTAATTAGAAAAATGTGTACGATATTATTCTTCCAACAGAGCTGAAGACTCAAATATACTTGCAAAGGGGTCTCCT 
 
C57BL/6   AGCTATGCTCTGGTCTCGGGGTCTGGGTCAGGTTAGTGTTCTCTGCTAATCAAAGAATGGAAATGAAAAGACAGGAAAAATCTCAGGCAGGACAAGTGAC 
BALB/c    AGCTATGCTCTGGTCTCGGGGTCTGGGTCAGGTTAGTGTTCTCTGCTAATCAAAGAATGGAAATGAAAAGACAGGAAAAATCTCAGGCAGGACAAGTGAC 
 
C57BL/6   GACAGCCTGAAGATTCTCATTGAGGCTGACAGAAACTGCTGTTTAAAAAAAAAAAAAAAAAAAAAAAACTTTATCAGGGAAGAGGAAATGCTACTCATAA 
BALB/c    GACAGCCTGAAGATTCTCATTGAGGCTGACAGAAACTGCTGTTTAAAAAAAAAAAAAAAAAAAA----CTTTATCAGGGAAGAGGAAATGCTACTCATAA 
 
C57BL/6   TAAGATAAGAAATGTTGTGGGTCTACCAGGTGTCCACGGTTCCCTTGCTACACATTGCGCGTGCGCGTTGTTTGCTTTCTCGATACTCTGCCGCTTAAAT 
BALB/c    TAAGATA-----TGTTGTGGGTCTACCAGGTGTCCACGGTTCCCTTGCTACACATTGCGCGTGCGCGTTGTTTGCTTTCTCGATACTCTGCCGCTTAAAT 
 
C57BL/6   CTCTACAAACAGATGACTTTACAATTCTCCCGTTGCCCGTCTCCCCGTCTCCCCTACTTTAAATGTGACAGCACTTAGTGTGTGAGTTTATTTTAAAAGA 
BALB/c    CTCTACAAACAGATGACTTTACAATTCTCCCGTTGCCCGTCTCCCCGTCTCCCCTACTTTAAATGTGACAGCACTTAGTGTGTGAGTTTATTTTAAAAGA 
 
C57BL/6   CTTGAGATTTCTCTTCATGAGAAGTCATGACTTCCGTTCACAGTTAAGGAGCTAATGGTTACTGCCCTGCCCTGTTTTTATAAGCAGTTGCCCTCAGGCT 
BALB/c    CTTGAGATTTCTCTTCATGAGAAGTCATGACTTCCGTTCACAGTTAAGGAGCTAATGGTTACTGCCCTGCCCTGTTTTTATAAGCAGTTGCCCTCAGGCT 
 
C57BL/6   GTGCAGAGGAAATGTTCAGGTTAACAACTGATCTGTTGTAACCCTGCAATTACCCTTTAGCCATAAAGGTAATTATTAAAATCAACAGGAAGAGAGGGAA 
BALB/c    GTGCAGAGGAAATGTTCAGGTTAACAATTGATCTGTTGTAACCCTGCAATTACCCTTTAGCCATAAAGGTAATTATTAAAATCAACAGGAAGAGAGGGAA 
 
C57BL/6   CGAGCCCCTTTGCAGTTCATAGAAAATTATATGTACAGAGGTACAGAAAGCTAAGGGACCCTGTGAACTTTATTACCTACCCTGTGTTCCATGATACCCT 
BALB/c    CGAGCCCCTTTGCAGTTCATAGAAAATTATATGTACAGAGGTACAGAAAGCTAAGGGACCCTGTGAACTTTATTATCTACCCTGTGTTCCGTGATACCCT 
 
C57BL/6   CTCACAGGACACGAATATTTTTCCAGGACATGGCTATTTTTTTTCTTGTATTTATTAGAATGGCTGTTACCACATTCTTATTTTTTCCCCATCTTGGATT 
BALB/c    CTCACAGGACACGAATATTTTTCCAGGACATGGCTATTTTTTTTCTTGTATTTATTAGAATGGCTGTTACCACATTCTTATTTTTTCCCCATCTTGGATT 
 
C57BL/6   TAGCAGGGTCGAGAAAGTAACCTTGCTACAAAAGAAAATCATTTTATTAATTTAAATGTATAGTGTAATTTCAAAAGAAGAAATCTAGACAGAGAAGTGA 
BALB/c    TAGCAGGGTCGAGAAAGTAACCTTGCTACAAAAGAAAATCATTTTATTAATTTAAATGTATAGTGTAATTTCAAAAGAAGAAACCTAGACAGAGAAGTGA 
 
C57BL/6   ATGAAACAGCGTGGCTCATACCCATCTCTTCTCAATGGAAAGGGGAAAATGACTTAACACATCCTGTGGAGAC 
BALB/c    ATGAAACAGCGTGGCTCATACCCATCTCTTCTCAATGGAAAGGGGAAAATGACTTAACACATCCTGTGGAGAC 
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AF 
Spint1  
chr2:118,930,972-118,931,837 
 
C57BL/6   ------------------------------------------------CAGAACCAGAGTGTGGAGTGCAGGGAGCAGGACACATAGGGCCAGTGCGACA 
BALB/c    ------------------------------------------------CAGAACCAGAGTGTGGAGTGCAGGGAGCAGGACACATAGGGCCAGTGCGACA 
 
C57BL/6   GACCCTTTCTCTCCAGGCTTCTTCCTACTAGGACCTATGGTAGACTAAAGGTCTGCTCTTCTAACTGTCCAATAGCGTCCAATAGCTCTCCTTGATCTCT 
BALB/c    GACCCTTTCTCTCCAGGCTTCTTCCTACTAGGACCTATGGTAGACTAAGGGTCTGCTCTTCTAACTGTCCAATAGCGTCCAATAGCTCTCCTTGATCTCT 
 
C57BL/6   GGGGAGACCCCAGGTGGGGATTCTGGAAAGTGGGGGATGCTGTGAAGTAGGTATCTCACTTGGTTAGCATTGGAGCCTGTTCCACAAGAACCTTACAGGA 
BALB/c    GGGGAGACCCCAGGTGGGGATTCTGGAAAATGGGGGATGCTGTGAAGTAGGTATCTCACTTGGTTAGCATTGGAGCCTGTTCCACAAGAACCTTACAGGA 
 
C57BL/6   CTCCCTTCCCCGGCCAGAACCTGAGTCTCTGGATCTGGGCCCCTTAGTCCTAGGGCCAGCCTTCCTCTTTCGGAAACCCCCAGAAATGGTCCATTTGGCG 
BALB/c    CTCCCTTCCCCGGCCAGAACCTGAGTCTCTGGATCTGGGCCGCTTAGTCCTAGGGCCAGCCTTCCTCTTTCGGAAACCCCCAGAAATGGTCCATTTGGCG 
 
C57BL/6   TGAGATAGGCTAGAATGGGGATTTTCCTGGAACATTTGAGGAGCTGGGTAGGGCTCAGGTGTTGTGTGCACTCCCGGCCATTCTCGGCTGTATCAGGGAT 
BALB/c    TGAGATAGGCTAGAATGGGGATTTTCCTGGAACATTCGAGGAGCTGGGTAGGGCTCAGGTGTTGTGTGCACTCCCGGCCATTCTCGGCTGTATCAGGGAT 
 
C57BL/6   ACTGTAAGGAAGTCCAGAAGCTTCATGTCGGTGGTCCCCGTGTCAGCCAAGTAGCCTAGAGGGGATGTGTCAAGAAACCTAAGCTGTTGGTTGATTCCTG 
BALB/c    ACTGTAAGGAAGTCCAGAAGCTTCATGTCGGTGGTCCCCGTGTCAGCCAAGTAGCCTAGAGGGGATGTGTCAAGAAACCTAAGCTGTTGGTTGATTCCTG 
 
C57BL/6   TGTTGGATGAACGAATCCTTCCCAGAATGGGTGGCTTGGGTCCCTTTTCCCAGCTTGTGGTTAGGCCAGGCAAGAAGACTCCAGCCCAGTAACTTGTTCT 
BALB/c    TGTTGGATGAACGAATCCTTCCCAGAATGGGTGGCTTGGGTCCCTTTTCCCAGCTTGTGGTTAGGCCAGGCAAGAAGACTCCAGCCCAGTAACTTGTTCT 
 
C57BL/6   TTCCCTGTGTCTGTGTCCCCTCACCCTGGCTAGTGGCTTGGGAGGCGGAGTCTGCAGTTCCTCAGATATGTCCTGAGGCCTGGTTTTATTGCCATTCCAG 
BALB/c    TTCCCTGTGTCTGTGTCCCCTCACCCTGGCTAGTGGCTTGGGAGGCGGAGTCTGCAGTTCCTCAGATATGTCCTGAGGCCTGGTTTTATTGCCATTCCAG 
 
C57BL/6   CCCTTTGCTCTCTGAGGGTAGGAAGAAGGGAGTGGTAGGTAAGGGTAGGGCATTTGCCCCTTGGTCTTGGGGCTTGGTGAGAG----CAGATAGGGGTTG 
BALB/c    CCCTTTGCTCTCTGAGGGTAGGAAGAAGGGAGTGGTAGGTTAGGGTAGGGCATTTGCCCCTTGGTCTTGGGGCTTGGTGAGAGAGAGCAGATAGGG-TTG 
 
C57BL/6   GGGGTGGGGCTGCTCCTCAT 
BALB/c    GGGGTGGGGCTGCTCCTCAT 
 
AG 
Zfp568  
chr7:29,691,813-29,692,926 
 
C57BL/6   -------------------------------------GCTATTCTAAGA-CAGAGGTCTTATCTCAGCCTTTAGGGAGCTCGCCCAGGCCTGGTGGTTTT 
BALB/c    -------------------------------------GCTATTCTAAGAACGGAGGTCTTATCTCAGCCTTTAGGGAGCTCGCCCAGGCCTGGTGGTTTT 
 
C57BL/6   ACTGCAGCTTGAAAGAAAGTAAGGCTTGCGGGCATGCAGTAAGATGGGGGCGGCCGTCCAATACCTGGGATCACTCTGGGCTCGGCACAAAGGAAAGCCC 
BALB/c    ACTGCAGCTTGAAAGAAAGTAAGGCTTGCGGGCATGCAGTAAGATGGGGGCGGCTGTCCAATACCTGGGATCACTCTGGGCTCGGCACAAAGGAAAGCCC 
 
C57BL/6   GGCTCTTTGTGGTTTGTAGTGCATTCTTTGCCTCTTTTGGGTAACTGACCTGGCAATGGGTAAAACTGGGAGTAGACATAAAAAAATTGTGACCCTCCAG 
BALB/c    GGCTCTTTGTGGTTTGTAGTGCATTCTTTGCCTCTTTTGGGTAACTGACCTGGCAATGGGTAAAACTGGGAGTAGACATAAAAAAATTGTGACCCTCCAG 
 
C57BL/6   GTCTTTCTTGGCCAGGCCAGAGATCATTACCAGCCTTGTCCCCATTATCCATCCTGCGTAGAGAATGGAGATTAGGAGAGAACTGGCACCCTGACCAATT 
BALB/c    GTCTTTCTTGGCCAGGCCAGAGATCATTACCAGCCTTGTCCCCATTATCCATCCTGCGTAGAGAATGGAGATTAGGAGAGAACTGGCACCCTGACCAATT 
 
C57BL/6   TGCGAATCTAAACCTCACCTCAGAGATTGTTCCCAGGAGCAGAGTTCTGAAGTCACAACCACTCGGGTGACAGGAGCCCCATGGTTACATGCAAGATGCC 
BALB/c    TGCGAATCTAAACCTCACCTCAGAGATTGTTCCCAGGAGCAGAGTTCTGAAGTCACAACCACTCGGGTGACAGGAGCCCCATGGTTACATGCAAGATGCC 
 
C57BL/6   ACATAGAGGTAGGCACAGTCTT------------------------------------------------------------------------------ 
BALB/c    ACATAGAGGTAGGCACAGTCTTTTTTTTGTTTGTTTGTTTGTTTTTTGTTTTTTTTTGTTTGTTTTTGTTTTTTTGAGACAGGGTTTCTCTGTATAGCCC 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    TGGCTGTCCTGGAACTCACTCTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCGCCTGCCTCTGCCTCCCGAGTGCTGAGATTAAAGGCGTGCGCCACC 
 
C57BL/6   -------------------------ACACTTAAGCCACAACTCCACAACGACCAGACATTTCATGTCCTCATAGAAAAGCTATCAGAATGTATTACAAAC 
BALB/c    ACGCCCGGCTGGTAGGCACAGTCTTACACTTAAGCCACAACTCCACAACGACCAGACATTTCATGTCCTCATAGAAAAGCTATCAGAATGTATTACAAAC 
 
C57BL/6   AACCACAAAAACTATTCCAGGGCACTGCGTCCGCCCAGTCGCAAGGCTCCTGCCGAGAGGCTGGACAGGCCACTAGCCTTTCTGGGAAATGTAGTCCACA 
BALB/c    AACCACAAAAACTATTCCAGGGCACTGCGTCCGCCCAGTCGCAAGGCTCCTGCCGAGAGGCTGGACAGGCCACTAGCCTTTCTGGGAAATGTAGTCCACA 
 
C57BL/6   AAGGGACAGCCACCTAGCGCCCCCAGCGCCTCCTCTGGTTGTTCCGGAAAAGACCGTCCCCGCAGCTGCTCACGTCCAGCGCTGCTTCGCCGGCGGCGTC 
BALB/c    AAGGGACAGCCACCTAGCGCCCCCAGCGCCTCCTCTGGTTGTTCCGGAAAAGACCGTCCCCACAGCTGCTCACGTCCAGCGCTGCTTCGCCGCCGGCGTC 
 
C57BL/6   ACCGTCTCGCCGCGCTAATGGGCTCAGCCACCTCGGCGCCTTCGGCCATGACTCCTGTCCCTAGCACAGGAAACGCCAGCCGAGCTCTGACCGGAAGTTG 
BALB/c    ACCGTCTCGCGGCGCTAATGGGCTCAGCCACCTCCGCGCCTTCGGCCATGACTCCTGTCCCTAGTACAGGAAACGCCAGCGGAGCTCTGACCGGAAGTTG 
 
C57BL/6   GGTCGGGCCGCGGGTCCTTCTGGGAGCACCTGTGCTCTGGGACATAACGGGCGCGCGCTGCCGCCCGAGTGGAGGGGCTGGCCGTGCGTGGCCCGCATGC 
BALB/c    GGTCGGGCCGCGGGTCCTTCTGGGAGCACCTGTGCTCTGGGACATAACGGGCGCGCGCTGCTGCCCGAGTGGAGGGGCTGGCCGTGCGTGGCCCGCATGC 
 
C57BL/6   CGCGTCTCTGAGGTTGCGTCTCGGGAGGTTTTGGCTGGTGGCGCTGCGGGGACCTCTCCACGGGAGAGGCACGGGTGGTCCGGTTTGCGCCGGCCGTGGG 
BALB/c    CGCGTCTCTGAGGTTGAGTCTCGGGAGGTTTTGGCTGGTGACGCTGCGGGGACCTCTCCACGGGAGAGGCACGGGTGGTCCGGTTTGCGCCGGCCGTGGG 
 
C57BL/6   CTTCGGGCTGGGCGCGGGCTCTCGGGGGGCTCGGAGTATCCCGGGTCACAGCTTT 
BALB/c    CTTCGGGCTGGGCGCGGGCTCTCGGGGGGCTCGGAGTATCCCGG-TCACAGTTTT 
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AH 
Tiam2  
chr17:3,352,121-3,353,556 
 
C57BL/6   ------------------------------------------TATTGTTCTCAATGTGGGTTCATATGTGTGAATGTATACATGTCAACAAGATATGTCT 
BALB/c    ------------------------------------------TATTGTTCTCAATGTGGGTTCATATGTGTGAATGTATACATGTCAACAAGATATGTCT 
 
C57BL/6   TAAAATCCAAATAGGGAATTACAAGTTTATCTAACTATAGTAGAATCTGGTCCTTAATAACTCACCAATGGCATATTTAGCTCAGTTCACTTTTTAAAAA 
BALB/c    TAAAATCCAAATAGGGAATTACAAGTTTATCTAACTATAGTAGAATCTGGTCCTTAATAACTCACCAATGGCATATTTAGCTCAGTTCACTTTTTAAAAA 
 
C57BL/6   ATTATTGGATATGTGCACTTATGCCACAGTGTGTGTATGGTCAGTGACAGATATCGGTGTCAGTTTGTCCTTCTACCTTGCTGAGGTAGGTGCTGGGTAC 
BALB/c    GTTATTGGATATGTGCACTTATGCCACAGTGTGTGTATGGTCAGTGACAGATATCGGTGTCAGTTTGTCCTTCTACCTTGCTGAGGTAGGTGCTGGGTAC 
 
C57BL/6   TGCAGTCTAGCCAGCTTGAGAGCTTTCCGGAGATTTCTTCCTGTCTCAATGTAGAAGTACCAGGATTACAGATGTACCCCACTGTATCTGGCCATTTTAT 
BALB/c    TGCAGTCTAGCCAGCTTGAGAGCTTTCCGGAGATTTCTTCCTGTCTCAATGTAGAAGTACCAGGATTACAGATGTACCCCACTGTATCTGGCCATTTTAT 
 
C57BL/6   GTGGCTTCCAGGGTTCATGATGTTTGTACCAGCAAGAAAGTTAATTCACTGAGCCATCTGAAGGACTTCTGTCACATTTTAAAATTAAGAATGTTACCAT 
BALB/c    GTGGCTTCCAGGGTTCATGATGTTTGTACCAGCAAGAAAGTTAATTCACTGAGCCATCTGAAGGACTTCTGTCACATTTTAAAAATAAGAATGTTACCAT 
 
C57BL/6   TATAAAGCTCTTGCCACATGTTCAGGATGGTTCAGGATGGGTTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATTTATATG 
BALB/c    TATAAAGCTCTTGCCACATGTTCAGGATGGTTCAGGATGGGTTGAG--------TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATTTATATG 
 
C57BL/6   TCTGAAAATGTAGGACTTTTGGTCATTCTGTGGAATATAAACACATAAATTTAAGCATGACAACAGAAATGTAATTTGATTCTATTCATCATAAAACAAC 
BALB/c    TCTGAAAATGTAAGACTTTTGGTCATTCTGTGGAATATACACACATAAATTTAAGCATGACAACAGAAATGTAATTTGATTCTATTCATCATAAAACAAC 
 
C57BL/6   AACAACAA---AAATCTAGTATAGAAATAACCTAGGGGCTGGAGAGATGGCTCAGAGGTTAAGAGCACTGGCTGCTTCTCCAGAGGTCCTGAGTTCAATT 
BALB/c    AACAACAACAAAAATCTAGTATAGAAATAACCTAGGGGCTGGAGAGATGGCTCAGAGGTTAAGAGCACTGGCTGCTTCTCCAGAGGTCCTGAGTTCAATT 
 
C57BL/6   CCCAGCAACCACATGGTGGCTCACAACCATCGGTAATGGGATCTGGTTTCTTCTTCTGGTATGCAGGTATACATACAGGCAGAACACTGTATCCATAGTA 
BALB/c    CCCAGCAACCACATGGTGGCTCACAACCATCGGTAATGGGATCTGGTTTCTTCTTCTGGTATGCAGGTATACATACAGGCAGAACACTGTATCCATAGTA 
 
C57BL/6   AATAAAAAAAT----------------------------------------------------------------------------------------- 
BALB/c    AATAAAAAAAAATCTTTTTTTGGGCTGGAGAGATGGCTCAGTGGTTAAGTAATGGCTGCTCAGCCAGGCATGGTGGAACACGCCTTTATCCCAGCACTCG 
 
C57BL/6   ---------------------------------------------------------------------------------------------------- 
BALB/c    GGAGGCAGAACAGGCAGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAAAGTGAGTTCCAGGACAGCCAGGGCTACATAGAGAAACCCTGTCTCAAAAAA 
 
C57BL/6   ---------------------------------------------------CTTTTTAAAAAATGACTTGAAAAAAATCTTGTATATTTTTAACATCTTT 
BALB/c    CAAACAAACAAACAAACCCAAAAAACAAAAAAACAAAAACAAAAAAAAAAACTTTTTAAAAAATGACTTGAAAAAAATCTTGTATATTTTTAACATCTTT 
 
C57BL/6   CATCAATGGTTACAGTGAGACTTCAAAATACTCTGCCTCTGTTGTATAGCCTTAATTTACAGTAATGTAATACATACTCTGGATAAAATGGCTCCGCATT 
BALB/c    CATCAATGGTTACAGTGAGACTTCAAAATACTCTGCCTCTGTTGTATAGCCTTAATTTACAGTAATGTAATACATACTCTGGATAAAATGGCTCCGCATT 
 
C57BL/6   TAGTTTCCAAGGACTTTGAGTGTAAGACTCTGTTGTGCTAACTTAAGGGGGGTGGGAAGCCCGATTCCAACAAGGAACACAGAATGAGGGTATACTCGAT 
BALB/c    TAGTTTCCAAGGACTTTGAGTGTAAGACTCTGTTGTGCTAACTTAAGGGGGGTGGGAAGCCCGATTCCAACAAGGAACACAGAATGAGGGTATACTCGAT 
 
C57BL/6   ATTCTGCAAACCATGGCAGCATTTCCTGGGGCTGTTCTAAAGGCAGTTCTGACCATAACATTCCATCTGTGGTTTTCACTGCTTCCCCAAACACAAGGAT 
BALB/c    ATTCTGCAAACCATGGCAGCATTTCCTGGGGCTGTTCTAAAGGCAGTTCTGACCATAACATTCCATCTGTGGTTTTCACTGCTTCCCCAAACACAAGGAT 
 
C57BL/6   GATAGGTGTGTATTCTCAGTGCTACAGGGCTTTATAAATGACGCCAGGGCAGCCCTGGTGAGTAGGGCTTTATTCTGTAACCCTTGGAGCCAGACTCCTA 
BALB/c    GATAGGTGTGTATTCTCAGTGCTACAGGGCTTTATAAATGACGCCAGGGCAGCCCTGGTGAGTAGGGCTTTATTCTGTAACCCTTGGAGCCAGACTCCTA 
 
C57BL/6   TGGAACTTCGGTGGTCATGGTGGATTGCTGGCCCAACAAGAGCCTAGTCATGGGCAGCCCCGTGTCTCTGAGGCGAGCATGGTGGCAGGCTGTCCCGGGT 
BALB/c    TGGAACTTCGGTGGTCATGGTGGATTGCTGGCCCAACAAGAGCCTAGTCATGGGCAGCCCCGTGTCTCTGAGGCGAGCATGGTGGCAGGCTGTCCCGGGT 
 
C57BL/6   AATCACTCCAGGCAGCCCATG 
BALB/c    AACCACTCCAGGCAGCCCATG 
 
 
 
 
 
Eidesstattliche Erklärung 
 
205 
13 Eidesstattliche Erklärung 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Arbeit ohne unzulässige Hilfe 
Dritter und ohne Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe; die 
aus anderen Quellen direkt oder indirekt übernommenen Daten und Konzepte sind unter 
Angabe des Literaturzitats gekennzeichnet. 
 
Weitere Personen waren an der inhaltlich-materiellen Herstellung der vorliegenden Arbeit 
nicht beteiligt. Insbesondere habe ich hierfür nicht die entgeltliche Hilfe eines 
Promotionsberaters oder anderer Personen in Anspruch genommen. Niemand hat von mir 
weder unmittelbar noch mittelbar geldwerte Leistungen für Arbeiten erhalten, die im 
Zusammenhang mit dem Inhalt der vorgelegten Dissertation stehen.  
 
Die Arbeit wurde bisher weder im Inland noch im Ausland in gleicher oder ähnlicher Form 
einer anderen Prüfungsbehörde vorgelegt. 
 
 
 
---------------------------------------                                                     ------------------------------------ 
                                                                                                             (Schilling Elmar) 
